

Hounsome, Jonathan David Arthur (2012) *Comparative outer membrane* proteomic analyses of bovine and ovine isolates of Mannheimia haemolytica and Mannheimia glucosida. PhD thesis.

http://theses.gla.ac.uk/3141/

Copyright and moral rights for this thesis are retained by the author

A copy can be downloaded for personal non-commercial research or study, without prior permission or charge

This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the Author

The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the Author

When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given

Glasgow Theses Service http://theses.gla.ac.uk/ theses@gla.ac.uk Comparative outer membrane proteomic analyses of bovine and ovine isolates of *Mannheimia haemolytica* and *Mannheimia* glucosida



# JONATHAN DAVID ARTHUR HOUNSOME

Institute of Infection, Immunity and Inflammation College of Medical, Veterinary and Life Sciences University of Glasgow

> January 2012 A thesis submitted for the degree of Doctor of Philosophy

# Summary

In the present study, recombinant proteins representing the transmembrane domain of *M. haemolytica* outer membrane protein A (OmpA) from a bovine serotype A1 isolate (rOmpA1) and an ovine serotype A2 isolate (rOmpA2) were over-expressed, purified and used to generate anti-rOmpA1 and anti-rOmpA2 antibodies, respectively. An examination of the binding specificities of these antibodies to M. haemolytica isolates representing different OmpA subclasses revealed that cross-absorbed anti-rOmpA1 antibodies recognised OmpA1-type proteins but not OmpA2-type proteins; conversely, cross-absorbed anti-rOmpA2 antibodies recognised OmpA2-type proteins but not OmpA1 type proteins. This demonstrated that OmpA1 and OmpA2 are surface-exposed and could potentially bind to different receptors in cattle and sheep. The outer membrane subproteomes of seven M. haemolytica isolates and one M. glucosida isolate were also characterised and compared after growth in complex growth medium in order to identify OMPs with putative roles in host-specificity and virulence. First, a simple bioinformatic workflow (E-Komon et al., 2011b) was used to confidently predict 93 unique OMPs encoded among the genomes of a bovine serotype A1 *M*. *haemolytica* isolate and two serotype A2 isolates (one bovine and one ovine). Secondly, a combination of gel-based and gel-free proteomic approaches employing MALDI-TOF-TOF and LC-ESI-QqTOF mass spectrometry identified 55 unique OMPs among the outer membrane fractions of seven M. haemolytica isolates and one M. glucosida isolate (of which 50 were predicted by the bioinformatic approach). A role in host-specific adaptation could not be established for any of the identified OMPs, however, the study represents the most comprehensive analysis of M. haemolytica and M. glucosida outer membrane subproteomes to date. In order to identify putative virulenceassociated OMPs, the outer membrane subproteomes of the same representative isolates were also characterised after in vitro growth under conditions that were designed to mimic the *in vivo* host respiratory tract microenvironment. These conditions included growth in iron-restricted medium, serum-supplemented tissue culture media and growth on solid-surface agar (in the absence or presence of Congo red). This approach allowed the identification of 13 additional OMPs that were not identified after growth in complex medium alone.

II

# **Table of Contents**

| SUMMARY II  |
|---|
| TABLE OF CONTENTSIII  |
| LIST OF TABLESIX  |
| LIST OF FIGURESXI   |
| LIST OF ACCOMPANYING MATERIALXV   |
| DEDICATIONXVI   |
| ACKNOWLEDGEMENTSXVII  |
| PRESENTATIONS/PUBLICATIONS XVIII  |
| DECLARATIONXIX  |
| ABBREVIATIONSXX   |
|   |
| 1. INTRODUCTION   |
| 1.1. The organisms  |
| 1.1 1 History and taxonomy of M. baomolytica and M. alucosida             |
| 1.1.2 Morphological and biochemical characteristics of M. haemolytica and |
| M. alucosida  |
| 1 1 2 1  Coll marphology  |
| 1 1 2 2 Cultural morphology   |
| 1 1 2 3 Biochemical characteristics                                       |
|   |
| 1.2 The diseases 3  |
| 1.2.1 Pneumonic pasteurellosis in cattle (shipping fever)                 |
| 1.2.2 Pneumonic pasteurellosis in sheep 5                                 |
|   |
| 1.3 The Gram-negative cell envelope                                       |
| 1.3.1 Inner membrane  |
| 1.3.2 Periplasm   |
| 1.3.3 Outer membrane  |
| 1.3.3.1 Getting things in: OMPs involved in nutrient uptake               |
| 1.3.3.1.1 General porins  |
| 1.3.3.1.2 Substrate-specific porins10                                     |
| 1.3.3.1.3 TonB-dependent receptors10                                      |
| 1.3.3.2 Getting things out: OMPs involved in secretion                    |

| 1.3.3.2.1        | Type I secretion (TolC export channel)                   | . 12 |
|------------------|--|------|
| 1.3.3.2.2        | Type II and type III secretion (secretin channels)       | . 14 |
| 1.3.3.2.3        | Type IV secretion (double membrane spanning channel)     | . 15 |
| 1.3.3.2.4        | Type V secretion (autotransporter pathway)               | . 15 |
| 1.3.3.3 OM       | MPs involved in outer membrane biogenesis and maintenanc | e 18 |
| 1.3.3.3.1        | The BAM complex (integral OMP assembly)                  | . 18 |
| 1.3.3.3.2        | The LolABCDE complex (lipoprotein assembly)              | . 19 |
| 1.3.3.3.3        | Wza (CPS transport)                                      | . 22 |
| 1.3.3.3.4        | LptD and LptE (LPS transport)                            | . 24 |
| 1.4 Virulence fa | actors of M. haemolytica                                 | . 24 |
| 1.4.1 Secret     | ed proteins  | . 24 |
| 1.4.1.1 Le       | ukotoxin (LktA)  | . 24 |
| 1.4.1.2 Gl       | ycoprotease (Gcp)  | . 26 |
| 1.4.1.3 Fil      | lamentous haemagglutinin (FhaB)                          | . 27 |
| 1.4.2 Cell w     | all carbohydrates and pili                               | . 28 |
| 1.4.2.1 Ca       | psular polysaccharide (CPS)                              | . 28 |
| 1.4.2.2 Lij      | popolysaccharide (LPS)                                   | . 28 |
| 1.4.2.3 Pi       | li   | . 29 |
| 1.4.3 Outer      | membrane proteins (OMPs)                                 | . 29 |
| 1.4.3.1 Ou       | uter membrane protein A (OmpA)                           | . 29 |
| 1.4.3.2 Irc      | on-acquisition OMPs                                      | . 30 |
| 1.4.3.2.1        | Transferrin binding receptor (TbpA and TbpB)             | . 31 |
| 1.4.3.2.2        | Haem/haemoglobin receptors                               | . 31 |
| 1.4.3.2.3        | Haem-haemopexin acquisition system (HxuCBA)              | . 32 |
| 1.4.3.2.4        | Siderophore uptake systems                               | . 32 |
| 1.4.3.3 Lij      | poproteins (PlpABC, PlpD and PlpE)                       | . 34 |
| 1.4.3.4 Se       | rotype-specific antigen (Ssa)                            | . 35 |
| 1.4.3.5 Ne       | euraminidase (NanH)                                      | . 35 |
| 1.4.3.6 lm       | munglobulin proteases                                    | . 36 |
| 1.4.3.7 Tr       | imeric autotransporter adhesins                          | . 37 |
| 1.5 Phenotypic   | and genetic variation of M. haemolytica and M. glucosida | . 37 |
| 1.5.1 Classif    | fication based on phenotypic relationships               | . 37 |
| 1.5.1.1 Ca       | psular serotyping  | . 37 |
| 1.5.1.2 LP       | S profiles   | . 38 |
|                  | IV   |      |

| 1.5.1.3 OMP profiles  | 38             |
|---|----------------|
| 1.5.2 Classification based on genetic relationships   | <del>1</del> 0 |
| 1.5.2.1 Nucleotide sequence analysis of the 16S rRNA gene   | 10             |
| 1.5.2.2 Multilocus enzyme electrophoresis (MLEE)  | 10             |
| 1.5.3 Evolution and host-switching in <i>M. haemolytica</i>   | <b>1</b> 1     |
|   |                |
| 1.6 Bioinformatic tools for discriminating proteins located in different  | 42             |
| subcellular compartments  | 13             |
| 1.6.1 Prediction tools for discrimination of UMPs   | 13             |
| 1.6.1.1 B-barrel predictors   | 13             |
| 1.6.1.2 Lipoprotein predictors  | 14             |
| 1.6.1.3 Subcellular localisation predictors   | 15             |
| 1.7 Mass spectrometry (MS)-based outer membrane proteomics  | 16             |
| 1.7.1 Outer membrane isolation  | 16             |
| 1.7.1.1 Selective detergent solubilisation  | 16             |
| 1.7.1.2 Spheroplasting  | 18             |
| 1.7.1.3 Sucrose density gradient centrifugation   | 18             |
| 1.7.2 MS principles and instrumentation   | 18             |
| 1.7.2.1 Ionisation techniques   | 19             |
| 1.7.2.2 Mass analysers  | 19             |
| 1.7.2.3 Peptide mass fingerprinting   | 53             |
| 1.7.2.4 MS/MS ion search5   | 54             |
| 1.7.3 Membrane protein identification   | 54             |
| 1.7.3.1 Gel-based approach5   | 55             |
| 1.7.3.2 Gel-free approach5  | 56             |
| 1.8 Objectives of research  | 56             |
|   |                |
| 2. OUTER MEMBRANE PROTEIN A (OMPA) OF BOVINE AND OVINE ISOLATES O   | ۶F             |
| M. HAEMOLYTICA IS SURFACE-EXPOSED AND CONTAINS HOST-SPECIES   |                |
| SPECIFIC EPITOPES5  | 19             |
| 2.1 Introduction  | 59             |
| 2.2 Materials and methods6  | 51             |
| 2.2.1 Bacterial strains and growth conditions $\dots \dots \dots$ | 51             |

|    | 2.2.2    | Capsule staining 63   |
|----|----------|---|
|    | 2.2.3    | Preparation of chromosomal DNAs63                                   |
|    | 2.2.4    | PCR amplification and plasmid construction                          |
|    | 2.2.5    | Expression of rOmpA64   |
|    | 2.2.6    | Purification of recombinant OmpA proteins (rOmpA1 and rOmpA2) 65    |
|    | 2.2.7    | Circular dichroism spectroscopy                                     |
|    | 2.2.8    | Anti-OmpA antibody preparation                                      |
|    | 2.2.9    | Serum cross-absorption  |
|    | 2.2.10   | Isolation of OMPs 67  |
|    | 2.2.11   | SDS-PAGE  |
|    | 2.2.12   | Western blotting  |
|    | 2.2.13   | Immunogold electron microscopy                                      |
|    | 2.2.14   | Immunofluorescence staining   |
|    | 2.2.15   | Crystallisation and X-ray analysis of rOmpA169                      |
| 2  | .3 Resu  | lts   |
|    | 2.3.1    | Recombinant OmpA proteins are comprised predominantly of B-         |
|    |          | sheets and exhibit heat-modifiability after heat treatment in the   |
|    |          | presence of SDS   |
|    | 2.3.2    | Anti-rOmpA1 and anti-rOmpA2 antibodies exhibit immune-specificity   |
|    |          | for the homologous proteins   |
|    | 2.3.3    | M. haemolytica OmpA is surface-exposed and recognised by anti-      |
|    |          | rOmpA antibodies <i>in vitro</i> in a strain-specific manner        |
|    | 2.3.4    | OmpA is surface-exposed at different stages of the growth cycle and |
|    |          | after growth in different media                                     |
|    | 2.3.5    | Binding specificities of cross-absorbed anti-rOmpA1 and anti-rOmpA2 |
|    |          | antibodies to M. haemolytica isolates representing different OmpA   |
|    |          | subclasses  |
|    | 2.3.6    | Crystallisation of rOmpA1   |
| 2  | .4 Discu | ussion  |
| 2  | COMP.    |   |
| э. |          | ISOLATES OF M HAFMOLYTICA AND M GUICOSIDA GROWN IN                  |
|    | СОМЫ     | FX MFDILIM 86   |
|    |          |   |

| 3.1 Intr | oduction  | . 86 |
|----------|---|------|
| 3.2 Mat  | erials and methods  | . 88 |
| 3.2.1    | Bioinformatic prediction of genome-encoded OMPs                 | . 88 |
| 3.2.2    | Bacterial isolates and growth conditions                        | . 90 |
| 3.2.3    | Preparation of OMPs.  | . 90 |
| 3.2.4    | Gel-based proteomic analysis                                    | . 90 |
| 3.2.5    | Gel-free proteomic analysis                                     | . 92 |
| 3.2.6    | MALDI-TOF-TOF MS and data analysis                              | . 92 |
| 3.2.7    | LC-ESI-QqTOF MS and data analysis                               | . 93 |
| 3.3 Res  | ults  | . 93 |
| 3.3.1    | Bioinformatic prediction of OMPs in three M. haemolytica genome | s.   |
|          |   | . 93 |
| 3.3.2    | Functional classifications of confidently predicted OMPs        | 102  |
| 3.3.3    | Amino acid sequence variation in confidently predicted OMPs     |      |
|          | between different M. haemolytica genomes                        | 104  |
| 3.3.4    | Identification of M. haemolytica OMPs by gel-based and gel-free |      |
|          | approaches  | 108  |
| 3.3.5    | Comparison of OMPs identified by proteomic approaches that are  |      |
|          | associated with different host species and phylogenies          | 118  |
| 3.4 Disc | cussion   | 122  |
| 4. COMP  | PARATIVE OUTER MEMBRANE PROTEOMIC ANALYSES OF BOVINE AN         | D    |
| OVINE    | E ISOLATES OF M. HAEMOLYTICA AND M. GLUCOSIDA GROWN UND         | ER   |
| VARIC    | OUS IN VITRO CONDITIONS DESIGNED TO MIMIC THE IN VIVO HOST      |      |
| ENVIR    | RONMENT   | 130  |
| 4 1 Intr | roduction   | 130  |
|          |   | 150  |
| 4.2 Mat  | erials and methods  | 132  |
| 4.2.1    | Bacterial isolates and growth conditions                        | 132  |
| 4.2.2    | Preparation of OMPs.  | 134  |
| 4.2.3    | Preparation of extracellular proteins                           | 134  |
| 4.2.4    | Gel-based proteomic analysis of OMPs                            | 134  |
| 4.2.5    | Gel-free proteomic analysis of OMPs                             | 135  |

|    | 4.2.6   | Gel-based analysis of extracellular proteins1                       | 35  |
|----|---------|---|-----|
|    | 4.2.7   | Gel band quantification1  | 35  |
|    | _       |   |     |
| 4. | 3 Resu  | ılts1   | 35  |
|    | 4.3.1   | Identification of M. haemolytica and M. glucosida OMPs which        |     |
|    |         | undergo changes in expression after growth in iron-restricted       |     |
|    |         | conditions1   | 35  |
|    | 4.3.2   | Identification of M. haemolytica OMPs which undergo changes in      |     |
|    |         | expression after growth in serum-supplemented tissue culture med    | ia  |
|    |         | and complete serum1   | 47  |
|    | 4.3.3   | Identification of M. haemolytica and M. glucosida OMPs which        |     |
|    |         | undergo changes in expression after growth on solid-surface BHIA in | n   |
|    |         | the absence or presence of Congo red dye1                           | 56  |
|    | 4.3.4   | Comparison of OMPs identified among different growth conditions.    |     |
|    |         |   | 61  |
|    | 4.3.5   | Extracellular protein expression after growth in iron-replete and   |     |
|    |         | iron-restricted BHIB1   | 61  |
|    |         |   |     |
| 4. | 4 Disc  | ussion1   | 65  |
| 5  | FINAL   | DISCUSSION 1  | 75  |
| J. |         |   | / 5 |
| 6. | REFER   | ENCES   | 81  |
|    |         |   |     |
| 7. | APPEN   | IDICES 2  | 12  |
| 7. | 1 Grov  | wth media composition2  | 12  |
| 7. | 2 Plası | mid DNA2  | 13  |
| 7. | 3 Mem   | Sys screen (Molecular Dimensions, UK)2                              | .14 |
| 7. | 4 Mem   | nGold screen (Molecular Dimensions, UK)2                            | 15  |

# **List of Tables**

| Table 1.1. | Biochemical characteristics of <i>M. haemolytica</i> and <i>M.glucosida</i> 4   |
|------------|---|
| Table 1.2. | Capsule structure of serotypes A1, A2, and A7 of M. haemolytica. 39   |
| Table 2.1. | Properties of bovine and ovine <i>M. haemolytica</i> isolates   |
| Table 3.1. | Properties of seven representative <i>M. haemolytica</i> isolates and one <i>M. glucosida</i> (PH344) isolate91   |
| Table 3.2. | Functional classifications of 93 confidently predicted OMPs encoded by three <i>M. haemolytica</i> genomes96  |
| Table 3.3. | Distribution of five confidently predicted OMPs present in only one or two <i>M. haemolytica</i> genomes101   |
| Table 3.4. | Confidently predicted OMPs with amino acid sequence identity<br>below 98% between the bovine serotype A2 and ovine serotype A2<br>genomes and/or between the bovine serotype A1 and A2<br>genomes                                     |
| Table 3.5. | Proteins identified in the outer membrane fractions of seven<br>representative isolates of <i>M. haemolytica</i> and one isolate of <i>M. glucosida</i> (PH344) using a combination of gel-based and gel-free<br>proteomic approaches |
| Table 4.1. | Properties of seven representative <i>M. haemolytica</i> isolates and one <i>M. glucosida</i> (PH344) isolate, and the final 2,2'-dipyridyl concentrations used to create iron-restricted growth conditions for each isolate          |

- Table 4.2.Proteins identified in the outer membrane fractions of seven<br/>representative isolates of *M. haemolytica* and one isolate of *M. glucosida* (PH344) after mid-log phase growth in iron-restricted<br/>BHIB using a combination of gel-based and gel-free proteomic<br/>approaches.140
- Table 4.4.Names and putative functions of OMPs that were identified under<br/>different growth conditions that were not identified after growth in<br/>iron-replete BHIB.163

# List of Figures

| Figure 1.1.  | Phylogenetic tree of members of the <i>Pasteurellaceae</i> produced                                    |
|--------------|--|
|              | sequences used are shown in parentheses  |
| Figure 1.2.  | Schematic diagram of the Gram-negative cell envelope   |
| Figure 1.3.  | The crystal structure of the <i>E. coli</i> OmpF porin homotrimer9                                     |
| Figure 1.4.  | Schematic diagram of TonB-dependent receptor transport 11  |
| Figure 1.5.  | Schematic diagram of the type 1 secretion pathway, including the crystal structure of the TolC protein |
| Figure 1.6.  | Schematic diagram of the different groups of type V<br>(autotransporter) secretion systems             |
| Figure 1.7.  | Schematic diagram of integral OMP biogenesis by the BAM complex in <i>E. coli</i>                      |
| Figure 1.8.  | Schematic diagram of outer membrane lipoprotein biogenesis by the Lol machinery in <i>E. coli</i>      |
| Figure 1.9.  | Synthesis and export of CPS export in <i>E</i> . coli, showing the crystal structure of Wza octomer    |
| Figure 1.10  | Transport of LPS from the inner membrane to the outer membrane via MsbA and the Lpt transport system   |
| Figure 1.11. | Schematic diagram of the <i>H. influenzae</i> HxuCBA haem-haemopexin uptake system                     |
| Figure 1.12. | The hypothesised route of <i>M. haemolytica</i> host switching   |

| Figure 1.13. | Ionisation and peptide sample introduction processes: (A) matrix- | -  |
|--------------|---|----|
|              | assisted laser desorption/ionisation (MALDI) and (B) electrospray |    |
|              | ionisation (ESI)  | 50 |

| Figure 1.14. | Examples of mass spectrometers used in proteome research: (A)     |      |
|--------------|---|------|
|              | reflector time-of-flight (TOF), (B) time-of flight/time-of-flight |      |
|              | (TOF-TOF), (C) triple quadrupole, (D) quadrupole time-of-flight   |      |
|              | (QqTOF)   | . 52 |

- Figure 2.3. Western-blot analysis of anti-rOmpA antibody binding to full-length OmpA and rOmpA of *M. haemolytica* isolates PH2 and PH278.....74
- Figure 2.4. Immunogold labelling of the OmpA protein of *M. haemolytica* isolates PH2 and PH278 using anti-rOmpA antibodies......75

- Figure 3.7. Distribution of 55 OMPs identified by proteomic analyses based on gel-based and/or gel-free approaches and bioinformatic prediction of a B-barrel and/or outer membrane (OM) lipoprotein......116

- Figure 4.5. Colony phenotypes of seven *M. haemolytica* isolates and one *M. glucosida* isolate after growth on BHIA<sub>CR</sub> for 18, 24, 48 and 72 h. 159
- Figure 4.7. Distribution of 66 OMPs identified by proteomic approaches after growth in iron-replete BHIB (grey shaded), iron-restricted BHIB, tissue culture media only and/or media containing serum. ......162

# List of Accompanying Material

This thesis is accompanied with a DVD containing all Supplementary Figures and Supplementary Tables.

# Dedication

This four year study is dedicated to my parents, Sandy and David Hounsome.

# **Acknowledgements**

First and foremost, I would like to express my deepest gratitude and most sincere thanks my supervisors Dr. Robert Davies and Dr. Richard Burchmore for their excellent supervision, support, encouragement and guidance over the last four years. I would also like to acknowledge my assessors Dr. Dan Walker and Dr. Roger Parton for their guidance and helpful advice during the course of my work.

I would like to thank Miss Susan Baillie, Dr. Mojtaba Noofeli, Dr. Alan Riboldi-Tunnicliffe, Dr. Sharon Kelly and Prof. Neil Isaacs for their contribution to the study of the OmpA protein. In particular, I would like to thank Dr. Mojtaba Noofeli for completing the immunogold labelling work and Miss Susan Baillie for completing the immunofluorescent staining work. I would also like to thank Susan for her incredible positivity, enthusiasm and support, not to mention her friendship.

I would like to thank Mr. Teerasak E-komon, Miss Chonchanok Teethakaew, Miss Sarah Othman, Miss Isabel Vincent, Mr. Liam O'Shea and all members of the GBRC for there friendship and comradery over the last four years.

I must sincerely thank my family whose support, love and encouragement made this task possible. I would also like to thank Miss Tracy Hutcheon, with whom I shared two years of my life in Glasgow.

Finally, I thank the BBSRC and Pfizer for funding my research and allowing me to carry out this research.

# **Presentations/Publications**

1. Hounsome, J. D. A., Baillie, S., Noofeli, M., Riboldi-Tunnicliffe, A., Burchmore, R. J. S., Isaacs, N. W. & Davies, R. L. (2011). Outer membrane protein A (OmpA) of bovine and ovine isolates of *Mannheimia haemolytica* is surface-exposed and contains host-species specific epitopes. *Infection and Immunity* **79**, 4332-4341.

2. Hounsome, J. D. A., Burchmore, R. J. S. & Davies, R. L. Comparative analyses of the outer membrane subproteomes of bovine and ovine *Mannheimia haemolytica* isolates grown under iron-replete and iron-restricted conditions. Poster presentation at the 8th International *Pasteurellaceae* Conference, 24th-27th August 2011, Helsingør, Denmark.

3. Hounsome, J. D. A., Baillie, S., Riboldi-Tunnicliffe, A., Isaacs, N. W., Burchmore, R. J. S. & Davies, R. L. Purification and crystallisation of outer membrane protein A (OmpA) of *Mannheimia haemolytica*. Poster presentation at the 7th International *Pasteurellaceae* Conference, 12th-15th October 2008, Sorrento, Italy.

4. Hounsome, J. D. A., Burchmore, R. J. S. & Davies, R. L. Comparative proteomic analysis of the outer membrane of *Mannheimia haemolytica* isolates from cattle and sheep Poster presentation at the 7th International *Pasteurellaceae* Conference, 12th-15th October 2008, Sorrento, Italy.

# **Declaration**

I hereby declare that the work presented in this thesis is my own, except where otherwise cited or acknowledged. No part of this thesis has been presented for any other degree. The research for this thesis was performed between September 2007 and September 2011.

Jonathan David Arthur Hounsome

# Abbreviations

| 1-D               | One-dimensional                                |
|-------------------|--|
| 2-DE              | Two-dimensional electrophoresis                |
| А                 | Adenine  |
| ABC               | ATP-binding cassette                           |
| ACN               | Acetonitrile                                   |
| АТР               | Adenosine triphosphate                         |
| BAM               | B-barrel assembly machinery                    |
| BHI               | Brain heart infusion                           |
| BHIA              | Brain heart infusion agar                      |
| BHIB              | Brain heart infusion broth                     |
| BSA               | Bovine serum albumin                           |
| °C                | Degrees Celsius                                |
| С                 | Cytosine                                       |
| cfu               | Colony forming unit(s)                         |
| CID               | Collision-induced dissociation                 |
| CO <sub>2</sub>   | Carbon dioxide                                 |
| CPS               | Capsular polysaccharide                        |
| Da                | Dalton(s)                                      |
| dH <sub>2</sub> O | Distilled water                                |
| DMEM              | Dulbecco's modified eagle medium               |
| DNA               | Deoxyribonucleic acid                          |
| DTT               | Dithiothreitol                                 |
| EDTA              | Ethylenediaminetetraacetic acid                |
| emPAI             | Exponentially modified protein abundance index |
| ESI               | Electrospray ionisation                        |
| ET                | Electrophoretic type                           |

| et al. | et alios (and others)                                 |
|--------|---|
| FCS    | Foetal calf serum                                     |
| FT     | Fourier transform                                     |
| × g    | A unit of force equal to the force exerted by gravity |
| g      | Gram(s)   |
| G      | Guanine   |
| GRAVY  | Grand average of hydropathicity                       |
| h      | Hour(s)   |
| HCl    | Hydrochloric acid                                     |
| HEPES  | 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid    |
| HGT    | Horizontal gene transfer                              |
| lg     | Immunoglubulin  |
| IM     | Inner membrane  |
| IPTG   | Isopropyl-B-D-thiogalactopyranoside                   |
| К      | Kelvin  |
| kDa    | Kilodalton(s)   |
| kV     | Kilovolt(s)   |
| LB     | Luria-bertani   |
| LC     | Liquid chromatography                                 |
| LDAO   | N,N-Dimethyldodecylamine N-oxide                      |
| Lol    | Lipoprotein localisation machinery                    |
| LOS    | Lipooligosaccharide                                   |
| LPS    | Lipopolysaccharide                                    |
| Μ      | Molar   |
| m/z    | Mass-to-charge  |
| M199   | Medium 199  |
| MALDI  | Matrix assisted laser desorption ionisation           |
| MFP    | Membrane fusion protein                               |

| μ                  | Microgram                                     |
|--------------------|---|
| mg                 | Milligram                                     |
| MgSO <sub>4</sub>  | Magnesium sulphate                            |
| μι                 | Microlitre(s)                                 |
| min                | Minute(s)                                     |
| ml                 | Millilitre(s)                                 |
| mm                 | Millimetre(s)                                 |
| MLEE               | Multilocus enzyme electrophoresis             |
| mM                 | Millimolar                                    |
| MOWSE              | Molecular weight search                       |
| MS                 | Mass spectrometry                             |
| NaCl               | Sodium chloride                               |
| NCBI               | National Centre for Biotechnology Information |
| nm                 | Nanometre(s)                                  |
| NCS                | Newborn calf serum                            |
| NPG                | nitrophenyl-B-D-galactopyraniside             |
| OD <sub>X nm</sub> | Optical density at wavelength X nm            |
| OM                 | Outer membrane                                |
| OMP                | Outer membrane protein                        |
| PBP                | Periplasmic binding protein                   |
| PBS                | Phosphate buffered saline                     |
| PCR                | Polymerase chain reaction                     |
| PDB                | Protein Data Bank                             |
| рН                 | A measure of the acidity of a solution        |
| pmol               | Picomole(s)                                   |
| POTRA              | Polypeptide transport-associated              |
| Q/g                | Quadrupole                                    |
| r                  | Recombinant                                   |

| RNA      | Ribonucleic acid   |
|----------|--|
| rpm      | Revolutions per minute                                     |
| RPMI     | Roswell Park Memorial Institute                            |
| rRNA     | Ribosomal RNA  |
| RTX      | Repeats-in-toxin   |
| S        | Second(s)  |
| SDS      | Sodium dodecyl sulphate                                    |
| SDS-PAGE | Sodium dodecyl sulphate-polyacrylamide gel electrophoresis |
| SS       | Sheep serum  |
| т        | Thymidine  |
| ТСА      | Trichloroacetic acid                                       |
| TFA      | Trifluoroacetic acid                                       |
| TOF      | Time-of-flight   |
| TPS      | Two-partner secretion                                      |
| Tris     | 2-amino-2-(hydroxymethyl)1,3-propandiol                    |
| TTBS     | 0.05% Tween 20 in TBS                                      |
| UV       | Ultraviolet  |
| V        | Volt(s)  |
| v/v      | Volume per volume  |
| VIS      | Visible  |
| w/v      | Weight per volume  |

# 1. INTRODUCTION

# 1.1 The organisms

## 1.1.1 History and taxonomy of *M. haemolytica* and *M. glucosida*

The causative agent of a disease which caused pneumonic pasteurellosis in calves was originally described as *Bacterium bipolare multocidum* in 1885 (Kitt, 1885). It was later renamed *Bacillus boviseptica* in 1896, and then further subdivided into separate groups that cause either bovine fibrinous pneumonia (Pasteurella boviseptica) or haemorrhagic septicaemia (now Pasteurella multocida) (Jones, 1921). Newsom & Cross studied this group in detail and suggested the name *Pasteurella haemolytica* for the bacterium that causes pneumonia in calves (Newsome and Cross, 1932). This species was subdivided into biotypes A and T, according to their ability to ferment L-arabinose and trehalose, respectively (Smith, 1961, Smith, 1959). Capsular serotyping of P. haemolytica has established seventeen different serotypes to date (Biberstein et al., 1960, Biberstein and Gills, 1962, Angen et al., 1999a). P. haemolytica was later removed from the genus Pasteurella based on DNA-DNA hybridization (Mutters et al., 1985). The trehalose fermenters were also later reclassified as a separate species, Pasteurella trehalosi (now Bibersteinia trehalosi), based on evidence from numerical taxonomic analyses and DNA-DNA hybridization (Sneath and Stevens, 1990, Biberstein and Francis, 1968). Twelve of the biotype A organisms (serotypes 1, 2, 5-9, 12-14, 16 and 17) have been reclassified as Mannheimia haemolytica and the A11 serotype has been renamed as a separate species, Mannheimia glucosida (Angen et al., 1999a).

*M. haemolytica* is no longer a *Pasteurella sensu stricto*, but now occupies a place in the *Mannheimia* genus on a branch of a phylogenetic tree within the gamma subdivision of the Proteobacteria, whose closest relatives are *B. trehalosi*, *Actinobacillus capsulatus*, and *Haemophilus parainfluenzae* (Highlander, 2001) (Fig. 1.1).

Figure 1.1. Phylogenetic tree of members of the *Pasteurellaceae* produced from 16S rRNA sequences. GenBank Accession numbers for the sequences used are shown in parentheses.

Phylogenetic tree adapted from Highlander *et al.* (2001).





# 1.1.2 Morphological and biochemical characteristics of *M. haemolytica* and *M. glucosida*

## 1.1.2.1 Cell morphology

*M. haemolytica* and *M. glucosida* are small, non-motile, encapsulated Gramnegative coccobacillus exhibiting slight pleomorphism and occasional bipolar staining (Adlam, 1989). Fimbriae have been described on the surface of serotype A1 *M. haemolytica* isolates grown in culture (Potter *et al.*, 1988, Morck *et al.*, 1987) and isolated from infected cattle (Morck *et al.*, 1989), but have not been identified on other *M. haemolytica* serotypes or on *M. glucosida*.

## 1.1.2.2 Cultural morphology

Colonies of *M. haemolytica* and *M. glucosida* are smooth and greyish in colour and are 1-2 mm in diameter after 24 h growth on blood agar (Angen *et al.*, 1999a). Most strains of *M. haemolytica* and all strains of *M. glucosida* are haemolytic on bovine blood agar (Angen *et al.*, 1999a).

## 1.1.2.3 Biochemical characteristics

The biochemical characteristics of *M. haemolytica* and *M. glucosida* have been previously described (Angen *et al.*, 1999a, Mutters *et al.*, 1989) and are summarised in Table 1.1. The two species have common characteristics for haemolysis and the fermentation of trehalose, D-sorbitol, D-xylose, maltose, dextrin, indole and D-melibiose, but can be differentiated by the NPG test.

# 1.2 The diseases

## **1.2.1** Pneumonic pasteurellosis in cattle (shipping fever)

*M. haemolytica* is the principal etiological agent of bovine pneumonic pasteurellosis, a disease which is often referred to as shipping fever (also transit fever, bovine respiratory disease, dust pneumonia, bronchial pneumonia, fibrinous pleuropneumonia and bovine epizootic pneumonia). Various combinations of environmental stresses can contribute to the pathogenesis of the disease, including shipment, weaning, overcrowding and inclement weather (Singh *et al.*, 2011). Several viruses that are ubiquitous in the cattle population are also associated with the disease, including bovine parainfluenzae virus 3,

| Table 1 1 | Biochemical characteristics of M haemolytica and M alucosida                   |
|-----------|--|
|           | Biochemical characteristics of <i>M. naemolytica</i> and <i>M. giucosida</i> . |

| Property                | M. haemolytica <sup>a</sup> | M. glucosida <sup>a</sup> |
|-------------------------|-----------------------------|---------------------------|
| Haemolysis              | +                           | +                         |
| Orthinine decarboxylase | -                           | +/                        |
| Trehalose               | _                           | _                         |
| L-Arabinose             | _                           | +/                        |
| D-Sorbitol              | +                           | +                         |
| D-Xylose                | +                           | +                         |
| Maltose                 | +                           | +                         |
| Dextrin                 | +                           | +                         |
| Glucosides              | _                           | +/                        |
| Gentiobiose             | _                           | +/                        |
| NPG (β-glucosidase)     | _                           | +                         |
| Meso-Inositol           | +/                          | +                         |
| ONPF (α-fucosidase)     | +                           | +/                        |
| ONPX (β-xylosidase)     | +/                          | +/                        |
| ONPG (β-galactosidase)  | +/                          | +                         |
| Indole                  | _                           | _                         |
| D-Melibiose             | _                           | _                         |

<sup>a</sup>See references Angen *et al.* (1999a) and Mutters *et al.*, 1989. '+' = positive; '-' = negative; '+/-' = positive or negative

bovine respiratory syncytial virus, bovine herpesvirus 1, bovine viral diarrhoeae virus, Mycoplasma species, and other bacteria (Singh et al., 2011). The processes by which environmental stresses or viral infections, either alone or in combination with each other, predispose cattle to shipping fever are not fully understood. In healthy cattle, *M. haemolytica* are carried in the nasopharynx and tonsils in low number and are not readily detected by nasal swab cultures (Frank, 1989). Under the context of immune suppression, caused by environmental stress or viral infection, specific serotypes of M. haemolytica rapidly multiply in the upper respiratory tract. Serotype A1 isolates are most commonly associated with cases of bovine disease (although serotype A6 isolates are responsible for an increasing proportion of disease cases), whereas serotype A2 isolates are frequently recovered from asymptomatic animals. The larger bacterial numbers result in aerosolised droplets containing bacteria accessing the trachea and lungs and causing pneumonia. Death can occur in as little as 2 to 3 days, or the infection can proliferate and cause chronic lung damage. The early clinical symptoms of the disease are fever, cough, depression, anorexia, dyspnoea, and nasal and eye discharge (Frank, 1989).

#### **1.2.2** Pneumonic pasteurellosis in sheep

Pasteurellosis is one of the most common infectious bacterial diseases of sheep (Gilmour and Gilmour, 1989). *M. haemolytica* is responsible for causing pneumonia in all ages of sheep and septicaemia in young lambs (Gilmour and Gilmour, 1989). All *M. haemolytica* serotypes are recovered from sheep. In ovine pneumonic pasteurellosis disease cases, serotype A2 is most frequently recovered, followed by serotypes A7 and A9, whereas serotype A1 isolates are frequently recovered from asymptomatic animals. Similar to bovine disease cases, predisposing factors to ovine pneumonic pasteurellosis include environmental stresses and viral infection. *M. glucosida* is an opportunistic pathogen of sheep that is not normally associated with disease conditions and probably represents part of the resident microflora in the upper respiratory tract (Biberstein and Gills, 1962, Angen *et al.*, 1999a).

# 1.3 The Gram-negative cell envelope

The cell envelope of Gram-negative bacteria is comprised of two membranes, the inner membrane and the outer membrane, separated by the periplasm. The inner membrane is at the boundary between the cytoplasm and the periplasm, whereas the outer membrane is at the boundary between the periplasm from the external environment. Although these two membranes are both lipid bilayers which contain proteins, their structure and composition are dramatically different as a result of their different functions and the dissimilar environments that they contact (Ruiz *et al.*, 2006) (Fig 1.2).

## 1.3.1 Inner membrane

The inner membrane is composed of a symmetrical phospholipid bilayer interspersed with proteins. Although inner membrane phospholipid content varies between different species of bacteria, in *E. coli* 70-80% is phosphatidylethanolamine, 15-20% is phosphatidylglycerol and 5% or less is cardiolipin (Kanemasa *et al.*, 1967, Yamagami *et al.*, 1970). These proteins can be of two types, integral proteins and lipoproteins. Integral inner membrane proteins span the inner membrane with  $\alpha$ -helical transmembrane domains, whereas inner membrane lipoproteins are anchored to the periplasmic side of the membrane by lipid modifications at the N-terminus of the prolipoprotein. Inner membrane proteins are involved in important cellular processes including energy production and conservation in the respiratory chain, signal transduction, cell division and transport across the membrane.

## 1.3.2 Periplasm

The periplasm is a highly viscous compartment that contains soluble proteins and a thin peptidoglycan layer. Proteins in this compartment are involved in processes such as protein folding, transport and degradation, outer membrane biogenesis, and sensing and responding to environmental stimuli. It is an oxidising environment and contains enzymes which catalyse disulphide bond formation, a crucial process for the folding and stability of proteins secreted through the cell envelope (Nakamoto and Bardwell, 2004). The peptidoglycan layer serves as an extracytoplasmic cytoskeleton that contributes to the rigidity of the cell envelope, maintains cell shape and prevents cell lysis.

### Figure 1.2. Schematic diagram of the Gram-negative cell envelope.

The cell envelope of Gram-negative bacteria is comprised of an inner membrane (IM), the periplasm and the outer membrane (OM). The inner membrane is a symmetrical phospholipid bilayer containing integral membrane proteins that have  $\alpha$ -helical transmembrane domains. The peptidoglycan separates the inner and outer membrane and contains a thin layer of peptidoglycan. The outer membrane is an asymmetrical lipid bilayer containing phospholipids on the inner leaflet and LPS on the outer leaflet. The outer membrane also contains integral proteins that mainly adopt B-barrel conformations. Both membranes contain lipoproteins that anchored to the periplasmic side. The outer membrane also contains lipoproteins which are exposed on the outer leaflet. Figure adapted from Ruiz *et al.* (2006).



7

## 1.3.3 Outer membrane

In contrast to the inner membrane, the outer membrane is asymmetric, with the inner leaflet composed of phospholipids and the outer leaflet composed mainly of LPS. The phospholipid composition is slightly different to that of the inner membrane, as the outer membrane is enriched with saturated fatty acids and phosphatidylethanolamine (Lugtenberg and Peters, 1976, White et al., 1972). The LPS functions as an effective permeability barrier due to its low fluidity and strong lateral interactions between molecules (Nikaido, 2003). Like the inner membrane, the outer membrane also contains both integral OMPs and lipoproteins; however, in contrast to the  $\alpha$ -helical integral proteins of the inner membrane, integral OMPs span the outer membrane predominantly with amphipathic antiparallel B-strands which adopt a B-barrel conformation that allows many OMPs to serve as channels (Koebnik et al., 2000, Schulz, 2002). Similar B-barrel proteins are also found in the membranes of chloroplasts (Schleiff *et al.*, 2003) and mitochondria (Casadio *et al.*, 2002). Outer membrane lipoproteins can be anchored to either the periplasmic or extracellular face of the outer membrane (Tokuda and Matsuyama, 2004). About 50% of the outer membrane mass consists of integral OMPs and lipoproteins (Koebnik et al., 2000).

## 1.3.3.1 Getting things in: OMPs involved in nutrient uptake

The outer membrane of Gram-negative bacteria is a very effective permeability barrier that also poses a challenge with respect to nutrient uptake. For this reason, Gram-negative bacteria possess a range of OMPs for either passive or active uptake of essential nutrients from the extracellular milieu.

## 1.3.3.1.1 General porins

The general porins form aqueous channels that allow diffusion of small hydrophilic molecules (< 600 Da) into the cell and show no particular substrate specificity (with the exception of preferences for cations or anions) (Nikaido, 2003). They are generally between 30 and 50 kDa in size (Nikaido, 2003). The first porin crystal structures were of the *Rhodobacter capsulatus* porin (Weiss *et al.*, 1991) and the *E. coli* general porins PhoE and OmpF (Cowan *et al.*, 1992) (Fig. 1.3). These revealed that the porins were present as homotrimers in the

# Figure 1.3. The crystal structure of the *E. coli* OmpF porin homotrimer.

Extracellular loops 2 (L2) and 3 (L3) are indicated for each subunit monomer. OmpF structure was adapted from Cowan *et al.* (1992); PDB reference 10PF.



outer membrane and that each monomer was a B-barrel containing 16 antiparallel B-strands. The size of the eyelet region of OmpF was measured at 0.7 by 1.1 nm (Cowan *et al.*, 1992). In porins, the third extracellular loop (L3) folds back into the barrel, forming a constriction zone and contributing significantly to the permeability properties of the pore (i.e. exclusion limit and ion selectivity). The second extreacellular loop (L2) bends over the wall of the neighbouring barrel subunit, playing a significant role in trimer stabilisation (Nikaido, 2003). Porins are able to transition between open or closed states depending on the transmembrane potential across the outer membrane (Koebnik *et al.*, 2000).

#### 1.3.3.1.2 Substrate-specific porins

Besides the general diffusion porins described above, the outer membrane also contains porins that are substrate-specific. The best-studied example is the *E*. *coli* maltoporin LamB, a specific transporter of maltooligosaccharides of various sizes. Like the general porins, LamB is present as a homotrimer in the outer membrane and each monomer is a 47 kDa  $\beta$ -barrel containing 18 antiparallel  $\beta$ -strands (Schirmer *et al.*, 1995). The L1, L3 and L6 loops fold back inside the barrel, forming a channel (0.5 to 0.6 nm in diameter) that is more constricted than the general porins (Schirmer *et al.*, 1995). The length of the channel interior contains a row of aromatic amino acid residues (greasy slide) that are lined up by polar residues (polar track), creating a maltooligosaccharide-specific translocation pathway that facilitates passage through the channel (Dutzler *et al.*, 1996). Similar structural characteristics are also seen in the *Salmonella typhimurium* sucrose-specific porin ScrY (Forst *et al.*, 1998).

#### 1.3.3.1.3 TonB-dependent receptors

TonB-dependent receptors bind and actively transport specific substrates across the outer membrane which are either poorly permeable through porins (> 600 Da) or are present at very low concentrations and require energised transport for their translocation. These substrates include host iron-binding proteins, siderophores, haemophores, vitamin B12, nickel chelates and carbohydrates (Schauer *et al.*, 2008). TonB-dependent receptors contain a C-terminal integral membrane B-barrel comprised of 22 antiparallel B-strands (Ferguson et al., 1998, Locher et al., 1998, Buchanan et al., 1999) (Fig. 1.4) that form a pore

#### Figure 1.4. Schematic diagram of TonB-dependent receptor transport.

A substrate binds to the TonB-dependent receptor with high-affinity and is transported across the outer membrane. In the periplasm, the substrate binds to a periplasmic-binding protein (PBP) that transports it across the periplasm to the inner membrane. The substrate is then transported across the inner membrane into the cytoplasm by an ATP-binding cassette (ABC) transporter. TonBdependent receptor structure was adapted from Ferguson *et al.* (1998); PDB reference 2FCP.



which is larger (3.5 by 4.7 nm) than that of the porins. The N-terminus forms a plug domain which occludes the pore and prohibits the passage of substrates. Substrate binding occurs at sites on the extracellular side of the plug domain and on the walls and extracellular loops of the B-barrel. Transport of the bound substrate through the B-barrel is an energy-dependent process; however, the outer membrane is not capable of producing energy due to the absence of either ATP-hydrolysing enzymes or a proton gradient. The required energy is obtained from the proton motive force of the inner membrane and transduced to the outer membrane via three inner membrane proteins: TonB, ExbB and ExbD. TonB is anchored to the inner membrane by the ExbB-ExbD transmembrane complex and interacts with an eight amino acid sequence in the receptor plug domain called the 'TonB box'. The exact mechanism of energy transduction is not understood. However, it is thought that upon substrate binding and subsequent energy transduction conformational changes in TonB result in a conformational change in the plug domain that allows transport of the substrate through the receptor. Once in the periplasm, the substrate is transported to the inner membrane by a periplasmic binding protein. At the inner membrane, the substrate is transported into the cytoplasm by an ATP-binding cassette (ABC) protein.

#### 1.3.3.2 Getting things out: OMPs involved in secretion

Gram-negative bacteria possess a wide array of secretion systems for exporting proteins and other substances out through the cell envelope. A range of different OMPs are utilised in these systems which act in conjunction with other proteins in the inner membrane and periplasm.

#### 1.3.3.2.1 Type I secretion (TolC export channel)

Type I secretion systems consist of three proteins: a pore-forming OMP (TolC) and two inner membrane proteins, a membrane fusion protein (MFP) and an ABC transporter protein (Fig. 1.5). The ABC transporter recognises a specific secretion signal motif at the C-terminal end of the protein which is to be secreted. Subsequent binding of the MFP protein to TolC allows secretion of the protein into the extracellular milieu. Hence, secretion occurs across the inner and outer membrane in one continuous step, without the formation of periplasmic intermediates. TolC is an outer membrane channel comprised of
Figure 1.5. Schematic diagram of the type 1 secretion pathway, including the crystal structure of the ToIC protein.

TolC structure adapted from Koronakis *et al.* (2000); PDB reference 1EK9.



three TolC monomers that each contribute four B-strands to the formation of a B-barrel containing 12 antiparallel B-strands (Koronakis *et al.*, 2000). The channel also possesses an  $\alpha$ -helical barrel that extends from the integral outer membrane B-barrel into the periplasm (Koronakis *et al.*, 2000). Efflux of antibacterial drugs and other small inhibitory molecules may also occur via an interaction between TolC, an MFP, and an inner membrane translocase which can be either an ABC protein, or a proton antiporter of either the resistance nodulation division or major facilitator superfamily classes (Koronakis *et al.*, 2004).

The *E. coli* alpha-haemolysin (HlyA) was the first RTX toxin described to be secreted via a type I secretion system (Gentschev *et al.*, 2002); however, another well characterised example is the secretion pathway of *M. haemolytica* LktA (described in 1.4.1.1).

#### 1.3.3.2.2 Type II and type III secretion (secretin channels)

Outer membrane proteins of the secretin family are present in type II (Brok *et al.*, 1999, Chami *et al.*, 2005) and type III (Marlovits *et al.*, 2004, Burghout *et al.*, 2004, Hodgkinson *et al.*, 2009) secretion systems. They are also present in type IV pilus biogenesis systems (Martin *et al.*, 1993, Collins *et al.*, 2001) and filamentous phage secretion systems (Opalka *et al.*, 2003). Secretins typically form highly stable oligomers of 12-14 subunits in the outer membrane.

In type II secretion, secreted proteins are first translocated across the inner membrane by either the Sec (Pugsley *et al.*, 1991) or Tat (Voulhoux *et al.*, 2001) translocons. They are subsequently transported out of the cell by a complex of 12-15 proteins which span the cell envelope (Pugsley, 1993, Sandkvist, 2001). The prototypical type II outer membrane secretin is the PulD protein of *Klebsiella oxytoca* which is required for the secretion of pullulanase (Chami *et al.*, 2005).

Type III secretion systems are used by many pathogenic bacteria to directly inject effector proteins into eukaryotic cells and are hence often referred to as 'injectisomes'. At least 20 different proteins are utilised in this system (Worrall *et al.*, 2011) of which several are genetically and structurally related to the bacterial flagellum (Blocker *et al.*, 2003). Proteins enter the injectisome directly

from the cytoplasm in a process that is Sec- and Tat- independent. The prototypical type III outer membrane secretin is the YscC protein of pathogenic *Yersinia* species (Burghout *et al.*, 2004). A putative type III secretion system has been identified in the sequenced bovine and ovine serotype A2 *M. haemolytica* genomes, but not the bovine serotype A1 *M. haemolytica* genome, that shows low to moderate homology to type III secretion components of E. coli O157 (Lawrence *et al.*, 2010b). Unlike typical type III secretion systems, the M. haemolytica genes encoding this putative system are not arranged in an operon or separate plasmid. The presence of this system may represent a new method of bacterial effector protein delivery into host cells for *M. haemolytica*.

#### 1.3.3.2.3 Type IV secretion (double membrane spanning channel)

The type IV secretion system is used by a variety of Gram-negative bacteria (and Gram-positive bacteria) to mediate the transfer of effector proteins into host cells or for the conjugation of plasmid DNA and transposons into other cells (Christie *et al.*, 2005). In *Agrobacterium tumefaciens*, the core complex of the type IV secretion system is composed of three proteins, VirB7, VirB9 and VirB10, that are each present in 14 copies and form a 1.1-megadalton two chambered structure that spans both the inner and outer membrane (Chandran *et al.*, 2009, Fronzes *et al.*, 2009). The outer membrane chamber is the largest secretion channel to be found associated with the outer membrane to date (Chandran *et al.*, 2009). It also contains a hydrophobic double  $\alpha$ -helical transmembrane domain that is the only other example, alongside Wza, of  $\alpha$ -helical insertions in the outer membrane (Chandran *et al.*, 2009).

#### 1.3.3.2.4 Type V secretion (autotransporter pathway)

Gram-negative bacteria possess a range of OMPs that contain the apparatus for the transport of their secreted domains across the outer membrane and are hence names autotransporters. These proteins are members of the type V secretion pathway and can be grouped into three distinct groups (Fig. 1.6) which reflect similarities in their primary structures and modes of biogenesis: classical autotransporters (type  $V_a$  secretion), two-partner secretion systems (type  $V_b$ 

# Figure 1.6. Schematic diagram of the different groups of type V (autotransporter) secretion systems.



Figure was adapted from Henderson et al. (2004).

secretion), and trimeric autotransporters (type  $V_c$  secretion) (Henderson *et al.*, 2004).

**Classical autotransporters (type V**<sub>a</sub>). The primary structure of classical autotransporters contains three distinct domains: the N-terminal signal sequence, the passenger domain and the C-terminal translocation unit (Henderson *et al.*, 2004). The signal sequence targets the protein to the inner membrane for Sec-dependent translocation into the periplasm. The passenger domain contains the effector function of the protein. The translocation unit consists of a short  $\alpha$ -helical linker region and a B-core that forms a B-barrel with 12 antiparallel B-strands after insertion into the outer membrane (Oomen et al., 2004, Barnard et al., 2007, van den Berg, 2010, Zhai et al., 2011), which facilitates translocation of the passenger domain from the periplasm to the bacterial surface. Once exposed on the bacterial surface, the passenger domain can either remain intact as a large protein extending into the extracellular milieu or it can be proteolytically cleaved. Cleavage results in the passenger domain being either released into the extracellular milieu or remaining noncovalently associated with the B-barrel domain. Proteolytic cleavage can occur by either autoproteolysis or by another membrane-bound protease. Examples of *M. haemolytica* proteins with homology to classical autotransporters are Ssa, NanH and Iga1-like proteases (described in 1.4.3.4, 1.4.3.5 and 1.4.3.6, respectively)

**Two-partner secretion (type V**<sub>b</sub>**).** Whereas in the autotransporter pathway the secreted protein is translated as a single polypeptide, in the two-partner secretion (TPS) pathway the passenger domain and the pore-forming B-barrel of the secreted protein are translated as two separate proteins, termed TpsA and TpsB proteins, respectively (Henderson *et al.*, 2004). The genes encoding these proteins are generally arranged in a *tpsA-tpsB* operon. The TpsA protein contains an N-terminal signal sequence which targets the protein for Sec-dependent transport into the periplasm. It also contains an N-proximal TPS domain which interacts specifically with the TpsB protein prior to translocation across the outer membrane. The crystal structure of one TpsB protein, FhaC of *Bordetella pertussis*, has been solved and contain 16 B-strands (Clantin *et al.*, 2007). They may also be involved in the processing of the TpsA protein into its active form.

The prototypical TPS system is that of the *B. pertussis* filamentous haemagglutinin protein, FhaB, which is secreted through the pore forming B-barrel FhaC (Locht *et al.*, 1992, Willems *et al.*, 1994). It has been reported that another *B. pertussis* autotransporter, SphB1, is involved in the surface maturation of FhaB (Coutte *et al.*, 2001). Genes encoding proteins that are orthologous to the FhaB and FhaC proteins of *B. pertussis* are present in *M. haemolytica* genomes (Gioia *et al.*, 2006, Lawrence *et al.*, 2010a) (described in 1.4.1.3).

**Trimeric autotransporters (type V**<sub>c</sub>). Trimeric autotransporters contains six distinct domains: (i) an N-terminal signal sequence, (ii) head, (iii) neck, (iv) stalk, (v) linker region, and (vi) a C-terminal region consisting of four B-strands (Hoiczyk *et al.*, 2000, Henderson *et al.*, 2004). The head, neck and stalk comprise the passenger domain and the linker and C-terminal region comprise the translocator domain. Trimerisation of C-terminal subunits creates a B-barrel with 12 B-strands that confers an overall lollipop-like structure to the protein displayed on the cell surface (Hoiczyk *et al.*, 2000). The prototypical trimeric autotransporter is the YadA protein of *Yersinia pestis* (Nummelin *et al.*, 2004). Several trimeric autotransporters have been described in *M. haemolytica* (described in 1.4.3.7).

#### 1.3.3.3 OMPs involved in outer membrane biogenesis and maintenance

In addition to controlling the passage of substances into and out of the cell, several OMPs are also involved in the biogenesis and maintenance of the outer membrane.

#### 1.3.3.3.1 The BAM complex (integral OMP assembly)

Nascent integral OMPs are synthesised in the cytoplasm and possess an Nterminal extension, the signal peptide, which is required to deliver the preproteins to the Sec translocon located in the inner membrane. Translocation of the nascent OMP across the Sec apparatus is dependent on the proton motive force (Driessen and Nouwen, 2008). Upon entering the periplasm, the signal peptide is removed by a signal peptidase enzyme and the nascent OMP associates with one or more periplasmic chaperones (Ruiz *et al.*, 2006). In *E. coli*, the periplasmic chaperones DegP, SurA and Skp mainly facilitate delivery to the outer membrane (Knowles et al., 2009). It has been proposed that SurA is primarily responsible for the assembly of most nascent OMPs, whereas Skp And DegP rescue those that have missed the normal assembly route (Sklar et al., 2007). Unlike the actively driven Sec translocon, the outer membrane contains the passive B-barrel assembly machinery (BAM) complex (Fig. 1.7). The BAM complex is required for the correct folding and insertion into the outer membrane of nearly all integral OMPs identified to date. In E. coli, the BAM complex is comprised of five proteins: BamA (formerly known as YaeT, or Omp85/D15 in N. meningitidis), an integral OMP, and four accessory lipoproteins, BamB (YfgL), BamC (NlpB), BamD (YfiO) and BamE (SmpA), which are localised to the inner leaflet of the outer membrane. BamA is universally present in all Gram-negative bacteria and contains two major domains: a set of five POTRA (polypeptide transport-associated) domains which extend into the periplasm and an integral B-barrel inserted into the outer membrane (Sanchez-Pulido et al., 2003). It is thought that the POTRA domains have a role in binding unfolded OMPs (Sanchez-Pulido et al., 2003, Robert et al., 2006). The BamA protein recognises a specific C-terminal motif in unfolded OMPs that is required for efficient assembly into the outer membrane in vivo (Robert et al., 2006, Struyve et al., 1991). The exact functions of the accessory outer membrane lipoproteins are unknown, but they have been demonstrated to have roles in OMP biogenesis as their depletion results in OMP assembly defects (Werner and Misra, 2005, Wu et al., 2005, Doerrler and Raetz, 2005, Malinverni et al., 2006).

#### 1.3.3.3.2 The LolABCDE complex (lipoprotein assembly)

Prelipoproteins are synthesised in the cytoplasm and possess an N-terminal signal peptide containing a consensus lipobox sequence close to the signal peptide cleavage site (Hayashi and Wu, 1990, Inouye *et al.*, 1977). The prelipoprotein is then translocated to the periplasmic face of the inner membrane by the Sec translocon and processed into its mature form. This is achieved by the attachment of a diacylglycerol moiety to the sidechain of a conserved cysteine residue in the lipobox (Sankaran and Wu, 1994). Mature lipoproteins are localised to the periplasmic face of the inner or outer membrane by the lipoprotein localisation (Lol) machinery, which consists of an inner membrane transmembrane protein complex (LolCDE), a periplasmic chaperone (LolA) and an outer membrane lipoprotein receptor (LolB) (Fig 1.8)

## Figure 1.7. Schematic diagram of integral OMP biogenesis by the BAM complex in *E. coli*.

Nascent unfolded OMPs are translocated across the inner membrane by the Sec translocon and delivered to outer membrane BAM complex by either SurA or Skp/DegP chaperones. The BAM complex inserts the protein into the outer membrane and folds it into its  $\beta$ barrel conformation. Figure was adapted from Knowles *et al.* (2009).



### Figure 1.8. Schematic diagram of outer membrane lipoprotein biogenesis by the Lol machinery in *E. coli*.

A lipoprotein destined for the outer membrane binds to LolE and is then subsequently transferred to LolC. The lipoprotein is accepted by LolA in an ATP-dependent manner. The LolA-lipoprotein complex traverses the periplasm and reaches the outer membrane. The lipoprotein is transferred from LolA to LolB and is subsequently inserted into the outer membrane. Figure adapted from Okuda and Tokuda (2009).



(Tokuda, 2009, Okuda and Tokuda, 2009). Lipoproteins which are targeted to the outer membrane are received by the LolCDE complex and subsequently released to LolA. The LolA-lipoprotein complex traverses the periplasm, whereby the lipoprotein is accepted by LolB and incorporated into the outer membrane. The determining factor which is responsible for a lipoprotein being directed to the outer membrane by the Lol apparatus or retained at the inner membrane was initially believed to be the identity of the amino acid adjacent to the conserved N-terminal cysteine residue, known as the +2 rule (Yamaguchi et al., 1988). An aspartate residue at this position acts as a LolCDE avoidance signal, leading to retention of the lipoprotein at the inner membrane. Substitution of this aspartate residue with a different amino acid results in Lol-mediated translocation to the outer membrane. The +2 rule is not universal (Seydel et al., 1999), and amino acid residues at positions +3 and +4 have been demonstrated to be involved in targeting lipoproteins to the outer membrane in other Gramnegative species (Narita and Tokuda, 2007, Silva-Herzog et al., 2008). Lipoproteins are also present on the outer leaflet of the outer membrane in several Gram-negative bacteria, although the mechanism by which they are translocated through the membrane remains unknown (Kovacs-Simon et al., 2011).

#### 1.3.3.3.3 Wza (CPS transport)

The *E. coli*, repeat polysaccharide polymer units are assembled in the cytoplasm by a reaction initiated by WbaP, and are subsequently flipped across the inner membrane by Wzx (Collins and Derrick, 2007). Polymerisation occurs at the periplasm and is dependent on the integral membrane protein Wzy, a putative polymerase (Collins and Derrick, 2007). Polymerisation by Wzy requires the activity of the tetrameric Wzc protein. Wzb is a protein tyrosine phosphate enzyme that enables the cycling phosphorylation of Wzc, a process that is crucial for export (Collins and Derrick, 2007). Wzc interacts with Wza to form a complex that spans the periplasm. Wza is an the outer membrane lipoprotein that forms ring-shaped multimeric complexes (Drummelsmith and Whitfield, 2000). The crystal structure of Wza revealed an octomer containing a unique  $\alpha$ helical transmembrane barrel structure (Dong *et al.*, 2006) (Fig. 1.9), representing a new structural paradigm for OMPs (Collins and Derrick, 2007).

## Figure 1.9. Synthesis and export of CPS export in *E.* coli, showing the crystal structure of Wza octomer.

Figure adapted from Dong *et al.* (2006). See text for details. Wza structure adapted from Dong *et al.* (2006). PDB ref. 2J58.



The capsule biosynthetic locus of serotype A1 *M. haemolytica* has been characterised and comprises twelve genes that are grouped into three regions based on their functions: capsule transport, capsule biosynthesis and phospholipid substitution (Lo *et al.*, 2001).

#### 1.3.3.3.4 LptD and LptE (LPS transport)

Biosynthesis of core-lipid A occurs at the inner leaflet of the inner membrane (Osborn et al., 1972) and is flipped across the inner membrane by the ABC transporter MsbA (Doerrler et al., 2001, Doerrler and Raetz, 2002). O-antigen repeat units are synthesised in the cytoplasm, flipped across to the periplasm, and ligated to core-lipid A to form mature LPS. Transport of mature LPS to the outer membrane requires the LPS transport (Lpt) machinery, a protein complex comprised of seven different proteins which spans the entire cell envelope (Sperandeo et al., 2009) (Fig. 1.10). The integral inner membrane proteins LptG and LptF, along with the cytoplasmic ABC protein LptB, most likely provide energy to the complex through ATP hydrolysis (Sperandeo et al., 2009). The integral protein LptD and the outer lipoprotein LptE form a complex in the outer membrane (Wu et al., 2006). It has recently been shown in E. coli that LptE is required at the outer membrane for the correct insertion of LptD (Chimalakonda et al., 2011). LptA, a periplasmic protein with a fibrillar structure (Suits et al., 2008), is expected to connect the inner membrane to and the LptD/LptE outer membrane components, and to chaperone LPS across the periplasm (Sperandeo et al., 2009). The function of LptC is currently unknown, although it is thought to be a docking site to the inner membrane for LptA (Sperandeo et al., 2009).

#### 1.4 Virulence factors of *M. haemolytica*

#### 1.4.1 Secreted proteins

#### 1.4.1.1 Leukotoxin (LktA)

The *M. haemolytica* LktA protein is a member of the RTX (repeats-in-toxin) poreforming cytotoxins (Linhartova *et al.*, 2010) that includes the *Escherichia coli* alpha-haemolysin (Strathdee and Lo, 1987) and toxins of other *Pasteurellaceae* (Kraig *et al.*, 1990, Frey *et al.*, 1993).

## Figure 1.10 Transport of LPS from the inner membrane to the outer membrane via MsbA and the Lpt transport system

Figure adapted from Sperandeo *et al.* (2009). See text for details.



LktA is produced by all *M. haemolytica* serotypes and in nearly all isolates examined to date (Burrows et al., 1993, Saadati et al., 1997). LktA is speciesspecific and has leukotoxic activity only against ruminant lymphocytes (Shewen and Wilkie, 1982, Kaehler et al., 1980, Clinkenbeard and Upton, 1991). It also has haemolytic activity (Murphy et al., 1995). Cytolysis is dependent on the interaction of LktA with the lymphocyte-function associated antigen 1 (LFA-1) molecule of target cells (Li et al., 1999, Jeyaseelan et al., 2000). At high concentrations, LktA creates pores in the cell membrane of target cells that results in swelling and lysis (Clinkenbeard et al., 1989). At sub-lytic concentrations, LktA activates neutrophils (Czuprynski et al., 1991), induces release of proinflammatory cytokines (Yoo et al., 1995b) and respiratory burst products (Maheswaran et al., 1992), and causes cytoskeletal changes resulting in apoptosis (Stevens and Czuprynski, 1996, Sun et al., 1999). LktA has also recently been demonstrated to target leukocyte mitochondria (Kisiela et al., 2010). LktA is a significant *M. haemolytica* virulence factor and is considered to be largely responsible for widespread tissue damage caused during infection (Highlander, 2001).

LktA is encoded in the *lktCABD* operon, where *lktA* encodes the inactive prototoxin, *lktC* is required for posttranslational activation of the prototoxin prior to secretion, *lktB* encodes an inner membrane ABC transporter, and *lktD* encodes a membrane fusion protein. Like other RTX proteins, LktA is secreted via a type I secretion mechanism directly from the cytoplasm into the extracellular space through a continuous channel created by LktB, LktD and TolC (Linhartova *et al.*, 2010). The *lktCABD* operon has a highly complex mosaic structure resulting from extensive inter- and intra-species horizontal DNA transfer and assortative recombination (Davies *et al.*, 2002, Davies *et al.*, 2001).

#### 1.4.1.2 Glycoprotease (Gcp)

The glycoprotease protein, Gcp, is a zinc metalloglycoprotease that cleaves Osialoglycoproteins from host cells (Abdullah *et al.*, 1992, Sutherland *et al.*, 1992, Otulakowski *et al.*, 1983). All serotypes of *M. haemolytica* possess the *gcp* gene and have glycoprotease activity whereas *M. glucosida* possesses the *gcp* gene but does not display glycoprotease activity (Abdullah *et al.*, 1990, Lee *et al.*, 1994). The protease is thought to enhance adhesion of *M. haemolytica* to host cells and is also capable of inducing platelet activation, adhesion, and aggregation, leading to their deposition in the lung alveoli (Nyarko *et al.*, 1998).

#### 1.4.1.3 Filamentous haemagglutinin (FhaB)

*M. haemolytica* encodes a putative filamentous haemagglutinin protein (FhaB) which shares significant amino acid similarity to the FhaB protein produced by the human respiratory pathogen Bordetella pertussis and other organisms (Gioia et al., 2006). The B. pertussis FhaB protein is a 220 kDa protein found both on the bacterial cell surface and in the extracellular milieu. It is transported across the outer membrane via FhaC, a pore-forming OMP encoded by a gene which lies immediately downstream of FhaB (Locht et al., 1992, Willems et al., 1994). An *fhaC* orthologue is also present adjacent to *fhaB* in *M*. *haemolytica*, suggesting that M. haemolytica FhaB is secreted via a similar mechanism (Gioia et al., 2006). In *B. pertussis* FhaB is a well characterised adhesin (Smith et al., 2001), but the function of FhaB in M. haemolytica is currently unknown. In Bordetella bronchiseptica, a respiratory pathogen of pigs, FhaB is required for the efficient establishment of colonisation in the lower respiratory tract (Cotter *et al.*, 1998) and *fhaB* mutants are unable to cause disease (Nicholson et al., 2009). An FhaB homologue in the bovine respiratory pathogen Histophilus somni was also suggested to have an important role in biofilm formation (Sandal *et al.*, 2009). In Actinobacillus pleuropneumoniae, the gene encoding an FhaB homologue was transcribed at much higher numbers in isolates recovered from diseased pig lungs compared to an isolate grown in complex growth medium (Deslandes et al., 2010). If the M. haemolytica FhaB protein does function as an adhesin then it must have a different binding physiology to *B. pertussis* FhaB, as it lacks an integrin-binding RGD motif (Gioia et al., 2006). It does, however, contain a bacterial intein-like (BIL) domain (Amitai et al., 2003) at the carboxyl terminus which does not feature in *B. pertussis* FhaB (Gioia *et al.*, 2006). These domains are involved in post-translational autoproteolysis, hence the possibility of allowing variability in receptor recognition and receptor release. Since autoproteolysis would change the structure of FhaB, it may also interfere with host immune recognition and help evade the host immune response. To date, no expressed FhaB protein been identified in *M. haemolytica*.

#### 1.4.2 Cell wall carbohydrates and pili

#### 1.4.2.1 Capsular polysaccharide (CPS)

To date, twelve different capsular serotypes have been identified in *M. haemolytica* (A1, A2, A5-A9, A12-A14, A16 and A17) and one in *M. glucosida* (A11) (Angen *et al.*, 1999b). The serotype A1 capsule has been implicated in diverse functions including adherence to alveolar surfaces (Brogden *et al.*, 1989), resistance to complement-mediated serum killing (Chae *et al.*, 1990), resistance to phagocytosis by bovine neutrophils and alveolar macrophages (Chae *et al.*, 1990, Czuprynski *et al.*, 1989), and facilitating microcolony formation in the bovine pneumonic lung (Morck *et al.*, 1989, Morck *et al.*, 1988).

#### 1.4.2.2 Lipopolysaccharide (LPS)

Lipopolysaccharide (LPS) is the major glycolipid molecule present in the cell envelope of Gram-negative bacteria and makes up between 12 and 25% of the dried cell weight of M. haemolytica (Keiss et al., 1964). The basic structure of LPS is composed of three well-defined regions: (i) lipid A, composed of sugars and fatty acids and anchors LPS to the outer membrane, (ii) the oligosaccharide core, composed of approximately 10 monosaccharides and connects the lipid A and O-antigen regions and, (iii) the O-specific antigen, consisting of repeating units containing between one to seven monosaccharides (Hitchcock et al., 1986). It is common for Gram-negative bacteria to possess LPS that does not contain Oantigen side chains. The two different LPS types, with and without O-antigen side chains, are commonly described as 'smooth-type' and 'rough-type' LPS, respectively, according to bacterial colony morphology (Hitchcock et al., 1986). Enteric bacteria generally possess smooth-type LPS whereas, in contrast, bacteria that reside on respiratory and genital mucosa have evolved a unique set of surface glycolipids called lipooligosaccharides (LOSs) (Preston *et al.*, 1996). The LOS molecules are analogous to LPS but their O-antigen side chains are limited to around ten saccharide units. M. haemolytica LPS is unusual in that both smooth- and rough-types occur independently in different isolates (Ali et al., 1992, Davies and Donachie, 1996, Lacroix et al., 1993, Davies et al., 1991). Interestingly, only a single O-antigen type is present in isolates possessing smooth-type LPS, suggesting that the gene encoding this part of the LPS molecule may have been recently obtained by horizontal transfer (Davies and

Donachie, 1996). It is possible that the structure of *M. haemolytica* LPS is actually closer to that of LOS, but this has not yet been demonstrated.

LPS is an important *M. haemolytica* virulence factor in serotype A1 isolates, causing damage to pulmonary endothelial cells (Paulsen *et al.*, 1989) and inducing alveolar macrophages to release proinflammatory cytokines (Yoo *et al.*, 1995a, Lafleur *et al.*, 1998) and reactive intermediates (Yoo *et al.*, 1996). It also forms aggregates with and enhances the effects of the leukotoxin LktA (Lafleur *et al.*, 2001, Li and Clinkenbeard, 1999).

1.4.2.3 Pili

The genomes of *M. haemolytica* contain genes that encode the type IV pili locus *pilABCD* (Gioia *et al.*, 2006, Lawrence *et al.*, 2010a). Type IV pili are known to be involved in several bacterial processes including adhesion, DNA uptake and twitching motility (Proft and Baker, 2009). The amino acid sequence of PilC is identical in the bovine serotype A1 and serotype A2 genomes, whereas in the ovine serotype A2 isolate there is a 29 amino acid deletion at the amino terminus (Lawrence *et al.*, 2010b). In *Neisseria gonorrhoeae*, PilC is localised to pili tips and acts as an adhesin which binds to human epithelial cells (Rudel *et al.*, 1995). It has been suggested that the amino-terminal deletion in the ovine serotype A2 PilC may serve as a modification for host species-specific binding to ovine epithelial cells (Lawrence *et al.*, 2010b).

#### 1.4.3 Outer membrane proteins (OMPs)

#### 1.4.3.1 Outer membrane protein A (OmpA)

The OmpA protein is a highly conserved, integral OMP that is universally present in Gram-negative bacteria and has been implicated in a diverse range of functions in different species (Smith *et al.*, 2007). It comprises an N-terminal transmembrane B-barrel domain embedded in the outer membrane and a Cterminal globular domain which extends into the periplasm and interacts with the underlying peptidoglycan (Demot and Vanderleyden, 1994). The N-terminal domain consists of eight membrane-spanning anti-parallel B-sheets and four relatively long, mobile, hydrophilic external loops (Pautsch and Schulz, 1998). Molecular mass heterogeneity of OmpA has been observed among bovine and ovine *M. haemolytica* isolates that correlates with the host of origin (Davies and Donachie, 1996). Subsequent comparative nucleotide sequence analysis of the ompA gene from 31 M. haemolytica isolates revealed the presence of hypervariable domains within the four surface-exposed loops (Davies and Lee, 2004). The amino acid sequences of these domains are very different in bovine and ovine isolates but are highly conserved among isolates recovered from the same host species. The ompA gene can be categorised into four distinct alleles, I to IV. The class I (ompA1) alleles are associated exclusively with bovine M. haemolytica isolates, whereas the class II to IV (ompA2 to ompA4) alleles occur only in ovine isolates of *M. haemolytica* (Davies and Lee, 2004). Significantly, the ompA1- and ompA2-type alleles are associated with the major pathogenic lineages of bovine [electrophoretic type 1 (ET 1)] and ovine (ETs 21 and 22) isolates, respectively (Davies et al., 1997). Based on the distribution of the OmpA1 and OmpA2 proteins among bovine and ovine isolates, respectively, and the localisation of the amino acid variation to the tips of the four loops, it was hypothesised that OmpA plays an important role in adherence and is involved in host specificity. The exact role of *M. haemolytica* OmpA is unknown, although studies from bovine serotype A1 M. haemolytica isolates have demonstrated binding of OmpA to bovine bronchial epithelial cells (Kisiela and Czuprynski, 2009) and fibronectin (Lo and Sorensen, 2007), indicating a role in host adhesion. It has been demonstrated in several other Gram-negative bacteria, including H. infuenzae, P. multocida, and E. coli, that OmpA plays an important role in adherence and invasion of host cells (Bookwalter et al., 2008, Dabo et al., 2003, Hill et al., 2001, Prasadarao et al., 1996, Reddy et al., 1996).

#### 1.4.3.2 Iron-acquisition OMPs

An essential prerequisite for successful colonisation of mammalian hosts by bacteria is the ability to adapt to a microenvironment containing virtually no free iron. In host tissues, nearly all iron is sequestered by high-affinity ironbinding proteins such as transferrin, lactoferrin, ferritin and haemoglobin. Highaffinity host haem-binding proteins such as haemopexin and haptoglobin also contribute to the sequestering of free haem. Bacteria which colonise mucosal surfaces have therefore evolved a number of iron acquisition systems including the secretion of siderophores (small molecules with high affinity for iron) and outer membrane receptors specific for iron-containing host proteins (Wandersman and Delepelaire, 2004, Wooldridge and Williams, 1993). In many bacteria, expression of iron acquisition proteins is under the control of a transcriptional repressor called the ferric uptake regulator (Fur) (Andrews *et al.*, 2003). *M. haemolytica* also possesses a fur gene, although its function may be atypical as its transcription is not repressed by iron (Gioia and Highlander, 2007).

#### 1.4.3.2.1 Transferrin binding receptor (TbpA and TbpB)

The *M. haemolytica* transferrin receptor, comprised of TbpA and TbpB, is responsible for acquiring iron that has been sequestered by host transferrin (Ogunnariwo *et al.*, 1997). TbpA is a TonB-dependent integral OMP that forms a pore through which iron passes after its release from transferrin. TbpB is a putatively surface-exposed outer membrane lipoprotein that is thought to increase the efficiency of iron uptake from transferrin (Moraes *et al.*, 2009). TbpA and TbpB have molecular masses of approximately 107 and 63 kDa, respectively, and together form a receptor that is highly specific for ruminant transferrin (Ogunnariwo and Schryvers, 1990, Yu *et al.*, 1992). The genes encoding the two proteins are arranged in an operon arrangement of *tbpB-tbpA*. In a recent study, comparative nucleotide sequence analysis revealed that the *tbpBA* in *M. haemolytica* and the closely related species *M. glucosida* and *B. trehalosi* (Lee and Davies, 2011).

#### 1.4.3.2.2 Haem/haemoglobin receptors

Transcription of genes encoding two putative haemoglobin receptors was strongly upregulated in a bovine serotype A1 *M. haemolytica* isolate under iron-restricted conditions and in infected lung tissue (Roehrig *et al.*, 2007). Furthermore, transcription of genes encoding a putative haemin [ferric (Fe<sup>3+</sup>) haem] receptor complex was also upregulated under iron-restriction (Roehrig *et al.*, 2007). It has been suggested that LktA could play an important role in the liberation of haemin and haemoglobin from host erythrocytes, thereby providing substrates for these receptors (Roehrig *et al.*, 2007).

#### 1.4.3.2.3 Haem-haemopexin acquisition system (HxuCBA)

The bovine and ovine serotype A2 M. haemolytica genomes encode the haemhaemopexin acquisition operon hxuCBA (Lawrence et al., 2010a). In the bovine serotype A1 genome only the hxuA gene has been described (Gioia et al., 2006). The HxuCBA system was first discovered in Haemophilus influenzae (Hanson et al., 1992) and is an important virulence determinant in this organism (Morton et al., 2007) and in Haemophilus parasuis (Melnikow et al., 2005) (Fig. 1.11). The HxuC protein is an outer membrane TonB-dependent receptor (Cope et al., 2001, Cope et al., 1995). The HxuB and HxuA proteins comprise a two-partner secretion (TPS) system, whereby HxuA is transported across the outer membrane by HxuB, a specific pore-forming OMP. HxuA binds to the host haem-haemopexin complex, and facilitates haem delivery to the cell surface via HxuC and an inner membrane ABC transporter (Cope et al., 1998, Cope et al., 1994). Recent evidence suggests that HxuA might not actually function as a haemophore in H. influenzae, but instead releases haem upon interaction with the haemhaemopexin complex (Fournier *et al.*, 2011). Furthermore, the primary activity of HxuA may actually be to sequester haemopexin in its inactive form, thereby decreasing the high-affinity binding of haem by the serum (Fournier et al., 2011). None of the HxuCBA components have been identified at the transcriptomic or protein level in M. haemolytica.

#### 1.4.3.2.4 Siderophore uptake systems

*M. haemolytica* does not produce siderophores, although genes encoding several proteins that are similar to siderophore uptake receptors of other Gram-negative bacteria have been identified. One of these proteins has significant homology to the *N. gonorrhoeae* FrpB protein that has been associated with ferric uptake from transferrin (Beucher and Sparling, 1995, Dyer *et al.*, 1988) and, more recently, as a receptor for the ferric siderophore enterobactin (Carson *et al.*, 1999). *N. gonorrhoeae* does not synthesise siderophores but can utilise those produced by other bacteria (xenosiderophores) such as *E. coli* aerobactin (West and Sparling, 1987) and enterobactin (Carson *et al.*, 1999, Rutz *et al.*, 1991). This suggests the possibility that the FrpB orthologue of *M. haemolytica* may also utilise xenosiderophores in a similar manner to *N. gonorrhoeae*. Indeed, some bacterial isolates of the bovine nasopharyngeal flora have been reported to

#### Figure 1.11. Schematic diagram of the *H. influenzae* HxuCBA haemhaemopexin uptake system.

HxuA is synthesised in the cytoplasm and translocated to the periplasm by the Sec translocon. HxuA is exported across the outer membrane into the host environment by HxuB. HxuA binds to the haem-haemopexin complex, releasing haem and allowing it to be imported back through the outer membrane via the TonB-dependent receptor HxuC, and then subsequently transported across the inner membrane by an ABC transporter.



stimulate growth of *M. haemolytica* and other closely-related Gram-negative bacteria (Corbeil *et al.*, 1985), possibly as a result of this mechanism.

Transcription of the *frpB* gene was upregulated in a bovine serotype A1 *M*. *haemolytica* isolate (Roehrig *et al.*, 2007) and in *A. pleuropneumoniae* (Klitgaard *et al.*, 2010) under iron-restricted conditions. In *A. pleuropneumoniae*, FrpB has been demonstrated to be both immunoreactive (Liao *et al.*, 2009) and an essential virulence determinant, as *frpB* deletion mutants are unable to colonise the host or cause clinical disease symptoms upon experimental infection (Buettner *et al.*, 2009).

Transcription of genes encoding proteins with homology to some of the proteins in the *A. pleuropneumoniae* ferrichrome uptake system FhuABCD (Mikael *et al.*, 2002) were upregulated in a bovine serotype A1 isolate under iron restricted conditions (Roehrig *et al.*, 2007). Although *fhuBCD* genes were all upregulated, the putative outer membrane receptor gene *fhuA* was not. In contrast to FrpB, the FhuA protein is not an essential virulence determinant in *A. pleuropneumoniae* (Baltes *et al.*, 2003).

1.4.3.3 Lipoproteins (PlpABC, PlpD and PlpE)

Several outer membrane-associated lipoproteins have been identified in *M. haemolytica*. Three contiguous genes arranged in an operon, *plpABC*, are present in all *M. haemolytica* and *M. glucosida* isolates that encode three 28-30 kDa lipoproteins (Cooney and Lo, 1993, Murphy and Whitworth, 1993). These proteins are highly immunogenic (Dabo *et al.*, 1994), and a *M. haemolytica* mutant lacking this operon was demonstrated to have increased susceptibility to complement-mediated killing and reduced survival *in vivo* (Murphy *et al.*, 1998). PlpA has been demonstrated to be surface-exposed and capable of binding to bovine bronchial epithelial cells *in vitro* (Kisiela and Czuprynski, 2009). It has also been identified in an immunoproteomic study of the OMPs of a bovine serotype A1 isolate (Ayalew *et al.*, 2010).

Another gene, *plpD*, is located on a different part of the chromosome to *plpABC* and encodes a 31 kDa lipoprotein (Nardini *et al.*, 1998). Amino acid sequence analysis indicates that PlpD is lipid modified at the N-terminus, but contains a C-terminal region that is similar to that of OmpA (Nardini *et al.*, 1998). This

protein is recognised by sera from calves immunised with a culture supernatant vaccine (Nardini *et al.*, 1998) but its exact function is yet to be determined.

The gene *plpE* is also located on a different part of the chromosome to *plpABC* and *plpD* and encodes a 45 kDa outer membrane lipoprotein that is present in all serotypes of *M. haemolytica* but not in *M. glucosida* (Pandher *et al.*, 1998). It has been demonstrated that anti-PlpE antibodies promote complement-mediated killing of bovine serotype A1 isolates (Nardini *et al.*, 1998, Ayalew *et al.*, 2004). The addition of recombinant PlpE to a commercial vaccine also conferred enhanced resistance against experimental challenge in cattle compared to the commercial vaccine alone (Confer *et al.*, 2003). The exact function of PlpE is also yet to be determined.

#### 1.4.3.4 Serotype-specific antigen (Ssa)

The Ssa protein was originally designated as Ssa1 (serotype-specific antigen-1) as it was identified in a bovine serotype A1 M. haemolytica isolate (Gonzalezrayos et al., 1986, Lo et al., 1991). The ssa gene has since been discovered in all serotypes examined, with the exception of A8, but is absent from M. glucosida (Gonzalez et al., 1991). Normally only M. haemolytica isolates of serotype A2 are identified in the upper respiratory tract of healthy cattle, and it was hypothesised that the Ssa protein might function as a specific adhesin in serotype A1 isolates which facilitates the selective colonisation of these isolates in the diseased bovine lung (Gonzalez et al., 1995). Ssa was later categorised as a classical autotransporter and a subtilisin-like serine protease (Siezen and Leunissen, 1997) which shares significant homology to similar proteins in other species including AasP of A. pleuropneumoniae (Ali et al., 2008), NalP of Neisseria meningitidis (Turner et al., 2002) and SphB1 of B. pertussis (Coutte et al., 2001), all of which act as surface maturation proteases of other autotransporters. A similar function has not yet been described in M. haemolytica.

#### 1.4.3.5 Neuraminidase (NanH)

A neuraminidase protein (NanH) was detected and active in all capsular serotypes of *M. haemolytica*, but not *M. glucosida* (Straus *et al.*, 1993). In *M. haemolytica*, NanH has been suggested to facilitate the colonisation of mucosal

surfaces (Straus *et al.*, 1998), most likely through the modification of sialic acid molecules on host cells. Its primary amino acid sequence is similar to that of a classical autotransporter.

#### 1.4.3.6 Immunglobulin proteases

Three genes encoding proteins that are orthologous to the Iga1 proteases of Gram-negative species including H. influenzae, N. meningitidis and N. gonorrhoeae, have been identified in M. haemolytica genomes (Gioia et al., 2006, Lawrence et al., 2010a). The M. haemolytica Iga1 orthologues contain Iga1 domains and conserved active serine protease sites that are similar to the active sites of *H. influenzae* Iga1 protease (Poulsen *et al.*, 1992). These serine protease sites cleave the hinge region of host IgA antibodies, thereby eliminating their agglutinating ability and facilitating host colonisation (St Geme, 2000). While IgA protease activity has not been detected in the supernatants of M. haemolytica (Abdullah et al., 1992), IgG-specific protease activity was detected in partially purified culture supernatants (Lee and Shewen, 1996). IgG is also the primary secretory antibody found in the lower respiratory tract of cattle (Duncan et al., 1972), whereas IgA is the predominant antibody in the upper respiratory tract (Wilkie and Markham, 1981). It is therefore possible that at least one of the Iga1 orthologues identified in M. haemolytica actually cleaves IgG instead of IgA. The Iga1 protease of *N. gonorrhoeae* was the first classical autotransporter protein to be studied in detail (Pohlner et al., 1987). In neisserial species, the C-terminal B-barrel domain of Iga1 integrates into the outer membrane and forms a specific pore for the translocation of the passenger domain (containing the serine protease site) from the periplasm to the extracellular space (Klauser et al., 1993, Pohlner et al., 1987). Once exposed on the bacterial surface the protein is able to undergo autoproteolysis (Vitovski and Sayers, 2007), thereby facilitating IgA cleavage at both the cell surface and in the extracellular milieu. The autotransporter protein NalP has also been reported to have a role in the modulation and processing of Iga1 in N. meningitidis at the cell surface (van Ulsen *et al.*, 2003). To date, no Iga1-like proteases have been identified at the protein level in any M. haemolytica isolates.

#### 1.4.3.7 Trimeric autotransporter adhesins

Two putative trimeric autotransporter proteins have been identified in *M.* haemolytica genomes (Gioia *et al.*, 2006, Lawrence *et al.*, 2010a). One has similarity to the Hsf proteins of *A. pleuropneumoniae* and *P. multocida*, and the other has similarity to the Hia protein of *H. influenzae* and Hia orthologues of *A. pleuropneumoniae* and *P. multocida*. Roles in adherence are common to most of the trimeric autotransporters identified to date (Cotter *et al.*, 2005). Indeed, roles in adherence to epithelial cells have been associated with Hsf in *A. pleuropneumoniae* (Auger *et al.*, 2009) and *H. influenzae* (Hallstrom *et al.*, 2006), and also Hia in *H. influenzae* (Barenkamp and StGeme, 1996). Another gene locus, designated *ahs*, was also identified in a serotype A1 isolate and encodes a collagen-binding trimeric autotransporter purported to be involved in host adhesion (results obtained using recombinant Ahs) (Lo *et al.*, 2006, Daigneault and Lo, 2009). Despite the presence of genes encoding these proteins in *M. haemolytica* they have not yet been identified at the protein level in any isolate.

# 1.5 Phenotypic and genetic variation of *M. haemolytica* and *M. glucosida*

#### **1.5.1** Classification based on phenotypic relationships

#### 1.5.1.1 Capsular serotyping

The serotypes of *M. haemolytica* isolates are determined by performing the indirect haemagglutination assay (IHA) using sera raised against reference capsular polysaccharide types (Fraser *et al.*, 1983). To date, twelve different capsular serotypes have been identified in *M. haemolytica* (A1, A2, A5-A9, A12-A14, A16 and A17) and one in *M. glucosida* (A11) (Angen *et al.*, 1999b); however, untypeable isolates of both organisms are frequently isolated (Donachie *et al.*, 1984, Gilmour and Gilmour, 1989). Capsular serotyping of other *M. haemolytica* like isolates that are phenotypically and genetically distinct from *M. haemolytica* have been shown to possess A6, A9 and A16 capsular serotypes, indicating that serotyping is of limited use in the differentiation of *M. haemolytica* isolates (Angen *et al.*, 1999b).

The various capsule structures of *M. haemolytica* have been previously characterised and are summarised in Table 1.2. The structure of the serotype A1 polysaccharide is highly similar to the widely distributed 'enterobacterial common antigen' (Adlam *et al.*, 1984). The polymer of serotype A2 polysaccharide is colaminic acid and is identical to the capsular polysaccharides of *N. meningitidis* B and *E. coli* K1 (Adlam *et al.*, 1987). Serotype A7 polysaccharide is similar to the phosphate-containing polysaccharides of *N. meningitidis* serogroup L and *H. influenzae* type F (Adlam *et al.*, 1986). It has been suggested that the production of similar or identical capsular structures among pathogenic bacteria from different genera represents a common defence mechanism developed through convergent evolution (Adlam, 1989).

#### 1.5.1.2 LPS profiles

The LPS profiles of *M. haemolytica* and *M. glucosida* were analysed by SDS-PAGE (Davies and Donachie, 1996, Ali *et al.*, 1992, Lacroix *et al.*, 1993). Eight LPS types were recognised in *M. haemolytica* and one in *M. glucosida* (Davies and Donachie, 1996). In *M. haemolytica* isolates there were four different types of core-oligosaccharide (1-4), each either associated or not associated (A or B) with a single O-antigen type. There was a clear association between LPS profiles and capsular serotypes: serotypes A1, A5, A6, A9 and A12 with LPS type 1A, serotypes A2, A8, A14 and A16 with LPS types 1B and 3B, and serotypes A7 and A13 with LPS type 4A (Davies and Donachie, 1996). *M. glucosida* isolates were represented by a single LPS type, designated type 4C, which possessed a core oligosaccharide region similar to LPS type 4 but with a distinct O-antigen type different from that in *M. haemolytica* isolates (Davies and Donachie, 1996).

#### 1.5.1.3 OMP profiles

The OMP profiles of *M. haemolytica* and *M. glucosida* isolates were analysed by SDS-PAGE (Davies and Donachie, 1996). Twenty different OMP profiles were recognised in *M. haemolytica* isolates and two in *M. glucosida* isolates. There was a clear association between the OMP profile types and capsular serotypes. Based on the variation in OMP profiles, the capsular serotypes of *M. haemolytica* could be sub-divided into three main groups: serotypes A1, A5, A6, A8, A9 and A12 with OMP type 1, serotypes A2, A14 and A16 with OMP type 2, and serotypes A7 and A13 with OMP type 3. The OMP profiles of *M. glucosida* were similar to

| Serotype | Capsule structure  | Similar capsule structure in other pathogens                             |
|----------|--|--|
| A1       | $\rightarrow$ 3)-O-(2-acetamido-2-deoxy-4-<br>O-acetyl- $\beta$ -D-<br>mannopyranosyluronic acid)-<br>(1 $\rightarrow$ 4)-O-(2-acetamido-2-deoxy- $\beta$ -<br>D-mannopyranose)-(1 $\rightarrow$ | Enterobacterial common antigen   |
| A2       | $\rightarrow$ 2)- $\alpha$ -D- <i>N</i> -acetylneuraminic acid-<br>(8 $\rightarrow$ (and a dextran polymer)  | <i>N. meningitidi</i> s serogroup B <i>E.</i><br><i>coli</i> K1          |
| A7       | $\rightarrow$ 3)- $\beta$ -2-acetamido-2-<br>deoxygalactopyranose-(1 $\rightarrow$ 3)- $\alpha$ -2-<br>acetamido-2-deoxy-6- <i>O</i> -<br>acetylglucopyranose-(1-<br>phosphate $\rightarrow$     | <i>N. meningitidis</i> serogroup L <i>H.</i><br><i>influenzae</i> type F |

# Table 1.2.Capsule structure of serotypes A1, A2, and A7 of M.haemolytica.

those of A7 and A13 and were also considered to be of OMP type 3. Furthermore, there were associations between specific OMP profiles and host of origin (i.e. cattle or sheep). For example, serotype A1 and A6 isolates were divided into two distinct subgroups, OMP types, 1.1 and 1.2, which were associated with cattle and sheep, respectively. A similar distinction could also be made for serotype A2 isolates (OMP types 2.1 and 2.2). The finding that bovine and ovine isolates of these three serotypes could be clearly differentiated based on their OMP profiles suggest that OMPs may contribute towards host-specificity.

#### 1.5.2 Classification based on genetic relationships

#### 1.5.2.1 Nucleotide sequence analysis of the 16S rRNA gene

Comparative nucleotide sequence analysis of the 16S rRNA gene demonstrated that *M. haemolytica* and *M. glucosida* isolates represent distinct phylogenetic lineages (Davies *et al.*, 1996, Angen *et al.*, 1999a). However, due to the highly conserved nature of the 16S rRNA only two different alleles were identified in all serotypes of *M. haemolytica*, demonstrating the limited use of this approach for differentiating isolates within a species (Davies *et al.*, 1996, Angen *et al.*, 1999a). Isolates of serotypes A1, A5 to A9, A12 to A14, and A16 had identical 16S rRNA nucleotide sequences and differed from the serotype A2 16S rRNA gene at only two nucleotide positions.

#### 1.5.2.2 Multilocus enzyme electrophoresis (MLEE)

Multilocus enzyme electrophoresis (MLEE) is a technique which can be used to examine genetic diversity and structure in natural populations of bacteria, providing a genetic framework for the analysis of variation in phenotypic characteristics (Selander *et al.*, 1986). Bacterial isolates are characterised by measuring variations in the electrophoretic mobility of several housekeeping proteins which can be directly equated to allelic variation at the corresponding gene loci (Selander *et al.*, 1986). MLEE was used to analyse the genetic diversity and population structure of *M. haemolytica* and *M. glucosida* isolates and subsequently correlate variation in capsular serotypes, LPS types and OMP types with the underlying genetic framework (Davies *et al.*, 1997). *M. haemolytica* isolates were classified into 22 electrophoretic types (ETs) based on allelic variation at 18 housekeeping gene loci. The serotype A1 and A6 isolates of ET1

were responsible for 75% of bovine disease cases, marking two virulent, cattlespecific clonal groups. Similarly, the serotype A2 isolates of ET 21 and 22 were responsible for 40% of ovine disease cases, marking a virulent, cattle-specific clonal group. Bovine serotype A1 and A6 isolates and bovine serotype A2 isolates were phylogenetically distinct from ovine isolates of the same serotypes, suggesting that different subpopulations of these serotypes are associated with disease in the two animals. Furthermore, the MLEE data also confirmed previous observations (Davies and Donachie, 1996) that bovine and ovine isolates of the A1, A2 and A6 capsular serotypes could be consistently differentiated based on their OMP profiles, indicating a role in host-specificity.

The MLEE data was consistent with previous findings of 16S rRNA sequence comparison (Davies *et al.*, 1996) that *M. glucosida* represents a heterogeneous group of bacteria that are phylogenetically distinct from *M. haemolytica* (Davies *et al.*, 1997).

#### 1.5.3 Evolution and host-switching in *M. haemolytica*

Comparative nucleotide sequence analysis has shown that horizontal DNA transfer and assortative (entire gene) recombination have contributed significantly to the evolution of the leukotoxin operon (Davies et al., 2001, Davies et al., 2002), the ompA gene (Davies and Lee, 2004) and the tbpBA operon (Lee and Davies, 2011). In these studies, the association of identical or nearly identical alleles and gene segments with divergent phylogenetic lineages of *M*. *haemolytica* collectively provide evidence to support the hypothesis that host switching of strains from cattle to sheep and vice versa have contributed to the emergence of new strains. In this hypothesis (Fig. 1.12) the serotype A1 and A6 strains, which evolved independently in sheep, were transmitted to cattle around the time of domestication of these animals (around 10,000 years ago). Similarly, the A2 strains, which evolved independently in cattle, were transmitted to sheep. Exchange of genetic material from the native, nonpathogenic strains to the newly-transmitted strains allowed for their adaptation to their new host environment, giving rise to the pathogenic serotype A1 and A6 strains in cattle and the pathogenic serotype A2 strains in sheep.

#### Figure 1.12. The hypothesised route of *M. haemolytica* host switching.

Transmission of serotype A2 strains from cattle to sheep occurred around the time of animal domestication. Subsequent horizontal gene transfer (HGT) of genetic material from the native ovine strains gave rise to the pathogenic ovine serotype A2 strains (red). Similarly, transmission of serotype A1 and A6 strains from sheep to cattle and subsequent genetic exchange gave rise to the pathogenic bovine serotype A1 and A6 strains (red).



# 1.6 Bioinformatic tools for discriminating proteins located in different subcellular compartments

Once a bacterial protein has been synthesised in the cytoplasm it can either remain there or be targeted to a different subcellular location. Several of the sorting signals that are responsible for targeting a nascent polypeptide to a particular location have been well characterised, including the N-terminal signal peptide for targeting proteins outside of the cytoplasm. Many proteins also have secondary structural signatures which indicate their most probable location, such as the transmembrane  $\alpha$ -helical secondary structures that are found in Gram-negative integral inner membrane proteins and the B-barrel secondary structures present in Gram-negative integral OMPs. These signals and structural signatures are generally encoded in the amino acid sequence of the protein itself and can therefore be identified computationally using bioinformatics approaches. The availability of publicly available sequence information has expanded rapidly over recent years and bioinformatic prediction of such sequence features has become an important part of microbiological research. Proteins which are surface-exposed and potential vaccine targets can be rapidly identified bioinformatically from sequence data rather than experimental data, a process referred to as reverse vaccinology (Rappuoli, 2000, Vivona et al., 2008). It is also useful to know the subcellular compartment that a protein is likely to be located in when designing protein isolation experiments and also for identifying contaminants in proteomic analyses.

#### 1.6.1 Prediction tools for discrimination of OMPs

Outer membrane proteins have several unique sorting signals and structural signatures that allow them to be differentiated from proteins located in other subcellular compartments by bioinformatic predictors. These predictors can be categorised into three groups: B-barrel predictors, outer membrane lipoprotein predictors and subcellular localisation predictors.

#### 1.6.1.1 B-barrel predictors

In general, two main types of structural signatures are present in Gram-negative integral membrane proteins, namely  $\alpha$ -helices and B-barrels, which are associated with the inner and outer membranes, respectively. The prediction of

integral inner membrane proteins is relatively easy, as the membrane-spanning regions consist of easily identifiable  $\alpha$ -helical stretches consisting of 15 to 25 mostly non-polar amino acids (Santoni et al., 2000). In contrast, predicting integral OMPs is more difficult, mainly due to the membrane-spanning B-strands being much shorter and having highly variable properties (Koebnik et al., 2000). In general, the amino acids of transmembrane B-strands alternate between polar and non-polar, with polar residues facing the lipid bilayer and protein interfaces and non-polar residues facing the inside of the B-barrel. However, some nonpolar residues may also point inside the barrel, interrupting the regular alternation between polar and non-polar residues and making transmembrane Bstrands more difficult to identify (Schulz, 2000). Transmembrane B-strands are also often flanked by a layer of aromatic amino acid residues (the 'aromatic girdle') which are believed to contribute towards providing stability in the outer membrane (Yau et al., 1998). The majority of integral B-barrel OMPs also contain a C-terminal signature sequence, in which there is a phenylalanine (or tryptophan) residue at the C-terminal position, and hydrophilic residues at positions 3, 5, 7 and 9 from the C-terminus (Struyve *et al.*, 1991). This sequence is required for translocation across the periplasm and correct insertion into the outer membrane by the BAM complex (Robert *et al.*, 2006).

Several bioinformatic methods have been developed for the prediction of integral B-barrels from protein amino acid sequences. In these methods, the amino acid sequence is first encoded into a feature vector and then secondly entered into a classification model to produce the prediction. Several web-based resources are available for the prediction of B-barrels, including TMB-Hunt (Garrow *et al.*, 2005), TMBETADISC-RBF (Ou *et al.*, 2008), MCMBB (Bagos *et al.*, 2004) and BOMP (Berven *et al.*, 2004).

#### 1.6.1.2 Lipoprotein predictors

Proteins that are targeted for secretion via the Sec translocon contain an Nterminal signal sequence that is required for translocation across the inner membrane. Once in the periplasm, lipoprotein signal sequences are cleaved by an enzyme called signal peptidase II (SPaseII), whereas signal sequences of other proteins are cleaved by signal peptidase I (SPaseI). The key to bioinformatically predicting lipoproteins from a set of membrane proteins lies in the ability to differentiate between these two signal sequences. In both lipoproteins and nonlipoproteins, signal sequences can be divided into three regions: an n-region, an h-region, and a c-region (Juncker et al., 2003). Both protein types have a similar n-region, which is characterised by the presence of positive amino acids lysine and/or arginine. The h-region consists of hydrophobic amino acids and is shorter in lipoproteins than in non-lipoproteins. The c-region contains the signal peptidase recognition site and is necessary for cleavage. In lipoproteins, the cregion contains an apolar consensus sequence of four amino acids around the cleavage site known as the lipobox. The most conserved amino acids in the lipobox are a leucine at position -3 from the cleavage site, alanine at position -2 and glycine or alanine at position -1, although other substitutions have been demonstrated. A cysteine residue at position +1 is essential:  $LA(G,A) \downarrow C$ (Vonheijne, 1989). In non-lipoproteins, the same region is polar and has small, uncharged residues at positions -3 and -1 (Vonheijne, 1989). Outer membrane lipoproteins can be further differentiated from inner membrane lipoproteins by examining the amino acid at position +2 from the cleavage site. In general, lipoproteins containing an aspartate residue at this position are retained at the inner membrane whereas those containing any other residue are translocated to the outer membrane (Yamaguchi et al., 1988).

Web-based resources are available for the prediction of lipoproteins including DOLOP (Babu and Sankaran, 2002), LIPO (Berven *et al.*, 2006) and LipoP (Juncker *et al.*, 2003).

#### 1.6.1.3 Subcellular localisation predictors

Subcellular localisation predictors are able to predict the localisation site of a protein from several different options. For Gram-negative bacterial proteins, these sites are the cytoplasm, inner membrane, periplasm, outer membrane and extracellular. Subcellular localisation predictors utilise many of the criteria described above for the differentiation of OMPs. The main advantage of using these predictors in conjunction with B-barrel and lipoprotein predictors is that they can predict if a protein is likely to have more than one localisation site.

Several web-based Gram-negative subcellular localisation predictors are available including PSORTb (Gardy *et al.*, 2003, Gardy *et al.*, 2005), Proteome

Analyst (Szafron *et al.*, 2004), CELLO (Yu *et al.*, 2006) and SOSUI-GramN (Imai *et al.*, 2008).

# 1.7 Mass spectrometry (MS)-based outer membrane proteomics

Mass spectrometry (MS) is the method of choice for the identification of proteins in simple or complex samples. Proteomics in general deals with the determination of complete protein sets belonging to either a whole cell (a proteome) or a particular subcellular compartment (a subproteome). MS-based proteomics has only been made possible by the availability of gene and genome sequence databases, modern computing and large advances in MS technology. Outer membrane proteomics deals specifically with the identification of all integral OMPs and outer membrane lipoproteins (the outer membrane subproteome) within the outer membrane of a given Gram-negative bacterium. In order to undertake comprehensive studies of the outer membrane subproteome, the outer membrane must first be isolated from other cellular components and purified in order to minimise contamination with non-OMPs. This can be achieved through subcellular fractionation based on the specific properties of cellular components from different compartments. Complementary MS-based proteomic approaches can then be utilised to allow comprehensive identification of OMPs within a purified outer membrane sample.

#### 1.7.1 Outer membrane isolation

This section will summarise three of the most popular techniques for the isolation of Gram-negative outer membranes: selective detergent solubilisation, spheroplasting and sucrose density gradient centrifugation.

#### 1.7.1.1 Selective detergent solubilisation

This technique involves using an appropriate detergent to selectively solubilise the inner membrane, leaving the outer membrane largely intact so it can be pelleted and isolated. Before this can occur the cell envelope must first be separated from the components of the cytoplasm. Cells are broken in order to release their cytoplasmic contents, usually through sonication or French press. The cell lysate is centrifuged to pellet any unbroken cells which are

subsequently removed. The remaining supernatant is then subjected to ultracentrifugation to pellet the cell envelopes. One of the earliest detergents used for selective inner membrane solubilisation was the non-ionic detergent Triton X-100, which selectively solubilised the inner membrane of E. coli in the presence of  $Mg^{2+}$  ions (Schnaitman, 1971). The mild ionic detergent Nlaurolysarcosine (Sarkosyl) was subsequently shown to selectively solubilise the inner membrane of *E. coli* in the absence of  $Mg^{2+}$  (Filip *et al.*, 1973), indicating that the selective solubilisation ability of Triton X-100 could be explained, at least in part, on the basis that  $Mg^{2+}$  cations stabilise the outer membrane. It is thought that divalent cations stabilise the outer membrane by interacting with the hydrophobic moiety of LPS (Schindler and Osborn, 1979). Sarkosyl has been demonstrated to selectively solubilise *M. haemolytica* inner membrane proteins more completely than Triton X-100 (Squire *et al.*, 1984) and yield more OMPs (Morton et al., 1996). Furthermore, a recent study using Campylobacter jejuni compared a total of nine different OMP purification protocols and found that selective inner membrane solubilisation using Sarkosyl produced the purest and most complete outer membrane preparations and was the most reproducible in terms of consistent identification of OMPs (Hobb et al., 2009). Sarkosyl is therefore a very popular choice for the isolation of OMPs in M. haemolytica (Davies and Donachie, 1996, McCluskey et al., 1994, Davies et al., 1994a, Davies et al., 1992, Kisiela and Czuprynski, 2009, Gatewood et al., 1994, Ayalew et al., 2010) and several other Gram-negative organisms including P. multocida (Davies et al., 2003b, Davies et al., 2003a, Davies et al., 2004), A. pleuropneumoniae (Chung et al., 2007), H. influenzae (Kaur et al., 2003), C. jejuni (Hobb et al., 2009), Shewanella oneidensis (Brown et al., 2010), Flavobacterium columnare (Liu et al., 2008), Coxiella burnetii (Papadioti et al., 2011), Helicobacter pylori (Baik et al., 2004) and Tannerella forsythia (Veith et al., 2009).

The mechanism of action of Sarkosyl is not fully understood, but it has been shown to be ineffective at dispersing LPS from the both *E. coli* and *Brucella abortus* cell envelopes which may also be the basis for its inability to solubilise the outer membrane (Moriyon and Berman, 1982). The length of its alkyl chain also appears to be a critical factor. Sarkosyl (which has an alkyl chain of 11 carbons) and Zwittergents 308 and 310 (alkyl chains of 8 and 10 carbons, respectively) are not effective in dispersing LPS in either *B. abortus* or *E. coli*,

whereas Zwittergents 312 and 316 (alkyl chains of 12 and 16 carbons, respectively) were very efficient at dispersing LPS in both bacteria (Moriyon and Berman, 1982). This suggests that a minimal alkyl chain length of 12 carbons is necessary for dispersing LPS and, therefore, that only detergents with 11 or fewer carbons are appropriate for the selective solubilisation of the inner membrane.

#### 1.7.1.2 Spheroplasting

Spheroplasting involves breaking the outer membrane using lysozyme and EDTA, which peels away from the cell while the cytoplasmic membrane remains intact (i.e. the spheroplast) and is pelleted by centrifugation (Birdsell and Cota-Robles, 1967, Hill and Sillence, 1997, Osborn and Munson, 1974, Witholt *et al.*, 1976, Costerto.Jw *et al.*, 1967). One of the limitations of this technique is that the outer membrane may not become completely separated from the inner membrane, allowing the possibility that some OMPs will not be present in the outer membrane fraction (Hobb *et al.*, 2009).

#### 1.7.1.3 Sucrose density gradient centrifugation

For sucrose density gradient centrifugation, a sucrose gradient is firstly created in a centrifuge tube whereby lower concentrations of sucrose are gently overlayed onto higher concentrations. Cell envelope samples are then loaded onto the top of the gradient and centrifuged. The membrane components move through the gradient until they reach the point at which their density matches that of the surrounding sucrose. The outer and inner membrane fractions are observed as separate bands within the gradient due to their different densities and can be subsequently isolated (Osborn *et al.*, 1972). Additional wash steps using chaotropic agents such as sodium bromide and sodium carbonate can be further used to remove contaminants (Schluesener *et al.*, 2005, Molloy *et al.*, 2000). Sucrose density gradient centrifugation is more laborious than detergentbased techniques and is generally not an appropriate technique for preparing several samples at once.

#### **1.7.2 MS principles and instrumentation**

Before the different strategies of MS-based OMP identification are discussed, it is first necessary to give an overview of the principles and instrumentation of MS. A
mass spectrometer consisting of three main components: an ion source that transfers peptides (from enzyme-digested proteins) into the gaseous phase, a mass analyser that measures the mass-to-charge (m/z) ratio of the ionised peptides, and a detector that records the number of ions at each m/z value. Protein identifications from MS data are made by peptide mass fingerprinting. By coupling two or more mass analysers together with a collision cell, peptides can be further fragmented to generate MS/MS spectra and produce protein identifications with greater sensitivity.

#### 1.7.2.1 Ionisation techniques

In order for peptides to be analysed by MS it must first be vaporised and ionised. The success of MS in the life sciences is largely due to the introduction of electrospray ionisation (ESI) (Yamashita and Fenn, 1984a, Yamashita and Fenn, 1984b, Fenn *et al.*, 1989, Lane, 2005) (Fig. 1.13A) and matrix-assisted laser desorption ionisation (MALDI) (Karas and Hillenkamp, 1988) techniques, which allow large, polar, thermally labile proteins to enter into the gaseous phase (Lane, 2005) (Fig. 1.13B).

Peptides to be ionised by ESI are first dissolved in a solvent. This solution flows through a small capillary tube to which a high voltage is applied, resulting in the release of a fine mist of charged droplets. As the droplets migrate to the counter electrode they pass through a heating element, allowing the solvent to evaporate leaving behind multiply-charged gas-phase ions.

MALDI sublimates and ionises samples out of a dry, crystalline matrix using laser pulses. Samples are co-crystallised with an excess of a matrix material that strongly absorbs light from a laser. The matrix expands into the gas phase as it absorbs light from the laser, taking with it intact peptides.

#### 1.7.2.2 Mass analysers

The mass analyser measures the m/z of ionised peptides to generate information-rich ion mass spectra from these peptides. There are four main types of mass analyser used in proteomics research: time-of-flight (TOF), quadrupole, ion trap and Fourier transform ion cyclotron (FT-MS) analysers. These can be either stand alone or, in some cases, put together in tandem to take advantage of the different strengths of each. Figure 1.13. Ionisation and peptide sample introduction processes: (A) matrix-assisted laser desorption/ionisation (MALDI) and (B) electrospray ionisation (ESI).

Figure was adapted from Lane et al. (2005).



MALDI is usually combined with TOF analysers (MALDI-TOF) (Aebersold and Mann, 2003), which determine m/z ratios by measuring the time that peptide ions take to move through a tube of specified length that is under vacuum (Fig. 1.14A). MS/MS analysis can be achieved by placing a collision cell either between two TOF analysers (MALDI-TOF-TOF) (Medzihradszky *et al.*, 2000) (Fig 1.14B) or between a quadrupole mass filter (described below) and a TOF analyser (MALDI-Q-TOF) (Loboda *et al.*, 2000). Ions of a particular m/z are selected in the first analyser, fragmented in the collision cell by collision-induced dissociation (CID) and the fragments read by the second analyser. MALDI-MS has traditionally been used to analyse relatively simple peptide mixtures, although MALDI-MS/MS can now facilitate the analysis of more complex samples.

ESI is most commonly coupled to triple quadrupoles for the generation of MS/MS spectra (Aebersold and Mann, 2003). A quadrupole consists of four parallel rods equally spaced around a central axis. One set of opposing rods have a direct current, the other an alternating current, producing opposing positive and negative fields. Peptide ions are introduced in a continuous beam along the central axis between the poles, and are filtered according to their m/z ratios. The two positive rods create a high-pass mass filter that allows ions above a critical m/z ratio to pass through the centre of the guadrupole. The two negative rods create a low-pass mass filter that allows ions below a critical m/zratio to pass through the centre of the guadrupole. The two overlapping mass filter regions create a 'band pass' area of mutual stability which allows ions of a certain m/z ratio to pass through. Ions outside of this area of mutual stability are not able to pass through the quadrupole and run into the rods. The m/z ratio of ions that are allowed to pass through the quadrupole is proportional to the voltage applied to the rods. For MS/MS analysis, three guadrupoles are combined whereby ions of a particular m/z are selected in the first, fragmented in the second by CID and the fragments read by third (Fig. 1.14C). The third quadrupole can also be substituted with a TOF analyser (ESI-QqTOF) to perform MS/MS analysis (Fig. 1.14D). ESI-MS systems are normally integrated with liquid chromatography (LC) technology for efficient separation of peptides prior to analysis.

Figure 1.14. Examples of mass spectrometers used in proteome research: (A) reflector time-of-flight (TOF), (B) time-of flight/time-of-flight (TOF-TOF), (C) triple quadrupole, (D) quadrupole time-of-flight (QqTOF).

Figure was adapted from Aebersold and Mann (2003).



#### 1.7.2.3 Peptide mass fingerprinting

Prior to analysis by MS, a protein must be digested into peptides using an enzyme of high specificity (such as trypsin). A highly specific enzyme ensures that the peptides are not too short (as almost any three or four residue peptide will be found in several database entries) and, if being analysed by MALDI-MS, that they do not fall into the low mass region (below ~500 Da) that is obscured by the presence of matrix peaks. After analysis by MS, a list of experimental peptide masses is generated that represents the peptide mass fingerprint of that particular protein. The protein is then identified by matching the experimental peptide masses to the calculated enzyme-digested peptide masses of protein entries on a database. Several parameters can be set prior to this database comparison to improve search performance. The digestion enzyme may not cleave the protein at all of the expected amino acid sites, therefore the number of missed cleavage sites can be set (usually only one or two) to allow for this. The range of experimental peptide mass values that are compared to the database can be set so that they are large enough to offer good discrimination, but not so large that they are likely to be peptides with missed cleavage sites. A peptide mass tolerance value can also be set to allow for small differences between experimental and theoretical peptide masses.

Confidence in protein identification may come from having independent supporting evidence. For example, if the protein originated from a protein band at approximately 60 kDa on a one-dimension (1-D) SDS-PAGE separation of bacterial proteins, then the anticipated result of a peptide mass fingerprint is a 60 kDa bacterial protein. If the protein with the closest peptide matches meets this expectation then the search can be deemed successful. If it is a 150 kDa protein from a different species then the search is likely to have failed. In addition to this approach, many MS search programmes provide a score for each protein match which reflects the significance of that match. The popular Mascot search engine (Perkins *et al.*, 1999) incorporates a probability based implementation of the molecular weight search (MOWSE) scoring algorithm (Pappin *et al.*, 1993). In Mascot, the significance level is normally set at 5%, so that if the score for a particular match exceeds this level there is less than a 1 in 20 chance that the observed match is a random event.

One of the main drawbacks to peptide mass fingerprinting is caused by uncertainty in the mass of intact proteins. A protein will often undergo posttranslational modification and processing after expression, resulting in experimental masses that are unlikely to be the same as that of the entry in the protein database. A peptide mass fingerprint can therefore only provide the statistically most probable identification, although this is still a much more advanced method than simply counting peptide mass matches. Peptide mass fingerprinting is also mostly suited to the identification of individual proteins, since mixtures of proteins create multiple peptide mass fingerprints and make protein identification more difficult.

#### 1.7.2.4 MS/MS ion search

An MS/MS ions search has a higher level of specificity compared to that achieved by peptide mass fingerprinting because, in addition to peptide mass, MS/MS provides information about peptide sequence. However, this information only provides detail of amino acid composition and is not easily translatable into full and unambiguous peptide sequences. The Mascot search engine again can be used to perform probability-based scoring using MS/MS data. Alternative software such as Sequest (Eng *et al.*, 1994) and MS-TAG (Mann and Wilm, 1994) are also available for MS/MS data analyses that use cross-correlation and peptide sequence tag approaches, respectively. Data from MS/MS is particularly useful when multiple proteins are present within a sample. Furthermore, relative abundance of different proteins can be estimated by the Exponentially Modified Protein Abundance Index (emPAI), which offers relative quantification of proteins in a mixture based on protein coverage by the peptide matches in a database search result.

#### 1.7.3 Membrane protein identification

There are two main approaches to the identification of membrane proteins using MS. The first is a combination of protein separation by 1-D SDS-PAGE or 2-DE and either MS or MS/MS (the gel-based approach). The second approach combines limited protein purification followed by MS/MS (the gel-free approach).

#### 1.7.3.1 Gel-based approach

The gel-based approach to identifying proteins by MS involves the separation of a complex mixture of proteins by either 1-D SDS-PAGE or 2-DE followed by subsequent in-gel trypsin digestion and peptide mass fingerprinting by MALDI-TOF. MALDI-TOF-TOF can also be used to perform MS/MS, which is more appropriate for analysis where more than one protein is expected to be present in a gel slice/spot.

One-dimensional SDS-PAGE is particularly useful for the separation of membrane proteins as they are readily solubilised upon heating in SDS sample buffer. The technique is also relatively quick and simple to perform, making it suitable for comparative analysis of several samples at the same time. The main disadvantage of 1-D SDS-PAGE is that proteins are separated only by molecular mass, which can result in inadequate quantification and resolution if proteins of similar molecular masses are present in the sample. However, relative quantification of different proteins within a protein band can be estimated using emPAI.

Two-dimensional electrophoresis couples isoelectric focusing in the first dimension followed by SDS-PAGE in the second dimension to allow the separation of complex mixtures of proteins by isoelectric point, molecular mass, solubility and relative abundance. However, there are limitations to the use of this technique for the separation of membrane proteins. Many membrane proteins are not solubilised in the non-detergent isoelectric focusing sample buffer due their hydrophobic nature, and those that are solubilised often precipitate at their isoelectric point (Wu and Yates, 2003). Isoelectric focusing with immobilised pH gradients also results in severe protein losses on 2-D gels as these membrane proteins do not enter the second dimension of separation (Pasquali et al., 1997, Adessi et al., 1997). More general disadvantages of 2-DE include the large amount of sample handling that is involved, poor reproducibility, and the extra time and labour that is required to perform the technique. Due to these limitations, 1-D SDS-PAGE is considered by some to be a more favourable strategy than 2-DE for the separation, resolution and identification of membrane proteins (Gorg et al., 2004).

#### 1.7.3.2 Gel-free approach

The gel-free proteomic approaches provides a powerful alternative to gel-based approaches. It involves using LC-ESI-MS/MS to identify proteins in complex mixtures (Hunt *et al.*, 1992). Proteins are trypsin-digested (without prior gel-based separation) and the peptide fragments separated by one or more steps of LC. The peptides are then ionised by ESI and subsequently enter the mass spectrometer, where a mass spectrum of the peptides eluting at this time point is taken. A prioritised list of peptides is generated by a computer and these are subsequently fragmented by energetic collision with gas. The resulting MS/MS spectrum is recorded and used to make protein identifications.

As with gel-based proteomic approaches the solubility of membrane proteins is also an issue for gel-free approaches. However, a number of methods have been developed to overcome this issue including the use of detergents (Han *et al.*, 2001), organic solvents (Blonder *et al.*, 2002, Goshe *et al.*, 2003) and organic acids (Washburn *et al.*, 2001). The main advantage of the gel-free approach is that it provides comprehensive coverage of all proteins within a complex protein sample without the need for prior gel-based separation. It also allows for the identification of low abundance proteins which may not be adequately resolved and identified by gel-based approaches.

## 1.8 Objectives of research

The objectives of this thesis were threefold. The first objective was to investigate the surface-exposure and immune specificity of OmpA among bovine and ovine *M. haemolytica* isolates. This work builds upon a previous study (Davies and Lee, 2004) which demonstrated that the amino acid sequences within hypervariable loop domains of *M. haemolytica* OmpA were very different in bovine and ovine isolates but were highly conserved among isolates recovered from the same host species. As a result of this it was hypothesised that the OmpA1 and OmpA2 proteins of bovine and ovine isolates, respectively, play an important role in adherence and are involved in host-specificity. To achieve this objective, recombinant OmpA1 (rOmpA1) and OmpA2 (rOmpA2) proteins were over-expressed, purified and used to generate anti-OmpA1 and anti-OmpA2 antibodies, respectively. These antibodies were then used to explore OmpA

surface-exposure and epitope specificity using electron microscopy and immunofluorescence techniques. Attempts were also made to crystallise rOmpA1.

The second objective was to characterise and compare the outer membrane subproteomes of seven M. haemolytica isolates and one M. glucosida isolate (that were carefully selected to represent different host origins, disease statuses, capsular serotypes, OMP-types and phylogenetic lineages) after growth in complex medium in order to identify OMPs with putative roles in hostspecificity and virulence under standard growth conditions. Previous work has demonstrated that bovine serotype A1 and A6 isolates and bovine serotype A2 M. haemolytica isolates are genetically distinct from ovine M. haemolytica isolates of the same serotypes, suggesting that different subpopulations of these serotypes are associated with disease in the two animals (Davies et al., 1997). Bovine and ovine isolates of these three serotypes can also be differentiated based on their OMP profiles (Davies and Donachie, 1996), suggesting that certain OMPs are likely to be involved in host specificity and virulence. Firstly, the entire repertoire of encoded OMPs in the genomes of three publicly available *M*. haemolytica genomes was predicted using a simple bioinformatic framework. Qualitative comparisons and amino acid sequence comparisons were performed on the OMPs predicted among the genomes to identify those with potential roles in host adaptation. Secondly, complementary proteomics approaches were used to identify these predicted OMPs in the outer membranes of the representative isolates after they had been grown in complex growth medium. This comparative approach provided a comprehensive overview of *M*. *haemolytica* and *M*. glucosida subproteomes and insights into the roles of OMPs in host-specificity, virulence and mechanisms of pathogenesis.

The third objective was to identify OMPs that were differentially expressed in the representative isolates after growth under *in vitro* conditions which were designed to mimic the *in vivo* host environment. These conditions included ironrestriction, serum-supplementation and solid-surface growth (in the absence or presence of Congo red dye). This approach allowed the identification of several potential virulence-associated proteins, many of which were not previously identified after growth in complex medium alone. Furthermore, an examination

of the extracellular subproteome of the representative isolates was undertaken after growth in iron-restricted and iron-replete media.

# 2. OUTER MEMBRANE PROTEIN A (OMPA) OF BOVINE AND OVINE ISOLATES OF *M. HAEMOLYTICA* IS SURFACE-EXPOSED AND CONTAINS HOST-SPECIES SPECIFIC EPITOPES

## 2.1 Introduction

The Gram-negative bacterium *M. haemolytica* is a commensal of cattle, sheep, and other ruminants, but also causes bovine and ovine pneumonic pasteurellosis; these infections are responsible for considerable economic losses to the livestock industries (Frank, 1989, Gilmour and Gilmour, 1989). Twelve different capsular serotypes of *M. haemolytica* have been identified to date, but A1 and A2 are the most prevalent (Highlander, 2001) and strains of these serotypes are responsible for the majority of pneumonia cases worldwide in cattle and sheep, respectively. M. haemolytica consists of genetically distinct subpopulations that are differentially adapted to, and elicit disease in, either cattle or sheep (Davies et al., 1997, Davies and Donachie, 1996). The molecular basis of host-adaptation and host-specificity in *M. haemolytica* is not understood, but it is likely that OMPs play important roles in these processes. The publication of the genome sequence of a bovine serotype A1 M. haemolytica isolate (Gioia et al., 2006) and, more recently, of the genome sequences of bovine and ovine serotype A2 isolates (Lawrence et al., 2010a), have revealed the presence of genes that encode various OMPs. Many of these proteins serve as adhesins that are involved in host receptor-specific binding (Daigneault and Lo, 2009) or as iron transport proteins (Roehrig et al., 2007).

There is growing evidence to suggest that the OmpA protein of *M. haemolytica* functions as an adhesin (Lo and Sorensen, 2007, Kisiela and Czuprynski, 2009). OmpA is a highly conserved, integral, OMP of Gram-negative bacteria that has been implicated in a diverse range of functions in different species [reviewed in (Smith *et al.*, 2007)]. It comprises an N-terminal transmembrane B-barrel domain embedded in the outer membrane and a C-terminal globular domain which extends into the periplasm to interact with the underlying peptidoglycan

(Demot and Vanderleyden, 1994). The N-terminal domain consists of eight membrane-traversing anti-parallel B-sheets and four relatively long, mobile, hydrophilic external loops (Pautsch and Schulz, 1998). In previous studies, molecular mass heterogeneity of OmpA was observed among bovine and ovine M. haemolytica isolates that correlated with the host of origin (Davies and Donachie, 1996). Subsequently, comparative nucleotide sequence analysis of the ompA gene from 31 M. haemolytica isolates revealed the presence of hypervariable domains within the four surface-exposed loops (Davies and Lee, 2004). The amino acid sequences of these domains are very different in bovine and ovine isolates but are highly conserved among isolates recovered from the same host species (Davies and Lee, 2004). The ompA gene can be categorised into four distinct allelic classes, I to IV. The class I (ompA1) alleles are associated almost exclusively with bovine *M. haemolytica* isolates, whereas the class II to IV (ompA2 to ompA4) alleles occur only in ovine M. haemolytica isolates (Davies and Lee, 2004). Significantly, the ompA1- and ompA2-type alleles are associated with the major pathogenic lineages of bovine (ET 1) and ovine (ETs 21 and 22) isolates, respectively (16). Based on the distribution of the OmpA1 and OmpA2 proteins among bovine and ovine isolates, respectively, and the localisation of the amino acid variation to the tips of the four loops, it was hypothesised that OmpA acts as a ligand, plays an important role in adherence and is involved in host-specificity (Davies and Lee, 2004). Subsequently, it was demonstrated that OmpA is involved in the binding of serotype A1 M. haemolytica to bovine bronchial epithelial cells (Kisiela and Czuprynski, 2009) and that fibronectin is a potential host receptor molecule in cattle (Lo and Sorensen, 2007).

The cell envelope of *M. haemolytica* is surrounded by a layer of capsular polysaccharide (CPS) (Adlam *et al.*, 1984, Lo *et al.*, 2001) which has been implicated in a number of functions including the adherence of the bacterium to alveolar surfaces (Brogden *et al.*, 1989, Whiteley *et al.*, 1990), inhibition of complement-mediated serum killing (Chae *et al.*, 1990), and inhibition of the phagocytic and bactericidal activities of neutrophils (Czuprynski *et al.*, 1989, Walker *et al.*, 1985). Visibly thicker capsules have been observed in *M. haemolytica* during *in vitro* early log phase growth compared to stationary phase growth in both capsular serotype A1 (Corstvet *et al.*, 1982) and A2 (Sutherland

*et al.*, 1990) isolates. Crucially, polysaccharide capsules have been shown to inhibit outer membrane adhesin function in a range of capsular types in different bacterial species (Schembri *et al.*, 2004, Virji *et al.*, 1995, Shifrin *et al.*, 2008, Favre-Bonte *et al.*, 1999). Indeed, an acapsular serotype A1 *M. haemolytica* mutant was shown to have greater fibronectin-binding activity than the capsular parental strain, suggesting a shielding role of the capsule. In other species, CPS may be downregulated upon contact with host cells (Deghmane *et al.*, 2002, Corcionivoschi *et al.*, 2009, Auger *et al.*, 2009) or as a consequence of phase variable expression (Krinos *et al.*, 2001, deVries *et al.*, 1996, Bacon *et al.*, 2001), thus allowing transient exposure of outer membrane adhesins. The shielding of OMPs, including OmpA, by CPS is likely to have important implications for the function of surface proteins but has yet to be investigated in *M. haemolytica*.

The objectives of this study were twofold. First, we wished to determine if the *M. haemolytica* OmpA protein is surface-exposed or whether it is masked by the polysaccharide capsule under various growth conditions. Second, we wanted to demonstrate whether the bovine OmpA1 and ovine OmpA2 proteins are antigenically distinct, i.e. whether antibodies raised against each of these proteins interact in a strain-specific manner. This would provide clues as to whether these proteins are likely to interact with host-cell receptors in a host-specific manner. To achieve these aims, recombinant OmpA1 (rOmpA1) and OmpA2 (rOmpA2) proteins were over-expressed, purified and used to generate anti-OmpA1 and anti-OmpA2 antibodies, respectively. These antibodies were used to explore OmpA surface-exposure and epitope specificity using electron microscopy and immunofluorescence techniques. In addition, attempts were made to determine the crystal structure of purified rOmpA1 using crystallisation screening methods and X-ray diffraction.

## 2.2 Materials and methods

#### 2.2.1 Bacterial strains and growth conditions

The *M. haemolytica* isolates used in this study are shown in Table 2.1. *E. coli* strains DH5 $\alpha$  and Rosetta 2 (DE3) pLysS were obtained from Invitrogen and Novagen, respectively. The *M. haemolytica* isolates were stored at -80°C in 50%

| Isolate | ET <sup>a</sup> | Serotype | Host<br>Species | Clinical<br>Status | Site of<br>Origin | ompA allele | Immunogold-labelling |                 | Immunofluorescence |                 |
|---------|-----------------|----------|-----------------|--------------------|-------------------|-------------|----------------------|-----------------|--------------------|-----------------|
|         |                 |          |                 |                    |                   |             | anti-<br>rOmpA1      | anti-<br>rOmpA2 | anti-<br>rOmpA1    | anti-<br>rOmpA2 |
| PH2     | 1               | A1       | Bovine          | Pneumonia          | Lung              | ompA1.1     | +                    | _               | +                  | _               |
| PH30    | 1               | A1       | Bovine          | Healthy            | Nasopharynx       | ompA1.1     | +                    | -               | +                  | +/              |
| PH376   | 1               | A6       | Bovine          | Pneumonia          | Lung              | ompA1.1     | +                    | _               | +                  | _               |
| PH540   | 2               | A1       | Bovine          | -                  | Nasopharynx       | ompA1.2     | +                    | _               | +                  | _               |
| PH202   | 21              | A2       | Bovine          | Healthy            | Nasopharynx       | ompA1.3     | +                    | _               | +                  | +/              |
| PH470   | 21              | A2       | Bovine          | Pneumonia          | Lung              | ompA1.3     | +                    | _               | +                  | -               |
| PH494   | 16              | A2       | Ovine           | Pneumonia          | Lung              | ompA1.4     | +                    | _               | +                  | -               |
| PH550   | 17              | A2       | Bovine          | Healthy            | Nasopharynx       | ompA1.5     | +                    | _               | +                  | +/              |
| PH8     | 6               | A1       | Ovine           | Pneumonia          | Lung              | ompA2.1     | -                    | +               | +/                 | +               |
| PH284   | 8               | A6       | Ovine           | Pneumonia          | Lung              | ompA2.1     | _                    | +               | +/                 | +               |
| PH66    | 10              | A14      | Ovine           | -                  | Lung              | ompA2.1     | _                    | +               | +/                 | +               |
| PH56    | 5               | A8       | Ovine           | Pneumonia          | Lung              | ompA2.2     | _                    | +               | +/                 | +               |
| PH278   | 21              | A2       | Ovine           | Pneumonia          | Lung              | ompA2.3     | _                    | +               | _                  | +               |
| PH292   | 22              | A2       | Ovine           | Pneumonia          | Lung              | ompA2.3     | -                    | +               | _                  | +               |
| PH196   | 18              | A2       | Bovine          | Healthy            | Nasopharynx       | ompA3.1     | -                    | +/              | _                  | +/              |
| PH296   | 12              | A7       | Ovine           | Pneumonia          | Lung              | ompA4.1     | _                    | +/              | _                  | +/              |
| PH484   | 14              | A7       | Ovine           | Pneumonia          | Lung              | ompA4.1     | -                    | +/-             | -                  | +/              |
| PH588   | 15              | A13      | Ovine           | Pneumonia          | Lung              | ompA4.2     | -                    | +/              | -                  | +/              |

## Table 2.1. Properties of bovine and ovine *M. haemolytica* isolates.

<sup>a</sup>ET = electrophoretic type (Davies *et al.*, 1997)

(v/v) glycerol in brain heart infusion (BHI) broth and were subcultured on BHI agar containing 5% (v/v) defibrinated sheep's blood (blood agar) overnight at 37°C. Liquid starter cultures were prepared by inoculating a few colonies into 10 ml volumes of BHI broth and incubating overnight at 37°C with shaking at 120 rpm. *E. coli* strain DH5 $\alpha$  was grown in Luria-Bertani (LB) broth containing 54 µg/ml carbenicillin. *E. coli* Rosetta 2 (DE3) pLysS was grown in LB broth containing 54 µg/ml carbenicillin and 34 µg/ml chloramphenicol. Both *E. coli* strains were grown at 37°C with shaking at 120 rpm.

#### 2.2.2 Capsule staining

The polysaccharide capsule of *M. haemolytica* was demonstrated using the Maneval method (Corstvet *et al.*, 1982).

#### 2.2.3 Preparation of chromosomal DNAs

Bacterial cells from 1 ml of overnight culture were harvested by centrifugation for 1 min at 13,000 × g and washed once with 1 ml of sterile distilled  $H_2O$ (d $H_2O$ ). DNAs were prepared using an InstaGene Matrix kit (Bio-Rad) according to the manufacturer's instructions and were stored at -20°C.

#### 2.2.4 PCR amplification and plasmid construction

The *M. haemolytica ompA* gene fragments corresponding to the transmembrane domain of OmpA1 (amino acid positions 19 to 217) and OmpA2 (amino acid positions 19 to 211) were amplified by PCR from total genomic DNA from *M. haemolytica* isolates PH2 and PH278, respectively, using the following forward and reverse primers: 5'-AAGTTCTGTTTCAGGGCCCGCAAGCTAACACTTTCTACGCAG G-3' and 5'-ATGGTCTAGAAAGCTTTAACCTTGACCGAAACGGTATG-3'. PCR products containing the *ompA1* or *ompA2* gene fragments were amplified from chromosomal DNA in 50 µl reaction mixes using Platinum Pfx DNA Polymerase (Invitrogen) with 2 mM MgSO<sub>4</sub> and 50 pmol of each forward and reverse primer. PCRs were carried out in a GeneAmp PCR System 9700 (Applied Biosystems) thermal cycler using the following amplification parameters: initial denaturation at 94°C for 2 min, followed by 30 cycles of denaturation at 94°C for 15 s, annealing at 65°C for 30 s, and extension at 68°C for 1 min 30 s. The production of PCR amplicons of the expected size was confirmed by electrophoresis in a 1% (w/v) agarose gel and visualisation with SybrSafe (Invitrogen). The PCR

amplicons were purified with a QIAquick PCR Purification Kit (Qiagen) and eluted in 30  $\mu$ l of sterile dH<sub>2</sub>O. Yields were assessed by agarose gel electrophoresis and the DNA stored at -20°C. The PCR products were cloned into separate pOPINF vectors (Oxford Protein Production Facility) (Berrow et al., 2007) according to the manufacturer's instructions. The resulting plasmids, designated ompA1/HispOPINF and ompA2/His-pOPINF, were verified by DNA sequencing. Five microlitres of ompA1/His-pOPINF or ompA2/His-pOPINF were added to a tube containing 50  $\mu$ L *E. coli* DH5 $\alpha$  cells (as supplied by the manufacturer) and incubated on ice for 30 min. The mixtures were heated in a water bath at 42°C for 30 s and returned to ice for 2 min. Four hundred and fifty microlitres of GS96 broth (QbioGene) were added to each tube, the contents mixed thoroughly and incubated at 37°C for 1 h. Transformant colonies were selected after plating onto LB agar containing 54  $\mu$ g/ml carbenicillin and incubating overnight at 37°C. An individual colony was used to inoculate 50 ml of LB containing 54 µg/ml carbenicillin and grown overnight at 37°C with shaking at 170 rpm. Five millilitres of the overnight culture were centrifuged at 5,000  $\times$  g for 15 min at 4°C to pellet the cells. Plasmids were recovered using a QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer's instructions and eluted in 50 µl of sterile dH<sub>2</sub>O. Plasmid size was confirmed by electrophoresis on a 1% (w/v) agarose gel and visualisation with SybrSafe (Invitrogen). The DNA was stored at -20°C.

#### 2.2.5 Expression of rOmpA.

Two microlitres of *ompA1*/His-pOPINF or *ompA2*/His-pOPINF plasmids recovered from *E. coli* DH5 $\alpha$  transformant cultures were added to a tube containing 100 µl *E. coli* Rosetta 2 (DE3) pLysS cells (Novagen) as supplied by the manufacturer and incubated on ice for 30 min. The bacterial cells were heated in a water bath at 42°C for 30 s and returned to ice for 2 min. Four hundred and fifty microlitres of GS96 broth were added to each tube, the contents mixed thoroughly and incubated at 37°C for 1 h. Transformant colonies were selected after plating onto LB agar containing 54 µg/ml carbenicillin and 34 µg/ml chloramphenicol and incubating overnight at 37°C. An individual colony was used to inoculate 15 ml LB and grown overnight at 37°C with shaking at 120 rpm. One hundred and fifty microlitres of overnight culture were inoculated into 30 ml LB broth containing 54 µg/ml carbenicillin and 34 µg/ml chloramphenicol and incubated at 37°C with shaking at 170 rpm until an OD<sub>600nm</sub> of 0.7-1.0 was achieved. Thirty microlitres of 1M isopropyl-B-D-thiogalactopyranoside (IPTG) was added and the culture incubated at 25°C with shaking at 170 rpm for a further 18 h. One and a half millilitres of overnight culture were centrifuged for 1 min at 13,000 × g and the pellet resuspended in 100 µl of sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. The sample was heated at 100°C for 5 min and analysed by SDS-PAGE to check for the presence of recombinant protein. A second colony from the *E. coli* Rosetta 2 (DE3) pLysS transformant plate was used to inoculate 15 ml LB broth and grown overnight at 37°C with shaking at 120 rpm. Two millilitres of overnight culture were used to inoculate each of eight 2-litre Ehrlenmeyer flasks containing 1 litre of LB broth supplemented with 54 µg/ml carbenicillin and 34 µg/ml chloramphenicol and incubated at 37°C with shaking at 170 rpm until an OD<sub>600nm</sub> of 0.7-1.0 was achieved. One millilitre of 1M IPTG was added and the culture incubated at 25°C with shaking at 170 rpm for a further 18 h.

#### 2.2.6 Purification of recombinant OmpA proteins (rOmpA1 and rOmpA2)

The protein purification protocol of Zhu et al. (Zhu et al., 2007) was followed, with modifications. Bacterial cells from each 1 litre of culture were harvested by centrifugation at  $10,000 \times g$  for 20 min at 4°C, resuspended in 25 ml of buffer A (25 mM Tris, 200 mM NaCl [pH 8.0]) and stored at -20°C. The cells from 2 litres of culture medium were disrupted by sonication (six cycles of 30 s on, 30 s off) and the lysates were centrifuged at  $4,700 \times g$  for 30 min at  $4^{\circ}C$  to pellet the inclusion bodies. These were resuspended in 1% Triton X-100 in buffer A and centrifuged at  $4,700 \times g$  for 30 min at  $4^{\circ}$ C. The inclusion bodies were solubilised overnight at 4°C in 50 ml of 6 M urea. The solubilised protein was added dropwise to 500 ml of 50 mM HEPES, 300 mM NaCl, 3% N,N-dimethyldodecylamine-Noxide (LDAO), 5 mM dithiothreitol (DTT) (pH 8.0) at 4°C and stirred slowly at 4°C for 72 h and dialysed against buffer B (50 mM Tris, 300 mM NaCl, 0.1% LDAO [pH 7.6]). The protein solution was loaded onto a 5 ml HiTrap (GE Healthcare) column equilibrated with buffer B. Bound recombinant protein was eluted from the column using an imidazole gradient (0 - 300 mM imidazole in buffer B) and collected in 5 ml fractions. Protein concentrations were quantified using a Perkin Elmer Lambda 40 UV/VIS Spectrophotometer. Ten milligrams of eluted protein were loaded onto a Superdex G-200 gel filtration column (Pharmacia Biotech) equilibrated with buffer B and collected in 5 ml fractions after running at 0.25 ml/min overnight. Concentrations of rOmpA in the collected fractions were determined by the modified Lowry procedure (Markwell *et al.*, 1978).

#### 2.2.7 Circular dichroism spectroscopy

Circular dichroism spectroscopy (Kelly *et al.*, 2005) was performed to examine the secondary structure of refolded PH2 rOmpA1 and PH278 rOmpA2. Mean residue ellipticity was measured between 190 and 240 nm on a Jasco J-810 Spectropolarimeter (Jasco, UK). Percentage estimates of secondary structure content ( $\alpha$ -helix,  $\beta$ -strand, turn, unordered) were calculated using the modified CONTINLL algorithm (Provencher and Glockner, 1981, Vanstokkum *et al.*, 1990) provided by the online server DICHROWEB (Lobley *et al.*, 2002, Whitmore and Wallace, 2008).

#### 2.2.8 Anti-OmpA antibody preparation

Purified rOmpA1 and rOmpA2 were sent to Eurogentec (Belgium; http://www.eurogentec.com/eu-home.html) and used to raise antibodies in rabbits using their 87-day Classic polyclonal antibody protocol. This protocol involves the injection of 0.2 mg of protein into each of two rabbits at days 0, 14, 28 and 56. Serum bleeds were obtained before the first injection (pre-immune) and 38, 66, and 87 (final bleed) days after the initial injection

#### 2.2.9 Serum cross-absorption

Two hundred and fifty millilitres of overnight cultures of PH2 and PH278 were centrifuged at  $10,000 \times g$  for 20 min at 4°C and the cells washed three times in 50 ml phosphate buffered saline (PBS). The bacterial cells were resuspended in 5 ml PBS and 1 ml aliquoted into each of five microfuge tubes. Each microfuge tube was centrifuged ( $13,000 \times g$ , 3 min) to pellet the cells and the supernatants removed. Cells from one tube were resuspended in 1 ml of heterologous final bleed serum and incubated at  $37^{\circ}$ C for 30 min on an orbital shaker. The cells were pelleted by centrifugation and the supernatant used to resuspend the cells in a second microfuge tube. These were incubated at  $37^{\circ}$ C for 30 min on an orbital shaker. This process was repeated for the remaining three tubes. The cross-absorbed sera were diluted 1:5 with dH<sub>2</sub>O, filter sterilised and stored at  $-80^{\circ}$ C.

#### 2.2.10 Isolation of OMPs

Briefly, OMPs of *M. haemolytica* isolates PH2 and PH278 were prepared as described by Davies et al. (1992). Bacterial growth was stopped by chilling the culture medium in ice-cold water for 5 min. Bacterial cells were harvested by centrifuging the culture medium at  $13,000 \times g$  for 20 min at 4°C. The pellet was washed in 50 ml of 20 mM Tris/HCl (pH 7.2) and centrifuged at  $12,000 \times g$  for 20 min at 4°C. The pellet was resuspended in 7 ml of 20 mM Tris/HCl (pH 7.2) and sonicated, on ice, for 5 min using a Soniprep sonicator (12 microns amplitude). The sonicated samples were brought to a total volume of 10 ml with additional 20 mM Tris/HCl (pH 7.2) and centrifuged at 11,000  $\times$  g for 30 min at 4° C to remove unbroken cells. The supernatants were centrifuged at  $84,000 \times g$  at 1 h for 4°C in a Sorvall ultracentrifuge to pellet the cell envelopes. The gelatinous pellets were vigourously resuspended in 0.5 % sodium N-lauroylsarcosine (Sarkosyl; Sigma) for 20 min at room temperature to solubilise the cytoplasmic membranes and then centrifuged at  $84,000 \times g$  for 1 h at 4°C to pellet the OMs. The gelatinous OMs were resuspended in 20 mM Tris/HCl (pH 7.2) and centrifuged at 84,000  $\times$  g for 1 h at 4°C. The final pellets were resuspended in approximately 1 ml of 20 mM-Tris/HCl (pH 7.2). Fifty microlitre aliquots of these suspensions were transferred to separate tubes and their protein concentrations determined by the modified Lowry procedure. One hundred microlitre aliquots of the OM suspensions were adjusted to 2 mg/ml with 20 mM Tris/HCl (pH 7.2) and stored at -80°C.

#### 2.2.11 SDS-PAGE

OMPs were separated by 1-D SDS-PAGE in a 12% polyacrylamide gel using the SDS continuous system (Laemmli, 1970) and the Hoefer SE600 electrophoresis equipment as previously described (Davies *et al.*, 1992).

#### 2.2.12 Western blotting

Briefly, Western-blotting was performed essentially as described by (Davies *et al.*, 1994b). SDS-PAGE gels were equilibrated in transfer buffer (25mM Tris, 192mM glycine [pH 8.3]) for 30 min and the proteins were transferred to nitrocellulose membranes overnight at 30 V. The nitrocellulose membranes were washed twice in TBS (20 mM Tris, 50 mM NaCl [pH 7.5]) for 5 min, blocked with

3% gelatin in TBS for 1 h and washed twice in TTBS (0.05% Tween 20 in TBS) for 5 min each. The membranes were incubated with final bleed anti-rOmpA antibody diluted 1:100 in antibody buffer (1% gelatin in TTBS) for 1 h at room temperature and washed twice in TTBS for 5 min each. This was followed by incubation with secondary horse radish peroxidase-conjugated anti-rabbit antibody diluted 1:1000 in antibody buffer for 1 h at room temperature, two 5 min washes in TTBS and one 5 min wash in TBS. The membranes were developed in a substrate solution containing 0.05% (w/v) 4-chloro-napthol (dissolved in 20 ml of ice-cold methanol) and 0.05% (v/v) hydrogen peroxide in 100 ml of TBS. Development was stopped by washing the membranes in dH<sub>2</sub>O.

#### 2.2.13 Immunogold electron microscopy

Bacterial cells from 25 ml volumes of 6 or 8 h BHI broth cultures, or 6 h BHI broth cultures containing 100  $\mu$ M 2,2'-dipyridyl, were harvested by centrifugation at  $3,500 \times g$  for 5 min and washed once with PBS. Alternatively, overnight cultures of bacteria were scraped off blood agar plates and washed once in PBS. The washed cells were resuspended in PBS to an OD<sub>600nm</sub> of 0.4 (equivalent to  $1.0 \times 10^8$  cfu/ml). One milliliter of this suspension was centrifuged at 13,000  $\times$  g for 1 min and the pellet resuspended in 1 ml 4% paraformaldehyde in PBS (pH 7.2) for 30 min at room temperature. The cells were washed twice in 50 mM glycine in PBS and resuspended in 0.5 ml 0.2% bovine serum albumin (BSA) in PBS for 30 min. The cells were centrifuged and resuspended in 100 µl primary anti-rOmpA antibody (1:10 dilution) in 0.2% BSA in PBS, incubated for 1 h, washed three times in 0.2% BSA in PBS and finally resuspended in 200 µl of 0.2% BSA in PBS. Twenty microlitres of this suspension were dropped onto a freshly prepared Poly L-Lysine-coated Formvar carboncoated nickel grid, allowed to stand for 15 min and the excess fluid removed. The grids were floated face-down on 50 µl of secondary goat anti-rabbit IgG antibody conjugated to 10 nm gold particles (1:20 dilution) in 0.2% BSA in PBS and incubated for 1 h at room temperature. The grids were washed once in 0.2% BSA in PBS, three times in PBS (1 min each), and once in 1% glutaraldehyde in PBS (pH 7.4) for 5 min. The grids were finally washed three times with filtered de-ionized water (1 min each), allowed to air dry, and the bacteria visualised using a Zeiss 912 AB energy filtering transmission electron microscope operating under standard conditions at 80 kV.

#### 2.2.14 Immunofluorescence staining

Bacteria were grown overnight on blood agar, resuspended in 5 ml PBS and adjusted to an  $OD_{600nm}$  of 0.5. The bacterial cells were mixed 1:1 with 8% paraformaldehyde in PBS (2×) for ten min. Five microlitres of bacterial suspension were added to each well of a multiwell microscope slide (Hendley-Essex, UK), allowed to air dry, and incubated with 20 µl of primary anti-rOmpA antibody (1:100 dilution) in 0.1% BSA in PBS for 60 min at room temperature. The slides were washed three times in 0.1% BSA in PBS and incubated with 20 µl of Alexa Fluor 488 (Invitrogen) goat anti-rabbit IgG antibody (15 µg/ml in 0.1% BSA in PBS) for 30 min. The slides were washed three times in 0.1% BSA in PBS and allowed to air dry. One or two drops of fluorescence mounting medium (Dako, Sweden) were added to each slide, covered with a cover slip, and sealed with clear nail varnish. Bacteria were visualised with a Zeiss Axioskop fluorescence microscope.

#### 2.2.15 Crystallisation and X-ray analysis of rOmpA1

Buffer B containing purified and refolded rOmpA1 was replaced with 0.6% tetraethylene glycol monooctyl ether ( $C_8E_4$ ) in dH<sub>2</sub>O using a PD-10 buffer exchange column (GE Healthcare) and the eluted rOmpA1 protein concentrated to 40 mg/ml. Crystallisation screens of rOmpA1 in 0.6%  $C_8E_4$  were set up by mixing 1 µl protein solution and 1 µl reservoir solution in MemGold and MemSys crystallisation screening trays (Molecular Dimensions) using the sitting-drop vapour diffusion method. Full details of screening conditions are shown in Appendices 7.3 and 7.4. Crystals were transferred to reservoir solution containing a cryoprotectant, mounted on a LithoLoop (Molecular Dimensions, UK), and placed directly in a cold nitrogen-gas stream at 100 K. X-ray diffraction images were collected using the MAR345dtb image plate detector system (MAR Research, Germany).

### 2.3 Results

# 2.3.1 Recombinant OmpA proteins are comprised predominantly of βsheets and exhibit heat-modifiability after heat treatment in the presence of SDS.

Heat-modifiability is a characteristic property of the OmpA family of proteins (Reithmeier and Bragg, 1974, Nakamura and Mizushima, 1976, Beher et al., 1980). The native form of the complete OmpA protein unfolds in the presence of SDS only after heat treatment at 100°C which exposes additional SDS-binding sites (Ohnishi et al., 1998, Dornmair et al., 1990). When analysed by SDS-PAGE, OmpA migrates through the gel according to its structural compactness with the native protein migrating faster than the fully denatured polypeptide (Dornmair et al., 1990, Kleinschmidt et al., 1999). Recombinant OmpA proteins from the *M. haemolytica* bovine isolate PH2 (rOmpA1) and ovine isolate PH278 (rOmpA2) were successfully expressed, purified and refolded. Mass spectrometric analysis of gel-extracted protein bands confirmed that native and heat-modified proteins (described below) represented M. haemolytica OmpA (Supplementary Table S2.1). The rOmpA1 and rOmpA2 proteins were heated at a range of temperatures between 50 and 100°C for 5 min prior to SDS-PAGE and both proteins exhibited heat-modifiability when analysed by SDS-PAGE, although this occurred at different temperatures (Fig. 2.1A). The native and heat-modified proteins migrated at approximately 24 and 22.5 kDa, respectively; however, PH2 rOmpA1 unfolded at 70°C whereas PH278 rOmpA2 unfolded at 100°C (Fig. 2.1A, arrows). In contrast, the native and heat-modified forms of the complete OmpA protein recovered from the outer membrane of *M. haemolytica* isolates PH2 and PH278 migrated at approximately 32 and 38 kDa, respectively, on SDS-polyacrylamide gels (Fig. 2.1B). In this case, the full-length OmpA protein of both isolates underwent heat modification at 100°C (Fig. 2.1B, arrows). The finding that rOmpA1 unfolds more readily at a lower temperature than rOmpA2 indicates a less stable structure for rOmpA1. Circular dichroism spectroscopy analysis predicted that the secondary structures of both recombinant proteins comprised predominantly B-sheets and turns, indicating that they have folded into a Bbarrel conformation similar to native *M. haemolytica* OmpA (Fig. 2.2). However, PH2 rOmpA1 has a lower B-sheet composition than PH278 rOmpA2 (33.6% and

#### Figure 2.1. Heat-modifiability of recombinant and full-length OmpA proteins of *M. haemolytica* isolates PH2 and PH278.

Panels A and B represent purified recombinant proteins rOmpA1 (PH2) and rOmpA2 (PH278) and Sarkosyl-extracted OMPs of bovine isolate PH2 (OmpA1) and ovine isolate PH278 (OmpA2), respectively. Samples were heated for 5 min at 50, 60, 70, 80, 90 and 100°C prior to separation by SDS-PAGE. Unmodified low-molecular-mass and heat-modified high-molecular-mass forms of rOmpA (A) and full-length OmpA (B) of isolates PH2 and PH278 are indicated by thick and thin arrows, respectively.



# Figure 2.2. Circular dichroism spectroscopy analysis of purified rOmpA proteins.

Mean residue ellipticity was measured between 190 and 240 nm for PH2 rOmpA1 ( $\blacktriangle$ ) and PH278 rOmpA2 ( $\blacksquare$ ). Percentage estimates of secondary structure content ( $\alpha$ -helix, B-strand, turn, unordered) for each recombinant protein were calculated using the modified CONTINLL algorithm (Provencher and Glockner, 1981, Vanstokkum *et al.*, 1990) provided by the online server DICHROWEB (Lobley *et al.*, 2002, Whitmore and Wallace, 2008).



| Protein | α-helix | β-strand | Turn  | Unordered | Total |
|---------|---------|----------|-------|-----------|-------|
| rOmpA1  | 0.109   | 0.336    | 0.228 | 0.327     | 1     |
| rOmpA2  | 0.08    | 0.406    | 0.213 | 0.301     | 1     |

40.6%, respectively), which is consistent with the heat-modifiability results indicating a less stable structure for PH2 rOmpA1.

# 2.3.2 Anti-rOmpA1 and anti-rOmpA2 antibodies exhibit immune-specificity for the homologous proteins.

The binding specificities of the anti-rOmpA1 and anti-rOmpA2 antibodies to Sarkosyl-extracted OMPs and rOmpA from the bovine isolate PH2 and the ovine isolate PH278 were assessed by Western blotting (Fig. 2.3). Unabsorbed antirOmpA1 antibodies bound to the full-length OmpA and rOmpA proteins of both PH2 [Fig. 2.3A(ii)] and PH278 [Fig. 2.3B(ii)]. Similarly, unabsorbed anti-rOmpA2 antibodies bound to the full-length OmpA and rOmpA proteins of both PH2 [Fig. 2.3A(iii)] and PH278 [Fig. 2.3B(iii)]. Significantly, no other M. haemolytica proteins were recognised by either antibody in the complete Sarkosyl-extracted OMP samples. After cross-absorption with the heterologous isolate PH278, antirOmpA1 antibodies bound to PH2 OmpA and rOmpA1 [Fig. 2.3A(iv)] but not PH278 OmpA and rOmpA2 [Fig. 2.3B(iv)]. Similarly, anti-rOmpA2 antibodies cross-absorbed with the heterologous isolate PH2 bound to PH278 OmpA and rOmpA2 [Fig. 2.3B(v)] but not PH2 OmpA and rOmpA1 [Fig. 2.3A(v)]. However, the intensity of staining with the cross-absorbed antisera was noticeably weaker than for the unabsorbed antisera. These results indicate that the cross-absorbed anti-rOmpA1 and -rOmpA2 antibodies bind specifically to OmpA1 and OmpA2, respectively.

## 2.3.3 *M. haemolytica* OmpA is surface-exposed and recognised by antirOmpA antibodies *in vitro* in a strain-specific manner.

The ability of anti-rOmpA antibodies to recognise OmpA on the surface of *M*. *haemolytica* was assessed by immunogold labelling (Fig. 2.4) and immunofluorescent staining (Fig. 2.5). Immunogold labelling demonstrated that the OmpA proteins of *M*. *haemolytica* isolates PH2 and PH278 are both recognised by unabsorbed anti-rOmpA1 [Fig. 2.4A and B(i)] and anti-rOmpA2 [Fig. 2.4A and B(ii)] antibodies. However, cross-absorbed anti-rOmpA1 antibodies recognised OmpA of isolate PH2 [Fig. 2.4A(iii)] but not of isolate PH278 [Fig. 2.4B(iii)]; conversely, cross-absorbed anti-rOmpA2 antibodies recognised OmpA of isolate PH2 [Fig. 2.4A(iii)] but not of isolate PH278 [Fig. 2.4B(iii)]. Antibody binding was evenly distributed over the surface of the bacterial cells and was

Figure 2.3. Western-blot analysis of anti-rOmpA antibody binding to fulllength OmpA and rOmpA of *M. haemolytica* isolates PH2 and PH278.

> Panels A and B represent protein samples from bovine isolate PH2 and ovine isolate PH278, respectively. Lanes 1 and 2 represent Sarkosyl-extracted OMPs and purified rOmpA, respectively. The protein samples were separated by SDS-PAGE and either stained with Coomassie blue (i) or transferred to nitrocellulose (ii to v). The blotted proteins were probed with anti-rOmpA1 antibodies (ii), anti-rOmpA2 antibodies (iii), anti-rOmpA1 antibodies after crossabsorption with isolate PH278 (iv) and anti-rOmpA2 antibodies after cross-absorption with isolate PH2 (v). This was followed by incubation with secondary goat horse radish peroxidase-conjugated anti-rabbit antibody. Molecular mass markers (in kDa) are shown on the right.



# Figure 2.4. Immunogold labelling of the OmpA protein of *M. haemolytica* isolates PH2 and PH278 using anti-rOmpA antibodies.

Panels A and B represent bovine isolate PH2 and ovine isolate PH278, respectively. Isolates were incubated with anti-rOmpA1 antibodies (i), anti-rOmpA2 antibodies (ii), anti-rOmpA1 antibodies after cross-absorption with isolate PH278 (iii), and anti-rOmpA2 antibodies after cross-absorption with isolate PH278 (iv). This was followed by incubation with secondary goat anti-rabbit IgG antibody conjugated with 10 nm gold particles. Isolates were visualised by electron microscopy. Magnification was × 10,000.

Immunogold labelling images were produced by Dr. Mojtaba Noofeli.



Figure 2.5. Immunofluorescent staining of *M. haemolytica* isolates PH2 and PH278 using cross-absorbed anti-rOmpA1 and anti-rOmpA2 antibodies.

Panels A and B represent bovine isolate PH2 and ovine isolate PH278, respectively. Isolates were incubated with anti-rOmpA1 antibodies after cross-absorption with isolate PH278 (i) or anti-rOmpA2 antibodies after cross-absorption with isolate PH2 (ii). These were then incubated with Alexa Fluor 488 (Invitrogen) goat anti-rabbit IgG antibody. Bound antibodies were visualised by immunofluorescence microscopy.

Immunofluorescent staining images were produced by Miss Susan Baillie.



not concentrated in any particular area. In addition, the density of labelling of isolate PH278 by the cross-absorbed anti-rOmpA2 antibody [Fig. 2.4B (iv)] was greater than that of PH2 by the cross-absorbed anti-rOmpA1 antibody [Fig. 2.4A (iii)] suggesting greater exposure of the OmpA2 protein in isolate PH278. Immunofluorescent staining confirmed that cross-absorbed anti-rOmpA1 antibodies recognised OmpA in isolate PH2 [Fig. 2.5A(i)] but not in isolate PH278 [Fig. 2.5B(i)], and that cross-absorbed anti-rOmpA2 antibodies recognised OmpA in isolate PH2 [Fig. 2.5A(i)] but not in isolate PH278 [Fig. 2.5B(ii)] but not in isolate PH278 [Fig. 2.5B(ii)].

\* Immungold labelling and immunofluorescent staining work was carried out by Dr. Mojtaba Noofeli and Miss Susan Baillie, respectively, in this section and also in sections 2.3.4 and 2.3.5.

# 2.3.4 OmpA is surface-exposed at different stages of the growth cycle and after growth in different media.

Isolates PH2 and PH278 were grown for 6 h (logarithmic phase) and 18 h (stationary phase) in BHI broth and cells incubated with cross-absorbed antirOmpA1 or anti-rOmpA2 antibodies. No differences were observed in the degree of antibody binding between bacteria grown for 6 and 18 h (results not shown). These results demonstrated that there was no appreciable difference in OmpA surface-exposure between logarithmic and stationary-phase cells. Isolates PH2 and PH278 were also grown for 18 h on blood agar or in iron-restricted (100 µM 2,2'-dipyridyl) BHI broth and cells incubated with cross-absorbed anti-rOmpA1 or anti-rOmpA2 antibodies. Again, no differences were observed in antibody binding between bacteria grown in iron-restricted BHI broth or on blood agar plates compared to bacteria grown in BHI broth (results not shown). Capsulation of bacteria grown under these various conditions was also examined by Maneval staining (results not shown); there were no major differences between isolates grown under different conditions with the exception that 18 hour stationary phase cultures contained cells that were less consistent in overall size and shape. Taken together, these results demonstrated that OmpA is not masked by the polysaccharide capsule and that the degree of surface-exposure remains relatively unchanged when bacteria are grown under different growth conditions. For subsequent experiments bacterial cells were grown in BHI broth for 6 h. \*Maneval staining work was carried out by Dr. Mojtaba Noofeli.

# 2.3.5 Binding specificities of cross-absorbed anti-rOmpA1 and anti-rOmpA2 antibodies to *M. haemolytica* isolates representing different OmpA subclasses.

Eleven distinct ompA alleles have previously been identified among 31 M. haemolytica isolates; these alleles were assigned to four subclasses, ompA1 to ompA4 (Davies and Lee, 2004). Individual alleles within each subclass were designated ompA1.1, ompA1.2, etc. The binding specificities of cross-absorbed anti-rOmpA1 and anti-rOmpA2 antibodies to 18 M. haemolytica isolates representing all eleven ompA alleles were determined by immunogold labelling and immunofluorescent staining (Table 2.1). Five ompA1-type alleles, representing the class I lineage, have been identified in *M. haemolytica* and these are associated almost exclusively with bovine isolates (Davies and Lee, 2004). The single exception, ovine isolate PH494, possesses a bovine-like LktA2type leukotoxin (Davies et al., 2001) in addition to a bovine-like OmpA1-type protein, and most likely represents a strain of bovine origin that has recently transferred to sheep. Anti-rOmpA1 antibodies were raised against bovine isolate PH2 OmpA, which possesses the ompA1.1 allele. At the amino acid level, OmpA1.1 is identical to OmpA1.2 and OmpA1.3; OmpA1.4 differs from OmpA1.1 at two amino acid positions in HV1 and OmpA1.5 differs from OmpA1.1 in having four amino acid deletions in HV1 (Figure 2.6). Cross-absorbed anti-rOmpA1 antibodies bound to all eight OmpA1-type *M*. haemolytica isolates when examined by both immunogold labelling and immunofluorescent staining (Table 2.1). Cross-absorbed anti-rOmpA2 antibodies showed a negative binding response to all OmpA1-type isolates when examined by immunogold labelling, although weak fluorescence was detected in three isolates when examined by immunofluorescent staining (Table 2.1).

Three *ompA2*-type alleles, representing the class II lineage, have been identified in *M. haemolytica* and these are associated exclusively with ovine isolates (Davies and Lee, 2004). Anti-rOmpA2 antibodies were raised against ovine isolate PH278 OmpA, which possesses the *ompA2.3* allele. OmpA2.1 and OmpA2.2 are identical and differ from OmpA2.3 at one amino acid position in HV1 and one in HV3 (Figure 2.6). Cross-absorbed anti-rOmpA2 antibodies showed positive binding to all six OmpA2-type *M. haemolytica* isolates when examined by both immunogold labelling and immunofluorescent staining (Table 2.1). There was a

# Figure 2.6 Distribution of variable amino acids in the transmembrane domains of the 11 OmpA proteins of *M. haemolytica*.

The major allele classes are represented by Roman numerals I to IV. Amino acid positions are designated above the sequences. Amino acids that match those of the first sequence are represented by dots. Gaps are indicated by dashes. The hypervariable regions within surface-exposed loops 1 to 4 are designated by HV1 to HV4. Membrane-spanning B-strands are shaded.



negative binding response to all OmpA2-type isolates with cross-absorbed antirOmpA1 antibodies when examined by immunogold labelling, although weak fluorescence was detected in four isolates by immunofluorescent staining (Table 2.1).

The *ompA3.1* allele, also belonging to the class II lineage, is associated with the bovine isolate PH196. The OmpA3.1 protein was recognised by cross-absorbed anti-rOmpA2 (weakly) but not by anti-rOmpA1 antibodies when examined by immunogold labelling and immunofluorescent staining. Two *ompA4*-type alleles, representing the class III lineage, have been identified in *M. haemolytica* and these are associated with ovine serotype A7 and A13 isolates. The OmpA4-type proteins (OmpA4.1 and OmpA4.2) were recognised by cross-absorbed anti-rOmpA2 (weakly) but not by anti-rOmpA1 antibodies when examined by immunogold labelling and immunofluorescent staining.

#### 2.3.6 Crystallisation of rOmpA1

Crystals of rOmpA1 in 0.6%  $C_8E_4$  detergent were obtained within 3 months of incubation in a MemSys crystallisation screening tray (Fig. 2.7). No crystals were obtained using the MemGold crystallisation screening tray. X-ray diffraction experiments were performed on rOmpA1 crystals from each screening condition shown in Fig. 2.7. None of the rOmpA1 crystals produced X-ray diffraction data, indicating that further optimisation of screening conditions will be necessary to improve crystal quality.

# 2.4 Discussion

In the present study, it has been clearly demonstrated that the OmpA protein of *M. haemolytica* is surface-exposed and able to bind anti-rOmpA antibodies *in vitro*. This was initially demonstrated in the bovine and ovine isolates PH2 and PH278 (Figs. 2.4 and 2.5), but was subsequently confirmed in a wide range of *M. haemolytica* isolates (Table 2.1). The degree of surface-exposure of OmpA in PH2 and PH278 was not affected by the stage of growth (i.e., logarithmic versus stationary phase) or the growth medium (i.e., blood agar and iron-replete or iron-restricted broth). Since a well-developed capsule was observed by Maneval staining in these isolates under different growth conditions, these findings strongly suggest that the capsule does not mask the OmpA protein since antibody

#### Figure 2.7. Crystallisation of rOmpA1 using a MemSys screening tray.

Panels A to D represent crystals that were obtained within three months of incubation in (A) 0.1 M MOPS, pH 7.0, 30% v/v PEG 400; (B) 0.1 M MOPS, pH 7.0, 12% PEG w/v 4000; (C) 0.1 M Na HEPES, pH 7.5, 12% w/v PEG 4000 and (D) 0.1 M sodium chloride, 0.1 M Na HEPES, pH 7.5, 12% w/v PEG 4000.



binding seemed unaffected. However, in a previous study the OmpA protein of an acapsular mutant was shown to have higher fibronectin-binding activity than the capsular parental strain (Lo and Sorensen, 2007), suggesting that the capsule may partially mask the protein.

The loops of the *M*. haemolytica OmpA protein range from 25 to 31 amino acids in length (Davies and Lee, 2004) and are estimated to extend less than 10 nm from the bacterial surface. However, the capsule of the parental strain of the acapsular mutant described above has been observed by electron microscopy to extend almost 200 nm from the bacterial surface (McKerral and Lo, 2002). It is therefore puzzling as to how the loops of OmpA are recognised by antibodies and, presumably, by host cell molecules through a capsule of this thickness. The M. haemolytica capsule is structurally fragile and it is possible that in vitro manipulation of bacterial cells causes sloughing of the capsule in some areas which exposes the tips of the loops and allows antibody binding. However, uniform immunogold labelling clearly demonstrated that OmpA is evenly distributed over the bacterial cell surface. The loops of the OmpA protein of M. haemolytica are longer than those of the OmpA protein of E. coli (Pautsch and Schulz, 1998), but not as long as the loops of other OMPs such as neisserial opacity (Opa) proteins which can extend to over fifty amino acids in length (de Jonge *et al.*, 2003). There are a number of reasons why OMPs might evolve loops of different lengths. The neisserial Opa proteins are involved in binding to host receptors and longer loops could be seen as advantageous for increasing the distance range to which they can bind host molecules. It is also reasonable to hypothesise that OMPs involved in host molecule binding might evolve loops which are long enough to traverse the capsule. However, this is contradicted by findings that long loops are still present in unencapsulated species such as N. gonorrhoeae and H. influenzae. Longer loops have also been correlated with virulence in neisserial species, where commensal organisms have shorter hypervariable domains (and thus shorter loops) than pathogenic species (Malorny et al., 1998). There is evidence to suggest that in a number of bacterial species the capsule can be downregulated upon contact with host cells (Deghmane et al., 2002, Corcionivoschi et al., 2009, Auger et al., 2009) and as a consequence of phase variable expression (Krinos et al., 2001, deVries et al., 1996, Bacon et al., 2001), thus allowing transient exposure of OMP adhesins. Also, blebbing of

outer membrane vesicles has been observed in several Gram-negative bacteria [reviewed in (Kulp and Kuehn, 2010)], allowing OMPs to traverse the capsule and reach the extracellular environment. These phenomena have not been demonstrated in *M. haemolytica*, although they would provide appropriate mechanisms for the transient exposure of OmpA and other adhesin molecules for host-molecule binding.

A wider examination of the binding specificities of the cross-absorbed antibodies to M. haemolytica isolates representing different ompA subclasses demonstrated that anti-rOmpA1 antibodies recognise OmpA1-type (class I) proteins present in bovine isolates, but not OmpA2-type (class II) proteins that occur in ovine isolates. Conversely, cross-absorbed anti-rOmpA2 antibodies recognise OmpA2but not OmpA1-type proteins. The ability of cross-absorbed anti-rOmpA antibodies to discriminate between OmpA proteins of the OmpA1 and OmpA2 subclasses is due to the greater degree of amino acid sequence variation (within the hypervariable domains) between each of the two subclasses compared to the variation within each subclass (Davies and Lee, 2004). There are only two variable amino acid sites within the OmpA1-type proteins; similarly, there are only two variable amino acid sites within the OmpA2-type proteins. However, there are 18 variable amino acid sites within the transmembrane domains of OmpA1 and OmpA2, all of which occur within the hypervariable regions (i.e., HV1 to HV4) located at the distal ends of the four external loops. The greater degree of variation between the two OmpA subclasses, compared to within each subclass, is sufficient to allow the cross-absorbed antibodies to discriminate between the bovine OmpA1- and ovine OmpA2-type subclasses. Overall, these results clearly demonstrate that the OmpA1 and OmpA2 proteins are sufficiently different in structure and epitope specificity that they are potentially capable of recognising host receptor molecules of differing specificities in cattle and sheep.

Previous studies have demonstrated that OmpA functions as a ligand, is involved in binding to specific host cell receptor molecules, and plays an important role in adherence and colonisation in a number of Gram-negative bacteria (Prasadarao *et al.*, 1996, Bookwalter *et al.*, 2008, Dabo *et al.*, 2003, Hill *et al.*, 2001, Reddy *et al.*, 1996, Millman *et al.*, 2001, Prasadarao, 2002, Torres and Kaper, 2003). In particular, it has been shown that the OmpA protein of bovine serotype A1 isolates of *M. haemolytica* binds to fibronectin (Lo and Sorensen, 2007) and to bovine bronchial epithelial cells (Kisiela and Czuprynski, 2009). However, a potential role of OmpA as an adhesin has yet to be investigated in ovine isolates of *M. haemolytica*. It has been previously shown that the OmpA1 and OmpA2 proteins are associated exclusively with bovine and ovine isolates, respectively, which led to the hypothesis that they are involved in binding to host-specific receptors in the upper respiratory tracts of these animals (Davies and Lee, 2004). This, in turn, might partially account for the different hostspecificities of strains carrying the OmpA1 and OmpA2 protein types. Importantly, the present work has extended this previous study (Davies and Lee, 2004) by demonstrating that the binding specificities of the OmpA1 and OmpA2 proteins are very different from each other but are conserved within bovine and ovine M. haemolytica isolates representing different capsular serotypes and evolutionary lineages; there is no association between allele/protein type and clinical status (Table 2.1). From the findings of the present study, it is reasonable to conclude that OmpA1 and OmpA2 are capable of binding to different receptors within cattle and sheep, respectively. Although bovine fibronectin has been demonstrated to be a potential receptor for the OmpA protein of a bovine serotype A1 strain (Lo and Sorensen, 2007), it is interesting that the OmpA (P5) protein of the related species H. influenzae targets a different molecule, namely the carcinoembryonic antigen (CEA) family of cell adhesion molecules. Thus, it is reasonable to speculate that different molecular variants or regions of fibronectin, or even different molecules, are targeted in cattle and sheep. The production of antibodies against OmpA1 and OmpA2, and the demonstration that they are highly strain and protein specific, will allow further studies to be performed designed to investigate the role of OmpA in the adherence and colonisation of *M. haemolytica* in cattle and sheep.

Commercial vaccines have been produced and are important for the prevention of respiratory disease in both cattle and sheep (Bowland and Shewen, 2000, Hjerpe, 1990). Several studies have demonstrated the importance of *M*. *haemolytica* OMPs as surface antigens and their potential as vaccine components (Morton *et al.*, 1995, Confer *et al.*, 1995, Mosier *et al.*, 1989, Pandher *et al.*, 1999, Ayalew *et al.*, 2010). Antibodies against the immunogenic and surfaceexposed lipoprotein PlpE contribute towards host defence (Pandher *et al.*, 1998) and the addition of recombinant PlpE to commercial vaccines significantly
enhances protection against experimental challenge (Confer et al., 2003, Confer et al., 2006). The incorporation of iron-regulated proteins into a vaccine was shown to enhance protection against experimental pasteurellosis in lambs (Gilmour *et al.*, 1991). An edible vaccine that expresses a fragment of the outer membrane antigen GS60 has also been developed (Lee et al., 2008). Immune sera from cattle vaccinated with live or killed M. haemolytica cells (Mahasreshti et al., 1997), and immune sera from naturally infected cattle (Zeng et al., 1999), contain antibodies that recognise OmpA. In addition, in the closely related species *P. multocida*, OmpA is the major protein that cattle produce antibodies to after experimental challenge (Prado et al., 2005). Clearly, OmpA is an important immunogen that should be considered for inclusion in M. haemolytica subunit vaccines. However, a critical property of any vaccine candidate is a high degree of amino acid conservation throughout bacterial populations. Hypervariability of surface-exposed loop regions is a common occurrence within OMPs of many bacterial species and poses a serious problem for vaccine design (Webb and Cripps, 1998, Duim et al., 1997, Bolduc et al., 2000, Martin et al., 2000). It was previously demonstrated that four distinct OmpA classes occur within bovine and ovine *M. haemolytica* strains; OmpA1 and OmpA2 are associated with those strains that are responsible for the majority of disease in cattle and sheep, respectively, and have very different hypervariable domains within their surface-exposed loops (Davies and Lee, 2004). In the present study, it has been shown that antibodies specific for the surface-exposed loops of OmpA1 will not recognise the same regions of OmpA2 and vice versa. Therefore, an animal exposed to OmpA1 will generate anti-OmpA antibodies that are unlikely to confer protection against M. haemolytica isolates possessing OmpA2 and vice versa (although some cross-reacting antibodies may be present). These findings clearly have important implications with regard to vaccine development and, in particular, to the inclusion of OmpA in subunit vaccines that are designed to provide universal protection against heterologous M. haemolytica isolates. Essentially, an OmpA-based M. haemolytica subunit vaccine would need to include OmpA from more than one class to provide universal protection against heterologous strains.

# 3. COMPARATIVE OUTER MEMBRANE PROTEOMIC ANALYSES OF BOVINE AND OVINE ISOLATES OF *M. HAEMOLYTICA* AND *M. GLUCOSIDA* GROWN IN COMPLEX MEDIUM

### 3.1 Introduction

The Gram-negative bacterium M. haemolytica is the etiological agent of bovine and ovine pneumonic pasteurellosis, infections that are responsible for considerable economic losses to the livestock industries (Highlander, 2001). Twelve different capsular serotypes of *M. haemolytica* have been identified to date. Serotype A1 isolates are most commonly associated with cases of bovine pneumonic pasteurellosis, although serotype A6 isolates are responsible for an increasing proportion of disease cases. Serotype A2 isolates are often recovered from the nasopharynxes of healthy cattle but seldom cause disease. In contrast, serotype A2 isolates are responsible for the majority of disease cases of ovine pneumonic pasteurellosis. A wide range of other serotypes are also associated with sheep, including serotypes A1 and A6, although these are recovered much less frequently than serotype A2 isolates. M. glucosida was previously classified as the A11 serotype of *M*. haemolytica and comprises a heterogeneous group of organisms with low virulence that are mainly opportunistic pathogens of sheep (Angen et al., 1999a, Davies et al., 1997). Bovine serotype A1 and A6 isolates and bovine serotype A2 M. haemolytica isolates are genetically distinct from ovine *M. haemolytica* isolates of the same serotypes, suggesting that different subpopulations of these serotypes are associated with disease in the two animals (Davies *et al.*, 1997). Bovine and ovine isolates of these three serotypes can also be differentiated based on their OMP profiles (Davies and Donachie, 1996) and nucleotide sequence variation of the ompA gene (Davies and Lee, 2004). These observations suggest that certain OMPs are likely to be involved in host specificity and virulence. However, the mechanisms by which OMPs facilitate host-specific infection and disease in *M. haemolytica* are poorly understood.

The outer membrane is an asymmetrical lipid bilayer comprising an inner leaflet of phospholipid and an outer leaflet of mainly LPS. It serves as a selective

barrier for the passage of nutrients and other materials into and out of the cell and is at the interface between bacterium and host. Two types of proteins are also present in the outer membrane: integral OMPs and lipoproteins. Integral OMPs span the outer membrane with amphipathic antiparallel B-strands that adopt a barrel-like conformation. Outer membrane lipoproteins are anchored to the outer membrane by N-terminal lipid modifications made at the inner membrane. The majority of proteins that are destined to be located in the outer membrane contain specific protein modifications, sorting signals and structural signatures that can be differentiated using bioinformatic prediction tools (Gromiha, 2005, Gromiha and Suwa, 2006, Jackups et al., 2006, Juncker et al., 2003). These predictors have been used to identify and quantify OMPs of several Gram-negative bacteria (Diaz-Mejia et al., 2009, Berven et al., 2006, Boyce et al., 2006, Huntley et al., 2007, Viratyosin et al., 2008). A simple bioinformatic prediction framework encompassing three categories of bioinformatic predictors (and 10 prediction programmes) was recently developed to predict the total number of OMPs encoded in two P. multocida genomes (E-Komon et al., 2011b). Complementary proteomic analyses can also be implemented to identify these putative OMPs in outer membrane fractions isolated from the bacterial cell envelope. Different proteomic methods have been used to characterise the outer membrane subproteome of several Gram-negative bacteria (Liu et al., 2008, Molloy et al., 2000, Cordwell et al., 2008, Veith et al., 2009). including the related species P. multocida (Boyce et al., 2006, E-Komon et al., 2011a) and A. pleuropneumoniae (Chung et al., 2007).

In *M. haemolytica*, much effort has been given to comparing OMP expression between different isolates (Davies and Donachie, 1996, Davies *et al.*, 1992, McCluskey *et al.*, 1994, Morton *et al.*, 1996), characterising individual OMPs (Davies and Lee, 2004, Nardini *et al.*, 1998, Pandher and Murphy, 1996, Cooney and Lo, 1993, Lo *et al.*, 1991), and identifying those of immunological importance (Pandher *et al.*, 1999, McVicker and Tabatabai, 2002). In a recent study an immunoproteomic approach was used to identify potential vaccine candidate antigens in a bovine serotype A1 isolate (Ayalew *et al.*, 2010). A number of studies have also investigated the roles of specific OMPs in *M. haemolytica* adherence to host tissue and cells (Kisiela and Czuprynski, 2009, Daigneault and Lo, 2009, Lo and Sorensen, 2007, De la Mora *et al.*, 2006).

However, a comprehensive analysis of the *M*. *haemolytica* outer membrane subproteome has yet to be performed.

The objectives of this study were twofold. First, the entire repertoire of OMPs encoded in the genomes of a bovine serotype A1 M. haemolytica isolate (Gioia et al., 2006) and two serotype A2 isolates (one bovine and one ovine) (Lawrence et al., 2010a) were predicted using the same bioinformatic prediction approach developed for P. multocida (E-Komon et al., 2011b). Comparative amino acid sequence analyses were also performed to identify predicted OMPs that could be involved in host-specific adaptation. Second, the OMPs present in the outer membrane fractions of seven M. haemolytica isolates which were carefully selected to represent different host species, disease statuses, capsular serotypes, OMP-types and phylogenetic lineages (Davies *et al.*, 1997, Davies and Donachie, 1996) were identified and compared using a combination of gel-based and gel-free proteomic approaches. The outer membrane fraction of a single M. glucosida isolate was also investigated for comparison. This is the first study to provide a comparative analysis of the outer membrane subproteomes of multiple isolates of *M. haemolytica*. This comparative approach will provide insights into the roles of OMPs in host-specificity in bovine and ovine hosts and identity putative virulence determinants and mechanisms of pathogenesis.

### 3.2 Materials and methods

#### 3.2.1 Bioinformatic prediction of genome-encoded OMPs

The publicly available genomes of a bovine serotype A1 *M. haemolytica* isolate (GenBank ID: AASA0000000), an ovine serotype A2 isolate (GenBank ID: ACZY0000000) and a bovine serotype A2 isolate (GenBank ID: ACZY0000000) were used for all bioinformatic analyses. All *M. haemolytica* protein sequences (2695, 2682 and 2552 open reading frames from the bovine serotype A1, ovine serotype A2 and bovine serotype A2 genomes, respectively) were retrieved from NCBI. Each genome was scrutinised by bioinformatic approaches according to the workflow described by E-Komon *et al.* (2011b) to predict proteins which localise to the outer membrane. Each genome was analysed by three categories of bioinformatic prediction software, using a total of ten prediction tools. Subcellular localisation predictors included Proteome Analyst (Szafron *et al.*,

2004), PSORTb (Gardy et al., 2005), CELLO (Yu et al., 2006) and SOSUI-GramN (Imai *et al.*, 2008); B-barrel predictors included TMB-Hunt (Garrow *et al.*, 2005), TMBETADISC-RBF (Ou et al., 2008), MCMBB (Bagos et al., 2004) and BOMP (Berven et al., 2004); and outer membrane lipoprotein predictors included LipoP (Juncker et al., 2003) and LIPO (Berven et al., 2006). A consensus prediction framework was followed whereby proteins that were predicted to (a) be localised to the outer membrane by at least two subcellular localisation predictors, (b) have a B-barrel conformation by at least three B-barrel predictors or (c) be outer membrane lipoproteins by at least one lipoprotein predictor, were considered to be putative OMPs. In several instances, two predicted proteins within a genome were determined to constitute a single functional protein and were therefore grouped as such. A list of putative OMPs within each genome was produced by integrating the results from each of the predictor categories. A final integrated list of putative OMPs from all three genomes was produced by performing BLAST searches to determine whether each putative OMP was present in one, two or all three genomes. When a putative OMP was present in only one or two genomes, a protein BLAST search was performed against all annotated proteins to determine whether it was actually present or not in these other genome(s). Similarly, nucleotide BLAST searches were performed against whole genome shotgun contigs (ctgs) in these other genomes to determine whether a gene encoding an OMP was present but had not been annotated. Proteins with close homology at the amino acid level in more than one genome were assumed to have similar functions and were assigned the same protein name. The putative OMPs were further scrutinised using additional domain, homology and literature searches to assign likely functions and to predict their subcellular localisations with greater confidence. Based on this further information, each putative OMP was assigned to one of three localisation categories: (1) confidently predicted OMPs, (2) putative OMPs without predicted subcellular location, and confidently (3) false positives. Physiochemical properties including molecular mass, theoretical pl, aliphatic index, grand average of hydropathicity (GRAVY) score, number of B-strands and helices, of putative OMPs were predicted by ProtParam (Gasteiger et al., 2005), TMHMM (Krogh et al., 2001), and TMBETA-NET (Jackups et al., 2006).

#### 3.2.2 Bacterial isolates and growth conditions

The eight bacterial isolates used in the present study are shown in Table 3.1. These included seven representative M. haemolytica isolates recovered from cattle (two) and sheep (five) and one *M. glucosida* isolate. These isolates were selected to represent the major clonal groups and electrophoretic types (ETs) that were previously identified by multilocus enzyme electrophoresis (MLEE) (Davies et al., 1997) (Fig. 3.1) and comparative analyses of capsular serotypes, OMP profile types and disease statuses (McCluskey et al., 1994, Davies and Donachie, 1996) (Table 3.1). Isolates were stored at  $-80^{\circ}$ C in 50% (v/v) glycerol in brain heart infusion (BHI) broth and were subcultured on BHI agar containing 5% (v/v) defibrinated sheep's blood overnight at  $37^{\circ}$ C. For preparation of outer membrane fractions, liquid starter cultures were prepared by inoculating a few colonies into 15 ml volumes of BHI broth and incubating overnight at 37°C with shaking at 120 rpm. Eight hundred microlitres of overnight culture were used to inoculate a 2-litre Ehrlenmeyer flask containing 400 ml of BHI broth and incubated at 37°C with shaking at 120 rpm until an OD<sub>600nm</sub> of 0.8-0.9 was achieved.

#### 3.2.3 Preparation of OMPs.

Outer membrane proteins were prepared by Sarkosyl extraction as previously described in section 2.2.10.

#### 3.2.4 Gel-based proteomic analysis

Twenty micrograms of each OMP preparation were separated by 1-D SDS-PAGE in a 12% linear polyacrylamide gel using the SDS discontinuous system (Laemmli, 1970) and the Hoefer SE600 electrophoresis equipment as previously described (Davies *et al.*, 1992, McCluskey *et al.*, 1994, Davies and Donachie, 1996, Davies *et al.*, 1994a). Proteins were visualised by staining with Coomassie brilliant blue. A total of 444 gel pieces, including both gel bands and gel fractions without protein bands from all isolates were manually excised and each gel piece placed into separate wells of 96-well plates. Automated in-gel trypsin digests were completed using an Ettan Spot Handling Workstation (Amersham Biosciences) according to the procedure described by Bridges *et al.* (Bridges *et al.*, 2008). Briefly, gel pieces were washed three times in 100 µl of 50 mM ammonium

| Isolate        | Animal<br>host | Electrophoretic<br>type <sup>a</sup> | Capsular<br>serotype | OMP<br>type | Disease<br>status |
|----------------|----------------|--------------------------------------|----------------------|-------------|-------------------|
| M. haemolytica |                |                                      |                      |             |                   |
| PH2            | Bovine         | 1                                    | A1                   | 1.1.1       | Pneumonia         |
| PH8            | Ovine          | 6                                    | A1                   | 1.2.1       | Pneumonia         |
| PH202          | Bovine         | 21                                   | A2                   | 2.1.2       | Healthy           |
| PH278          | Ovine          | 21                                   | A2                   | 2.2.2       | Pneumonia         |
| PH292          | Ovine          | 22                                   | A2                   | 2.2.1       | Pneumonia         |
| PH296          | Ovine          | 12                                   | A7                   | 3.1.1       | Pneumonia         |
| PH588          | Ovine          | 15                                   | A13                  | 3.3.2       | Pneumonia         |
| M. glucosida   |                |                                      |                      |             |                   |
| PH344          | Ovine          | N/A                                  | A11                  | 3.2.2       | Septicaemia       |
|                |                |                                      |                      |             |                   |

Table 3.1.Properties of seven representative *M. haemolytica* isolates and<br/>one *M. glucosida* (PH344) isolate.

Figure 3.1. Evolutionary relationships of seven representative *M. haemolytica* isolates and one *M. glucosida* (PH344) isolate, based on MLEE analysis.

Figure adapted from Davies et al. (1997).



bicarbonate, 50% v/v methanol and then twice in 100  $\mu$ l of 75% v/v acetonitrile (ACN) before drying. Gel pieces were rehydrated with trypsin solution [20  $\mu$ g trypsin/ml (Promega) in 20 mM ammonium bicarbonate] and incubated at 37°C for 4 h. Peptides were extracted by washing the gel pieces twice in 100  $\mu$ l of 50% v/v ACN, 0.1% v/v trifluoroacetic acid (TFA), before being transferred in solution to a new 96-well plate and dried. Dried peptide samples were stored at -20°C until analysed by MALDI-TOF-TOF MS and/or LC-ESI-QqTOF MS.

#### 3.2.5 Gel-free proteomic analysis

Outer membrane fractions were directly digested with trypsin without prior separation by 1-D SDS-PAGE using the methanol-aided trypsin digestion protocol as previously described by Bridges *et al.* (Bridges *et al.*, 2008). Briefly, twenty microlitres of 4 mg/ml protein was resuspended in 44  $\mu$ l of 50 mM ammonium bicarbonate and placed in a sonicator bath for 20 min (with regular vortexing), before being incubated at 60°C for 20 min. Samples were placed on ice for 3 min before adding 60  $\mu$ l of methanol and incubating for a further 5 min in the sonicator bath with regular vortexing. Sixteen microlitres of 200  $\mu$ g/ml trypsin (Promega) in 25mM ammonium bicarbonate was added followed by 60  $\mu$ l of methanol. After vortexing briefly samples were incubated at 37 °C for 12-16 h. The digested samples were dried down in an Eppendorf SpeedVac and stored at -20°C until analysis by mass spectrometry.

#### 3.2.6 MALDI-TOF-TOF MS and data analysis

One microlitre of peptide solution was mixed with an equivalent volume of matrix solution (10 mg cyano-4-hydroxycinnamic acid in 500  $\mu$ l 50% ACN, 0.1% TFA) on a MALDI-TOF target plate. Peptides were analysed using an Applied Biosystems 4700 Proteomics Analyzer. MS/MS was performed on the ten most intense precursor ions in each peptide sample. GPS Explorer Software (Applied Biosciences) was used to automate submission of collected data to MASCOT for searching the NCBI Eubacteria protein database with methionine oxidation selected as a variable modification, peptide and MS/MS tolerances of 1.2 and 0.5 Da, respectively, with one missed cleavage allowed. Only proteins identified with a significant MOWSE score ( $p \le 0.05$ ) were accepted. Each peptide sample was analysed three times. Any unidentified peptide samples were further analysed by LC-ESI-QqTOF MS.

#### 3.2.7 LC-ESI-QqTOF MS and data analysis

The peptide samples obtained by gel-free trypsin-digestion were analysed by ESI-MS on a QSTAR XL Hybrid LC/MS/MS System according to the parameters described in Bridges *et al.* (Bridges *et al.*, 2008). Briefly, MASCOT Daemon Software (Matrix Science) was used to automate submission of collected data to MASCOT for searching the NCBI Eubacteria protein database with methionine oxidation selected as a variable modification, peptide and MS/MS tolerances of 1.2 and 0.4 Da, respectively, with one missed cleavage allowed. Only proteins identified with a significant MOWSE score ( $p \le 0.05$ ) were accepted.

#### 3.3 Results

#### 3.3.1 Bioinformatic prediction of OMPs in three *M. haemolytica* genomes.

Ten different bioinformatic tools were used to predict putative OMPs encoded in the fully-sequenced genomes of three *M. haemolytica* isolates (bovine serotype A1, ovine serotype A2 and bovine serotype A2) following the bioinformatic workflow of E-Komon et al. (2011b). These tools were categorised into three groups: subcellular localisation predictors (PA, PSORTb, CELLO, SOSUI-GramN), B-barrel protein predictors (TMB-Hunt, TMBETADISC-RBF, BOMP, MCMBB), and outer membrane lipoprotein predictors (LIPO and LipoP). One hundred and sixtyfour, 174 and 163 unique protein annotations (Supplementary Tables S3.1, S3.2) and S3.3) were predicted to be putative OMPs in the bovine serotype A1, ovine serotype A2 and bovine serotype A2 genomes, respectively, after following a consensus prediction framework and subsequently integrating the results within each genome. In some instances, two predicted annotations within a genome were deemed to comprise a single protein and were subsequently paired together to represent one protein. This reduced the number of putative OMPs to 164, 168 and 154 in the bovine serotype A1, ovine serotype A2 and bovine serotype A2 genomes, respectively. BLAST searches were performed on putative OMP amino acid sequences to determine if each was present in one, two or all three genomes. In some instances a protein was predicted to be a putative OMP in one or two genomes, but was not predicted in the other genome(s) despite its presence in that genome(s). This most often occurred when a protein annotation in one proteome had been annotated so that an important signal motif, such as an N-terminal signal sequence, had been excluded from the annotation and hence not recognised by the bioinformatic predictors. Similarly, nucleotide BLAST searches were also performed against whole-genome shotgun contigs in each genome to determine if OMP-encoding genes were present that had not been annotated. Proteins which fell into these categories were included in the predicted proteins in their respective genomes. This amended the numbers of putative OMPs to 196, 202 and 188 in the bovine serotype A1, ovine serotype A2 and bovine serotype A2 genomes, respectively. A total of 217 unique putative OMPs were predicted across the three genomes. Of these proteins, 102 (47%), 67 (31%) and 114 (53%) were predicted by subcellular localisation, B-barrel and outer membrane lipoprotein predictor categories, respectively. The 217 putative OMPs were further scrutinised using additional domain, homology and literature searches to predict the subcellular location of each protein with greater confidence and to remove false positives (Fig. 3.2). In this way, 93 (42.9%) proteins were confidently predicted to localise at the outer membrane (Table 3.2). Seventy proteins could not be predicted with great confidence to be localised to a particular subcellular compartment and were likely to include false positives as well as some true OMPs (Supplementary Table S3.4). Furthermore, 54 proteins were predicted to be localised to the cytoplasm, inner membrane, periplasm, or extracellular compartment and were therefore determined to be false-positives (Supplementary Table S3.5). Of the 93 confidently predicted OMPs, 63 (68%) were predicted by subcellular localisation predictors, 44 (47%) by B-barrel predictors, and 39 (42%) by outer membrane lipoprotein predictors (Fig. 3.3A). Eighty-nine proteins were present in the bovine serotype A1 genome, 92 in the ovine serotype A2 genomes and 92 in the bovine serotype A2 genome (Fig. 3.3B), with 88 being present among all three genomes. Five OMPs were present in either one or two genomes (Table 3.3). Ninety-two OMPs were present among both bovine and ovine genomes, of which four were exclusively present in both the bovine and ovine serotype A2 genomes One OMP (PulD), was exclusively present in only the bovine serotype A1 genome. There were no OMPs present exclusively in either of the serotype A2 genomes. The finding that there were more OMPs present in both the bovine and ovine serotype A2 genomes (four) than between the bovine serotype A1 genome and either the bovine serotype A2 genome (zero) or the ovine serotype A2 genome (zero) is consistent with the hypothesis of serotype A2 host switching from cattle

Figure 3.2. Subcellular locations of 217 putative OMPs predicted by 10 bioinformatic prediction tools across three *M. haemolytica* genomes after further domain, homology and literature searches had been carried out on each protein.



Outer membrane (42.8%)

□ Unknown (32.3%)

Cytoplasm (10.6%)

- □ Inner membrane (6.9%)
- Periplasm (6.9%)
- □ Extracellular (0.4%)

| Name                       | Bovine A1 <sup>a</sup> | Ovine A2 <sup>a</sup> | Bovine A2 <sup>a</sup> | Protein function  | Sub <sup>b</sup> | ТМ <sup>ь</sup> | Lipo <sup>b</sup> | Isol <sup>c</sup> |
|----------------------------|------------------------|-----------------------|------------------------|---|------------------|-----------------|-------------------|-------------------|
| 1. Outer membrane biogenes | is and integrity       |                       |                        |   |                  |                 |                   |                   |
| OmpA                       | MHA_1054               | COI_1980              | COK_0402               | Outer membrane integrity                                      | +                | +/-             | -                 | 8                 |
| Omp85                      | MHA_0691               | COI_1174              | COK_1967               | Correct OMP folding and assembly                              | +                | +               | -                 | 8                 |
| Imp/LptD                   | MHA_0291               | COI_2627              | COK_0922               | LPS assembly  | +                | +               | -                 | 8                 |
| Pal                        | MHA_0263               | COI_2595              | COK_1835               | Cell envelope integrity/peptidoglycan anchor                  | +                | -               | +                 | 8                 |
| VacJ                       | MHA_2837               | COI_1320              | COK_1388               | Phospholipid homeostasis                                      | -                | -               | +                 | 7                 |
| LppB/NlpD                  | MHA_1804               | COI_0885              | COK_0647               | Cell wall formation and maintenance                           | +                | +               | +                 | 4                 |
| RIpB/LptE                  | MHA_0669               | COI_1194              | COK_1987               | LPS assembly  | -                | -               | +                 | 3                 |
| MltC                       | MHA_0242               | COI_0470              | COK_0285               | Peptidoglycan maintenance and processing                      | +                | -               | +                 | 3                 |
| ComL                       | MHA_1560               | COI_0129              | COK_2068               | Outer membrane biogenesis/DNA transport                       | +                | -               | +                 | 3                 |
| MItA                       | MHA_1133               | COI_1670              | COK_0590               | Peptidoglycan maintenance and processing                      | +                | +               | +                 | 2                 |
| LolB                       | MHA_2544               | COI_0062              | COK_2183               | Chaperone & lipoprotein transport activity                    | +                | -               | +                 |                   |
| NIpE                       | MHA_1616               | COI_0339              | COK_2132               | Cell envelope stress response/copper homeostasis<br>regulator | -                | -               | +                 |                   |
| SmpA                       | MHA_1340               | COI_0370              | COK_0445               | Cell envelope integrity and $\beta$ -barrel protein assembly  | -                | -               | +                 |                   |
| WzzB                       | MHA_0727               | COI_1084              | COK_0353               | Lipopolysaccharide biosynthesis                               | +                | -               | -                 |                   |
| MltB                       | ctg173_107             | COI_2519              | COK_0949               | Peptidoglycan maintenance and processing                      | _                | -               | +                 |                   |

#### Table 3.2. Functional classifications of 93 confidently predicted OMPs encoded by three *M. haemolytica* genomes.

<sup>a</sup> Proteins annotations are shaded in grey if they were not predicted by bioinformatic software but have a homologue that was predicted in another genome.

Proteins annotations which were predicted by bioinformatic software are not shaded. Absence of protein homologue is shown by '-'

<sup>b</sup> Subcellular localisation, transmembrane β-barrel and lipoprotein prediction result; '+' = predicted in all genomes; '-' = not predicted in any genome;

+/-' = predicted in one/two genomes (see Supplementary tables 1-3 for specific result)

<sup>c</sup> The number of representative isolates that each protein has been identified in (see Table 3 and Figure 4)

| Name                      | Bovine A1 | Ovine A2   | Bovine A2  | Protein function   | Sub | тм  | Lipo | Isol |
|---------------------------|-----------|------------|------------|--|-----|-----|------|------|
| 2. Transport and receptor |           |            |            |  |     |     |      |      |
| TolC                      | MHA_1410  | COI_0732   | COK_0022   | Protein secretion/transporter activity                   | +   | +   | +    | 8    |
| OmpP1/FadL                | MHA_0639  | COI_1221   | COK_2014   | Hydrophobic compound transport                           | +   | +   | -    | 8    |
| Wza                       | MHA_0527  | COI_1313   | COK_0141   | Capsular polysaccharide transport                        | +   | +   | +    | 8    |
| OmpP2-like                | MHA_1793  | COI_0051   | COK_2166   | Porin/ion transport activity                             | +   | +   | -    | 8    |
| FrpB                      | MHA_2109  | COI_0085   | COK_0218   | Receptor and transporter activities                      | +   | +   | -    | 8    |
| TbpA                      | MHA_0196  | COI_2333   | COK_1753   | Transferrin receptor & transport                         | +   | +   | -    | 7    |
| OmpP4                     | MHA_2158  | COI_0840   | COK_2233   | Heme acquisition/factor V utilisation                    | +   | -   | +    | 6    |
| OmpP2                     | MHA_0735  | ctg112     | COK_1380   | Porin/ion transport activity                             | +   | +   | -    | 4    |
| FhaC                      | MHA_0867  | COI_0226   | COK_0335   | Secretion of filamentous haemagglutinin (FhaB)           | +   | +   | -    | 3    |
| OmpW                      | MHA_2399  | COI_1652/3 | COK_1583/4 | Small hydrophobic molecule transport                     | +   | -   | -    | 2    |
| TonB-dependent receptor   | MHA_0860  | COI_1565   | COK_2304   | Receptor and transporter activities                      | +   | +   | -    | 2    |
| HmbR1                     | MHA_2261  | COI_2258   | COK_1624   | Haemoglobin receptor                                     | +   | +   | -    | 2    |
| HxuB                      | MHA_1005  | COI_1367   | COK_1209   | Heme-hemopexin acquisition                               | +   | +   | -    | 2    |
| ТbpВ                      | MHA_0197  | COI_2332   | COK_1752   | Transferrin receptor & transport                         | +   | +/- | +    | 1    |
| HxuC                      | ctg59     | COI_1368   | COK_1207/8 | Heme-hemopexin acquisition                               | +   | +   | -    | 1    |
| TonB-dependent receptor   | MHA_1346  | COI_1921   | ctg265     | Receptor and transporter activities                      | +   | +   | -    | 1    |
| LamB                      | MHA_0232  | COI_2297   | COK_1718   | Maltoporin transport                                     | +   | +   | -    |      |
| ComE                      | MHA_0164  | COI_2362   | COK_1782   | DNA transport  | +   | -   | -    |      |
| PulD                      | MHA_2514  | -          | -          | Secretin   | +   | -   | -    |      |
| HxuA                      | MHA_1004  | COI_1366   | COK_1210   | Heme-haemopexin acquisition (Subcellular location: OM/E) | -   | -   | +    |      |
| FhuA                      | ctg68     | COI_1905   | COK_2465   | Ferric hydroxamate receptor                              | +   | +   | -    |      |

| Name                      | Bovine A1        | Ovine A2   | Bovine A2   | Protein function                                     | Sub | ТМ  | Lipo | Isol |
|---------------------------|------------------|------------|-------------|--|-----|-----|------|------|
| FhuE                      | MHA_1541         | COI_0658   | COK_1513    | Ferric hydroxamate receptor                          | +   | +   | _    |      |
| HmbR2                     | ctg86            | COI_1762/3 | COK_2539/40 | Haemoglobin receptor                                 | +   | +   | _    |      |
| Haemin receptor           | ctg61            | COI_2252/3 | COK_1629/30 | Haemin receptor                                      | +   | +   | -    |      |
| Haemin-uptake lipoprotein | MHA_2255         | COI_2251   | COK_1631    | Haemin-uptake lipoprotein                            | -   | -   | +    |      |
| TonB-dependent receptor   | ctg58            | COI_0092   | COK_0224    | Receptor and transporter activities                  | +   | -   | _    |      |
| TonB-dependent receptor   | ctg85            | COI_0006   | COK_0109    | Receptor and transporter activities                  | +   | -   | -    |      |
| TonB-dependent receptor   | ctg58            | COI_0090   | COK_0222    | Receptor and transporter activities                  | -   | +   | _    |      |
| 3. Adherence              |                  |            |             |  |     |     |      |      |
| YadA-like                 | MHA_0302         | COI_2651   | COK_0897/8  | Adherence  | +   | +   | -    | 2    |
| Hsf                       | MHA_2701         | COI_2393   | COK_1437    | Adherence  | +   | +/- | -    |      |
| Hia                       | MHA_1367         | COI_1943/5 | COK_2433/5  | Adherence  | +   | -   | -    |      |
| Ahs                       | ctg73_110_124_88 | COI_1315   | COK_1394    | Adherence  | +   | -   | -    |      |
| FhaB_1                    | MHA_0866         | ctg15      | COK_0334    | Adherence (Subcellular location: OM/E)               | +   | +   | _    |      |
| FhaB_2                    | ctg89_27_137     | COI_1569   | COK_2300    | Adherence (Subcellular location: OM/E)               | -   | +   | -    |      |
| 4. Enzymatic activity     |                  |            |             |  |     |     |      |      |
| Ssa                       | MHA_2492         | COI_0850   | COK_2411    | Serine protease                                      | +   | +   | -    | 8    |
| lga1_2                    | MHA_0563         | COI_2430   | COK_0634    | Cleavage of host mucosal antibody                    | -   | +   | _    | 6    |
| lga1_3                    | MHA_1965         | COI_1820   | COK_2480    | Cleavage of host mucosal antibody                    | +/- | +   | _    | 3    |
| NanH                      | MHA_1532         | COI_0667   | COK_1504    | Terminal sialic acid hydrolysis from glycoconjugates | +   | +   | -    | 4    |
| lga1_1                    | MHA_2800         | COI_2438   | COK_1350    | Cleavage of host mucosal antibody                    | +   | +   | -    |      |
| lgA1_4                    | _                | COI_0585/6 | COK_1280/81 | Cleavage of host mucosal antibody                    | +   | +   | _    |      |
| GlpQ                      | MHA_2244         | COI_1297   | COK_0157    | Glycerophosphodiester hydrolysis                     | +   | _   | -    |      |

| Name                         | Bovine A1 | Ovine A2 | Bovine A2  | Protein function                                     | Sub | ТМ | Lipo | Isol |
|------------------------------|-----------|----------|------------|--|-----|----|------|------|
| NIpC/P60                     | MHA_1650  | COI_0987 | COK_0966   | Cell wall hydrolysis during cell growth and division | +   | -  | +    |      |
| NlpD-like_1                  | MHA_1467  | COI_0383 | COK_1077   | Metalloendopeptidase activity                        | +   | -  | -    |      |
| NlpD-like_2                  | MHA_0321  | COI_0246 | COK_0129   | Metalloendopeptidase activity                        | +   | -  | -    |      |
| AmiC                         | MHA_0064  | COI_1886 | COK_0789   | Cell envelope degradation                            | +   | -  | -    |      |
| 5. Others                    |           |          |            |  |     |    |      |      |
| Bor/Iss_2                    | MHA_0387  | COI_1469 | COK_1002   | Survival in animal host                              | -   | -  | +    | 7    |
| Bor/Iss_1                    | MHA_0386  | COI_1470 | COK_1001   | Survival in animal host                              | -   | -  | +    | 1    |
| fHbp_1                       | MHA_0965  | COI_1330 | COK_2564/5 | Binding to complement factor H                       | -   | -  | +    | 4    |
| fHbp_2                       | MHA_1406  | COI_0728 | COK_0018   | Binding to complement factor H                       | -   | -  | +    |      |
| N1pl                         | MHA_0837  | COI_2516 | COK_0946   | Cell division  | -   | -  | +    |      |
| PilF                         | MHA_2059  | COI_1784 | COK_2516   | Pilus assembly/stability                             | -   | -  | +    |      |
| EcnA                         | -         | COI_0131 | COK_2070   | Toxin/antidote protein (cell apoptosis)              | -   | -  | +    |      |
| 6. Unknown                   |           |          |            |  |     |    |      |      |
| PlpA                         | MHA_1433  | COI_0758 | COK_0049   | Unknown  | -   | -  | +    | 8    |
| Possible OMP                 | MHA_0486  | COI_0902 | COK_2254   | Unknown  | +   | +  | -    | 8    |
| Rickettsia-like surface ant. | -         | COI_1456 | COK_1118   | Unknown  | -   | -  | +    | 8    |
| Lpp38                        | MHA_2152  | COI_0845 | COK_2238   | Unknown  | -   | -  | +    | 7    |
| OMP18/16                     | MHA_2237  | COI_2485 | COK_1303   | Unknown  | +   | -  | -    | 7    |
| YajG                         | -         | COI_0336 | COK_2129   | Unknown  | -   | -  | +    | 6    |
| YtfM                         | MHA_0323  | COI_0250 | COK_0133   | Unknown  | +   | +  | -    | 6    |
| Lpp/PCP/SlyB                 | MHA_0760  | COI_1053 | COK_0435   | Unknown  | -   | -  | +    | 6    |
| HlpB                         | MHA_2282  | COI_2279 | COK_1699   | Unknown  | -   | -  | +    | 5    |

| Name            | Bovine A1 | Ovine A2   | Bovine A2  | Protein function | Sub | тм | Lipo | Isol |
|-----------------|-----------|------------|------------|------------------|-----|----|------|------|
| PIpE            | MHA_1514  | COI_1139   | COK_0733   | Unknown          | _   | _  | +    | 5    |
| Possible OMP    | MHA_0718  | COI_2021   | COK_0360   | Unknown          | +   | -  | -    | 5    |
| PlpD            | MHA_1464  | COI_0386   | COK_1074   | Unknown          | +   | -  | +/-  | 3    |
| PlpC            | MHA_1435  | COI_0760   | COK_0051   | Unknown          | _   | -  | +    | 3    |
| LppC            | MHA_2734  | COI_0540   | COK_2366/7 | Unknown          | +   | +  | +    | 2    |
| Possible OMP    | MHA_0964  | COI_1329   | COK_2563   | Unknown          | +   | +  | _    | 1    |
| Possible OMP    | MHA_2054  | COI_1788   | COK_2512   | Unknown          | -   | +  | -    | 1    |
| Possible OMP    | MHA_2761  | COI_0565   | COK_2341   | Unknown          | +   | +  | _    |      |
| Possible OMP    | MHA_1407  | COI_0729   | COK_0019   | Unknown          | +   | +  | -    |      |
| Possible OMP    | MHA_0862  | COI_1567   | COK_2302   | Unknown          | +   | -  | -    |      |
| Skp/Omp26       | MHA_0690  | COI_1175   | COK_1968   | Unknown          | +   | -  | _    |      |
| ОарВ            | MHA_2703  | COI_1631   | COK_1107   | Unknown          | -   | -  | +    |      |
| PlpB            | MHA_1434  | COI_0759   | COK_0050   | Unknown          | -   | -  | +    |      |
| Autotransporter | ctg108    | COI_1968/9 | COK_0413/4 | Unknown          | +   | +  | _    |      |
| Autotransporter | MHA_0080  | COI_1870   | COK_0773   | Unknown          | +   | +  | _    |      |
| Lipoprotein     | MHA_1803  | COI_0886   | COK_0646   | Unknown          | -   | -  | +    |      |
| Lipoprotein     | MHA_1802  | COI_0887   | COK_0645   | Unknown          | -   | _  | +    |      |

Figure 3.3. Distribution of 93 confidently predicted OMPs based on (A) the three categories of bioinformatic predictors (subcellular localisation, β-barrel and OM lipoprotein predictors) and (B) the three *M. haemolytica* genomes that were analysed (bovine A1, bovine A2, ovine A2).



Table 3.3.Distribution of five confidently predicted OMPs present in only<br/>one or two *M. haemolytica* genomes.

| Confidently predicted OMP       | Bovine A1 | Bovine A2 | Ovine A2 |
|---------------------------------|-----------|-----------|----------|
| lga1_4                          | -         | +         | +        |
| EcnA                            | -         | +         | +        |
| Rickettsia-like surface antigen | -         | +         | +        |
| YajG                            | -         | +         | +        |
| PulD                            | +         | _         | -        |

to sheep. The two serotype A2 genomes are expected to have similar gene content because of their common ancestral origin.

#### 3.3.2 Functional classifications of confidently predicted OMPs.

The 93 confidently predicted OMPs could be assigned to six broad functional categories based on information gathered from the additional searches (Fig. 3.4; Table 3.2). Fifteen confidently predicted OMPs were involved in outer membrane biogenesis and integrity, all of which were present in the three genomes (OmpA, Omp85, Imp/LptD, Pal, VacJ, LppB/NlpD, RlpB/LptE, MltC, ComL, MltA, LolB, NlpE, SmpA, WzzB and MltB). Twenty-eight confidently predicted OMPs were involved in transport and receptor activities, of which 27 were present in all three genomes (TolC, OmpP1/FadL, Wza, OmpP2-like, FrpB, TbpA, OmpP4, OmpP2, FhaC, OmpW, TonB-dependent receptor MHA 0860/COI 1565/ TbpB, HxuC, COK\_2304, HmbR1, HxuB, TonB-dependent receptor MHA\_1346/COI\_1921, LamB, ComE, HxuA, FhuE, HmbR2, haemin receptor, haemin-uptake lipoprotein, TonB-dependent receptor COI\_0092/COK\_0224, TonB-dependent receptor COI\_0006/COK\_0109 and TonB-dependent receptor COI\_0090/COK\_0222). The PulD protein was present only in the bovine serotype A1 genome. Notably, this was the only protein out of the 93 confidently predicted OMPs to be present (exclusively) in only one of the three genomes (Fig. 3.3B). Six confidently predicted OMPs were involved in adherence (YadAlike, Hsf, Hia, Ahs, FhaB\_1 and FhaB\_2), all of which were present in the three genomes. Eleven confidently predicted OMPs had enzymatic activity, of which 10 were present in all three genomes (Ssa, Iga1\_2, Iga1\_3, NanH, Iga1\_1, GlpQ, NlpC/P60, two NlpD-like proteins, and AmiC). A fourth Iga1-like protein (Iga1\_4) was predicted in both the bovine and ovine serotype A2 genomes but was notably absent from the bovine serotype A1 genome. Seven confidently predicted OMPs had functions which did not fall into any of the categories above. These included two proteins, Bor/Iss\_1 and Bor/Iss\_2, which promote bacterial resistance to serum complement killing and virulence (Barondess and Beckwith, 1995), two homologues of the neisserial factor H-binding protein (fHbp\_1 and fHbp\_2) (Welsch and Ram, 2008) and a pilus assembly protein (PilF). The remaining twenty-six confidently predicted OMPs were of unknown function; 24 of these were present in all three genomes.

Figure 3.4. Functional classifications of 93 confidently predicted OMPs present across three *M. haemolytica* genomes after domain, homology and literature searches were carried out on each protein.



Transport and receptor (30.1%)
Unknown (28.0%)
OM biogenesis and integrity (16.1%)
Enzymatic activity (11.8%)
Other (7.5%)

■ Adherence (6.5%)

# 3.3.3 Amino acid sequence variation in confidently predicted OMPs between different *M. haemolytica* genomes.

In order to identify OMPs that might be involved in host-specific adaptation, amino acid sequence comparisons were performed on the 93 confidently predicted OMPs in the three different *M. haemolytica* genomes. The OMPs present among the bovine and ovine serotype A2 genomes (Fig 3.5A) showed a higher degree of amino acid identity to each other than to the OMPs present among either of these two genomes and the bovine serotype A1 genome (Fig. 3.5B). Ninety-two confidently predicted OMPs were present in both the bovine and ovine serotype A2 genomes, of which 83 (92%) had an amino acid identity of 98% and above (Fig. 3.5A). The remaining nine OMPs (PlpE, Ssa, TbpB, OmpA, LppC, fHbp\_2, Pal, Ahs and Hia) had amino acid identities ranging from 60 to 97% (below 98%), suggesting possible diversification that might be related to host adaptation (Fig. 3.5A; Table 3.4). However, only three of these proteins, OmpA, PlpE, and Ahs, had a higher amino acid identity when the bovine serotype A1 and A2 genomes were compared (Fig. 3.5B; Table 3.4). OmpA was 100% identical in the bovine serotype A1 and bovine serotype A2 genomes but was 95% identical when the genomes were compared to the ovine serotype A2 genome. PlpE was 91% identical in the bovine serotype A1 and A2 genomes but only 60% identical when these genomes were compared to the ovine serotype A2 genome, suggesting possible horizontal gene transfer. Ahs was 100% identical in the bovine serotype A1 and bovine serotype A2 genomes but was 97% identical when these genomes were compared to the ovine serotype A2 genome. Of the 88 confidently predicted OMPs that were present in both the bovine serotype A1 and A2 genomes, 67 (76%) had an amino acid identity of 98% and above (Fig. 3.5B). The remaining 21 OMPs (TbpB, TonB-dependent receptor COI\_0090/COK\_0222, fHbp\_2, Hsf, OmpW, Ssa, FrpB, YadA-like, PlpE, OmpP2like, TbpA, Pal, autotransporter COI\_1968-9/COK\_0413-4, possible OMP MHA\_0862/COI\_1567/COK\_2302, LppC, fHbp\_1, Hia, Wza, FhuA, FhaC and LolB) had amino acid identities ranging from 57 to 97% (below 98%) (Fig. 3.5B; Table 3.4). With the exception of PlpE, it is possible that these proteins have little or no role in host adaptation, and may be able to function in cattle and sheep equally well. The fact that there was a higher degree of amino acid conservation in OMPs present between the bovine and ovine serotype A2 genomes than between the bovine serotype A1 genome and bovine serotype A2 genome is

Figure 3.5. Amino acid sequence identity of 93 confidently predicted OMPs among (A) bovine and ovine serotype A2 genomes and (B) bovine serotype A1 and bovine serotype A2 genomes.

Bars are coloured based on the functional classifications of each OMP: OM biogenesis and maintenance (pink), transport and receptor (red), adherence (green), enzymatic activity (orange), other (yellow), unknown (blue).





#### Figure 3.5 (continued)

Table 3.4. Confidently predicted OMPs with amino acid sequence identity below 98% between the bovine serotype A2 and ovine serotype A2 genomes and/or between the bovine serotype A1 and A2 genomes.

| Confidently predicted OMP                       | Bov. A2 vs.<br>Ov. A2 <sup>a</sup> | Bov. A1 vs.<br>Bov. A2 <sup>a</sup> |
|---|------------------------------------|-------------------------------------|
| PlpE  | 60                                 | 91                                  |
| Ssa   | 83                                 | 83                                  |
| TbpB  | 92                                 | 57                                  |
| OmpA  | 95                                 | 100                                 |
| LppC  | 96                                 | 96                                  |
| fHbp_2  | 96                                 | 75                                  |
| Pal   | 96                                 | 94                                  |
| Ahs   | 97                                 | 100                                 |
| Hia   | 97                                 | 96                                  |
| OmpP2-like                                      | 98                                 | 92                                  |
| FhuA  | 98                                 | 97                                  |
| TonB-dependent receptor ctg58/COI_0090/COK_0222 | 99                                 | 70                                  |
| FrpB  | 99                                 | 84                                  |
| ТbpА  | 99                                 | 94                                  |
| Possible OMP MHA_0862/COI_1567/COK_2302         | 99                                 | 96                                  |
| FhaC  | 99                                 | 97                                  |
| LolB  | 99                                 | 97                                  |
| Wza   | 100                                | 96                                  |
| Autotransporter ctg108/COI_1968-9/COK_0413-4    | 100                                | 95                                  |
| Hsf   | 100                                | 78                                  |
| OmpW  | 100                                | 82                                  |
| YadA-like                                       | 100                                | 85                                  |
| fHbp_1  | 100                                | 96                                  |

Proteins with higher percentage amino acid sequence identity between the bovine serotype A1 and A2 genomes than between the bovine serotype A2 and ovine serotype A2 genomes are shaded in grey. <sup>a</sup>Percentage amino acid sequence identity.

further evidence to support the hypothesis of serotype A2 host switching from cattle to sheep.

# 3.3.4 Identification of *M. haemolytica* OMPs by gel-based and gel-free approaches.

The outer membrane fractions of seven *M. haemolytica* isolates and one *M. glucosida* isolate were extracted using the Sarkosyl extraction technique and analysed using gel-based and gel-free approaches. A 1-D SDS-polyacrylamide gel showing the OMP profiles of the representative isolates is shown in Fig. 3.6.

A total of 98 different proteins were identified using a combination of gel-based and gel-free approaches, of which 55 were classified as OMPs (Table 3.5). Fifty of these OMPs were confidently predicted to be OMPs using the bioinformatic prediction approach (Table 3.2). However, five proteins, LemA, HbpA, OapA, RlpA and CsgG were not predicted by the bioinformatic approach but were indicated by literature searches to be OMPs. Henceforth, the 50 confidently predicted OMPs and the five proteins described above will collectively be referred to together as OMPs.

Fifty-seven different proteins were identified using the gel-based approach. Forty-four of these were OMPs (Table 3.5; Figure 3.6), of which 21 were predicted to be B-barrel proteins, 11 were predicted to be outer membrane lipoproteins, 6 were predicted to be both B-barrel proteins and outer membrane lipoproteins and six were not predicted to be either (Fig. 3.7). Eighty-seven different proteins were identified using the gel-free approach. Forty-seven of these were OMPs (Table 3.5), of which 18 were predicted to be B-barrel proteins, 18 were predicted to be outer membrane lipoproteins, five were predicted to be both B-barrel proteins and outer membrane lipoproteins and six were not predicted to be either (Fig 3.7). A total of thirty-six OMPs were identified by both gel-based and gel-free methods. The gel-based approach exclusively identified eight OMPs that were not identified by the gel-free approach: Iga1\_2, possible OMP MHA\_0718/COI\_2021/COK\_0360, LppB/NlpD, HmbR1, HxuB, TonB-dependent receptor MHA\_1346/COI\_1921, possible OMP MHA\_2054/COI\_1788/COK\_2512 and CsgG. Of these proteins, five were predicted to be B-barrel proteins, one was predicted to be both a B-barrel protein and an outer membrane lipoprotein and two were not predicted to be either (Fig. 3.7).

# Figure 3.6. One-dimensional SDS-PAGE separation of outer membrane fractions from seven *M. haemolytica* isolates and one *M. glucosida* isolate.

Numbered proteins were identified by proteomic analysis (Table 3.5). Twenty micrograms of protein were loaded into each lane. Protein bands were stained with Coomassie brilliant blue.

| PI<br>I<br>A | H2 PI<br>B (<br>\1 A                    | H8 PH2<br>D E<br>1 A | 202 PH2<br>3 C<br>2 A2 | 278 PH2<br>0 0<br>2 A2 | 92 PH29<br>O<br>2 A7 | 06 PH34<br>O<br>A11 | 44 PH588<br>O<br>1 A13 | kDa  |       |
|--------------|---|----------------------|------------------------|------------------------|----------------------|---------------------|------------------------|------|-------|
|              |   | 43                   |                        | 43                     |                      |                     |                        |      |       |
|              |   |                      |                        |                        |                      |                     |                        |      |       |
|              |   | 39                   | 39<br>73               |                        | 39<br>73             |                     |                        |      |       |
|              |   |                      | 10                     |                        |                      | 53                  |                        |      |       |
| 17           | 17                                      | , 17                 | 17                     | 17                     | 17                   | 6                   | 17                     | 1000 | 97    |
| 2            | 6 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | 6 2                  | 2                      | 6<br>2<br>44           | 244<br>33.45         | 23                  | 6 2                    |      | 01    |
| 12           | 12                                      | 3,45                 | 12                     | 3,30                   | 12                   | 12                  | 12                     |      |       |
| 22<br>6      | 48<br>22                                | 22                   | 22                     | 12                     | 42,52                |                     | 22                     | -    | 66    |
| 6            | 37,42                                   |                      | 37                     | 37                     |                      |                     |                        |      |       |
|              | 28                                      | 28,46                | 32                     | 32,46                  | 32                   |                     |                        |      |       |
| 7            | 7                                       | 7                    | 7                      | 7                      | 7                    | 10                  | 7                      |      |       |
| 4,26<br>70   | 4<br>67,70                              | 4                    | 4                      | 4                      | 4 79                 | 4                   | 4                      |      |       |
| 67           |   | 67                   | 07                     | 67,70                  | 07                   | 7                   | 67                     |      | 45    |
| 29           | 11<br>29                                | 11                   | 11                     | 11                     | 29                   | 11                  | 11<br>29               |      |       |
| 1            | 1<br>9,72                               |                      | 1<br>9,40              | 1<br>9,27,72           | 1<br>9,72            | 1<br>9              | 16                     |      |       |
| 24,27        | 24                                      | 24,27                | 27                     | 24                     | 24                   | 27                  | 93<br>24               |      |       |
|              |   |                      |                        |                        |                      |                     |                        |      |       |
|              |   |                      |                        |                        |                      |                     |                        |      |       |
| 1            | 31                                      | 1                    | 1                      | 1                      | 1                    | 1                   | 1                      |      |       |
| 8            | 8<br>18                                 | 8,31<br>36           |                        | 31                     | 8<br>18              |                     | 8,20<br>78             | -    | 30    |
|              |   |                      |                        |                        |                      |                     |                        |      |       |
|              |   |                      |                        |                        | 36                   |                     |                        |      |       |
|              | 41                                      |                      |                        |                        | 25                   | 41                  |                        |      |       |
| 25           | 25                                      |                      | 76                     | 25                     | 25                   | 25,55               |                        |      |       |
|              |   |                      |                        |                        |                      |                     |                        |      |       |
| 57           |   | 57                   | 57                     | 57                     |                      |                     |                        |      |       |
| 14           | 14                                      | 14                   | 14                     | 14                     | 14                   | 14                  | 14                     |      | 00.4  |
|              |   |                      |                        |                        |                      |                     |                        |      | 20.1  |
|              |   |                      |                        |                        |                      |                     |                        |      |       |
| 5 40 50      | 5,19,56                                 | 19.56                | 19.56                  | 19,56                  | 5                    | 19,56               | 5,19,56                |      |       |
| 5,19,56      | 5                                       | 5                    | 5                      | 5                      | 5,23                 | 5                   | 5,23                   |      |       |
| 5,23         | au tertin                               | 23                   | 5,23                   |                        | 5                    |                     |                        |      |       |
| 15           | 15                                      |                      |                        |                        | 15                   |                     |                        |      |       |
| 15           | 15                                      | 68                   | 68                     | 68                     | 15                   |                     | 15                     |      | 14 4  |
|              |   |                      |                        |                        |                      |                     |                        |      | 1 1.4 |
| 15           | 15.62                                   | 59                   | 59                     |                        | 15.59                |                     | 15.59                  |      |       |

| Table 3.5. | Proteins identified in the outer membrane fractions of seven representative isolates of <i>M. haemolytica</i> and one |
|------------|---|
|            | isolate of <i>M. glucosida</i> (PH344) using a combination of gel-based and gel-free proteomic approaches.            |

|       |  |        |                   |           |          |           |                                 | Protein identifications in different isolates <sup>d</sup> |     |       |                       |                       | es <sup>d</sup>       |       |                       |       |
|-------|--|--------|-------------------|-----------|----------|-----------|---------------------------------|--|-----|-------|-----------------------|-----------------------|-----------------------|-------|-----------------------|-------|
| No.ª  | Subcellular<br>Localisation <sup>b</sup> | тм°    | Lipo <sup>c</sup> | Bovine A1 | Ovine A2 | Bovine A2 | Name                            | PH2  | PH8 | PH202 | PH278                 | PH292                 | PH296                 | PH344 | PH588                 | Total |
| 1. Co | onfidently predic                        | ted OM | //Ps              |           |          |           |                                 |  |     |       |                       |                       |                       |       |                       |       |
| 1     | OM                                       | +/-    | -                 | MHA_1054  | COI_1980 | COK_0402  | OmpA                            | +  | +   | +     | +                     | +                     | +                     | +     | +                     | 8     |
| 2     | OM                                       | +      | -                 | MHA_0691  | COI_1174 | COK_1967  | Omp85                           | +  | +   | +     | +                     | +                     | +                     | +     | +                     | 8     |
| 3     | OM                                       | +      | -                 | MHA_0291  | COI_2627 | COK_0922  | Imp/LptD                        | +  | +   | +     | +                     | +                     | +                     | +     | +                     | 8     |
| 4     | OM                                       | +      | +                 | MHA_1410  | COI_0732 | COK_0022  | TolC                            | +  | +   | +     | +                     | +                     | +                     | +     | +                     | 8     |
| 5     | OM                                       | -      | +                 | MHA_0263  | COI_2595 | COK_1835  | Pal                             | +  | +   | +     | +                     | +                     | +                     | +     | +                     | 8     |
| 6     | OM                                       | +      | -                 | MHA_2492  | COI_0850 | COK_2411  | Ssa                             | +  | +   | +     | +1                    | +                     | +                     | +     | +                     | 8     |
| 7     | OM                                       | +      | -                 | MHA_0639  | COI_1221 | COK_2014  | OmpP1/FadL                      | +  | +   | +     | +                     | +                     | +                     | +1    | +                     | 8     |
| 8     | OM                                       | -      | +                 | MHA_1433  | COI_0758 | COK_0049  | PlpA                            | +  | +   | +     | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | +                     | +2    | +                     | 8     |
| 9     | OM                                       | +      | +                 | MHA_0527  | COI_1313 | COK_0141  | Wza                             | +2   | +   | +2    | +                     | +                     | +                     | +     | <b>+</b> <sup>2</sup> | 8     |
| 10    | OM                                       | +      | -                 | MHA_0486  | COI_0902 | COK_2254  | Possible OMP                    | +2   | +2  | +2    | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | +1    | <b>+</b> <sup>2</sup> | 8     |
| 11    | OM                                       | +      | -                 | MHA_1793  | COI_0051 | COK_2166  | OmpP2-like                      | +  | +1  | +1    | +                     | +                     | +                     | +1    | +1                    | 8     |
| 12    | OM                                       | +      | -                 | MHA_2109  | COI_0085 | COK_0218  | FrpB                            | +  | +1  | +     | +                     | +                     | +                     | +     | +                     | 8     |
| 13    | OM                                       | -      | +                 | -         | COI_1456 | COK_1118  | Rickettsia-like surface antigen | +2   | +2  | +2    | +2                    | +2                    | +2                    | +2    | +2                    | 8     |

Proteins that were predicted to be putative OMPs by the ten bioinformatic predictors are grey-shaded.

<sup>a</sup>Numbers correspond to the location of the protein on Figure 3.6 if identified by gel-based proteomics.

<sup>b</sup>Confidently predicted subcellular locations; 'OM' = outer membrane; 'P' = periplasm; 'IM' = inner membrane; 'C' = cytoplasm; 'E' = extracellular; 'U' = unknown. <sup>c</sup>Transmembrane  $\beta$ -barrel and lipoprotein prediction result; '+' = predicted in all genomes; '-' = not predicted in any genome; '+/-' = predicted in one/two genomes (see Supplementary Tables S3.1, S3.2 and S3.3 for specific result).

<sup>d</sup>Two proteomics methods were compared; '+'' = proteins identified by gel-based method;  $'+^{2'} =$  proteins identified by gel-free method; '+' = proteins identified by both methods; '-' = no identification.

|    |                           |    |      |           |          |            |              | Protein identifications in different isolate |                       |       |                       |                       | tes                   |                       |                       |       |
|----|---------------------------|----|------|-----------|----------|------------|--------------|--|-----------------------|-------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-------|
| No | Subcellular<br>. location | тм | Lipo | Bovine A1 | Ovine A2 | Bovine A2  | Name         | PH2  | PH8                   | PH202 | PH278                 | PH292                 | PH296                 | PH344                 | PH588                 | Total |
| 14 | OM                        |    | •    | MHA_0704  | COI_1162 | COK_1955   | LemA         | +1   | +1                    | +1    | +                     | +                     | +1                    | +1                    | +1                    | 8     |
| 15 | OM                        | -  | +    | MHA_0387  | COI_1469 | COK_1002   | Bor/Iss_2    | +  | +                     | +2    | -                     | <b>+</b> <sup>2</sup> | +                     | <b>+</b> <sup>2</sup> | +                     | 7     |
| 16 | OM                        | -  | +    | MHA_2152  | COI_0845 | COK_2238   | Lpp38        | +2   | <b>+</b> <sup>2</sup> | +2    | + <sup>2</sup>        | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | -                     | +                     | 7     |
| 17 | OM                        | +  | -    | MHA_0196  | COI_2333 | COK_1753   | TbpA         | +  | +                     | +     | +1                    | +                     | +                     | -                     | +                     | 7     |
| 18 | OM                        | -  | +    | MHA_2837  | COI_1320 | COK_1388   | VacJ         | +2   | +                     | -     | + <sup>2</sup>        | <b>+</b> <sup>2</sup> | +                     | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | 7     |
| 19 | OM                        | -  | -    | MHA_2237  | COI_2485 | COK_1303   | OMP18/16     | +1   | +1                    | +1    | +1                    | +                     | -                     | +1                    | +1                    | 7     |
| 20 | OM                        | -  | +    | MHA_2158  | COI_0840 | COK_2233   | OmpP4        | +2   | +2                    | +2    | -                     | -                     | +2                    | <b>+</b> <sup>2</sup> | +                     | 6     |
| 21 | OM                        | -  | +    | -         | COI_0336 | COK_2129   | YajG         | +2   | +2                    | +2    | +2                    | +2                    | +2                    | _                     | _                     | 6     |
| 22 | OM                        | +  | _    | MHA_0323  | COI_0250 | COK_0133   | YtfM         | +1   | +                     | +1    | +                     | -                     | +1                    | -                     | +1                    | 6     |
| 23 | OM                        | -  | +    | MHA_0760  | COI_1053 | COK_0435   | Lpp/PCP/SlyB | +1   | _                     | +1    | +1                    | +2                    | +1                    | _                     | +1                    | 6     |
| 24 | OM                        | +  | _    | MHA_0563  | COI_2430 | COK_0634   | lga1_2       | +1   | +1                    | +1    | _                     | +1                    | +1                    | -                     | +1                    | 6     |
| 25 | OM                        | -  | +    | MHA_2282  | COI_2279 | COK_1699   | HlpB         | +  | +                     | _     | _                     | +1                    | +                     | +1                    | _                     | 5     |
| 26 | OM                        | -  | +    | MHA_1514  | COI_1139 | COK_0733   | PlpE         | +  | +2                    | -     | -                     | +2                    | +2                    | -                     | +2                    | 5     |
| 27 | OM                        | _  | _    | MHA_0718  | COI_2021 | COK_0360   | Possible OMP | +1   | -                     | +1    | +1                    | +1                    | -                     | +1                    | -                     | 5     |
| 28 | OM/P/IM                   |    |      | MHA_1007  | COI_1369 | COK_1206   | HbpA         | -  | +                     | +     | <b>+</b> <sup>2</sup> | -                     | <b>+</b> <sup>2</sup> | -                     | <b>+</b> <sup>2</sup> | 5     |
| 29 | OM                        | +  | _    | MHA_0735  | ctg112   | COK_1380   | OmpP2        | +  | +                     | _     | -                     | -                     | +                     | _                     | +                     | 4     |
| 30 | ОМ                        | +  | _    | MHA_1532  | COI_0667 | COK_1504   | NanH         | +1   | +                     | _     | +                     | <b>+</b> <sup>1</sup> | _                     | _                     | _                     | 4     |
| 31 | ОМ                        | -  | +    | MHA_0965  | COI_1330 | COK_2564/5 | fHbp_1       | +1   | +                     | +1    | -                     | <b>+</b> <sup>1</sup> | _                     | _                     | _                     | 4     |
| 32 | ОМ                        | +  | +    | MHA_1804  | COI_0885 | COK_0647   | LppB/NlpD    | _  | _                     | +1    | +1                    | +1                    | +1                    | _                     | -                     | 4     |
| 33 | ОМ                        | _  | +    | MHA_0669  | COI_1194 | COK_1987   | RIpB/LptE    | +2   | +2                    | +2    | _                     | _                     | -                     | -                     | -                     | 3     |

|     |                         |     |      |           |            |            |                         | Protein identifications in different isolates |                       |       |                       |       |       |       |       |       |
|-----|-------------------------|-----|------|-----------|------------|------------|-------------------------|---|-----------------------|-------|-----------------------|-------|-------|-------|-------|-------|
| No. | Subcellular<br>location | тм  | Lipo | Bovine A1 | Ovine A2   | Bovine A2  | Name                    | PH2   | PH8                   | PH202 | PH278                 | PH292 | PH296 | PH344 | PH588 | Total |
| 34  | OM                      | -   | +/-  | MHA_1464  | COI_0386   | COK_1074   | PlpD                    | <b>+</b> <sup>2</sup>                         | +2                    | -     | _                     | -     | +2    | -     | -     | 3     |
| 35  | OM                      | -   | +    | MHA_0242  | COI_0470   | COK_0285   | MItC                    | -   | +2                    | _     | _                     | +2    | -     | -     | +2    | 3     |
| 36  | OM                      | -   | +    | MHA_1560  | COI_0129   | COK_2068   | ComL                    | -   | +2                    | +1    | _                     | -     | +     | -     | -     | 3     |
| 37  | OM                      | +   | -    | MHA_0867  | COI_0226   | COK_0335   | FhaC                    | -   | +                     | -     | +1                    | +1    | -     | -     | -     | 3     |
| 38  | OM                      | -   | +    | MHA_1435  | COI_0760   | COK_0051   | PlpC                    | -   | _                     | +2    | -                     | -     | +2    | -     | +2    | 3     |
| 39  | OM                      | +   | -    | MHA_1965  | COI_1820   | COK_2480   | lga1_3                  | -   | _                     | +     | +                     | -     | +     | -     | -     | 3     |
| 40  | OM                      | +   | +    | MHA_1133  | COI_1670   | COK_0590   | MItA                    | +2  | _                     | -     | +                     | -     | -     | -     | -     | 2     |
| 41  | OM                      | -   | -    | MHA_2399  | COI_1652/3 | COK_1583/4 | OmpW                    | -   | +                     | _     | _                     | _     | _     | +     | _     | 2     |
| 42  | OM                      | +   | +    | MHA_2734  | COI_0540   | COK_2366/7 | LppC                    | -   | +                     | -     | -                     | -     | +1    | -     | -     | 2     |
| 43  | OM                      | +   | -    | MHA_0302  | COI_2651   | COK_0898   | YadA-like protein       | -   | _                     | +     | _                     | +     | _     | _     | _     | 2     |
| 44  | OM                      | +   | -    | MHA_0860  | COI_1565   | COK_2304   | TonB-dependent receptor | -   | _                     | -     | -                     | +     | +     | -     | -     | 2     |
| 45  | OM                      | +   | -    | MHA_2261  | COI_2258   | COK_1624   | HmbR1                   | -   | _                     | +1    | -                     | -     | +1    | -     | -     | 2     |
| 46  | OM                      | +   | -    | MHA_1005  | COI_1367   | COK_1209   | HxuB                    | -   | _                     | +1    | -                     | +1    | -     | -     | -     | 2     |
| 47  | ОМ                      |     |      | MHA_2702  | COI_1630   | COK_1108   | OapA                    | _   | -                     | -     | <b>+</b> <sup>2</sup> | -     | +2    | -     | -     | 2     |
| 48  | OM                      | +/- | +    | MHA_0197  | COI_2332   | COK_1752   | ТbpВ                    | -   | +                     | -     | _                     | -     | -     | _     | -     | 1     |
| 49  | OM                      | +   | -    | MHA_0964  | COI_1329   | COK_2563   | Possible OMP            | -   | <b>+</b> <sup>2</sup> | -     | -                     | -     | -     | -     | -     | 1     |
| 50  | OM                      | -   | +    | MHA_0386  | COI_1470   | COK_1001   | Bor/Iss_1               | -   | +2                    | -     | -                     | -     | -     | -     | -     | 1     |
| 51  | OM                      | +   | -    | ctg59     | COI_1368   | COK_1207/8 | HxuC                    | -   | _                     | -     | -                     | -     | -     | -     | +2    | 1     |
| 52  | OM                      | +   | -    | MHA_1346  | COI_1921   | ctg265     | TonB-dependent receptor | -   | _                     | -     | -                     | -     | +1    | -     | -     | 1     |
| 53  | OM                      | +   | _    | MHA_2054  | COI_1788   | COK_2512   | Possible OMP            | _   | _                     | -     | _                     | _     | _     | +1    | _     | 1     |

|   |                         |         |           |            |          |           |                      | Protein identifications in different i |                       |                       |                       |                       |                       |                       | t isola               | ates  |
|---|-------------------------|---------|-----------|------------|----------|-----------|----------------------|--|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-------|
| No.   | Subcellular<br>location | тм      | Lipo      | Bovine A1  | Ovine A2 | Bovine A2 | Name                 | PH2                                    | PH8                   | PH202                 | PH278                 | PH292                 | PH296                 | PH344                 | PH588                 | Total |
| 54  | OM                      |         |           | MHA_0470   | COI_0918 | COK_2270  | RlpA                 | _                                      | -                     | -                     | -                     | -                     | -                     | + <sup>2</sup>        | -                     | 1     |
| 55  | OM                      |         |           | _          | -        | -         | CsgG                 | -                                      | -                     | -                     | _                     | _                     | _                     | +1                    | _                     | 1     |
| 2. Proteins without confident localisation prediction |                         |         |           |            |          |           |                      |  |                       |                       |                       |                       |                       |                       |                       |       |
| 56  | U                       | +       | +         | MHA_2025   | COI_1815 | COK_2485  | Hypothetical protein | +                                      | +                     | +                     | +                     | +                     | +2                    | +                     | +                     | 8     |
| 57  | U                       |         |           | MHA_2087   | COI_1609 | COK_1902  | Hypothetical protein | +                                      | +2                    | +                     | +1                    | +1                    | -                     | -                     | -                     | 5     |
| 58  | U                       |         |           | MHA_1782   | COI_0313 | COK_0888  | Hypothetical protein | _                                      | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | -                     | <b>+</b> <sup>2</sup> | -                     | <b>+</b> <sup>2</sup> | 5     |
| 59  | U                       | -       | +         | MHA_0761/2 | COI_1052 | COK_0436  | Hypothetical protein | -                                      | -                     | +1                    | +1                    | -                     | +1                    | -                     | +1                    | 4     |
| 60  | U                       |         |           | MHA_2789   | COI_2198 | COK_1686  | PqiB                 | _                                      | -                     | <b>+</b> <sup>2</sup> | -                     | -                     | +2                    | -                     | -                     | 2     |
| 61  | U                       | -       | +         | MHA_0804   | COI_2411 | COK_1455  | Patatin              | -                                      | -                     | -                     | -                     | -                     | +2                    | -                     | -                     | 1     |
| 62  | U                       | -       | +         | MHA_0452   | ctg39    | ctg44     | Hypothetical protein | -                                      | +1                    | -                     | -                     | -                     | -                     | -                     | -                     | 1     |
| 63  | U                       |         |           | MHA_1898   | COI_0630 | COK_1217  | LysM domain protein  | _                                      | -                     | <b>+</b> <sup>2</sup> | -                     | -                     | -                     | -                     | -                     | 1     |
| 64  | U                       |         |           | MHA_1828   | COI_2056 | COK_0536  | Hypothetical protein | _                                      | _                     | -                     | <b>+</b> <sup>2</sup> | -                     | -                     | -                     | -                     | 1     |
| 65  | U                       |         |           | -          | COI_2639 | COK_0910  | Hypothetical protein | _                                      | -                     | -                     | -                     | <b>+</b> <sup>2</sup> | -                     | -                     | -                     | 1     |
| 66  | U                       |         |           | MHA_0324   | COI_0251 | COK_0134  | Hypothetical protein | _                                      | _                     | -                     | -                     | -                     | +2                    | -                     | -                     | 1     |
| 3. No   | n-outer membra          | ane loc | calised p | proteins   |          |           |                      |  |                       |                       |                       |                       |                       |                       |                       |       |
| 67  | Р                       | +       | -         | MHA_0371   | COI_1485 | COK_0985  | AcrA_1               | +1                                     | +1                    | +                     | +                     | +1                    | +                     | -                     | +                     | 7     |
| 68  | IM                      |         |           | MHA_1448   | COI_0774 | COK_0064  | YajC                 | +2                                     | <b>+</b> <sup>2</sup> | +                     | +                     | +                     | +2                    | -                     | <b>+</b> <sup>2</sup> | 7     |
| 69  | IM                      |         |           | MHA_1228   | COI_1149 | COK_1941  | PntA                 | _                                      | +2                    | + <sup>2</sup>        | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | +2                    | +1                    | <b>+</b> <sup>2</sup> | 7     |
| 70  | С                       |         |           | MHA_2176   | COI_1521 | COK_1096  | EF1A                 | +1                                     | +                     | +1                    | + <sup>2</sup>        | +                     | +                     | -                     | +                     | 7     |
| 71  | С                       |         |           | MHA_1682   | COI_0958 | COK_1425  | RplB                 | +2                                     | _                     | + <sup>2</sup>        | <b>+</b> <sup>2</sup> | _                     | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | + <sup>2</sup>        | 6     |

|     |                         |     |      |           |          |           |                |     | Protein identifications in different isolates |                       |                       |       |       |                       |                       |       |  |
|-----|-------------------------|-----|------|-----------|----------|-----------|----------------|-----|---|-----------------------|-----------------------|-------|-------|-----------------------|-----------------------|-------|--|
| No. | Subcellular<br>location | тм  | Lipo | Bovine A1 | Ovine A2 | Bovine A2 | Name           | PH2 | PH8   | PH202                 | PH278                 | PH292 | PH296 | PH344                 | PH588                 | Total |  |
| 72  | IM                      | +/- | +    | MHA_0528  | COI_1312 | COK_0142  | Wzf            | -   | +   | +2                    | -                     | +1    | +     | -                     | -                     | 4     |  |
| 73  | IM                      |     |      | MHA_0370  | COI_1486 | COK_0984  | AcrB           | -   | -   | -                     | +1                    | -     | +     | + <sup>2</sup>        | +2                    | 4     |  |
| 74  | С                       |     |      | MHA_1040  | COI_1994 | COK_0388  | RpIA           | -   | +2  | <b>+</b> <sup>2</sup> | _                     | -     | +2    | _                     | <b>+</b> <sup>2</sup> | 4     |  |
| 75  | С                       |     |      | MHA_1552  | COI_0122 | COK_2061  | RpIT           | -   | +2  | <b>+</b> <sup>2</sup> | -                     | -     | +2    | <b>+</b> <sup>2</sup> | -                     | 4     |  |
| 76  | IM                      | -   | +    | MHA_1287  | COI_1274 | COK_0180  | AtpF           | -   | +2  | -                     | +1                    | -     | -     | -                     | +2                    | 3     |  |
| 77  | IM                      |     |      | MHA_1625  | COI_0002 | COK_0113  | LctP           | +2  | <b>+</b> <sup>2</sup>                         | -                     | +2                    | -     | -     | -                     | -                     | 3     |  |
| 78  | С                       |     |      | MHA_0315  | COI_0240 | COK_0123  | RpsB           | +2  | -   | -                     | -                     | -     | -     | +2                    | <b>+</b> <sup>1</sup> | 3     |  |
| 79  | С                       |     |      | MHA_1041  | COI_1993 | COK_0389  | RplK           | -   | -   | -                     | -                     | -     | +2    | +2                    | +2                    | 3     |  |
| 80  | IM                      |     |      | ctg147    | COI_1296 | COK_0158  | GlpT           | -   | <b>+</b> <sup>2</sup>                         | -                     | -                     | -     | -     | -                     | +2                    | 2     |  |
| 81  | С                       |     |      | MHA_2378  | COI_1451 | COK_1123  | RpIE           | -   | <b>+</b> <sup>2</sup>                         | -                     | -                     | -     | -     | +2                    | -                     | 2     |  |
| 82  | С                       |     |      | MHA_1678  | COI_0962 | COK_1421  | RpIP           | -   | +2  | -                     | -                     | -     | -     | -                     | +2                    | 2     |  |
| 83  | С                       |     |      | MHA_2371  | COI_1444 | COK_1130  | RpIO           | -   | <b>+</b> <sup>2</sup>                         | -                     | -                     | -     | -     | +2                    | -                     | 2     |  |
| 84  | С                       |     |      | MHA_2364  | COI_1437 | COK_1137  | RpIQ           | -   | -   | -                     | -                     | -     | -     | +2                    | +2                    | 2     |  |
| 85  | Р                       | -   | +    | MHA_0980  | COI_1345 | COK_2582  | YgiW           | -   | -   | -                     | +2                    | -     | -     | -                     | -                     | 1     |  |
| 86  | Р                       | -   | +    | MHA_2224  | COI_2497 | COK_1291  | NikA/DppA/OppA | -   | -   | -                     | -                     | -     | +2    | -                     | -                     | 1     |  |
| 87  | E                       | +   | -    | MHA_0254  | COI_0481 | COK_0274  | LktA           | -   | -   | -                     | -                     | -     | -     | <b>+</b> <sup>2</sup> | -                     | 1     |  |
| 88  | IM                      | -   | +    | -         | COI_2478 | COK_1310  | NhaC           | +2  | -   | -                     | -                     | -     | -     | -                     | —                     | 1     |  |
| 89  | IM                      |     |      | MHA_1656  | COI_1498 | COK_0973  | GltP           | -   | +2  | -                     | -                     | -     | -     | -                     | -                     | 1     |  |
| 90  | IM                      |     |      | MHA_1795  | COI_2038 | COK_1899  | PtnC           | -   | <b>+</b> <sup>2</sup>                         | -                     | -                     | -     | -     | -                     | -                     | 1     |  |
| 91  | IM                      |     |      | MHA_2180  | COI_2587 | COK_1843  | CydA           | _   | -   | -                     | <b>+</b> <sup>2</sup> | -     | -     | -                     | -                     | 1     |  |

|     |                         |    |      |           |          |           |                                     | Protein identifications in different isolat |                       |       |       |       |       |       |                       | ates  |
|-----|-------------------------|----|------|-----------|----------|-----------|-------------------------------------|---|-----------------------|-------|-------|-------|-------|-------|-----------------------|-------|
| No. | Subcellular<br>location | тм | Lipo | Bovine A1 | Ovine A2 | Bovine A2 | Name                                | PH2   | PH8                   | PH202 | PH278 | PH292 | PH296 | PH344 | PH588                 | Total |
| 92  | IM                      |    |      | MHA_1822  | COI_1555 | COK_1560  | TatA                                | -   | -                     | -     | -     | -     | _     | -     | <b>+</b> <sup>2</sup> | 1     |
| 93  | IM                      |    |      | MHA_2518  | COI_1395 | COK_1180  | FtsN                                | _   | _                     | _     | -     | _     | _     | _     | +1                    | 1     |
| 94  | IM                      |    |      | MHA_1229  | COI_1148 | COK_1940  | PntB                                | -   | <b>+</b> <sup>2</sup> | -     | -     | -     | -     | -     | _                     | 1     |
| 95  | С                       |    |      | MHA_0822  | COI_0990 | COK_0963  | RpsA                                | -   | <b>+</b> <sup>2</sup> | -     | -     | -     | -     | -     | _                     | 1     |
| 96  | С                       |    |      | MHA_2178  | COI_1637 | COK_1101  | RpsG                                | -   | <b>+</b> <sup>2</sup> | -     | -     | -     | -     | -     | _                     | 1     |
| 97  | С                       |    |      | MHA_0991  | COI_1354 | COK_2591  | RpmB                                | -   | <b>+</b> <sup>2</sup> | -     | -     | -     | -     | -     | _                     | 1     |
| 98  | С                       |    |      | MHA_1029  | COI_2005 | COK_0376  | RpIL                                | -   | -                     | -     | -     | -     | -     | -     | +2                    | 1     |
|     |                         |    |      |           |          |           | Total number of proteins identified | 42  | 62                    | 48    | 44    | 41    | 54    | 35    | 48                    |       |
|     |                         |    |      |           |          |           | Total number of OMPs identified     | 33  | 39                    | 34    | 29    | 33    | 37    | 24    | 29                    |       |

Figure 3.7. Distribution of 55 OMPs identified by proteomic analyses based on gel-based and/or gel-free approaches and bioinformatic prediction of a β-barrel and/or outer membrane (OM) lipoprotein.



The gel-free approach exclusively identified 11 OMPs that were not identified by the gel-based approach (*Rickettsia*-like surface antigen, YajG, RlpB/LptE, PlpD, MltC, PlpC, OapA, possible OMP MHA\_0964/COI\_1329/COK\_2563, Bor/Iss\_1, HxuC and RlpA). Of these, two were predicted to be ß-barrel proteins, seven were predicted to be outer membrane lipoproteins and two were not predicted to be either.

The subcellular localisations of eleven identified proteins could not be confidently predicted, and therefore remain unknown (Table 3.2; Supplementary Table S3.4). Four of these proteins (hypothetical protein MHA\_2025/COI\_1815/COK\_2485, hypothetical protein MHA\_0761/COI\_1052/COK\_0436, patatin, and hypothetical protein MHA\_0452) were putative OMPs predicted by the three categories of bioinformatic predictors but could not be confirmed as OMPs or false-positives after additional searches. The remaining seven proteins were not predicted by the bioinformatic approach, and additional searches could not confidently predict their subcellular locations.

Thirty-two identified proteins were confidently predicted to be localised to cellular compartments other than the outer membrane and were therefore classified as false-positives (Table 3.5; Supplementary Table S3.5). Seven of these proteins were putative OMPs predicted by the three categories of bioinformatic predictors, but were confirmed as false positives after additional searches. These included three periplasmic proteins (AcrA\_1, YgiW and NikA/DppA/OppA), three inner membrane proteins (Wzf, AtpF and NhaC) and the secreted leukotoxin protein LktA. The remaining twenty-five proteins were not predicted by the bioinformatic approach, but additional searches confirmed their localisation in compartments other than the outer membrane. Thirteen of these were ribosomal proteins located in the cytoplasm (RplB, RplA, RplT, RpsB, RplK, RplE, RplP, RplO, RplQ, RpsA, RpsG, RpmB and RplL). The other twelve were inner membrane proteins (YajC, PntA, AcrB, LctP, GlpT, GltP, PtnC, CydA, TatA, FtsN and PntB) and the cytoplasmic EF1A protein.

In addition to the identification of OMPs in the outer membrane described above, whole cell envelope fractions of the eight representative isolates were also analysed by the gel free approach to determine whether any OMPs were lost as a result of the inner membrane solubilisation. One hundred and thirty two unique proteins were identified among whole cell envelope fractions (Supplementary Table 3.6), of which 56 were identified among outer membrane fractions. The remaining 76 proteins were mainly comprised of inner membrane and periplasmic proteins and did not contain any confidently predicted OMPs that were not already identified among outer membrane fractions. This indicates that OMPs are not lost as a result of inner membrane solubilisation.

# 3.3.5 Comparison of OMPs identified by proteomic approaches that are associated with different host species and phylogenies.

The total number of OMPs identified in each of the seven M. haemolytica isolates varied from 29 (isolates PH278 and PH588) to 39 (PH8) (Table 3.5); twenty-four OMPs were identified in the *M. glucosida* isolate (PH344). Forty-one OMPs were identified in both bovine and ovine *M. haemolytica* isolates (Fig. 3.8). Of these, 20 were also identified in the M. glucosida isolate. Ten OMPs (MltC, FhaC, LppC, TonB-dependent receptor MHA 0860/COI 1565/COK 2304, OapA, TbpB, possible OMP MHA\_0964/COI\_1329/COK\_2563, Bor/Iss\_1, HxuC, TonB-dependent receptor MHA\_1346/COI\_1921) were identified exclusively in ovine M. haemolytica isolates. Three OMPs (possible OMP MHA\_2054/COI\_1788/ COK\_2512, RlpA and CsgG) were identified exclusively in the *M. glucosida* ovine isolate and one OMP (OmpW) was identified exclusively in both an ovine M. haemolytica isolate and the M. glucosida isolate. No OMPs were identified exclusively in the *M*. haemolytica bovine isolates and there were no proteins identified exclusively in both the bovine *M. haemolytica* isolates and the *M.* glucosida isolate. With the exception of CsgG, which was an Α. pleuropneumoniae orthologue, all of the OMPs identified in ovine M. haemolytica isolates and the M. glucosida isolate were present in either the bovine serotype A1 or bovine serotype A2 genomes. Therefore, these proteins may be present in bovine isolates but were not detected by proteomics approach used in this study. Alternatively, they may be expressed under different growth conditions. The putative bovine host-specific protein PulD that was predicted in the bovine serotype A1 genome was not identified in any representative isolates. These findings show that it has not been possible to establish any clear link between any of the identified OMPs and host-specificity.

Figure 3.8. Distribution of 55 OMPs identified by proteomic analyses based on identification in bovine *M. haemolytica* isolates, ovine *M. haemolytica* isolates and/or an *M. glucosida* isolate.



Fourteen OMPs were identified in all eight representative isolates (OmpA, Omp85, Imp/LptD, TolC, Pal, Ssa, OmpP1/FadL, PlpA, Wza, possible OMP MHA\_0486/COI\_0902/COK\_2254, OmpP2-like, FrpB, *Rickettsia*-like surface antigen and LemA), indicating core functions in both *M. haemolytica* and *M. glucosida*. Hypothetical protein MHA\_2025/COI\_1815/COK\_2485 was also identified in all eight isolates but did not have a confidently predicted location. Furthermore, two OMPs were identified in all seven *M. haemolytica* isolates (Lpp38 and TbpA) but not in the *M. glucosida*.

There appeared to be a clear association between OmpP2 and isolates of serotypes A1, A7 and A13, but not of A2. The OmpP2 porin was identified by both gel-based and gel-free proteomic approaches in the serotype A1 isolates PH2 and PH8, the serotype A7 isolate PH296 and the serotype A13 isolate PH588. However, OmpP2 was not identified in any of the serotype A2 isolates or the *M*. *glucosida* isolate. In contrast, the OmpP2-like porin was identified in all eight representative isolates and exhibited considerable molecular mass variation.

The four putative trimeric autotransporters, YadA-like, Hsf, Hia and Ahs, were confidently predicted OMPs in all three genomes. However, the Hsf, Hia and Ahs proteins were not detected in any of the isolates. The YadA-like protein was identified in only two serotype A2 isolates, PH202 and PH292, by both gel-based and gel-free proteomic approaches. The protein was identified in the uppermost section of the polyacrylamide gel at the interface between the stacking and resolving gel, indicating that the trimeric  $\beta$ -barrel domain does not undergo dissociation into its monomeric subunits during boiling in SDS sample buffer and cannot pass into the resolving gel. This is consistent with similar findings for Ahs (Daigneault and Lo, 2009) and other trimeric autotransporters (Sheets *et al.*, 2008).

The three *M. haemolytica* genomes each encoded three confidently predicted OMPs (Iga1\_1, Iga1\_2 and Iga1\_3) that are homologous to the *H. influenzae* and *N. meningitidis* autotransporter Iga1, an IgA protease. A fourth Iga1-like protein, Iga1\_4, was present only in the serotype A2 genomes. Iga1\_1 and Iga1\_4 were not detected in any of the eight representative isolates. Iga1\_2 was detected by gel-based methods only in six isolates (PH2, PH8, PH202, PH292, PH296 and
PH588). The expected molecular mass of the Iga1\_2 protein after removal of the N-terminal signal sequence is 152.9 kDa (data not shown), but all identified Iga1\_2 proteins had an apparent molecular mass of approximately 35 kDa when resolved by 1-D SDS-PAGE. Examination of the mass spectrometry data for Iga1\_2 showed better coverage and a greater degree of confidence for identified peptides in the C-terminal B-barrel domain (data not shown), suggesting that the N-terminal passenger domain might have been proteolytically cleaved. Iga1\_3 was identified by both gel-based and gel-free methods in isolates PH202, PH278 and PH296 at an apparent molecular mass of 156 kDa, which is consistent with the expected molecular mass after removal of the N-terminal signal peptide. Iga1\_3 of a lower molecular mass was not identified, suggesting that Iga1\_3 does not undergo cleavage and remains intact on the cell surface. Similarly, the Ssa protein was identified at 97 kDa in all isolates, but was also identified at 66.4 and 64.0 kDa in isolate PH2. This suggests that Ssa may also undergo a similar cleavage process in this isolate.

Three OMPs (possible OMP MHA\_2054/COI\_1788/COK\_2152, RlpA and CsgG) were identified exclusively in the *M. glucosida* isolate PH344. Rare lipoprotein A (RlpA) was present in the three *M. haemolytica* genomes analysed by bioinformatics. Therefore, it is possible that RlpA is expressed in *M. haemolytica* but was simply not detected by proteomics. CsgG is an outer membrane lipoprotein (Loferer *et al.*, 1997) required for the secretion and stabilisation of two other proteins, CsgA and CsgB (yet to be identified in *M. glucosida*), which form curli amyloid fibres on the extracellular surface. These fibres have been implicated in a number of processes including biofilm formation, attachment and invasion of host cells, interaction with host proteins and activation of the immune system (Barnhart and Chapman, 2006). Given that CsgG was identified by proteomics only in the *M. glucosida* isolate and that it was absent in the three *M. haemolytica* genomes analysed by bioinformatics, it is reasonable to suggest that this protein is expressed solely in *M. glucosida* and not in *M. haemolytica*.

Although 55 OMPs were identified by proteomic approaches, there remained 43 confidently predicted OMPs that were not identified; 15 were predicted to be β-barrel proteins, 15 were predicted to be outer membrane lipoproteins and 13 were not predicted to be either. Of these 43 unidentified proteins, five are involved in outer membrane biogenesis and integrity (LolB, NlpE, SmpA, WzzB

and MltB), twelve have transport and receptor activities (LamB, ComE, PulD, HxuA, FhuA, FhuE, HmbR2, haemin receptor, haemin-uptake lipoprotein, and three TonB-dependent receptors), five are involved in adherence (Hsf, Hia, Ahs, FhaB\_1 and FhaB\_2) and seven have enzymatic activity (Iga1\_1, Iga1\_4, GlpQ, NlpC, NlpD-like\_1, NlpD-like\_2 and AmiC protein). Fourteen confidently predicted OMPs with other or unknown functions were also not identified (fHbp\_2, N1pI, PilF, EcnA, three possible OMPs, Omp26, OapB, PlpB, two autotransporter proteins and two lipoproteins).

#### 3.4 Discussion

A bioinformatic workflow developed for *P. multocida* (E-Komon *et al.*, 2011b) was used to identify outer membrane-localised proteins in the genomes of three *M. haemolytica* isolates (a bovine serotype A1 isolate and bovine and ovine serotype A2 isolates). Using this approach, 93 confidently predicted OMPs were identified across the three genomes, representing 3.3%, 3.4% and 3.6% of the bovine serotype A1, ovine serotype A2 and bovine serotype A2 genomes, respectively. These figures are lower than those obtained for the *P. multocida* avian genome (4.8% of the proteome) (E-Komon *et al.*, 2011b) and that of the closely related *A. pleuropneumoniae* genome (4.3% of the proteome) (Chung *et al.*, 2007); however, the genomes of these organisms contain fewer open reading frames (2015 and 2241, respectively) than any of the three *M. haemolytica* genomes analysed in this study (between 2552 and 2695 open reading frames). Likely functions were assigned to 67 (72%) of the 93 confidently predicted OMPs. Further information is required to characterise the functions of the remaining 26 proteins.

A greater number of confidently predicted OMPs were present exclusively in both the bovine and ovine serotype A2 genomes than between either of these two genomes and the serotype A1 genome. Furthermore, amino acid sequence comparisons demonstrated that OMPs present in the bovine and ovine serotype A2 genomes show a higher degree of identity in relation to each other than to proteins in the bovine serotype A1 genome. The greater similarities between the two serotype A2 outer membrane subproteomes are consistent with a previous study of genetic diversity within the *M. haemolytica* population (Davies *et al.*, 1997) and a previous comparative genomic study (Lawrence *et al.*, 2010b). These findings provide further evidence to suggest that bovine and ovine serotype A2 isolates of *M. haemolytica* have a common ancestral origin and have recently switched from one host to another. Three OMPs, OmpA, PlpE and Ahs, shared amino acid identity that was significantly greater between the bovine serotype A1 and A2 genomes than between either of these two genomes and the ovine serotype A2 genome. In a previous study, comparative nucleotide sequence analysis of the *ompA* gene revealed hypervariable regions in the distal tips of the surface-exposed loops (Davies and Lee, 2004). These regions vary considerably between bovine and ovine isolates but are highly conserved among isolates from each host species and it was suggested that OmpA is involved in binding to host-specific cell receptor (Davies and Lee, 2004). The exact function of PlpE is currently unknown; however, anti-PlpE antibodies have been demonstrated to promote complement-mediated killing of bovine serotype A1 isolates (Ayalew et al., 2004, Nardini et al., 1998) and the addition of recombinant PlpE to a commercial vaccine also confers enhanced resistance against experimental challenge in cattle compared to the commercial vaccine alone (Confer et al., 2003). And has the predicted structural architecture of a trimeric autotransporters and has been demonstrated to bind collagen in vitro (Daigneault and Lo, 2009). A higher percentage similarity in PlpE and Ahs between bovine serotype A1 and bovine serotype A2 genomes, compared to either of these and the ovine serotype A2 genome, suggests that these two proteins may have a role in host adaptation.

Using a combination of MALDI-TOF-TOF and LC-ESI-QqTOF mass spectrometry, a total of 55 OMPs were identified among the eight representative isolates of *M. haemolytica* and *M. glucosida*. Fifty of these proteins were confidently predicted by the bioinformatic prediction approach. The other five identified proteins, LemA, HbpA, OapA, RlpA and CsgG were not predicted by the bioinformatic approach but were indicated to be OMPs after subsequent literature searches. The LemA protein was identified in all eight representative isolates and is a homologue of the LemA protein originally identified in the Gram positive bacterium *Listeria monocytogenes*, a facultative intracellular pathogen (Lenz *et al.*, 1996). The function of this protein is currently unknown, although the N-terminus is thought to be surface-exposed on the outside of the bacterium. The HbpA protein has been identified in association with the outer membrane of

other Pasteurellaceae species (Hanson and Hansen, 1991, Hanson et al., 1992, Garrido *et al.*, 2003) and has been implicated in the importation of both haem and glutathione (Vergauwen et al., 2010, Hanson and Hansen, 1991, Hanson et al., 1992). In H. influenzae, opacity-associated protein A (OapA) has been demonstrated to be a cell envelope protein that is required for efficient colonisation of the nasopharynx in an infant rat model (Weiser et al., 1995) and contributes to epithelial cell binding (Prasadarao *et al.*, 1999). This protein was identified in only two ovine serotype A2 isolates (PH278 and PH296). In E.coli, rare lipoprotein A (RlpA) is thought to link the outer membrane to peptidoglycan during cell division (Arends et al., 2010). The CsgG protein, which was not present in any of the three *M*. haemolytica genomes analysed by bioinformatic analysis, was identified by searching against a genome of the closely related species A. pleuropneumoniae. The CsgG protein is involved in the secretion of amyloid fibres and may have a role in biofilm formation (Robinson et al., 2006). Thirty-six OMPs were identified by both gel-based and gel-free methods, whereas eight were identified exclusively by the gel-based method and 11 by the gel-free method. The gel-based method identified a higher proportion of Bbarrel proteins than outer membrane lipoproteins. Conversely, the gel-free method identified a higher proportion of outer membrane lipoproteins than Bbarrel proteins. These findings are consistent with the results of E-Komon et al. (E-Komon et al., 2011a) and further reinforce the importance of using complementary approaches to maximise total proteomic coverage of OMPs. Furthermore, no additional OMPs were identified after gel-free analysis of whole cell envelope fractions. This indicated that no OMPs were lost as a result of inner membrane solubilisation and further demonstrated the reliability of Sarkosyl as an appropriate selective solubilisation detergent.

No OMPs were identified exclusively in bovine *M. haemolytica* isolates. This is not surprising given that only one of the 93 confidently predicted OMPs, PulD, was present exclusively in a bovine *M. haemolytica* genome. Fourteen OMPs were identified in the ovine *M. haemolytica* and *M. glucosida* isolates that were not identified in the bovine *M. haemolytica* isolates. Even though these proteins represent potential ovine-specific proteins, all but one (CsgG, an *A. pleuropneumoniae* orthologue detected exclusively in the *M. glucosida* isolate) were present in either the bovine serotype A1 or A2 genomes. Therefore, either

the proteomics approaches failed to identify these proteins or they may be expressed under different growth conditions.

A recent study using immunoproteomic analyses identified 132 immunoreactive proteins in the outer membrane fraction of a serotype A1 *M*. *haemolytica* isolate from a bovine host (Ayalew et al., 2010). Of these, 35 proteins were identified in the outer membrane fractions of eight representative isolates in the present study (Supplementary Table S3.7). However, according to the bioinformatic analyses performed in this study, 25 of the 35 proteins were OMPs, one was a hypothetical protein of unknown function, and nine were false-positives. The immunoproteomic analyses failed to identify the remaining 30 OMPs identified in the present study or any of the 43 confidently predicted OMPs that were not identified in the present study. However, seven proteins (HbpA, MltC, ComL, OmpW, LppC, TonB-dependent receptor MHA 0860/COI 1565/ COK 2304 and TbpB) were identified that were not identified in the bovine serotype A1 M. haemolytica isolate (PH2) used in the present study, although these proteins were identified in one or more of the other representative isolates. The approaches used in the present study and in the study of Ayalew et al. (Ayalew et al., 2010) can potentially discriminate between those OMPs which are surface-exposed and immunogenic and those which are not.

Fourteen OMPs (Table 3.5) were identified in all eight representative isolates, suggesting core functions in the biology of *M. haemolytica* and *M. glucosida*. One of these proteins, the Ssa autotransporter protein, is a subtilisin-like serine protease which shares significant identity with similar autotransporters in other species including AasP of *A. pleuropneumoniae* (Ali *et al.*, 2008), NalP of *N. meningitidis* (van Ulsen *et al.*, 2003, Turner *et al.*, 2002) and SphB1 of *B. pertussis* (Coutte *et al.*, 2001), all of which act as surface maturation proteases. This function has not yet been determined for Ssa, or indeed any other *M. haemolytica* OMP, but may be appropriate given that some surface-exposed proteins have not been identified in as many isolates as expected. For example, the transferrin-binding proteins A and B (TbpA and TbpB) are OMPs involved in the uptake of iron from host transferrin. TbpA is an integral TonB-dependent transporter and was identified in all seven representative *M. haemolytica* isolates (but not in *M. glucosida* isolate PH344). However, TbpB is a surface-exposed lipoprotein and was identified in only one isolate. Both OMPs are

encoded in the same operon and are expected to be expressed in similar quantities, but it would appear that TbpB is largely absent from the outer membrane of most isolates. One explanation is that TbpB is lost from the outer membrane during the extraction process. However, the NalP protein of N. meningitidis has recently been found to cleave lactoferrin-binding protein B (LbpB), a close homologue of TbpB, from the bacterial cell surface (Roussel-Jazede *et al.*, 2010). Therefore, an alternative explanation for the apparent absence of TbpB is that Ssa is cleaving this protein from the bacterial cell surface, as has been shown for NalP. Interestingly, in isolate PH2, Ssa was identified at 66.4 and 64.0 kDa in addition to its expected molecular mass of 97 kDa. Autocatalytic processing of passenger domains is a characteristic of NalP (van Ulsen et al., 2003) and SphB1 (Coutte et al., 2001), but not of AasP (Ali et al., 2008), therefore it is possible that Ssa in isolate PH2 possesses similar autocatalytic ability. Differences in Ssa amino acid sequences among the representative isolates might explain why this was only observed in one isolate. Furthermore, the ssa gene was previously considered to be absent from M. glucosida isolates (Gonzalez et al., 1991), yet its expression at the outer membrane has been clearly demonstrated in the present study.

Two other serine protease autotransporters were also identified. These were Iga1 2 (in two bovine and four ovine isolates) and Iga1 3 (in one bovine and two ovine isolates), which are orthologous to Iga1 in the human pathogens N. meningitidis and H. influenzae. In these pathogens, Iga1 cleaves host mucosal IgA1 antibody, destroying its agglutinating activity and facilitating bacterial colonisation by immunoevasion. While IgA protease activity has not been detected in the supernatants of M. haemolytica (Abdullah et al., 1992), IgGspecific protease activity was detected in partially purified culture supernatants (Lee and Shewen, 1996). IgG is also the predominant secretory antibody found in the lower respiratory tract of cattle (Duncan *et al.*, 1972), whereas IgA is the predominant antibody in the upper respiratory tract (Wilkie and Markham, 1981). It is therefore possible that at least one of the Iga1 orthologues identified in *M. haemolytica* actually cleaves IgG instead of IgA. In *N. meningitidis* and *H.* influenzae, the Iga1 protease passenger domain is released from the outer membrane-embedded B-barrel domain by autoproteolysis. Interestingly, the findings of the present study suggest that proteolysis occurs in Iga1 2, but not in

Iga1\_3, even though both contain an active serine protease site. One explanation is that Iga1\_3 does not contain a self-recognition sequence for autoproteolytic cleavage and therefore remains as a full length protease anchored to the cell surface by the B-barrel domain. Alternatively, proteolysis may be mediated by another surface-exposed protein. In *N. meningitidis*, Iga1 can be proteolytically cleaved by NalP (van Ulsen *et al.*, 2003), therefore it is possible that *M. haemolytica* Ssa has a role in the proteolytic cleavage of *M. haemolytica* Iga1like proteins.

Four trimeric autotransporters were predicted in the bioinformatic analyses (YadA-like, Hsf, Hia and Ahs), all of which have putative roles in adhesion to host molecules. However, only expression of the YadA-like protein was confirmed in one bovine and one ovine serotype A2 isolates (by both gel-based and gel-free approaches). This is the first case of a trimeric autotransporter being detected at the proteomic level in *M. haemolytica*. The Hsf and Hia proteins have been discussed previously in *M. haemolytica* (Gioia *et al.*, 2006), although their exact functions have not yet been characterised. The Ahs protein has previously been reported to be involved in collagen binding (Daigneault and Lo, 2009) and to be transcribed *in vivo* (Lo *et al.*, 2006) in a serotype A1 isolate from a bovine host, although this protein was not identified in any of the representative isolates of the present study.

In the present study, 32 proteins were identified that were predicted to be localised to cellular compartments other than the outer membrane (Table 3.5). The possibility cannot be ruled out that some of these proteins may have secondary functions at the outer membrane, or indeed be true OMPs, even though they were predicted to be located elsewhere. For example, the haembinding protein HbpA was identified in the outer membrane fractions of five *M*. *haemolytica* isolates (Table 3.5) but has a C-terminal motif which indicates that it is a lipoprotein anchored to the inner membrane. However, in the closely-related species *H. influenzae*, HbpA has been identified in both inner membrane and outer membrane fractions (Hanson and Hansen, 1991, Hanson *et al.*, 1992), and has been suggested to be involved in the shuttling of material between the two membranes. The identification of HbpA in this study also suggests a likely function at the outer membrane of *M. haemolytica*, hence its inclusion as an OMP. Another protein, Lpp38, was identified in all seven *M. haemolytica* isolates

and has an amino acid sequence that is 55% identical (70% when conservative amino acid substitutions are included) to the periplasmic *E. coli* protein PotD which is involved in polyamine transport. Lpp38 would have been considered to be a periplasmic protein had it not been for experimental evidence that demonstrated partial exposure of Lpp38 on the surface of *M. haemolytica* (Pandher and Murphy, 1996). This illustrates that even though an identified protein is very similar to another protein in a different species it does not necessarily have the same function and/or subcellular location as that protein.

Forty-three of the 93 confidently predicted OMPs across the three genomes were not identified by proteomic analyses. It is possible that some of these proteins are actually present in the outer membrane but only at low levels which are insufficient to permit detection by the methods used in this study. The expression of OMPs also differs when isolates are grown under conditions that mimic the *in vivo* host environment. A previous study examined gene expression changes in a M. haemolytica serotype A1 isolate when grown in iron-restricted conditions to mimic the paucity of iron in the host lung (Roehrig et al., 2007). Several genes encoding OMPs were upregulated, including four confidently predicted OMPs that were not identified in the present study: haemin receptor, HmbR2, fHbp-like\_2 and possible OMP MHA\_2761/COI\_0565/COK\_2341 (Roehrig et al., 2007). Expression of several M. haemolytica OMPs was also affected by the addition of different antibiotics to the growth medium (Nardini *et al.*, 1998). It is therefore important to consider the effect that different growth conditions have on OMP expression when attempting to characterise outer membrane subproteomes.

In summary, a comprehensive bioinformatic workflow was implemented to predict the outer membrane subproteomes of three *M. haemolytica* genomes from isolates with different capsular serotypes and host origins. Subsequently, a total of 55 OMPs were identified from the outer membrane fractions of seven *M. haemolytica* isolates, together with a single *M. glucosida* isolate, which are representative of different phylogenetic lineages (ETs), capsular serotypes and host origins. Many of these OMPs are associated with particular isolates and/or capsular serotypes and have been identified at the protein level for the first time. Despite not being able to establish involvement in host-specific adaptation for the OMPs identified in this study, it will serve as a springboard for further

research into the roles of these diverse proteins in the pathobiology of *M*. *haemolytica*.

## 4. COMPARATIVE OUTER MEMBRANE PROTEOMIC ANALYSES OF BOVINE AND OVINE ISOLATES OF *M. HAEMOLYTICA* AND *M. GLUCOSIDA* GROWN UNDER VARIOUS *IN VITRO* CONDITIONS DESIGNED TO MIMIC THE *IN VIVO* HOST ENVIRONMENT

#### 4.1 Introduction

*M. haemolytica* colonises the nasopharynx and tonsils of healthy cattle and sheep, but under the context of immune suppression (induced by stress or concurrent viral infection) bacteria rapidly increase in number and gain access to the lungs and trachea via aerosolised droplets and cause pneumonia (Gilmour and Gilmour, 1989, Frank, 1989). In most opportunistic pathogens, certain proteins associated with virulence are only expressed during infection in target tissues (Mekalanos, 1992). Therefore, it is likely that *M. haemolytica* only expresses certain virulence-associated proteins when growing in the upper respiratory tract of healthy animals and the lungs of pneumonic hosts, or under conditions which closely mimic this microenvironment.

An essential prerequisite of successful respiratory tract colonisation by *M. haemolytica* is being able to adapt to an environment containing very low levels of free iron. With the exception of some lactobacilli (Weinberg, 1997, Bruyneel *et al.*, 1989, Duhutrel *et al.*, 2010) iron is an essential micronutrient to all bacteria. It is a cofactor in the catalytic core of enzymes involved in a diverse range of cellular processes such as respiration and nucleic acid synthesis and repair. However, iron concentration is tightly regulated in host tissues as it can cause oxidative damage if present in excess amounts. Thus, in host tissues nearly all iron is sequestered by high-affinity iron-binding proteins such as transferrin, lactoferrin, ferritin, haemoglobin and other compounds. To overcome these low iron levels, bacteria which reside on respiratory tract mucosa have evolved a number of iron acquisition systems. These include the secretion of siderophores (small molecules with high affinity for iron) and the expression of outer

membrane receptors specific for iron-containing host proteins (Wandersman and Delepelaire, 2004). In *M. haemolytica*, iron can be obtained from host transferrin via the outer membrane-located transferrin binding proteins A and B (TbpA and TbpB) (Ogunnariwo *et al.*, 1997, Lee and Davies, 2011). Additional OMPs present in the published *M. haemolytica* genomes are also predicted to have roles in iron acquisition, including components of a putative haem-haemopexin acquisition system (Gioia *et al.*, 2006, Lawrence *et al.*, 2010a). Microarray analysis of gene regulation under iron-restricted conditions has been completed in a single bovine serotype A1 *M. haemolytica* isolate which demonstrated the upregulation of transcripts encoding other receptors for the transport of haem, haemoglobin and, possibly, siderophores (Roehrig *et al.*, 2007). However, a comparative proteomic analysis of OMP expression in several *M. haemolytica* isolates under iron-restricted conditions is still lacking.

*M. haemolytica* is also likely to encounter host serum factors contained in the fibrinous exudate which leaks into the lungs as a result of lung tissue damage caused by virulence factors including leukotoxin (Czuprynski *et al.*, 1991, Yoo *et al.*, 1995b, Stevens and Czuprynski, 1996, Sun *et al.*, 1999) and lipopolysaccharide (Keiss *et al.*, 1964, Li and Clinkenbeard, 1999). These serum factors include complement, antibodies, hormones and other host proteins which may interact with the bacterial cell surface. In other Gram-negative organisms serum components have been demonstrated to interact with and modulate the expression of OMPs (Hellman *et al.*, 2000, Johansson *et al.*, 2003).

It is believed that biofilm formation is a mechanism by which several Gramnegative mucosal pathogens establish long-term colonisation in the host (Luke *et al.*, 2007, Hall-Stoodley *et al.*, 2006, Kaplan *et al.*, 2004, Lam *et al.*, 1980, Greiner *et al.*, 2005, Yi *et al.*, 2004). However, at present there is only limited evidence of biofilm formation in *M. haemolytica* (Olson *et al.*, 2002, Haig, 2011). *M. haemolytica* resides in the respiratory tract via surface-associated growth on host tissues. Previous studies have demonstrated *in vitro* binding of *M. haemolytica* to epithelial cells (Kisiela and Czuprynski, 2009, Clarke and Morton, 2000, Galdiero *et al.*, 2002, Vilela *et al.*, 2004) and implicated several OMPs as host adhesion molecules, including outer membrane protein A (OmpA) (Kisiela and Czuprynski, 2009, Lo and Sorensen, 2007, Davies *et al.*, 2001) and Ahs (Daigneault and Lo, 2009). Some genes that are potentially involved in

adherence and biofilm synthesis have been demonstrated to be upregulated during adhesion to epithelial cells in the closely-related bacteria *A*. *pleuropneumoniae* (Auger *et al.*, 2009). Surface-associated growth, as opposed to planktonic growth, may result in the differential expression of OMPs involved in biofilm formation and adherence to host tissues.

A comprehensive comparative proteomic analysis of OMPs expressed by several representative M. haemolytica isolates and one M. glucosida isolate after in vitro growth in complex growth medium was completed in the previous chapter. In the present chapter, using a similar comparative proteomic approach, the outer membrane subproteomes of the same representative isolates were characterised after in vitro growth under conditions that were designed to mimic the *in vivo* pneumonic lung microenvironment. These conditions included growth in iron-restricted complex growth medium, serum-supplemented tissue culture media and growth on solid-surface agar (in the absence or presence of the dye Congo red). This approach has allowed the identification of several virulence-associated proteins, many of which have not previously been identified in these organisms. Furthermore, an examination of the extracellular subproteome of the representative isolates was undertaken after growth in ironrestricted and iron-replete complex growth media to identify secreted proteins and OMPs fragments that could have been proteolytically cleaved from the bacterial cell surface.

#### 4.2 Materials and methods

#### 4.2.1 Bacterial isolates and growth conditions

The eight bacterial isolates used in this study have been described previously in section 3.2.2. Isolates were stored at -80°C in 50% (v/v) glycerol in brain heart infusion broth (BHIB) and were subcultured on BHI agar (BHIA) containing 5% (v/v) defibrinated sheep blood overnight at 37°C. For growth under iron-restricted conditions, optimum concentrations of the iron chelator 2,2'-dipyridyl were determined (to the nearest 10  $\mu$ M) for each isolate from growth rate experiments where growth, in the presence of increasing concentrations of 2,2'-dipyridyl, was followed spectrophotometrically at 660 nm. The optimum concentration of 2,2'-dipyridyl for each isolate was deemed to be the maximum

concentration at which a cell density of  $0.8 \text{ OD}_{660nm}$  was achieved within a 12 h period. For outer membrane preparations after growth in iron-restricted conditions, liquid starter cultures were prepared by inoculating a few colonies into 15 ml volumes of BHIB and incubating overnight at 37°C with shaking at 120 rpm. Eight hundred microlitres of overnight culture were used to inoculate a 2litre Ehrlenmeyer flask containing 400 ml of BHIB and the optimum final concentration of 2,2'-dipyridyl and incubated at 37°C with shaking at 120 rpm until an OD<sub>600nm</sub> of 0.8-0.9 was achieved (mid-log phase) or for 18 h (stationary For outer membrane preparations under serum-supplemented phase). conditions, liquid starter cultures were prepared by inoculating a few colonies into 15 ml volumes of BHIB and incubating overnight at 37°C with shaking at 120 rpm. Six hundred microlitres of overnight culture were used to inoculate 1-litre Ehrlenmeyer flasks containing 300 ml of either (a) Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g glucose/L, 110 mg sodium pyruvate/L and Lglutamine (Sigma), (b) RPMI-1640 containing L-glutamine and NaHCO<sub>3</sub> (Sigma) or (c) Medium 199 (M199) containing Earle's salts and L-glutamine (Gibco), (d) 270 ml of the three aforementioned media supplemented with 30 ml of either decomplemented (56 °C for 30 min) foetal calf serum (FCS) (Sigma) or sheep serum (SS) (Sigma), and (e) 300 ml of either complete decomplemented FCS, SS or newborn calf serum (NCS). The flasks were incubated at 37 °C with shaking at 120 rpm until an OD<sub>600nm</sub> of 0.8-0.9 was achieved. For outer membrane preparations of bacteria after growth on solid surface agar, bacterial suspensions were prepared by resuspending 6-12 colonies in 3 ml of sterile PBS in a bijou. One hundred microlitres of this suspension was spread over each of 24 BHIA plates, or 24 BHIA plates supplemented with Congo red dye at 0.8 g/L (BHIA<sub>CR</sub>) and incubated for 24 h at 37°C. Cells were scraped off with a sterile plastic inoculating loop and resuspended in 50 ml of 20 mM Tris, pH 7.2. For outer membrane preparations after growth in BHIB containing Congo red ( $BHIB_{CR}$ ), liquid starter cultures were prepared by inoculating a few colonies into 15 ml volumes of BHIB and incubating overnight at 37°C with shaking at 120 rpm. Eight hundred microlitres of overnight culture were used to inoculate a 2-litre Ehrlenmeyer flask containing 400 ml of BHIB supplemented with Congo red dye at 0.8 g/L (BHIB<sub>CR)</sub> and incubated at 37°C with shaking at 120 rpm until an OD<sub>600nm</sub> of 0.8-0.9 was achieved. For extracellular protein preparations, liquid starter cultures were prepared by inoculating a few colonies into 15 ml volumes of BHIB and incubating overnight at 37°C with shaking at 120 rpm. Four hundred microlitres of overnight culture were used to inoculate a 1-litre Ehrlenmeyer flask containing 200 ml of BHIB in the absence or presence of the optimum final concentration of 2,2'-dipyridyl and incubated at 37°C with shaking at 120 rpm until stationary phase growth had been achieved (12 h and 18 h for iron-replete and iron-restricted growth, respectively).

#### 4.2.2 Preparation of OMPs.

Outer membrane proteins were prepared by Sarkosyl extraction as previously described in section 2.2.10

#### 4.2.3 Preparation of extracellular proteins

The extracellular proteins were prepared as described previously (Xia *et al.*, 2008, Nandakumar *et al.*, 2006) with some modifications. Cells were removed by centrifugation at 10,000 × g for 20 min at 4°C. Forty millilitres of the clear supernatant were collected, passed through a 0.2 µm filter, mixed with an equal volume of ice cold 20% (w/v) TCA in acetone for 3 h at -20°C. The precipitate was collected by centrifugation at 5,500 × g for 20 min at 4°C. The precipitated protein pellet was washed twice with ice cold acetone to remove TCA and air-dried. The final pellets were resuspended in approximately 500 µl of 20 mM Tris/HCl (pH 7.2). Fifty microlitre aliquots of these suspensions were transferred to separate tubes and their protein concentrations determined by the modified Lowry procedure. One hundred microlitre aliquots of the extracellular protein suspensions were adjusted to 4 mg/ml with 20 mM Tris/HCl (pH 7.2) and stored at -80°C. Eighty micrograms of each extracellular protein preparation were separated by 1-D SDS-PAGE

#### 4.2.4 Gel-based proteomic analysis of OMPs

Twenty micrograms of each OMP preparation were separated by 1-D SDS-PAGE as previously described in section 3.2.4. Gel pieces were manually excised and digested with trypsin as previously described in 3.2.4. Peptides were analysed by LC-ESI MS/MS as previously described in section 3.2.7 using either the QSTAR XL Hybrid LC/MS/MS system or the Bruker amaZon ETD system (coupled to the Dionex UltiMate 3000 nano LC).

#### 4.2.5 Gel-free proteomic analysis of OMPs

Outer membrane fractions were directly digested with trypsin without prior separation by 1-D SDS-PAGE as previously described in 3.2.5. Peptides were analysed by LC-ESI MS/MS using the QSTAR XL Hybrid LC/MS/MS as previously described in section 3.2.5.

#### 4.2.6 Gel-based analysis of extracellular proteins

Eighty micrograms of each extracellular protein preparation were separated by 1-D SDS-PAGE as previously described in section 3.2.4.

#### 4.2.7 Gel band quantification

Gel images were scanned using the GeneScan (Syngene) gel documentation system. Band quantification was performed using GeneTools (Syngene).

### 4.3 Results

# 4.3.1 Identification of *M. haemolytica* and *M. glucosida* OMPs which undergo changes in expression after growth in iron-restricted conditions.

To understand how OMPs are involved in the adaptation of *M. haemolytica* and *M. glucosida* to the low levels of free iron in the host respiratory tract, representative isolates were grown in the presence of 2,2'-dipyridyl, an iron-chelating agent that has been used in several previous studies to create iron-restricted conditions (Paustian *et al.*, 2001, Merrell *et al.*, 2003, McHugh *et al.*, 2003, Klitgaard *et al.*, 2010, Roehrig *et al.*, 2007). In order to obtain sufficient cells for outer membrane extraction, a concentration of 2,2'-dipyridyl was chosen for each representative isolate that gave significant growth-rate reduction (indicating iron-restriction), but which still allowed the growth of relatively high cell numbers. These were determined by following the growth of each representative isolate spectrophotometrically at 660 nm in BHIB in the presence of increasing concentrations of 2,2'-dipyridyl until a concentration had been reached that still allowed mid-log phase growth (OD<sub>660nm</sub> 0.8-0.9) to be achieved within 12 h. As has been noted previously in *M. haemolytica* (Davies *et al.*, 1992), growth of each representative isolate was inhibited within a very

narrow range of concentrations. Interestingly, the different isolates displayed a broad range of tolerances towards growth in the presence of 2,2'-dipryridyl (Fig. 4.1). The seven *M. haemolytica* isolates grew to mid-log phase within 12 h at 2,2'-dipryridyl concentrations ranging between 120 and 245  $\mu$ M; the *M. glucosida* isolate grew to mid-log phase within 12 h at a 2,2'-dipryridyl concentration of 310  $\mu$ M (Table 4.1). OMP profiles of these isolates grown to mid-log phase in iron replete BHIB (Fig. 4.2A) were compared with those of the same isolates grown in presence of the optimum concentrations of 2,2'-dipryridyl (Fig. 4.2B).

In comparison to growth in iron-replete BHIB (Fig. 4.2A), the OMP expression profiles of all isolates were dramatically altered after growth in iron-restricted BHIB (Fig. 4.2B). In particular, upregulation of several high molecular mass proteins was observed. A total of 72 unique proteins were identified among the outer membrane fractions of the representative isolates after growth in ironrestricted BHIB using a combination of gel-based and gel-free approaches (Table 4.2). Fifty-nine of these proteins were previously identified in the previous chapter after growth in iron-replete BHIB, and included 38 OMPs, 5 proteins of unknown location, and 16 proteins predicted to be localised to cellular compartments other than the outer membrane. The other 13 proteins were not previously identified under growth in iron-replete BHIB and are possible virulence-associated proteins. Eight of these proteins were confidently predicted to be OMPs and included a putative haemin receptor, LamB (the substratespecific maltoporin), FhuA (a putative ferrichrome receptor), autotransporter MHA 0080/COI\_1870/ COK\_0773 (function unknown), EcnA (possibly involved in programmed cell apoptosis), HmbR2 (a putative haemoglobin receptor), HxuA (a putative haemophore involved in haem-haemopexin uptake) and Iga1 4 (an Iga1like protease). The subcellular localisations of two identified proteins with unknown functions (hypothetical protein MHA\_1307/COI\_1292/COK\_0162 and lipoprotein MHA\_2737/COI\_0543/COK\_2363) could not be confidently determined. The remaining three identified proteins (PenP, NqrC and RpsP) were predicted to be localised to cellular compartments other than the outer membrane.

The expression of several OMPs was increased in all eight representative isolates after growth in iron-restricted BHIB compared to iron-replete BHIB. There was a 1.1- to 5.1-fold increase in the expression of TbpA (number 17; Fig 4.2B) among

Figure 4.1. Growth curves of seven *M. haemolytica* isolates and one *M. glucosida* isolate in BHIB in the absence or presence of various concentrations of the iron chelator 2,2'-dipyridyl.



Table 4.1.Properties of seven representative *M. haemolytica* isolates and<br/>one *M. glucosida* (PH344) isolate, and the final 2,2'-dipyridyl<br/>concentrations used to create iron-restricted growth conditions<br/>for each isolate.

| Isolate        | Animal<br>host | Electro-<br>phoretic<br>type | Capsular<br>serotype | OMP<br>type | Disease<br>status | 2,2'-dipryridyl<br>concentration<br>(mM) |
|----------------|----------------|------------------------------|----------------------|-------------|-------------------|--|
| M. haemolytica |                |                              |                      |             |                   |  |
| PH2            | Bovine         | 1                            | A1                   | 1.1.1       | Pneumonia         | 160                                      |
| PH8            | Ovine          | 6                            | A1                   | 1.2.1       | Pneumonia         | 200                                      |
| PH202          | Bovine         | 21                           | A2                   | 2.1.2       | Healthy           | 170                                      |
| PH278          | Ovine          | 21                           | A2                   | 2.2.2       | Pneumonia         | 120                                      |
| PH292          | Ovine          | 22                           | A2                   | 2.2.1       | Pneumonia         | 175                                      |
| PH296          | Ovine          | 12                           | A7                   | 3.1.1       | Pneumonia         | 245                                      |
| PH588          | Ovine          | 15                           | A13                  | 3.3.2       | Pneumonia         | 190                                      |
| M. glucosida   |                |                              |                      |             |                   |  |
| PH344          | Ovine          | N/A                          | A11                  | 3.2.2       | Septicaemia       | 310                                      |

Figure 4.2. One-dimensional SDS-PAGE separation of outer membrane fractions from seven *M. haemolytica* isolates and one *M. glucosida* isolate after growth to mid-log phase in (A) iron-replete and (B) iron-restricted BHIB.

Numbered proteins were subsequently identified by proteomic analysis (Table 4.2).



Table 4.2. Proteins identified in the outer membrane fractions of seven representative isolates of *M. haemolytica* and one isolate of *M. glucosida* (PH344) after mid-log phase growth in iron-restricted BHIB using a combination of gel-based and gel-free proteomic approaches.

|                  |                          |        |                   |                |          |           |              |                |     | Prot  | ein id | entifi | catior | is <sup>d</sup> |       |
|------------------|--------------------------|--------|-------------------|----------------|----------|-----------|--------------|----------------|-----|-------|--------|--------|--------|-----------------|-------|
| No. <sup>a</sup> | Sub. Local. <sup>b</sup> | тм°    | Lipo <sup>c</sup> | Bovine A1      | Ovine A2 | Bovine A2 | Name         | PH2            | PH8 | PH202 | PH278  | PH292  | PH296  | PH344           | PH588 |
| 1. Pro           | teins previously         | identi | fied in i         | ron-replete BH | IB       |           |              |                |     |       |        |        |        |                 |       |
| 1                | ОМ                       | +/-    | -                 | MHA_1054       | COI_1980 | COK_0402  | OmpA         | +2             | +2  | +2    | +2     | +2     | +2     | + <sup>2</sup>  | +2    |
| 2                | ОМ                       | +      | -                 | MHA_0691       | COI_1174 | COK_1967  | Omp85        | +              | +   | +     | +      | +      | +      | +2              | +     |
| 3                | ОМ                       | +      | -                 | MHA_0291       | COI_2627 | COK_0922  | Imp/LptD     | +              | +   | +     | +      | +      | +      | +               | +     |
| 4                | ОМ                       | +      | +                 | MHA_1410       | COI_0732 | COK_0022  | TolC         | +              | +   | +     | +      | +      | +      | +1              | +     |
| 5                | ОМ                       | -      | +                 | MHA_0263       | COI_2595 | COK_1835  | Pal          | + <sup>2</sup> | +2  | +2    | +2     | +2     | +2     | +2              | +2    |
| 6                | OM                       | +      | -                 | MHA_2492       | COI_0850 | COK_2411  | Ssa          | +              | +   | +     | +1     | +      | +      | +               | +     |
| 7                | OM                       | +      | -                 | MHA_0639       | COI_1221 | COK_2014  | OmpP1/FadL   | +              | +   | +     | +      | +      | +      | +2              | +     |
| 8                | ОМ                       | -      | +                 | MHA_1433       | COI_0758 | COK_0049  | PlpA         | +2             | +2  | +2    | +2     | -      | -      | + <sup>2</sup>  | +2    |
| 9                | OM                       | +      | +                 | MHA_0527       | COI_1313 | COK_0141  | Wza          | +2             | +2  | +2    | +2     | -      | +2     | -               | -     |
| 10               | ОМ                       | +      | -                 | MHA_0486       | COI_0902 | COK_2254  | Possible OMP | +1             | +1  | +1    | +1     | +1     | +1     | +1              | +1    |
| 11               | OM                       | +      | -                 | MHA_1793       | COI_0051 | COK_2166  | OmpP2-like   | -              | -   | +2    | +2     | +2     | +2     | -               | +2    |
| 12               | ОМ                       | +      | -                 | MHA_2109       | COI_0085 | COK_0218  | FrpB         | +              | +   | +     | +      | +      | +      | +               | +     |

Proteins that were bioinformatically predicted to be putative OMPs are grey-shaded.

<sup>a</sup>Numbers correspond to the location of the protein in Figure 4.2B if identified by gel-based proteomics.

<sup>b</sup>Confidently predicted subcellular locations; 'OM' = outer membrane; 'P' = periplasm; 'IM' = inner membrane; 'C' = cytoplasm; 'E' = extracellular; 'U' = unknown <sup>c</sup>Transmembrane  $\beta$ -barrel and lipoprotein prediction result; '+' = predicted in all genomes; '-' = not predicted in any genome; '+/-' = predicted in one/two genomes (see Supplementary Tables S3.1, S3.2 and S3.3 for specific result).

<sup>d</sup>Two proteomics methods were compared; '+<sup>1</sup>' = proteins identified by gel-based method; '+<sup>2</sup>' = proteins identified by gel-free method; '+' = proteins identified by both methods; '-' = no identification.

|     |             |    |      |           |            |            |                         |     |     | Pro   | otein i               | denti                 | icatio                | ons   |                       |
|-----|-------------|----|------|-----------|------------|------------|-------------------------|-----|-----|-------|-----------------------|-----------------------|-----------------------|-------|-----------------------|
| No. | Sub. Local. | тм | Lino | Bovine A1 | Ovine A2   | Bovine A2  | Name                    | PH2 | PH8 | PH202 | PH278                 | PH292                 | PH296                 | PH344 | PH588                 |
| 13  | OM          | -  | +    | -         | COI_1456   | COK_1118   | Rickettsia-like antigen | +2  | +2  | +2    | +2                    | +2                    | +2                    | +2    | +2                    |
| 14  | ОМ          |    |      | MHA_0704  | COI_1162   | COK_1955   | LemA                    | -   | -   | -     | -                     | <b>+</b> <sup>2</sup> | -                     | -     | -                     |
| 16  | OM          | _  | +    | MHA_2152  | COI_0845   | COK_2238   | Lpp38                   | +2  | +2  | +2    | -                     | +2                    | +2                    | -     | +2                    |
| 17  | OM          | +  | -    | MHA_0196  | COI_2333   | COK_1753   | ТbpА                    | +   | +   | +     | +1                    | +                     | +                     | +     | +                     |
| 18  | OM          | _  | +    | MHA_2837  | COI_1320   | COK_1388   | VacJ                    | -   | -   | -     | +2                    | +2                    | -                     | -     | -                     |
| 19  | OM          | -  | -    | MHA_2237  | COI_2485   | COK_1303   | OMP18/16                | -   | -   | -     | <b>+</b> <sup>2</sup> | -                     | <b>+</b> <sup>2</sup> | -     | -                     |
| 20  | OM          | _  | +    | MHA_2158  | COI_0840   | COK_2233   | OmpP4                   | +2  | -   | -     | -                     | -                     | -                     | +2    | +2                    |
| 21  | OM          | -  | +    | -         | COI_0336   | COK_2129   | YajG                    | +2  | +2  | +2    | -                     | <b>+</b> <sup>2</sup> | -                     | -     | +2                    |
| 22  | OM          | +  | -    | MHA_0323  | COI_0250   | COK_0133   | YtfM                    | +1  | -   | -     | -                     | -                     | -                     | -     | -                     |
| 25  | OM          | _  | +    | MHA_2282  | COI_2279   | COK_1699   | HlpB                    | +2  | -   | -     | -                     | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | -     | -                     |
| 26  | OM          | -  | +    | MHA_1514  | COI_1139   | COK_0733   | PlpE                    | +   | +2  | +2    | -                     | <b>+</b> <sup>2</sup> | -                     | -     | +2                    |
| 28  | IM/P/OM     |    |      | MHA_1007  | COI_1369   | COK_1206   | HbpA                    | _   | +   | +     | <b>+</b> <sup>2</sup> | <b>+</b> <sup>2</sup> | <b>+</b> <sup>1</sup> | -     | <b>+</b> <sup>2</sup> |
| 29  | OM          | +  | -    | MHA_0735  | ctg112     | COK_1380   | OmpP2                   | +   | +1  | -     | -                     | -                     | <b>+</b> <sup>2</sup> | -     | +                     |
| 30  | OM          | +  | -    | MHA_1532  | COI_0667   | COK_1504   | NanH                    | +   | +   | +1    | +                     | +1                    | -                     | -     | +1                    |
| 33  | OM          | -  | +    | MHA_0669  | COI_1194   | COK_1987   | RIpB/LptE               | +2  | -   | -     | <b>+</b> <sup>2</sup> | -                     | -                     | -     | -                     |
| 34  | OM          | -  | +/-  | MHA_1464  | COI_0386   | COK_1074   | PlpD                    | +2  | +2  | -     | -                     | -                     | -                     | -     | + <sup>2</sup>        |
| 35  | OM          | -  | +    | MHA_0242  | COI_0470   | COK_0285   | MItC                    | _   | +2  | -     | -                     | -                     | -                     | -     | -                     |
| 38  | OM          | -  | +    | MHA_1435  | COI_0760   | COK_0051   | PlpC                    | +2  | +2  | -     | -                     | -                     | -                     | -     | -                     |
| 40  | OM          | -  | +    | MHA_1133  | COI_1670   | COK_0590   | MItA                    | +2  | +2  | -     | -                     | -                     | -                     | -     | -                     |
| 41  | OM          | _  | -    | MHA_2399  | COI_1652/3 | COK_1583/4 | OmpW                    | -   | -   | -     | _                     | _                     | +1                    | +1    | -                     |

|     |             |     |      |            |          |            |                      |                |                       | Pro   | otein i               | denti | ficatio | ons   |       |
|-----|-------------|-----|------|------------|----------|------------|----------------------|----------------|-----------------------|-------|-----------------------|-------|---------|-------|-------|
| No. | Sub. Local. | тм  | Lipo | Bovine A1  | Ovine A2 | Bovine A2  | Name                 | PH2            | PH8                   | PH202 | PH278                 | PH292 | PH296   | PH344 | PH588 |
| 44  | OM          | _   | -    | MHA_0860   | COI_1565 | COK_2304   | TBDR                 | -              | -                     | _     | _                     | -     | +1      | -     | -     |
| 45  | OM          | _   | _    | MHA_2261   | COI_2258 | COK_1624   | HmbR1                | +              | +                     | +     | <b>+</b> <sup>1</sup> | +     | +       | +     | +     |
| 46  | OM          | +   | -    | MHA_1005   | COI_1367 | COK_1209   | HxuB                 | -              | +                     | +     | +                     | +     | +       | -     | +     |
| 47  | ОМ          |     |      | MHA_2702   | COI_1630 | COK_1108   | OapA                 | -              | +2                    | -     | -                     | -     | -       | -     | +2    |
| 48  | ОМ          | +/- | +    | MHA_0197   | COI_2332 | COK_1752   | ТbpВ                 | +2             | +                     | +2    | -                     | -     | +2      | +2    | +2    |
| 51  | ОМ          | +   | -    | ctg59      | COI_1368 | COK_1207/8 | HxuC                 | -              | +                     | +     | +                     | +     | +       | -     | +     |
| 56  | U           | +   | +    | MHA_2025   | COI_1815 | COK_2485   | Hypothetical protein | +2             | +2                    | +2    | +2                    | +2    | +2      | +2    | +2    |
| 57  | U           |     |      | MHA_2087   | COI_1609 | COK_1902   | Hypothetical protein | +2             | <b>+</b> <sup>2</sup> | _     | -                     | -     | -       | -     | -     |
| 58  | U           |     |      | MHA_1782   | COI_0313 | COK_0888   | Hypothetical protein | -              | -                     | _     | +2                    | -     | -       | -     | -     |
| 59  | U           | -   | +    | MHA_0761/2 | COI_1052 | COK_0436   | Hypothetical protein | -              | -                     | -     | -                     | -     | -       | +2    | -     |
| 63  | U           |     |      | MHA_1898   | COI_0630 | COK_1217   | LysM domain protein  | -              | <b>+</b> <sup>2</sup> | _     | _                     | -     | -       | -     | _     |
| 67  | Р           | +   | _    | MHA_0371   | COI_1485 | COK_0985   | AcrA_1               | +2             | -                     | -     | -                     | -     | -       | -     | +     |
| 68  | IM          |     |      | MHA_1448   | COI_0774 | COK_0064   | YajC                 | +2             | +2                    | +2    | +2                    | -     | +2      | -     | -     |
| 69  | IM          |     |      | MHA_1228   | COI_1149 | COK_1941   | PntA                 | +2             | <b>+</b> <sup>2</sup> | +2    | -                     | -     | -       | -     | -     |
| 70  | С           |     |      | MHA_2176   | COI_1521 | COK_1096   | EF1A                 | +2             | -                     | -     | -                     | -     | -       | -     | -     |
| 71  | С           |     |      | MHA_1682   | COI_0958 | COK_1425   | RplB                 | + <sup>2</sup> | +2                    | _     | -                     | -     | -       | -     | +2    |
| 73  | IM          |     |      | MHA_0370   | COI_1486 | COK_0984   | AcrB                 | -              | -                     | _     | +2                    | -     | -       | -     | -     |
| 74  | С           |     |      | MHA_1040   | COI_1994 | COK_0388   | RpIA                 | -              | +2                    | _     | -                     | -     | -       | -     | -     |
| 75  | С           |     |      | MHA_1552   | COI_0122 | COK_2061   | RpIT                 | + <sup>2</sup> | -                     | -     | -                     | -     | -       | -     | -     |
| 78  | С           |     |      | MHA_0315   | COI_0240 | COK_0123   | RpsB                 | -              | -                     | -     | -                     | _     | _       | _     | +2    |

|       |                 |       |          |                 |            |             |                      |                |                       | Pro   | otein i | dentif | icatio                | ons                   |       |
|-------|-----------------|-------|----------|-----------------|------------|-------------|----------------------|----------------|-----------------------|-------|---------|--------|-----------------------|-----------------------|-------|
| No.   | Sub. Local.     | тм    | Lipo     | Bovine A1       | Ovine A2   | Bovine A2   | Name                 | PH2            | PH8                   | PH202 | PH278   | PH292  | PH296                 | PH344                 | PH588 |
| 80    | IM              |       | •        | ctg147          | COI_1296   | COK_0158    | GlpT                 | +2             | -                     | -     | -       | -      | -                     | -                     | _     |
| 81    | С               |       |          | MHA_2378        | COI_1451   | COK_1123    | RpIE                 | _              | <b>+</b> <sup>2</sup> | -     | -       | -      | -                     | -                     | -     |
| 84    | С               |       |          | MHA_2364        | COI_1437   | COK_1137    | RplQ                 | _              | -                     | +2    | -       | -      | -                     | -                     | -     |
| 87    | Е               | +     | -        | MHA_0254        | COI_0481   | COK_0274    | LktA                 | +2             | -                     | -     | -       | _      | -                     | -                     | -     |
| 89    | IM              |       |          | MHA_1656        | COI_1498   | COK_0973    | GltP                 | +2             | + <sup>2</sup>        | _     | -       | _      | -                     | -                     | +2    |
| 95    | С               |       |          | MHA_0822        | COI_0990   | COK_0963    | RpsA                 | + <sup>2</sup> | -                     | -     | -       | -      | -                     | -                     | -     |
| 97    | С               |       |          | MHA_0991        | COI_1354   | COK_2591    | RpmB                 | + <sup>2</sup> | -                     | _     | -       | -      | -                     | -                     | -     |
| 2. Pr | oteins identifi | ed ex | clusivel | y in iron-restr | icted BHIB |             |                      |                |                       |       |         |        |                       |                       |       |
| 99    | OM              | +     | -        | ctg61           | COI_2252/3 | COK_1629/30 | Haemin receptor      | _              | +1                    | +     | -       | -      | <b>+</b> <sup>1</sup> | <b>+</b> <sup>2</sup> | -     |
| 100   | OM              | +     | -        | MHA_0232        | COI_2297   | COK_1718    | LamB                 | -              | -                     | -     | +       | +      | -                     | -                     | +1    |
| 101   | OM              | +     | -        | ctg68           | COI_1905   | COK_2465    | FhuA                 | -              | -                     | -     | -       | +      | <b>+</b> <sup>1</sup> | +2                    | -     |
| 102   | OM              | +     | -        | MHA_0080        | COI_1870   | COK_0773    | Autotransporter      | -              | +1                    | -     | +1      | +1     | -                     | -                     | -     |
| 103   | OM              | _     | +        | -               | COI_0131   | COK_2070    | EcnA                 | -              | -                     | +2    | -       | _      | _                     | _                     | -     |
| 104   | OM              | +     | -        | ctg86           | COI_1762/3 | COK_2539/40 | HmbR2                | -              | -                     | -     | -       | -      | -                     | +2                    | -     |
| 105   | OM/E            | _     | +        | MHA_1004        | COI_1366   | COK_1210    | HxuA                 | -              | +1                    | -     | -       | -      | -                     | -                     | -     |
| 106   | OM              | +     | -        | -               | COI_0585/6 | COK_1280/81 | lga1_4               | -              | -                     | -     | -       | -      | -                     | +1                    | -     |
| 107   | U               | _     | +        | MHA_2737        | COI_0543   | COK_2363    | Lipoprotein          | -              | +2                    | _     | -       | _      | _                     | _                     | -     |
| 108   | U               |       |          | MHA_1307        | COI_1292   | COK_0162    | Hypothetical protein | _              | + <sup>2</sup>        | -     | -       | -      | -                     | -                     | -     |
| 109   | Е               |       |          | -               | _          | -           | PenP                 | + <sup>2</sup> | -                     | -     | -       | -      | _                     | -                     | -     |
| 110   | IM              |       |          | MHA_2767        | COI_0571   | COK_2335    | NqrC                 | +2             | -                     | -     | -       | _      | _                     | -                     | -     |

|     |             |    |      |           |          |           |                                     |     |                       | Pro   | otein i | denti | icatio | ons   |       |
|-----|-------------|----|------|-----------|----------|-----------|-------------------------------------|-----|-----------------------|-------|---------|-------|--------|-------|-------|
| No. | Sub. Local. | тм | Lipo | Bovine A1 | Ovine A2 | Bovine A2 | Name                                | PH2 | PH8                   | PH202 | PH278   | PH292 | PH296  | PH344 | PH588 |
| 111 | С           |    |      | MHA_2535  | COI_1411 | COK_1164  | RpsP                                | -   | <b>+</b> <sup>2</sup> | -     | _       | -     | -      | -     | -     |
|     |             |    |      |           |          |           | Total number of proteins identified | 42  | 43                    | 29    | 28      | 27    | 28     | 22    | 32    |
|     |             |    |      |           |          |           | Total number of OMPs identified     | 27  | 31                    | 25    | 24      | 26    | 26     | 20    | 27    |

M. haemolytica isolates and a 23-fold increase in the M. glucosida isolate PH344. Expression changes in TbpB could not be quantified due to its close proximity to other proteins on the 1-D SDS PAGE gel; however, it was identified in six isolates after growth in iron-restricted BHIB whereas it was identified in only one isolate after growth in iron-replete BHIB. There was a 4.6 to 14.8-fold increase in the expression of the putative haemoglobin receptor HmbR1 (number 45, Fig. 4.2B) among M. haemolytica isolates and an 18.8-fold increase in the M. glucosida isolate. Another putative haemoglobin receptor, HmbR2, was also identified by the gel-free approach in the M. glucosida isolate PH344 that had not been previously identified after growth in iron-replete BHIB [although transcripts of the gene encoding this protein were previously shown to be upregulated in a bovine serotype A1 M. haemolytica isolate under iron-restriction (Roehrig et al., 2007)]. In the previous chapter, the putative siderophore receptor FrpB was identified in a protein band of approximately 69 kDa in all eight representative isolates after growth in iron-replete BHIB (number 12; Fig 4.2A). After growth in iron-restricted BHIB, expression of FrpB (number 12; Fig 4.2B) increased 11.8and 14.6-fold in isolates PH2 and PH344, respectively. FrpB was also identified in the other six isolates but other proteins were identified alongside it including HxuC, haemin receptor, FhuA and autotransporter MHA\_0080/COI\_1870/ COK 0773. Despite the presence of these other proteins, FrpB was consistently identified with the high protein scores and emPAI values, indicating that it is a predominantly expressed protein in these bands.

HxuB and HxuC, the outer membrane components of a putative haemhaemopexin uptake system, were identified by both gel-free and gel-based proteomic approaches in all isolates except for the bovine serotype A1 *M*. *haemolytica* isolate PH2 and the *M*. *glucosida* isolate PH344. Expression of a band containing HxuB (number 46; Fig. 4.2B) increased 3.5- to 17.4-fold among these isolates. The putative haem/glutathione transporter HbpA (number 28; Fig. 4.2B) was also identified in the same protein band as HxuB in isolates PH8, PH202 and PH296 but at much lower protein scores and emPAI values than HxuB, indicating that HxuB is the predominantly expressed protein in these bands. The expression change in HxuC (number 46; Fig. 4.2B) could not be quantified due to its close proximity to other proteins, including FrpB, on the 1-D SDS-PAGE gel.

HxuA (number 105; Fig. 4.2B) was identified only in isolate PH8 in a very faint protein band.

Expression of a protein band that contained the putative fatty acid transporter FadL (number 7; Fig 4.2B) increased 1.8-, 1.4-, 2.6-, and 3.9-fold in serotype A2 isolates PH202, PH278, PH292 and in serotype A7 isolate PH296, respectively, in iron-restricted after mid-log phase growth BHIB. Possible OMP MHA\_0486/COI\_0902/COK\_2252 (number 10; Fig 4.2B) was also identified in the same protein band as FadL in the seven *M. haemolytica* isolates but at much lower protein scores and emPAI values than FadL, indicating that FadL is the predominantly expressed protein in these bands. Interestingly, after growth to stationary phase in iron-restricted BHIB this protein band was expressed at levels below that observed after mid-log phase growth in iron-replete BHIB in all isolates (Supplementary Fig. S4.1), indicating a more important role for FadL during mid-log phase iron-restricted growth than at stationary phase.

There was a 2.4-, 2.2-, 1.4- and 1.8-fold increase in the expression of the porin OmpP2 (number 29; Fig. 4.2B) in isolates PH2, PH8, PH296 and PH588, respectively. This protein was found to be absent from the outer membranes of serotype A2 isolates PH202, PH278, PH292 and *M. glucosida* isolate PH344 after growth in iron-replete BHIB, and was still absent in the present study after growth in iron-restricted BHIB. This is consistent with the finding that the *ompP2* gene is either absent or truncated in serotype A2 isolates (Lawrence *et al.*, 2010a). Expression of the other major porin OmpP2-like (number 11; Fig. 4.2B) was relatively unchanged in all isolates.

A 157 kDa protein band that was not previously identified under iron-replete conditions in any of the representative isolates was present exclusively in *M. glucosida* isolate PH344 under iron-restricted conditions. This protein was identified as Iga1\_4 by gel-based proteomics (number 106; Fig 4.2B), and represents the first Iga1-like protease identified in *M. glucosida*.

## 4.3.2 Identification of *M. haemolytica* OMPs which undergo changes in expression after growth in serum-supplemented tissue culture media and complete serum.

During an *M. haemolytica* infection, fibrinous exudate leaks into the lungs as a result of vascular and pulmonary damage to host tissue. In order to determine what influence this exudate may have on the expression of OMPs in the pneumonic lung, *M. haemolytica* outer membranes were extracted from four *M*. haemolytica isolates (PH2, PH8, PH202 and PH278) after growth in tissue culture media in the presence or absence of serum (which has a composition similar to that of lung exudate). Fig. 4.3 shows the OMP profiles of the bovine (PH2) and ovine (PH8) serotype A1 isolates (Fig. 4.3A) and the bovine (PH202) and ovine (PH278) serotype A2 isolates (Fig. 4.3B) after growth to mid-log phase in DMEM in the absence or presence of either 10% FCS or SS. Outer membranes were also extracted after growth in M199 and RPMI in the absence or presence of 10% FCS or SS, and also in complete FCS, SS and NCS (Supplementary Figures S4.2 and S4.3). A total of 103 unique proteins were identified among the four isolates under all growth conditions using a combination of gel-based and gel-free proteomic approaches (Table 4.3). Sixty of these proteins were previously identified after growth in iron-replete BHIB, and included 42 OMPs, 3 proteins of unknown location, and 15 proteins predicted to be localised to cellular compartments other than the outer membrane. The remaining 43 proteins that were not previously identified after growth in iron-replete BHIB included five OMPs, seven proteins of unknown location, and 31 proteins predicted to be localised to cellular compartments other than the outer membrane. The five OMPs were the haemin receptor, LamB, Hsf (a putative adhesin/serum-(function unknown), possible resistance protein), PlpB and OMP MHA\_0862/COI\_1567/COK\_2302 (function unknown). Both the haemin receptor and LamB had been previously identified after growth in iron-restricted BHIB. Possible OMP MHA 0862/COI 1567/COK 2302 was identified in isolates PH2, PH8 and PH202 after growth in DMEM alone, and also in isolate PH202 after growth in RPMI alone. PlpB and Hsf were the only OMPs that were identified exclusively after growth in the presence of serum. PlpB was identified in the bovine isolates PH2 and PH202 only after growth in complete FCS.

Figure 4.3. One-dimensional SDS-PAGE separation of outer membrane fractions from (A) bovine (PH2) and ovine (PH8) serotype A1 *M. haemolytica* isolates, and (B) bovine (PH202) and ovine (PH278) serotype A2 *M. haemolytica* isolates after growth in DMEM only, DMEM + 10% FCS and DMEM + 10% SS.

> OMP profiles after growth in iron-replete and iron-restricted BHIB are also shown for comparison. Numbered proteins were subsequently identified by proteomic analysis (Table 4.3). Twenty micrograms of protein were loaded into each lane. Protein bands were stained with Coomassie brilliant blue.





|    |                 |  |                 |                   |                  |           |                |               |                            |                             |           |                |                           |                     |                             |           |                |                            |                             |                             |           | F              | Prote    | ein ie                      | dent     | tifica           | ntion                           | sd                          |                |                            |                  |               |                     |                     |                             |                |               |           |                                 |                             |                |                            |                               |          |
|----|-----------------|--|-----------------|-------------------|------------------|-----------|----------------|---------------|----------------------------|-----------------------------|-----------|----------------|---------------------------|---------------------|-----------------------------|-----------|----------------|----------------------------|-----------------------------|-----------------------------|-----------|----------------|----------|-----------------------------|----------|------------------|---------------------------------|-----------------------------|----------------|----------------------------|------------------|---------------|---------------------|---------------------|-----------------------------|----------------|---------------|-----------|---------------------------------|-----------------------------|----------------|----------------------------|-------------------------------|----------|
|    |                 |  |                 |                   |                  |           |                |               |                            | PH                          | 2         |                |                           |                     |                             |           |                |                            |                             | PH                          | 8         |                |          |                             |          |                  |                                 |                             |                | PH2                        | 02               |               |                     |                     |                             |                |               |           | Р                               | H27                         | 8              |                            |                               |          |
| N  | 0. <sup>a</sup> | Subcellular<br>Localisation <sup>b</sup> | TM <sup>c</sup> | Lipo <sup>c</sup> | Name             | DMEM only | DMEM + 10% FCS | DMEM + 10% SS | RPMI ONY<br>RPMI + 10% FCS | RPMI + 10% SS               | M199 only | M199 + 10% FCS | M199 + 10% SS<br>FCE auto | rus only<br>SS only | NCS only                    | DMEM only | DMEM + 10% FCS | DIMEM + 10% 55<br>RPMI anh | RPMI + 10% FCS              | RPMI + 10% SS               | M199 only | M199 + 10% FCS | FCS only | SS only                     | NCS only | DMEM only        | DMEM + 10% FCS<br>DMEM + 10% SS | RPMI only                   | RPMI + 10% FCS | RPMI + 10% SS<br>M400 auto | M199 + 10% FCS   | M199 + 10% SS | FCS only<br>SS code | as only<br>NCS only | DMEM only                   | DMEM + 10% FCS | DMEM + 10% SS | RPMI only | KPMI + 10% FCS<br>RPMI + 10% SS | M199 only                   | M199 + 10% FCS | M199 + 10% 55<br>Er S antu | SS only                       | NCS only |
| 1. | Pro             | teins p                                  | revi            | ous               | ly identified in | iro       | on r           | epl           | ete                        | B                           | IВ        |                |                           |                     |                             |           |                |                            |                             |                             |           |                |          |                             |          |                  |                                 |                             |                |                            |                  |               |                     |                     |                             |                |               |           |                                 |                             |                |                            |                               |          |
|    | 1               | OM                                       | +/-             | -                 | OmpA             | +2        | +2             | +2 .          | +2 +                       | <sup>2</sup> + <sup>2</sup> | +2        | +2             | +2 .                      | +2 +                | <sup>2</sup> + <sup>2</sup> | +2        | +2             | +2 +                       | <sup>2</sup> + <sup>2</sup> | <sup>2</sup> + <sup>2</sup> | +2        | +2 ·           | +2 +     | <sup>2</sup> + <sup>2</sup> | +2       | +2 .             | + <sup>2</sup> +                | <sup>2</sup> + <sup>2</sup> | +2             | +2 .                       | +2 +3            | +2            | +2 .                | +2 +3               | <sup>2</sup> + <sup>2</sup> | +2             | +2            | +2        | +2 +                            | <sup>2</sup> + <sup>2</sup> | +2             | +2 +                       | · <sup>2</sup> + <sup>2</sup> | +2       |
|    | 2               | OM                                       | +               | -                 | Omp85            | +         | -              | +2 .          | +2 -                       | · + <sup>2</sup>            | +2        | +2             |                           | +2 -                | +2                          | +         | +2             | +2 +                       | + +                         | <sup>2</sup> + <sup>2</sup> | +2        | +2             | - +      | 2 -                         | +2       | + ·              | + <sup>2</sup> +                | <sup>2</sup> + <sup>2</sup> | +2             |                            | +2 +3            | +2            | +2 .                | +2 +3               | <sup>2</sup> +              | +2             | +2            | +2        | +2 +                            | 2 -                         | +2             | - +                        | · <sup>2</sup> + <sup>2</sup> | +2       |
| :  | 3               | OM                                       | +               | -                 | Imp/LptD         | +2        | +2             | -             |                            |                             | -         | -              |                           | +2 -                | · -                         | +1        | -              | - +                        | ·1 _                        | -                           | -         | -              | - +      | 2 _                         | -        | +2               |                                 |                             | -              | +1                         | - + <sup>3</sup> |               | +2                  |                     | +1                          | +2             | -             | +         | +1 -                            |                             | +2             | - +                        | <sup>2</sup> –                | -        |
| 4  | 4               | OM                                       | +               | +                 | ToIC             | +2        | -              |               | +1 -                       |                             | -         | +2             |                           | +2 -                | · -                         | -         | -              | - +                        | 2 -                         | -                           | -         | +2             |          | · -                         | -        | -     ·          | +2 -                            |                             | +2             |                            | - + <sup>3</sup> | -             | +2                  |                     | -                           | -              | -             | -         |                                 |                             | +2             |                            |                               | -        |
| :  | 5               | OM                                       | -               | +                 | Pal              | +2        | -              | +2 .          | +2 +                       | <sup>2</sup> + <sup>2</sup> | +2        | +2             | +2 .                      | +2 +                | <sup>2</sup> + <sup>2</sup> | +2        | +2 ·           | +2 +                       | <sup>2</sup> + <sup>2</sup> | <sup>2</sup> + <sup>2</sup> | +2        | +2 ·           | +2 +     | <sup>2</sup> + <sup>2</sup> | +2       | +2 ·             | +2 +                            | <sup>2</sup> + <sup>2</sup> | +2             | +2 .                       | +2 +3            | +2            | +2 .                | +2 +3               | <sup>2</sup> + <sup>2</sup> | +2             | +2            | +2        | +2 +                            | <sup>2</sup> + <sup>2</sup> | +2             | +2 +                       | <sup>2</sup> + <sup>2</sup>   | +2       |
|    | 6               | OM                                       | +               | -                 | Ssa              | +         | +              | + ·           | +2 +                       | + +                         | +2        | +2             | +2 .                      | +2 +                | <sup>2</sup> + <sup>2</sup> | +         | +2 .           | +2 -                       |                             | -                           | -         | -              |          | · -                         | -        | + ·              | +2 +                            | +2                          | +2             | +2 .                       | +2 +3            | +2            | +2 .                | +1 +3               | 2 –                         | +2             | -             | -         |                                 |                             | -              |                            |                               | -        |
|    | 7               | OM                                       | +               | -                 | OmpP1/FadL       | +2        | -              | +2 .          | +2 +                       | 2 -                         | +2        | +2             |                           | +2 -                | · _                         | -         | +2 ·           | +2 -                       | - +                         | 2 -                         | +2        | +2             | - +      | 2 _                         | -        | _ ·              | +2 -                            |                             | +2             |                            | - +              |               | +2                  |                     | +2                          | +2             | -             | -         | +2 -                            | +2                          | +2             | - +                        | <sup>2</sup> –                | -        |
|    | 8               | OM                                       | -               | +                 | PIpA             | -         | -              | +2            |                            |                             | -         | -              |                           | +2 +                | <sup>2</sup> + <sup>2</sup> | -         | +2 ·           | +2 -                       | - +                         | <sup>2</sup> + <sup>2</sup> | -         | +2             | - +      | <sup>2</sup> + <sup>2</sup> | +2       | + <sup>2</sup> · | +2 +                            | 2 _                         | +2             |                            | - +              |               | +2 .                | +2 +3               | 2 +2                        | +2             | -             | -         | +2 -                            |                             | +2             | - +                        | · <sup>1</sup> –              | +2       |
|    | 9               | OM                                       | +               | +                 | Wza              | -         | -              |               |                            |                             | -         | -              |                           |                     | · -                         | +2        | +2 ·           | +2 -                       | - + <sup>2</sup>            | 2 -                         | $+^2$     | +2             | - +      | 2 -                         | -        |                  |                                 |                             | +2             |                            |                  | -             | +2 -                |                     | -                           | +2             | -             | -         | +2 -                            |                             | -              | - +                        | <sup>2</sup> –                | -        |
| 1  | 0               | OM                                       | +               | -                 | Possible OMP     | -         | -              |               |                            |                             | -         | -              |                           |                     | · -                         | -         | -              |                            |                             | -                           | -         | -              |          | · -                         | -        |                  |                                 |                             | -              |                            |                  | -             |                     |                     | -                           | -              | -             | -         |                                 |                             | +2             | - +                        | <sup>2</sup> –                | -        |
| 1  | 1               | OM                                       | +               | -                 | OmpP2-like       | -         | -              | -             | - +                        | 2 -                         | +2        | +2             |                           |                     |                             | +2        | +2             | - +                        | 2 +2                        | 2 –                         | +2        | +2             | - +      | <sup>2</sup> + <sup>2</sup> | -        |                  | +2 -                            | +2                          | +2             | +2 .                       | +2 +3            | -             | +2                  | - +                 | 2 +2                        | +2             | +2            | +2        | +2 +                            | 2 +2                        | +2             | - +                        | + <sup>2</sup> + <sup>2</sup> | +2       |
| 1  | 2               | OM                                       | +               | -                 | FrpB             | +         | -              | +2            | - +                        | <sup>2</sup> + <sup>2</sup> | -         | +2             | +2 .                      | +2 +                | 2 -                         | +         | -              | + +                        | 2 +2                        | <sup>2</sup> + <sup>2</sup> | +2        | -              | - +      | <sup>2</sup> + <sup>2</sup> | -        | + ·              | +2 +                            | 2 +                         | +2             | +2 .                       | +2 +3            | +2            | +2 .                | +2 +3               | 2 +                         | +              | +             | +         | +2 +                            | + +2                        | +2             | +2 +                       | <sup>2</sup> + <sup>1</sup>   | +2       |

Table 4.3.Proteins identified in the outer membrane fractions of four *M. haemolytica* isolates (PH2, PH8, PH202 and PH278)after growth in DMEM, RPMI and M199 in the absence of presence of 10% FCS or SS, and in total FCS, SS and NCS.

Proteins that were bioinformatically predicted to be putative OMPs are grey-shaded.

<sup>a</sup>Numbers correspond to the location of the protein in Figure 4.3 if identified by gel-based proteomics.

<sup>b</sup>Confidently predicted subcellular locations; 'OM' = outer membrane; 'P' = periplasm; 'IM' = inner membrane; 'C' = cytoplasm; 'E' = extracellular; 'U' = unknown.

<sup>c</sup>Transmembrane  $\beta$ -barrel and lipoprotein prediction result; '+' = predicted in all genomes; '-' = not predicted in any genome; '+/-' = predicted in one/two genomes.

<sup>d</sup>Two proteomics methods were compared;  $'+^{1'}$  = proteins identified by gel-based method;  $'+^{2'}$  = proteins identified by gel-free method; '+' = proteins identified by both methods; '-' = no identification.

|     |                             |    |      |                 |                             |                |                             |               |           |                                  |                  |         |          |                             |                             |           |                                 |                             |                             | Pro           | tein                | ider                | ntific    | catio          | ns            |                              |                             |                             |                  |          |         |          |                             |                  |           |                |               |                             |               |          |                     |
|-----|-----------------------------|----|------|-----------------|-----------------------------|----------------|-----------------------------|---------------|-----------|----------------------------------|------------------|---------|----------|-----------------------------|-----------------------------|-----------|---------------------------------|-----------------------------|-----------------------------|---------------|---------------------|---------------------|-----------|----------------|---------------|------------------------------|-----------------------------|-----------------------------|------------------|----------|---------|----------|-----------------------------|------------------|-----------|----------------|---------------|-----------------------------|---------------|----------|---------------------|
|     |                             |    |      |                 |                             |                |                             | Р             | H2        |                                  |                  |         |          |                             |                             |           | Р                               | H8                          |                             |               |                     |                     |           |                |               |                              | PH                          | 202                         |                  |          |         |          |                             |                  |           |                | PH2           | 278                         |               |          |                     |
| No. | Subcellular<br>Localisation | TM | Lipo | Name            | DMEM only<br>DMEM + 10% FCS | DMEM + 10% SS  | RPMI only<br>PDMI ± 40% ECS | RPMI + 10% SS | M199 only | M199 + 10% FCS<br>M100 + 10% FCS | FCS only         | SS only | NCS only | DMEM only<br>DMEM + 10% FCS | DMEM + 10% SS               | RPMI only | RPMI + 10% FCS<br>RPMI + 10% SS | M199 only                   | M199 + 10% FCS              | M199 + 10% SS | FCS only<br>SS only | as only<br>NCS only | DMEM only | DMEM + 10% FCS | DMEM + 10% SS | RPMI 61119<br>RPMI + 10% FCS | RPMI + 10% SS               | M199 only<br>M100 ± 10% ECS | M199 + 10% SS    | FCS only | SS only | NCS only | DMEM only<br>DMEM ± 40% ECS | DMEM + 10% SS    | RPMI only | RPMI + 10% FCS | RPMI + 10% SS | M199 only<br>M199 + 10% FCS | M199 + 10% SS | FCS only | SS only<br>NCS only |
| 13  | OM                          | -  | +    | Rickettsia-like | +2 -                        | -              |                             |               | -         |                                  |                  | -       | -        |                             | -                           | -         |                                 | · + <sup>2</sup>            | <sup>2</sup> + <sup>2</sup> | -             | +2 ·                |                     | -         | -              | +2            |                              | -                           | +2 ·                        | - +              | 2 -      | -       | -        |                             |                  | -         |                | +2            |                             | +2            | -        |                     |
| 14  | OM                          |    |      | LemA            |                             | -              |                             |               | -         |                                  |                  | -       | -        |                             | -                           | -         |                                 |                             | +2                          | -             |                     |                     | -         | -              | -             |                              | -                           |                             |                  | -        | -       | -        |                             |                  | -         | -              | -             | - +                         | 2 -           | -        |                     |
| 15  | OM                          | -  | +    | Bor/Iss_2       | +2 -                        | -              | +2 .                        |               | +2        |                                  | - + <sup>2</sup> | -       | +2       | +2 +3                       | 2 -                         | +2        | +2 +                            | <sup>2</sup> + <sup>2</sup> | <sup>2</sup> + <sup>2</sup> | -             | +2 .                |                     | +2        | +2             |               | +2 +3                        | <sup>2</sup> + <sup>2</sup> |                             | <sup>2</sup> –   | -        | -       | +2       | +2 +                        | + <sup>2</sup> - | +2        | -              | -             | - + <sup>3</sup>            | 2 -           | +2       |                     |
| 16  | OM                          | -  | +    | Lpp38           |                             | -              |                             |               | -         |                                  |                  | -       | -        | - + <sup>3</sup>            | <sup>2</sup> + <sup>2</sup> | -         | +2 +                            | <sup>2</sup> + <sup>2</sup> | <sup>2</sup> + <sup>2</sup> | +2            | + <sup>2</sup> ·    |                     | -         | +2             | +2            | - + <sup>3</sup>             | <sup>2</sup> + <sup>2</sup> |                             | - <sup>2</sup> - | -        | -       | -        | +2 +                        | +2 +3            | 2 _       | +2             | +1            | +2 -                        | -             | +2       |                     |
| 17  | OM                          | +  | -    | ТbpА            | +2 +2                       | <sup>2</sup> + | +2 +                        | +2 +3         | 2 _       | +2 +                             | +2 +2            | +2      | -        | +2 +3                       | <sup>2</sup> + <sup>2</sup> | +2        | +2 +                            | · + <sup>2</sup>            | 2 -                         | +             | +2 +                | +2 +3               | 2 +       | +2             | +             | +2 +3                        | 2 +                         | +2 +                        | +2 +             | +2       | +       | +        | +2 .                        |                  | +2        | -              | -             | - + <sup>3</sup>            | 2 -           | -        |                     |
| 18  | OM                          | -  | +    | VacJ            |                             | -              |                             |               | -         |                                  |                  | -       | -        |                             | -                           | -         |                                 | · -                         | -                           | -             | + <sup>2</sup> ·    |                     | -  -      | -              | -             |                              | -                           |                             |                  | +2       | -       | -        | - +                         | + <sup>2</sup> - | -         | -              | -             | - + <sup>3</sup>            | 2 -           | -        |                     |
| 19  | OM                          | -  | -    | OMP18/16        |                             | -              |                             |               | -         |                                  |                  | -       | -        |                             | -                           | -         |                                 | · -                         | -                           | -             |                     |                     | -         | -              |               | +2 -                         | -                           |                             |                  | -        | -       | -        |                             |                  | +2        | -              | -             | - +                         | 2 -           | -        |                     |
| 20  | OM                          | -  | +    | OmpP4           | +2 -                        | -              |                             |               | -         |                                  |                  | -       | -        | +2 +3                       | <sup>2</sup> + <sup>2</sup> | +2        | +2 -                            | · -                         | -                           | -             |                     |                     | +2        | +2             | -             | - +                          | 2 -                         |                             |                  | -        | -       | -        |                             | + <sup>2</sup> - | -         | -              | -             | +2 -                        | -             | -        |                     |
| 21  | OM                          | -  | +    | YajG            |                             | -              |                             |               | -         |                                  |                  | -       | -        | +2 +3                       | 2 -                         | -         | +2 -                            | · -                         | +2                          | -             | + <sup>2</sup> ·    |                     | +2        | +2             | -             | - +;                         | 2 -                         |                             | <sup>2</sup> –   | +2       | -       | +2       | - +                         | + <sup>2</sup> - | -         | +2             | -             | - +;                        | 2 -           | +2       |                     |
| 24  | OM                          | +  | -    | lgA1_2          |                             | +1             |                             |               | -         |                                  |                  | -       | -        |                             | +1                          | -         |                                 | · -                         | -                           | -             |                     |                     | -         | -              | -             |                              | -                           |                             |                  | -        | -       | -        |                             |                  | -         | -              | -             |                             | -             | -        |                     |
| 25  | OM                          | -  | +    | HlpB            |                             | -              |                             |               | +2        |                                  |                  | -       | -        |                             | -                           | +2        |                                 | · -                         | -                           | -             |                     |                     | -         | -              | -             |                              | -                           |                             |                  | -        | -       | -        |                             |                  | -         | -              | -             |                             | -             | -        |                     |
| 27  | OM                          | -  | _    | Possible OMP    |                             | _              |                             |               | -         | +1 -                             |                  |         | -        |                             | -                           | -         |                                 | · + <sup>2</sup>            | 2 -                         | -             |                     |                     | -         | _              | -             |                              | _                           |                             |                  | -        | -       | -        |                             |                  | -         |                | -             | - + <sup>3</sup>            | 2 -           | -        |                     |
| 28  | IM/P/OM                     |    |      | НbpA            |                             | -              |                             |               | -         |                                  | - +1             | -       | -        |                             | -                           | -         |                                 |                             | -                           | -             | +2 +                | +2 +2               | 2 -       | -              | -             |                              | -                           |                             |                  | +2       | +2      | +2       | +2 .                        |                  | -         | -              | -             |                             | -             | +2       |                     |
| 29  | OM                          | +  | -    | OmpP2           |                             | -              | +2 -                        |               | -         | +2 .                             | - +'             | -       | +2       |                             | -                           | -         |                                 |                             | -                           | -             | +2                  | + +                 | 2 -       | -              | -             |                              | -                           |                             |                  | _        | -       | -        |                             |                  |           | -              | -             |                             | -             | -        |                     |
| 30  | OM                          | +  | -    | NanH            | +1 -                        | -              |                             |               | -         | +2 -                             |                  | -       | -        | + +                         | <sup>2</sup> + <sup>2</sup> | +1        | +2 +                            | <sup>2</sup> + <sup>2</sup> | <sup>2</sup> + <sup>2</sup> | -             | +2 .                |                     | +2        | +2             |               | +2 +3                        | <sup>2</sup> + <sup>1</sup> | +2 +                        | +2 +             | 2 -      | -       | -        | +1 -                        | - +              | 2 +       | +1             | +2            | - + <sup>3</sup>            | 2 -           | +2       |                     |
| 31  | OM                          | -  | +    | fHbp_1          | - +2                        |                |                             |               | -         | +' -                             |                  | -       | -        |                             | -                           | -         | +2 -                            | · + <sup>2</sup>            | 2 +2                        | -             |                     |                     | -         | +2             | -             |                              | -                           |                             |                  | -        | -       | -        |                             |                  | -         | -              | -             |                             | -             | -        |                     |
| 32  | OM                          | +  | +    | LppB/NlpD       |                             | -              |                             |               | -         |                                  |                  | -       | -        |                             | -                           | -         |                                 | · –                         | -                           | -             |                     |                     | -         | -              | -             |                              | -                           |                             |                  | -        | -       | -        |                             |                  | -         | +2             | -             |                             | -             | -        |                     |
| 34  | OM                          | -  | +/-  | PlpD            |                             | -              |                             |               | -         |                                  |                  | -       | -        |                             | _                           | -         |                                 | . –                         | +2                          | -             |                     |                     | -         | -              | -             |                              | _                           |                             |                  |          | -       | -        |                             |                  |           | -              | -             |                             | _             | -        |                     |
| 36  | OM                          | -  | +    | ComL            | +2 -                        | -              |                             |               | -         |                                  |                  | -       | -        | - +'                        |                             | +2        | +2 +                            | 2 -                         | +2                          | -             | +2 .                | - +,                | 2 -       | +2             | -             | - +,                         |                             |                             | - +              | 2 +2     | +2      | -        |                             | - +              | 2 +2      | -              | -             | - +,                        |               | +        |                     |
| 37  | OM                          | +  | -    | FhaC            |                             | -              |                             |               | -         |                                  |                  | -       | -        | +' -                        | -                           | -         |                                 | · –                         | -                           | -             |                     |                     | -         | -              | -             |                              | -                           |                             |                  | -        | -       | -        |                             |                  | -         | -              | -             |                             | -             | -        |                     |
| 38  | OM                          | -  | +    | PIpC            |                             | -              |                             |               | -         |                                  |                  | -       | -        |                             | -                           | -         |                                 | • -                         | -                           | -             |                     |                     | -         | -              | -             |                              | -                           |                             |                  | -        | -       | -        |                             |                  | -         | -              | -             |                             | _             | +'       |                     |
| 40  | OM                          | +  | +    | MItA            |                             | -              |                             |               | -         |                                  |                  | -       | -        |                             | -                           | -         |                                 |                             | +2                          | -             |                     |                     | -         | -              | -             |                              | -                           |                             | +2 -             | -        | -       | -        | - +                         | +2 -             | -         | +2             | -             | - +                         | - `           | +2       |                     |
| 41  | OM                          | -  | -    | OmpW            |                             | -              |                             |               | -         |                                  |                  | -       | -        | - +                         | - 2                         | -         |                                 |                             | -                           | -             |                     |                     | -         | -              | -             |                              | -                           |                             |                  | -        | -       | -        |                             |                  | -         | -              | -             |                             | -             | -        |                     |

|      |  |     |      |                 |                               |                             |                             |               |                             |                                 |                |                     |      |                                 |                             |                |                            |                             | Pro           | tein                | iden                        | tific     | atior                           | IS                          |                             |               |                               |               |                     |          |           |                                 |                               |                             |               |                             |                             |          |                     |
|------|--|-----|------|-----------------|-------------------------------|-----------------------------|-----------------------------|---------------|-----------------------------|---------------------------------|----------------|---------------------|------|---------------------------------|-----------------------------|----------------|----------------------------|-----------------------------|---------------|---------------------|-----------------------------|-----------|---------------------------------|-----------------------------|-----------------------------|---------------|-------------------------------|---------------|---------------------|----------|-----------|---------------------------------|-------------------------------|-----------------------------|---------------|-----------------------------|-----------------------------|----------|---------------------|
|      |  |     |      |                 |                               |                             |                             | Pł            | 2                           |                                 |                |                     |      |                                 |                             | F              | PH8                        |                             |               |                     |                             |           |                                 |                             |                             | PH2           | 02                            |               |                     |          |           |                                 |                               |                             | PH            | 278                         |                             |          |                     |
| No.ª | Subcellular<br>Localisation <sup>b</sup> | TM  | Lipo | Name            | DMEM only<br>DMEM + 10% FCS   | DMEM + 10% SS               | RPMI only<br>PDMI ± 40% ECS | RPMI + 10% SS | M199 only<br>M400 - 40% ECS | M199 + 10% FCS<br>M199 + 10% SS | FCS only       | SS only<br>NCS only |      | DMEM + 10% FCS<br>DMEM + 10% SS | RPMI only                   | RPMI + 10% FCS | KPWI + 10% >><br>M199 only | M199 + 10% FCS              | M199 + 10% SS | FCS only<br>SS only | SS ONLY                     | DMEM only | DMEM + 10% FCS<br>DMEM + 10% SS | RPMI only                   | RPMI + 10% FCS              | RPMI + 10% SS | M199 4 10% FCS                | M199 + 10% SS | FCS only<br>SS only | NCS only | DMEM only | DMEM + 10% FCS<br>DMEM + 10% SS | RPMI only                     | RPMI + 10% FCS              | RPMI + 10% SS | M199 only<br>M199 + 10% FCS | M199 + 10% SS               | FCS only | SS only<br>NCS only |
| 42   | OM                                       | +   | +    | LppC            |                               | -                           |                             |               |                             |                                 |                |                     | -    |                                 | -                           | -              |                            |                             | -             | +2 -                |                             | -         |                                 | - +1                        | ' -                         | -             |                               | -             |                     | -        | -         |                                 |                               | -                           | -             |                             |                             | -        |                     |
| 44   | OM                                       | +   | -    | TonB-dep. rece  | + -                           | -                           |                             |               |                             |                                 | · -            |                     | +    |                                 | +1                          | -              |                            |                             | -             |                     |                             | +         |                                 | - + <sup>2</sup>            | 2 -                         | -             |                               | -             |                     | -        | +         |                                 |                               | -                           | -             |                             | · -                         | -        |                     |
| 45   | OM                                       | +   | -    | HmbR1           | + -                           | -                           |                             |               |                             |                                 | · -            |                     | +    |                                 | +                           | -              |                            |                             | -             |                     |                             | +         | - +                             | <sup>2</sup> + <sup>2</sup> | 2 -                         | +             | +2 -                          | -             | +2 -                | -        | +         |                                 | - +                           | +1                          | -             |                             | · -                         | -        |                     |
| 46   | OM                                       | +   | -    | HxuB            |                               | -                           |                             |               |                             |                                 | · -            |                     | +    |                                 | +2                          |                | - +                        | 2 -                         | -             |                     |                             | +2        | - +                             | <sup>2</sup> + <sup>2</sup> | 2 -                         | +2            |                               | +2            | - +                 | 2 -      | +         | +2 -                            | - + <sup>2</sup>              | <sup>2</sup> +              | -             |                             | · -                         | -        | +2 -                |
| 47   | OM                                       |     |      | ОарА            |                               | -                           |                             |               |                             |                                 |                |                     | -    |                                 | -                           | -              |                            | · + <sup>2</sup>            | -             | +2 -                |                             | -         |                                 |                             | -                           | -             |                               | -             |                     | -        | -         |                                 |                               | -                           | -             |                             | · -                         | -        |                     |
| 48   | OM                                       | +/- | +    | ТbpВ            | +2 +3                         | <sup>2</sup> + <sup>2</sup> |                             | +2 +          |                             | +2 -                            | · -            |                     | +    | +2 +                            | +2                          | +2 .           | +2 +                       | <sup>2</sup> + <sup>2</sup> | -             |                     | - + <sup>2</sup>            | +2        | - +                             | 2 +                         | -                           | +2            | +2 -                          | +2            | - +                 | 2 -      | +         |                                 | - +                           | -                           | -             |                             | . –                         | -        | +1 -                |
| 51   | OM                                       | +   | -    | HxuC            |                               | -                           |                             |               |                             |                                 | · -            |                     | +    |                                 | +2                          |                | +2 +                       | 2 -                         | -             | +2 -                |                             | +         |                                 | - +                         | -                           | -             | +2 -                          | -             |                     | -        | +         | +2 -                            | - +                           | +2                          | -             | +2 +                        | 2 -                         | -        |                     |
| 56   | U  | +   | +    | Hypothetical pr | + <sup>2</sup> + <sup>2</sup> | <sup>2</sup> + <sup>2</sup> | +2 +                        | 2 -           | +2 +                        | +2 -                            | + <sup>2</sup> | - +2                | 2 +2 | +2 -                            | +2                          | +2             | - +                        | <sup>2</sup> + <sup>2</sup> | -             | +2 -                |                             | +2        | +2 -                            | - + <sup>2</sup>            | <sup>2</sup> + <sup>2</sup> | +2            | + <sup>2</sup> + <sup>2</sup> | +2            | +2 -                | +2       | +2        | +2 +                            | +2 +2                         | <sup>2</sup> + <sup>2</sup> | -             | +2 +                        | 2 -                         | +2       | - + <sup>2</sup>    |
| 57   | U  |     |      | Hypothetical pr | +2 -                          | -                           | +2 -                        |               | +2                          |                                 | +2             |                     | -    |                                 | -                           | -              |                            |                             | -             |                     |                             | -         |                                 |                             | -                           | -             |                               | -             |                     | -        | -         |                                 |                               | -                           | -             |                             |                             | -        |                     |
| 58   | U  |     |      | Hypothetical pr | (                             | -                           |                             |               |                             |                                 |                |                     | -    |                                 | +2                          | -              |                            |                             | -             |                     |                             | -         |                                 |                             | -                           | -             |                               | -             |                     | -        | -         |                                 |                               | -                           | -             |                             |                             | -        |                     |
| 68   | IM                                       |     |      | YajC            |                               | +2                          |                             | - +2          | +2                          |                                 | +2             |                     | +2   | +2 +2                           | <sup>2</sup> + <sup>2</sup> | +2 ·           | +2 -                       |                             | -             | +2 -                | - + <sup>2</sup>            | -         | +2 -                            |                             | -                           | -             |                               | -             | +2 -                | +2       | +2        | +2 -                            | - + <sup>2</sup>              | <sup>2</sup> + <sup>2</sup> | -             | - +                         | 2 _                         | -        |                     |
| 69   | IM                                       |     |      | PntA            | +2 -                          | +2                          |                             |               | +2 ·                        |                                 | +2             | - +2                | 2 +2 | +2 +2                           | 2 _                         | +2 .           | +2 +                       | <sup>2</sup> + <sup>2</sup> | $+^2$         | +2 +                | <sup>2</sup> + <sup>2</sup> | +2        | +2 +                            | <sup>2</sup> + <sup>2</sup> | 2 +2                        | +2            | +2 +2                         | +2            | +2 -                | +2       | +2        | +2 +                            | + <sup>2</sup> + <sup>2</sup> | <sup>2</sup> + <sup>2</sup> | $+^2$         | +2 +                        | <sup>2</sup> + <sup>2</sup> | $+^2$    | - + <sup>2</sup>    |
| 70   | С  |     |      | EF1A            |                               | -                           | + -                         |               | +2 ·                        |                                 | · _            |                     | -    | - +                             | +2                          | -              |                            |                             | -             |                     |                             | -         |                                 |                             | -                           | -             |                               | -             |                     | -        | -         |                                 |                               | -                           | -             |                             |                             | -        |                     |
| 71   | С  |     |      | RpIB            |                               | -                           | +2 -                        |               | +2 ·                        |                                 | · _            |                     | -    |                                 | -                           | -              |                            | +2                          | -             | +2 -                |                             | -         |                                 |                             | -                           | -             |                               | -             |                     | -        | -         |                                 |                               | -                           | -             |                             |                             | -        |                     |
| 74   | С  |     |      | RpIA            |                               | -                           | +2 .                        |               |                             |                                 | · -            |                     | -    |                                 | -                           | -              |                            |                             | -             |                     |                             | -         |                                 |                             | -                           | -             |                               | -             |                     | -        | -         |                                 |                               | -                           | -             |                             |                             | -        |                     |
| 75   | С  |     |      | RpIT            |                               | -                           |                             |               | +2 ·                        |                                 | · -            |                     | -    |                                 | -                           | -              |                            |                             | -             |                     |                             | -         | +2 -                            |                             | -                           | -             |                               | -             | +2 -                | +2       | -         |                                 |                               | -                           | -             |                             |                             | -        |                     |
| 78   | С  |     |      | RpsB            |                               | -                           | +2 .                        |               |                             | +2 -                            | · -            | - +2                | 2 -  | +2 -                            | -                           | -              |                            |                             | -             |                     |                             | -         |                                 |                             | +2                          | -             | - +2                          | -             |                     | -        | -         |                                 |                               | +2                          | -             |                             |                             | -        |                     |
| 79   | С  |     |      | RpIK            |                               | -                           | +2 .                        |               |                             |                                 |                |                     | -    |                                 | -                           | _              |                            |                             | -             |                     |                             | -         |                                 |                             | -                           | -             |                               | -             |                     | -        | -         |                                 |                               | -                           | -             |                             |                             | -        |                     |
| 81   | С  |     |      | RpIE            |                               | _                           | +2 -                        |               | +2                          |                                 | · _            |                     | -    |                                 | -                           | _              |                            |                             | -             |                     |                             | -         |                                 |                             | _                           | _             |                               | -             |                     | -        | -         |                                 |                               | _                           | _             |                             |                             | -        |                     |
| 84   | С  |     |      | RpIQ            |                               | _                           | +2 -                        |               |                             |                                 | · _            |                     | -    |                                 | -                           | _              |                            |                             | -             |                     |                             | -         |                                 |                             | _                           | _             |                               | -             |                     | -        | -         |                                 |                               | _                           | -             |                             |                             | -        |                     |
| 85   | Р  | -   | +    | YgiW            |                               | -                           |                             |               |                             |                                 |                |                     | -    |                                 | -                           |                |                            |                             | -             |                     |                             | -         |                                 |                             | -                           | -             |                               | -             |                     | -        | -         |                                 |                               | -                           | -             | + <sup>2</sup> -            |                             | -        |                     |
| 87   | Е  | +   | -    | LktA            |                               | +                           |                             | - +           |                             | - +                             | · -            | +2 +                | -    | - +                             | -                           | -              | + -                        |                             | +             | - +                 | <sup>2</sup> + <sup>2</sup> | +2        |                                 | + -                         | -                           | +2            |                               | +2            | - +                 | +        | -         | - +                             | 2 _                           | -                           | +2            |                             | +2                          | -        | +2 +2               |
| 89   | IM                                       |     |      | GItP            |                               | -                           |                             |               |                             |                                 | +2             | +2 +2               | 2 -  |                                 | -                           | -              |                            |                             | -             | +2 +                | 2_                          | -         |                                 |                             | -                           | -             |                               | -             |                     | -        | -         |                                 |                               | -                           | -             |                             |                             | -        |                     |

|        |                             |       |      |                  |                             |               |                             |               |                             |               |          |                     |                             |               |                              |                |           | Р                               | rotei    | n ider              | ntifica   | ation                           | s                |                                 |                  |                |                           |         |                       |                  |               |                             |               |                             |                  |          |                     |
|--------|-----------------------------|-------|------|------------------|-----------------------------|---------------|-----------------------------|---------------|-----------------------------|---------------|----------|---------------------|-----------------------------|---------------|------------------------------|----------------|-----------|---------------------------------|----------|---------------------|-----------|---------------------------------|------------------|---------------------------------|------------------|----------------|---------------------------|---------|-----------------------|------------------|---------------|-----------------------------|---------------|-----------------------------|------------------|----------|---------------------|
|        |                             |       |      |                  |                             |               |                             | PH            | 2                           |               |          |                     |                             |               |                              | PH             | 8         |                                 |          |                     |           |                                 |                  | P                               | H202             | 2              |                           |         |                       |                  |               |                             | PH            | 278                         |                  |          |                     |
| No.    | Subcellular<br>Localisation | TM    | Lipo | Name             | DMEM only<br>DMEM + 10% FCS | DMEM + 10% SS | RPMI only<br>RPMI + 10% FCS | RPMI + 10% SS | M199 only<br>M199 + 10% FCS | M199 + 10% SS | FCS only | ss only<br>NCS only | DMEM only<br>DMEM + 40% ECS | DMEM + 10% SS | RPMI only<br>DDMI - 4000 FCS | RPMI + 10% FCS | M199 only | M199 + 10% FCS<br>M199 + 10% SS | FCS only | SS only<br>NCS only | DMEM only | DMEM + 10% FCS<br>DMEM + 10% SS | RPMI only        | RPMI + 10% FCS<br>RDMI + 10% SS | M199 only        | M199 + 10% FCS | M199 + 10% SS<br>FCS only | SS only | NCS only<br>DMEM code | DMEM + 10% FCS   | DMEM + 10% SS | RPMI only<br>RPMI + 10% FCS | RPMI + 10% SS | M199 only<br>M400 - 40% ECS | M199 + 10% SS    | FCS only | SS only<br>NCS only |
| 94     | IM                          |       |      | PntB             |                             | -             |                             |               |                             |               | -        |                     | - ·                         |               | -                            |                | -         |                                 | -        |                     | -         |                                 | -                |                                 |                  | -              |                           | -       | -   -                 | - + <sup>2</sup> | -             |                             |               |                             |                  | -        |                     |
| 95     | С                           |       |      | RpsA             |                             | · -           | +2 -                        |               |                             |               | -        |                     | - ·                         |               | +2                           |                | -         |                                 | -        |                     | -         |                                 | · -              |                                 |                  | -              |                           | -       | - -                   |                  | -             |                             |               |                             |                  | -        |                     |
| 2. Pr( | oteins p                    | previ | ous  | ly identified in | iron                        | -res          | stric                       | ted           | BHI                         | в             |          |                     |                             |               |                              |                |           |                                 |          |                     |           |                                 |                  |                                 |                  |                |                           |         |                       |                  |               |                             |               |                             |                  |          |                     |
| 99     | OM                          | +     | -    | Haemin recepto   |                             |               |                             |               |                             |               | -        |                     | + ·                         |               |                              |                | -         |                                 | -        |                     | +         |                                 | · + <sup>2</sup> |                                 |                  | -              |                           | -       | - +                   | · <sup>1</sup> – | -             |                             |               |                             |                  | -        |                     |
| 100    | OM                          | +     | -    | LamB             |                             | · -           |                             |               |                             |               | -        |                     | - ·                         |               |                              |                | -         |                                 | -        |                     | +1        |                                 | · -              |                                 |                  | -              |                           | -       | -   -                 | - + <sup>1</sup> | -             |                             |               |                             |                  | -        |                     |
| 107    | U                           | -     | +    | Lipoprotein      |                             | · -           |                             |               |                             |               | . – .    |                     |                             |               |                              |                | . – .     | +2 -                            | +2       |                     | -         |                                 | ·                |                                 |                  |                |                           |         |                       |                  |               |                             |               |                             |                  |          |                     |
| 108    | U                           |       |      | Hypothetical pro |                             | · -           |                             |               |                             |               | -        |                     | - ·                         |               | -                            |                | -         |                                 | -        |                     | -         |                                 | · -              |                                 | - + <sup>2</sup> | -              |                           | -       | - -                   |                  | -             |                             |               |                             |                  | -        |                     |
| 109    | E                           |       |      | PenP             |                             | -             |                             |               |                             |               | +2       |                     | - ·                         |               | -                            |                | -         |                                 | -        |                     | -         |                                 | -                |                                 |                  | -              |                           | -       | -   -                 |                  | -             |                             |               |                             |                  | -        |                     |
| 3. Pr( | oteins i                    | dent  | ifie | d exclusively ir | DM                          | EM,           | RPI                         | MIa           | nd N                        | VI19          | 9 in     | the                 | pre                         | send          | e o                          | r ab           | ser       | nce                             | ofs      | erun                | n, an     | nd ir                           | 1 tota           | al s                            | erur             | n              |                           |         |                       | _                |               | _                           |               |                             | _                |          |                     |
| 112    | OM                          | -     | -    | Possible OMP     | +' -                        | · -           |                             |               |                             |               | -        |                     | +' ·                        |               |                              |                | -         |                                 | -        |                     | +2        |                                 | · +'             |                                 |                  | -              |                           | -       | -   -                 |                  | -             |                             |               |                             |                  | -        |                     |
| 113    | OM                          | +/-   | -    | Hsf              |                             | · -           |                             |               |                             |               | -        |                     | - ·                         |               |                              | +2 -           | -         | +2 -                            | -        | - +;                | -<br>-    |                                 | · -              |                                 |                  | -              |                           | _       | -   -                 |                  | -             |                             |               |                             |                  | -        |                     |
| 114    | OM                          | -     | +    | PlpB             |                             | · -           |                             |               |                             |               | +2       |                     | - ·                         |               |                              |                | -         |                                 | -        |                     | -         |                                 | · -              |                                 |                  | -              | - + <sup>2</sup>          |         | -   -                 |                  | -             |                             |               |                             |                  | -        |                     |
| 115    | U                           | -     | +    | Hypothetical pro |                             | · -           |                             |               | - +                         | +2 -          | -        |                     |                             |               |                              |                | -         | +2 -                            | +2       |                     | -         |                                 | · + <sup>2</sup> | +2 -                            |                  | +2             |                           | -       | -   -                 | - +2             | -             | +2 -                        |               |                             | · <sup>2</sup> – | -        |                     |
| 116    | U                           | -     | +    | Hypothetical pro | +2 +                        | 2 -           |                             |               |                             |               | -        |                     | +2 .                        |               | +2                           |                | -         |                                 | -        |                     | -         |                                 | · -              |                                 |                  | -              |                           | -       | -   -                 |                  | -             |                             |               |                             |                  | -        |                     |
| 117    | U                           | -     | +    | Hypothetical pro |                             | · -           |                             |               |                             |               |          |                     |                             |               |                              |                | . – .     |                                 | -        |                     | +-        |                                 | · +              |                                 |                  |                |                           |         | - +                   | <sup>-</sup>     |               |                             |               |                             |                  |          |                     |
| 118    | U                           |       |      | Hypothetical pro |                             | -             |                             |               |                             |               | -        |                     | - ·                         |               |                              |                | -         |                                 | -        |                     | -         |                                 | · +*             |                                 |                  | -              |                           | -       | -   +                 | - +-             | -             | +- +                        |               |                             |                  | -        |                     |
| 119    | U                           |       |      | Hypothetical pro |                             | -             |                             |               | +* -                        |               | -        |                     | - ·                         |               |                              |                | -         |                                 | _        |                     | -         |                                 | · _              |                                 |                  | _              |                           | -       | -   -                 |                  | -             |                             |               |                             |                  | -        |                     |
| 120    | IM                          |       |      | CstA             |                             | -             |                             |               |                             |               | -        |                     | - +                         | +* +*         |                              | ÷ –            | -         | +* -                            | +2       |                     | -         | +                               | · +-             | +                               |                  | +-             |                           | -       | -   -                 |                  | -             | - +                         |               |                             |                  | -        |                     |
| 121    | IM                          |       |      | MgIC             |                             | -             |                             | - +-          |                             |               | -        |                     |                             | - +*          |                              | - +-           | -         |                                 | -        |                     | -         | +* +                            | - <u>-</u>       | +- +                            |                  | +-             | +                         | -       | -  -                  |                  | -             |                             |               |                             |                  | -        |                     |
| 122    | IM                          |       |      | WecC             |                             | · -           | + -                         |               |                             |               | -        |                     | - ·                         |               |                              |                | -         |                                 | -        |                     | -         |                                 | · -              |                                 |                  | -              |                           | -       | -   -                 |                  | -             |                             |               |                             |                  | -        |                     |
| 123    | IM                          |       |      | UraA             |                             | · +2          |                             | - +-          |                             |               | -        |                     | - ·                         | - +2          | -                            | - +2           | -         | +" -                            | -        |                     | <u> </u>  | - +                             | <br>,            | - +                             |                  | -              |                           | -       | - -                   |                  | -             |                             |               |                             |                  | -        |                     |
| 124    | IM                          |       |      | PTS_EIIB         |                             |               |                             |               |                             |               | -        |                     | - ·                         |               |                              |                | -         | +                               | -        |                     | +-        |                                 | · +2             |                                 |                  | -              |                           | -       | -   -                 |                  | -             |                             |               |                             |                  | -        |                     |
| 125    | IM                          |       |      | NupC             |                             |               |                             |               |                             |               | -        |                     |                             |               | -                            |                | -         |                                 | -        |                     | -         |                                 | · -              |                                 |                  | -              |                           | -       | -   +                 | ÷ _              | -             | - +                         | <sup>-</sup>  |                             |                  | -        |                     |

|     |                             |    |                  |                             |               |                             |               |                             |               |          |                     |                             |               |           |                                 |           |                | Prot          | ein i   | den      | tific     | atior                           | IS        |                |               |                             |               |          |                     |           |                |               |                             |               |           |                |                            |         |          |
|-----|-----------------------------|----|------------------|-----------------------------|---------------|-----------------------------|---------------|-----------------------------|---------------|----------|---------------------|-----------------------------|---------------|-----------|---------------------------------|-----------|----------------|---------------|---------|----------|-----------|---------------------------------|-----------|----------------|---------------|-----------------------------|---------------|----------|---------------------|-----------|----------------|---------------|-----------------------------|---------------|-----------|----------------|----------------------------|---------|----------|
|     |                             |    |                  |                             |               |                             | PH            | 2                           |               |          |                     |                             |               |           | P                               | H8        |                |               |         |          |           |                                 |           |                | PH2           | 202                         |               |          |                     |           |                |               |                             | P             | 1278      | 3              |                            |         |          |
| No. | Subcellular<br>Localisation | TM | 2<br>5 Name      | DMEM only<br>DMEM + 10% FCS | DMEM + 10% SS | RPMI only<br>RPMI + 10% FCS | RPMI + 10% SS | M199 only<br>M199 + 10% FCS | M199 + 10% SS | FCS only | ss only<br>NCS only | DMEM only<br>DMEM - 40% FCS | DMEM + 10% 55 | RPMI only | KPMI + 10% FCS<br>RPMI + 10% SS | M199 only | M199 + 10% FCS | M199 + 10% SS | SS only | NCS only | DMEM only | DMEM + 10% FCS<br>DMEM + 10% SS | RPMI only | RPMI + 10% FCS | RPMI + 10% SS | M199 only<br>M199 + 10% FCS | M199 + 10% SS | FCS only | SS only<br>NCS only | DMEM only | DMEM + 10% FCS | DMEM + 10% SS | RPMI only<br>PDMI + 40% ECS | RPMI + 10% SS | M199 only | M199 + 10% FCS | M199 + 10% 55<br>Ef S antu | SS only | NCS only |
| 126 | IM                          |    | 4-aminobutyrat   |                             | -             | +2 -                        | -             |                             |               | -        |                     | -                           |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | - ·            |                            |         |          |
| 127 | IM                          |    | NhaP             |                             | -             |                             | -             |                             |               | -        |                     | +2                          |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | - ·            |                            |         |          |
| 128 | IM                          |    | HfIC             |                             | -             |                             | -             |                             |               | -        |                     |                             |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | +2        | - 2            | -             |                             |               | -         |                |                            |         |          |
| 129 | С                           |    | ⊦ CarB           |                             | -             | +2 -                        |               |                             |               | -        |                     |                             |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         |                |                            |         |          |
| 130 | C/IM                        |    | Thioredoxin-like |                             | -             | +2 -                        | -             | +2 -                        |               | -        |                     |                             |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         |                |                            |         |          |
| 131 | С                           |    | Pta              |                             | -             | +2 -                        | -             | +2 -                        |               | -        |                     |                             |               | -         |                                 | -         | -              | -             |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | - ·            |                            |         |          |
| 132 | С                           |    | PurL             |                             | -             | + -                         | -             |                             |               | -        |                     | -                           |               | +2        |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | - ·            |                            |         |          |
| 133 | С                           |    | GapA             |                             | -             |                             | -             | +2 -                        |               | -        |                     | -                           |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | - ·            |                            |         |          |
| 134 | С                           |    | RpsC             |                             | -             |                             | -             | +2 -                        |               | -        |                     |                             |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         |                |                            |         |          |
| 135 | С                           |    | AceE             |                             | -             |                             | -             | +2 -                        |               | -        |                     |                             |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | _ ·            |                            |         |          |
| 136 | С                           |    | TktA             |                             | -             |                             | -             | +2 -                        |               | -        |                     | -                           |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | _ ·            |                            |         |          |
| 137 | С                           |    | RpsD             |                             | -             | +2 -                        | -             |                             |               | -        |                     |                             |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | _ ·            |                            |         |          |
| 138 | С                           |    | EF2/FusA         |                             | -             | +2 -                        | -             |                             |               | -        |                     | -                           |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | - ·            |                            |         |          |
| 139 | С                           |    | RpoA             |                             | -             | +2 -                        | -             |                             |               | -        |                     |                             |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | - ·            |                            |         |          |
| 140 | С                           |    | EF1B             |                             | -             | +2 -                        | -             |                             |               | -        |                     |                             |               | -         |                                 | _         | -              | -             |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         |                |                            |         |          |
| 141 | С                           |    | Hsp33            |                             | -             | +2 -                        | -             |                             |               | -        |                     | -                           |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         |                |                            |         |          |
| 142 | С                           |    | Electron transp  |                             | -             | +2 -                        | -             |                             |               | -        |                     |                             |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         |                |                            |         |          |
| 143 | С                           |    | LeuB             |                             | -             | +2 -                        | -             |                             |               | -        |                     |                             |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         |                |                            |         |          |
| 144 | С                           |    | AsnA             |                             | -             | +2 -                        | -             |                             |               | -        |                     |                             |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | _ ·            |                            |         |          |
| 145 | С                           |    | FabG             |                             | -             | +2 -                        | -             |                             |               | -        |                     | -                           |               | -         |                                 | _         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | _ ·            |                            |         |          |
| 146 | С                           |    | DnaK             |                             | -             | +2 -                        | -             |                             |               | -        |                     | -                           |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | - ·            |                            |         |          |
| 147 | С                           |    | PurN             |                             | -             | +1 -                        | -             |                             |               | -        |                     | -                           |               | -         |                                 | -         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | _ ·            |                            |         |          |
| 148 | С                           |    | PurA             |                             | -             | +1 -                        | -             |                             |               | -        |                     |                             |               | -         |                                 | _         | -              |               |         | -        | -         |                                 |           | -              | -             |                             |               | -        |                     | -   -     | -              | -             |                             |               | -         | _ /            |                            |         |          |

|   |  |                   |                             |               |           |                |           |                                 |          |         |          |                             |               |           |                                 |                            |                | Pro           | otein               | ider                | ntific    | ation                           | s         |                |                            |                |               |                     |                     |           |                                 |           |                |               |                             |               |          |                     |
|---|--|-------------------|-----------------------------|---------------|-----------|----------------|-----------|---------------------------------|----------|---------|----------|-----------------------------|---------------|-----------|---------------------------------|----------------------------|----------------|---------------|---------------------|---------------------|-----------|---------------------------------|-----------|----------------|----------------------------|----------------|---------------|---------------------|---------------------|-----------|---------------------------------|-----------|----------------|---------------|-----------------------------|---------------|----------|---------------------|
|   |  |                   |                             |               |           | P              | 2         |                                 |          |         |          |                             |               |           | P                               | PH8                        |                |               |                     |                     |           |                                 |           | - 1            | PH2(                       | )2             |               |                     |                     |           |                                 |           |                | PH2           | 278                         |               |          |                     |
|   | ,⊖S<br>Subcellular<br>Localisation<br>TM<br>Lipo | Name              | DMEM only<br>DMEM + 10% FCS | DMEM + 10% SS | RPMI only | RPMI + 10% FUS | M199 only | M199 + 10% FCS<br>M199 + 10% SS | FCS only | SS only | NCS only | DMEM only<br>DMEM + 10% FCS | DMEM + 10% SS | RPMI only | RPMI + 10% FCS<br>PDMI + 40% SS | KPWI + 10% 55<br>M199 only | M199 + 10% FCS | M199 + 10% SS | ECS only<br>SS only | as only<br>NCS only | DMEM only | DMEM + 10% FCS<br>DMEM + 10% SS | RPMI only | RPMI + 10% FCS | KPMI + 10% SS<br>M199 only | M199 + 10% FCS | M199 + 10% SS | FCS only<br>SS only | os only<br>NCS only | DMEM only | DMEM + 10% FCS<br>DMEM + 10% SS | RPMI only | RPMI + 10% FCS | RPMI + 10% SS | M199 only<br>M199 + 10% ECS | M199 + 10% SS | FCS only | SS only<br>NCS only |
| 1 | 149 C  | GInA              |                             | -             | -         |                | -         |                                 |          | -       | -        |                             |               | -         |                                 |                            |                | -             |                     |                     | -         |                                 | -         | -              |                            | -              | -             |                     |                     | +2        |                                 |           | -              | -             |                             |               | -        |                     |
|   | Total number of pr                               | oteins identified | 22 8                        | 15            | 37        | 9 11           | 23        | 17                              | 6 20     | 8       | 12       | 26 2                        | 2 21          | 25        | 22 1                            | 17 19                      | 9 29           | 6             | 30                  | 11 13               | 25        | 23 1                            | 6 25      | 23             | 18 1                       | 5 22           | 15            | 22 1                | 12 16               | 27        | 25 1                            | 1 20      | 24             | 10            | 11 2                        | 26 6          | 20       | 89                  |
|   | Total number of (                                | DMPs identified   | 18 6                        | 10            | 9         | 87             | 8         | 14                              | 5 14     | 6       | 7        | 21 1                        | 7 14          | 18        | 18 1                            | 12 17                      | 7 21           | 4             | 22                  | 8 10                | 20        | 17 1                            | 2 18      | 17             | 13 1                       | 2 16           | 11            | 18 1                | 11 11               | 19        | 19 8                            | 15        | 17             | 8             | 8 2                         | 21 4          | 18       | 76                  |

Hsf was identified only in ovine serotype A1 isolate PH8 after growth in RPMI + 10% FCS, M199 + 10% FCS and complete NCS.

Of the seven identified proteins that were of unknown location, lipoprotein MHA\_2737/COI\_0543/COK\_2363 was the only one to be identified only under growth conditions containing serum. It was identified only in isolate PH8 after growth in M199 containing 10% FCS and also in complete FCS. The remaining six proteins were identified either in tissue culture media or both tissue culture media and serum-supplemented media.

Three of the 31 identified proteins predicted to be localised to cellular compartments other than the outer membrane were identified only under growth conditions containing serum: PenP, MglC and UraA. PenP, a penicillinase, was identified in isolate PH2 after growth in complete FCS; this protein was also identified in the same isolate after growth under iron-restricted conditions. MglC and UraA, inner membrane proteins involved in galactose and uracil transport, respectively, were identified in isolates PH2, PH8 and PH202 only after growth in serum-supplemented conditions.

In the four isolates examined, growth in DMEM resulted in OMP profiles that were similar to those observed after growth in iron-restricted BHIB. This is most likely due to the fact that iron in DMEM is available only in the form of ferric nitrate (Conrad, 2007) and is not a favourable iron source for M. haemolytica. In serotype A1 isolate PH8, growth in DMEM supplemented with FCS or SS resulted in an OMP profile which resembled that observed after growth in iron-replete BHIB (Fig 4.2A). This suggests that isolate PH8 is able to acquire iron from serum of both cattle and sheep. A similar observation was made for isolate PH2, although some iron-acquisition proteins including TbpA and FrpB are still expressed at higher levels after growth in the presence of serum from either animal compared to growth in iron-replete BHIB. In the serotype A2 isolates, it appears that there is a correlation between the host of origin and the ability to acquire iron more readily from serum of the same host. In the bovine serotype A2 isolate (PH202), the protein band containing the putative siderophore receptor FrpB (number 12; Fig. 4.3) is expressed at higher levels after growth in the presence of SS than that of FCS, indicating a greater ability to acquire iron from serum of cattle than sheep. Conversely, in the ovine serotype A2 isolate

(PH278), the protein band containing the FrpB protein is expressed at a higher level after growth in the presence of FCS than that of SS, indicating a greater ability to acquire iron from serum of sheep than cattle. This is particularly interesting considering that PH202 and PH278 belong to the same ET and are identical in terms of their housekeeping genes.

In a previous study, a 98 kDa protein band was identified in the OMP profiles of two *M. haemolytica* isolates after growth in NCS (Davies *et al.*, 1992), although the identity of this protein was not determined. Furthermore, expression of this protein was not repressed after the addition of FeCl<sub>3</sub> to the NCS, indicating that its expression was not iron-regulated (Davies *et al.*, 1992). In the present study, this protein was identified as the leukotoxin protein LktA (number 87; Fig. 4.3). It was identified in a 98 kDa protein band in isolates PH2, PH8 and PH202 after growth in tissue culture media containing 10% SS and in complete NCS by gelbased proteomic analysis. It was also identified in isolates PH278 by gel-free proteomic analysis under the same growth conditions.

## 4.3.3 Identification of *M. haemolytica* and *M. glucosida* OMPs which undergo changes in expression after growth on solid-surface BHIA in the absence or presence of Congo red dye.

In order to identify OMPs that are potentially involved in mediating surfaceassociated growth and possible biofilm formation, the OMP profiles of the eight representative isolates were examined after 24 h growth on BHIA (Fig. 4.4). The OMP profiles were not too dissimilar to that observed after growth in ironreplete BHIB (Fig. 4.2A). Several iron-acquisition OMPs were identified including HmbR1, HxuB and HxuC, although they were expressed at lower levels than that observed after growth in iron-restricted BHIB. Expression of these OMPs is most likely due to locally available iron being depleted by high cell densities and also the slower diffusion of this nutrient through solid medium compared to liquid medium. Gel-based proteomic analysis revealed no new proteins identified in any of the isolates that had not been identified in iron-replete or iron-restricted BHIB.
Figure 4.4. One-dimensional SDS-PAGE separation of outer membrane fractions from seven *M. haemolytica* isolates and one *M. glucosida* isolate after growth on BHIA for 24 h.

Numbered proteins were subsequently identified by proteomic analysis. Twenty micrograms of protein were loaded into each lane. Protein bands were stained with Coomassie brilliant blue.



Gel-free proteomic analysis resulted in poor coverage of identified proteins and was therefore not included.

The seven *M. haemolytica* isolates and the *M. glucosida* isolate were grown on BHIA supplemented with 0.8 g/L Congo red (BHIA<sub>CR</sub>). Within 24 h, in all isolates, the agar surrounding areas of growth had turned from red to black and there were black dots in the centres of individual colonies (Fig. 4.5). However, after incubation between 48 and 72 h the colonies turned a deep red colour, suggesting that it was only the underlying agar that turned black within 24 h and not the colonies themselves.

To determine any physiological effect that Congo red might be having on OMP expression, outer membrane fractions were extracted after 24 h growth on BHIA<sub>CR</sub>. Outer membrane protein profiles were virtually identical to those observed after growth on BHIB (Fig. 4.4), except for the presence of previously unseen protein bands in the upper molecular mass region of the gel (Fig. 4.6). Two protein bands were present at 131 and 135 kDa in all M. haemolytica isolates but not in the M. glucosida isolate. Iga1\_1 (number 151; Fig. 4.6) and Iga1\_2 (number 24; Fig. 4.6) were identified in these bands in one and six isolates, respectively, but given the close proximity of the bands it was not possible to determine which protein was contained in which protein band. Another OMP, the putative filamentous haemagglutinin FhaB\_1 (number 150; Fig. 4.6), was identified in a 159 kDa protein band in isolate PH8. Iga1 3 (number 39; Fig. 4.6) was also identified at 146 kDa in isolates PH292 and PH588. This protein had been identified in the previous chapter in isolates PH202, PH278 and PH296 after growth in iron-replete BHIB. The Iga1\_1, Iga1\_2 and FhaB\_1 proteins were also visible when isolates were grown in BHIB supplemented with Congo red dye (Fig. 4.6) indicating that expression of these OMPs is dependent on the presence of Congo red dye and not on solid-surface growth.

Figure 4.5. Colony phenotypes of seven *M. haemolytica* isolates and one *M. glucosida* isolate after growth on  $BHIA_{CR}$  for 18, 24, 48 and 72 h.



Figure 4.6. One-dimensional SDS-PAGE separation of outer membrane fractions from seven *M. haemolytica* isolates and one *M. glucosida* isolate after growth on BHIA<sub>CR</sub> for 24 h. The OMP profiles of *M. haemolytica* isolate PH2, PH8, PH202 and PH278 after growth to mid-log phase in BHIB<sub>CR</sub> are also shown.

Twenty micrograms of protein were loaded into each lane. Protein bands were stained with Coomassie brilliant blue.

| BHIA + Congo red |                 |                  |                  |                  |                  |                   | BHIB + Congo red  |                |                |                  |                  |     |    |
|------------------|-----------------|------------------|------------------|------------------|------------------|-------------------|-------------------|----------------|----------------|------------------|------------------|-----|----|
| PH2<br>B<br>A1   | PH8<br>O<br>A1  | PH202<br>B<br>A2 | PH278<br>O<br>A2 | PH292<br>O<br>A2 | PH296<br>O<br>A7 | PH344<br>O<br>A11 | PH588<br>O<br>A13 | PH2<br>B<br>A1 | PH8<br>O<br>A1 | PH202<br>B<br>A2 | PH278<br>O<br>A2 | kDa |    |
| 24               | 150<br>24<br>24 | 24               | 24,151           | 39<br>24<br>24   | 24               |                   | 39                |                |                |                  |                  |     |    |
|                  | =               | =                | -                | -                |                  |                   |                   | =              | =              |                  |                  | -   | 97 |
|                  |                 | -                |                  | -                |                  |                   |                   |                |                |                  |                  | -   | 66 |

### 4.3.4 Comparison of OMPs identified among different growth conditions.

A total of 55 OMPs were identified in the previous chapter after growth in ironreplete BHIB. In the present study, a further thirteen OMPs were identified using a range of different growth conditions (Fig 4.7; Table 4.4). Six OMPs (FhuA, autotransporter MHA\_0080/COI\_1870/COK\_0773, EcnA, HmbR2, HxuA and Iga1\_4) were identified exclusively after growth in iron-restricted BHIB. Possible OMP MHA\_0862/COI\_1567/COK\_2302 was identified exclusively after growth in tissue culture media alone. Two OMPs (Hsf and PlpB), were identified exclusively after growth in media containing serum. The haemin receptor was identified after growth in both iron-restricted BHIB and tissue culture media alone. The maltoporin LamB was identified after growth in iron-restricted BHIB, tissue culture media only and in media containing serum. Iga1\_1 and FhaB\_1 were identified exclusively after growth in the presence of Congo red dye (not shown in Fig. 4.7).

## 4.3.5 Extracellular protein expression after growth in iron-replete and ironrestricted BHIB.

The present work has provided evidence to suggest that proteolytic cleavage occurs in the passenger domains of OMPs such as Iga1\_2 and Ssa. Furthermore, the finding that HxuA is only present in the outer membrane of one isolate after growth in iron-restricted BHIB suggests that it is a secreted protein. To identify these proteins in the extracellular medium and gain an understanding of the overall extracellular subproteome of M. haemolytica, proteins from cell-free culture supernatants were precipitated and analysed by 1-D SDS-PAGE after growth to stationary phase in iron-replete (Fig. 4.8A) and iron-restricted (Fig. 4.8B) BHIB. Supernatants from stationary phase growth were used because only limited protein was obtained from supernatants after growth to mid-log phase (results not shown). This finding is consistent with what has been observed for extracellular proteins of other bacteria in the stationary phase (Voigt et al., 2006, Gohar et al., 2002, Xia et al., 2008, Kim et al., 2005). Similar to OMP expression profiles, the extracellular protein profiles of the representative isolates differ considerably after growth in iron-restricted BHIB compared to iron-replete BHIB. Proteins have not yet been identified by proteomic approaches, but will be in future experiments.

Figure 4.7. Distribution of 66 OMPs identified by proteomic approaches after growth in iron-replete BHIB (grey shaded), iron-restricted BHIB, tissue culture media only and/or media containing serum.



Names and putative functions of OMPs that were identified under different growth conditions that were not identified Table 4.4. after growth in iron-replete BHIB.

| No. <sup>a</sup> | Name            | Function                          | Iron-restricted<br>BHIB | Tissue culture<br>media only | Media<br>containing sera | BHIA <sub>CR</sub> |
|------------------|-----------------|-----------------------------------|-------------------------|------------------------------|--------------------------|--------------------|
| 99               | Haemin receptor | Haemin receptor                   | +                       | +                            | -                        | _                  |
| 100              | LamB            | Maltoporin transport              | +                       | +                            | +                        | _                  |
| 101              | FhuA            | Ferric hydroxamate receptor       | +                       | _                            | -                        | _                  |
| 102              | Autotransporter | Unknown                           | +                       | _                            | -                        | _                  |
| 103              | EcnA/B          | Programmed cell apoptosis         | +                       | _                            | -                        | _                  |
| 104              | HmbR2           | Haemoglobin receptor              | +                       | _                            | -                        | _                  |
| 105              | HxuA            | Haem-haemopexin acquisition       | +                       | _                            | -                        | _                  |
| 106              | lga1_4          | Cleavage of host mucosal antibody | +                       | _                            | -                        | _                  |
| 112              | Possible OMP    | Unknown                           | _                       | +                            | _                        | _                  |
| 113              | Hsf             | Adherence/serum resistance        | _                       | _                            | +                        | _                  |
| 114              | PlpB            | Unknown                           | _                       | _                            | +                        | _                  |
| 150              | FhaB_1          | Adherence                         | _                       | _                            | _                        | +                  |
| 151              | lga1_1          | Cleavage of host mucosal antibody | -                       | _                            | -                        | +                  |

<sup>a</sup>Numbers correspond to the location of the protein in Figures 4.2, 4.3, 4.4 and 4.6 if identified by gel-based proteomics. '+' = identified in at least one isolate; '-' = not identified in any isolates.

Figure 4.8. One-dimensional SDS-PAGE separation of extracellular proteins from seven *M. haemolytica* isolates and one *M. glucosida* isolate after growth to stationary phase in (A) iron-replete and (B) iron-restricted BHIB.

Eighty micrograms of protein were loaded into each lane. Protein bands were stained with Coomassie brilliant blue.



## 4.4 Discussion

In the present study, the OMP expression profiles of seven representative *M*. *haemolytica* isolates and one *M*. *glucosida* isolate were examined after growth under several *in vitro* conditions designed to mimic the *in vivo* pneumonic lung microenvironment. Subsequently, a combination of proteomic approaches were used to identify new OMPs and determine which OMPs were differentially expressed under these conditions, indicating potential roles in virulence and host-specificity.

### Growth in iron-restricted conditions

Firstly, the tolerances of the representative isolates to growth in increasing concentrations of the iron chelator 2,2'-dipyridyl were examined in order to determine the maximum concentration at which each isolate could grow to midlog phase. Interestingly, isolates PH2 and PH278, which represent groups of pathogenic isolates that cause the majority of disease cases in cattle and sheep, respectively, tolerated the lowest levels of 2,2'-dipyridyl (160 and 120  $\mu$ M, respectively). One might expect that the most pathogenic isolates would be able to tolerate higher levels of 2,2'-dipyridyl than weakly pathogenic isolates. Also, notably, the weakly pathogenic *M. glucosida* isolate was able to grow at the highest concentration of 2,2'-dipyridyl (310  $\mu$ M). These findings suggest that the ability to tolerate increasing concentrations of 2,2'-dipyridyl could be inversely correlated with virulence in these species.

Under iron-restricted growth conditions, eight OMPs were identified that were not previously identified under growth in iron-replete BHIB. These were a haemin receptor, LamB, FhuA, autotransporter MHA\_0800/COI\_1870/COK\_0773, EcnA, HmbR2, HxuA and Iga1\_4. The haemin receptor and putative haemoglobin receptor HmbR2 have been described previously in a bovine *M. haemolytica* isolate after iron-restricted growth (Roehrig *et al.*, 2007). LamB is a putative maltoporin involved in substrate-specific uptake of maltodextrins. The autotransporter contains a C-terminal translocator domain that is characteristic of other autotransporters but its function is currently unknown. EcnA, shares 45% amino acid identity with the EcnA protein of *E. coli*. In *E. coli*, the *ecnA* and *ecnB* genes comprise the two-gene entericidin locus, whereby EcnB 'the toxin'

and EcnA 'the antitoxin' contribute programmed cell apoptosis (Bishop *et al.*, 1998). During the course of balanced growth, EcnB is constantly neutralised by EcnA; however, metabolic changes brought about by nutrient stress disturbs this balance and EcnB 'poisons' the cell, allowing surviving cells to use the lysis products for nourishment. A counterpart EcnB protein was not predicted in *M. haemolytica* genomes by bioinformatics, therefore it can only be speculated as to whether *M. haemolytica* EcnA functions in a similar manner to *E. coli* EcnA. Iga1\_4 was identified exclusively in *M. glucosida* and represents the first Iga1-like protease to be identified in this species under iron-restricted conditions. Members of this protein family were identified in the previous chapter in all *M. haemolytica* isolates after growth in iron-replete BHIB, but not in *M. glucosida*. HxuA and FhuA are described in further detail below in the context of their respective expression systems.

Under iron-restricted growth conditions, protein components of a putative HxuCBA haem-haemopexin utilization system were identified in several M. haemolytica isolates. This system was first discovered in H. influenzae (Hanson et al., 1992) and is an important virulence determinant in this organism (Morton et al., 2007) and in H. parasuis (Melnikow et al., 2005). HxuC is a TonBdependent receptor protein (Cope et al., 2001, Cope et al., 1995). HxuB and HxuA comprise a two-partner (TPS) system, whereby HxuA (the TpsA protein) is transported across the outer membrane by HxuB (the TpsB protein) (Cope et al., 1995). HxuA binds the haem-haemopexin complex and facilitates haem delivery to the cell surface via HxuC (Cope et al., 1994, Cope et al., 1998). Recent evidence suggests that HxuA might not actually function as a haemophore in H. influenzae, but instead releases haem upon interaction with the haemhaemopexin complex (Fournier *et al.*, 2011). Furthermore, the primary activity of HxuA may actually be to sequester haemopexin in its inactive form, thereby decreasing the high-affinity binding of haem by the serum (Fournier et al., 2011). In the present study, HxuB and HxuC were expressed in the outer membranes of all M. haemolytica isolates except for the bovine serotype A1 isolate PH2, and the M. glucosida isolate PH344, after growth in iron-restricted BHIB. In the previous chapter, HxuB and HxuC were identified after growth in iron-replete BHIB in two (PH202 and PH292) and one (PH588) isolates, respectively, but at much lower expression levels than that observed after

growth in iron-restricted BHIB. HxuA was identified in only one M. haemolytica isolate (PH8) under the same conditions, although in a very faint protein band. In H. influenzae, HxuA has been identified as both surface-associated (Fournier et al., 2011) and released into the culture medium (Wong et al., 1995). The amino acid sequences of HxuA in the three *M. haemolytica* genomes contain two conserved cysteine residues at their C-terminus that have been demonstrated to be essential for the cell-surface anchoring of TpsA proteins in other microorganisms (Jacob-Dubuisson et al., 2004, Buscher et al., 2006, Fournier et al., 2011). It is therefore surprising that HxuA was absent (with the exception of one isolate) from M. haemolytica outer membrane fractions and suggests that HxuA is released from the cell surface. This is the first study to report HxuCBA expression in the outer membrane of *M. haemolytica*. The presence of HxuCBA has not previously been reported in *M. haemolytica* because outer membrane studies have almost exclusively examined the expression of OMPs in bovine serotype A1 isolates (Ayalew et al., 2010, Lo et al., 2006, Roehrig et al., 2007) which, according to the findings presented here, do not express a functional HxuCBA system. Results from the present study, and the failure to detect HxuCBA expression in other bovine serotype A1 isolate studies (Ayalew et al., 2010, Lo et al., 2006, Roehrig et al., 2007), indicate that the HxuCBA system is not expressed in bovine serotype A1 M. haemolytica isolates, nor in M. glucosida isolates, but is expressed under iron-restricted conditions in all other isolates examined in this study.

Expression of the putative siderophore receptor FrpB was significantly upregulated in two isolates (PH2 and PH344) and was predominantly expressed among other OMPs in an upregulated protein band in the remaining six isolates under iron-restricted growth conditions. Transcription of the *frpB* gene has previously been shown to be upregulated in a bovine serotype A1 *M. haemolytica* isolate (Roehrig *et al.*, 2007) and in the closely related species *A. pleuropneumoniae* (Klitgaard *et al.*, 2010) under iron-restriction conditions. In *A. pleuropneumoniae* FrpB has been demonstrated to be both immunoreactive (Liao *et al.*, 2009) and an essential virulence determinant, as *frpB* deletion mutants are unable to colonise the host or cause clinical disease symptoms upon experimental infection (Buettner *et al.*, 2009). The function of FrpB in *M. haemolytica*, *M. glucosida* and *A. pleuropneumoniae* is currently unknown.

However, in *N. gonorrhoeae* it has been associated with ferric iron uptake from transferrin (Dyer et al., 1988, Beucher and Sparling, 1995) and, more recently, as a receptor for the ferric siderophore enterobactin (Carson et al., 1999). N. gonorrhoeae does not synthesise siderophores but can utilise those produced by other bacteria (xenosiderophores), such as E. coli aerobactin (West and Sparling, 1987) and enterobactin (Rutz et al., 1991, Carson et al., 1999). M. haemolytica and *M. glucosida* do not produce their own siderophores either, suggesting the possibility that these species may utilise xenosiderophores via FrpB in a similar manner to N. gonorrhoeae and other Gram-negative bacteria (Thulasiraman et al., 1998). Indeed, some bacterial isolates of the bovine nasopharyngeal flora have been reported to stimulate the growth of *M*. *haemolytica* and other closely related Gram-negative species, possibly as a result of this mechanism (Corbeil et al., 1985). Another putative siderophore receptor, FhuA, which shares 24% identity with the A. pleuropneumoniae FhuA protein, was also identified in three M. haemolytica isolates (PH292, PH296 and PH344) under iron-restricted conditions. In M. haemolytica serotype A2 genomes, the fhuA gene and fhuCDB genes that encode attendant proteins are arranged in an operon with the same structure as that in A. pleuropneumoniae (Mikael et al., 2002). In A. pleuropneumoniae, FhuA is involved in the uptake of the hydroxamate siderophore ferrichrome and, in contrast to FrpB, is not required for virulence (Baltes *et al.*, 2003). Given that the annotations of the FrpB and FhuA proteins of *M. haemolytica* have been allocated solely based on sequence homologies, and the previous finding that *M. haemolytica* is unable to utilise either exogenous enterobactin or ferrichrome under iron-limited conditions (Reissbrodt et al., 1994, Graham and Lo, 2002), it is likely these proteins do not function as enterobactin and ferrichrome receptors, respectively, but are involved in the uptake of other as yet unknown molecules. Indeed, M. haemolytica FhuA actually shares greater identity (34%) with the E. coli FhuE protein than A. pleuropneumoniae FhuA. FhuE is a receptor for ferrioxamine B (Sauer et al., 1990, Hantke, 1983), a siderophore which has been demonstrated to support M. haemolytica growth under iron-restricted conditions (Reissbrodt et al., 1994) and may be a more appropriate substrate for *M*. haemolytica FhuA binding.

Expression of the FadL protein increased after growth to mid-log phase under iron-restricted conditions in several isolates; however, expression returned to

below baseline levels after growth to stationary phase under iron-restricted conditions. The function of FadL (also referred to as OmpP1) in *M. haemolytica* is not known. In E. coli, FadL is an OMP involved in the uptake of long-chain fatty acids (LCFAs) through the outer membrane (Black et al., 1987). LCFAs and their derivatives are important for a wide variety of cellular processes, including fatty acid and phospholipid synthesis, membrane permeability and enzyme activation (Black and DiRusso, 2003). Upregulation of genes encoding enzymes that metabolise LCFAs have been observed during the early stages of infection with Salmonella enterica (Mahan et al., 1995), indicating that transport of LCFAs is also important from a pathophysiological perspective. During bacterial infections, high concentrations of LCFAs (including arachidonic acid) are found in the extracellular inflammatory milieu that are released from host cells. It has been suggested that subsequent uptake of arachidonic acid by FadL might suppress the local inflammatory immune response and hence confer bacteria with an advantage during early colonisation of the host (Black and DiRusso, 2003). If FadL were to have a similar role in *M. haemolytica* then this might explain why expression of FadL is increased during mid-log phase growth (representing early stage infection) in several isolates, but not at stationary phase growth (representing late stage infection). The *M. haemolytica* leukotoxin stimulates the release of arachidonic acid and its derivatives from host neutrophils (Wang et al., 1998, Clinkenbeard et al., 1994). Therefore, an increase in FadL expression may limit inflammatory immune responses and prevent lung tissue damage during early colonisation. The observation that FadL is present in the outer membrane at much lower levels after iron-restricted stationary phase growth compared to iron-restricted mid log phase growth also raises the question of how this OMP and others are removed from the outer membrane when they are no longer required. Several Gram-negative organisms release outer membrane through the production of outer membrane vesicles (OMVs) (Kulp and Kuehn, 2010), and FadL-like proteins have been identified in OMVs released by N. meningitidis (Uli et al., 2006, Vaughan et al., 2006, Vipond et al., 2006, Williams et al., 2007), Pseudomonas aeruginosa (Bauman and Kuehn, 2006), Moraxella catarrhalis (Schaar et al., 2011). OMV release has not yet been demonstrated in *M. haemolytica* but may provide an appropriate mechanism by which FadL and other OMPs are discarded from the outer membrane.

#### Growth in the presence of serum

Four representative *M. haemolytica* isolates were grown in three different tissue culture media (DMEM, RPMI and M199) in the presence or absence of 10% FCS and 10% SS, and also in complete FCS, SS and NCS. Two OMPs, Hsf (in one ovine isolate) and PlpB (in the two bovine isolates), were identified only after growth in media supplemented with serum. Both of these proteins were not identified after growth in iron-replete and iron-restricted BHIB.

In the human respiratory tract pathogen H. influenzae, Hsf is associated with attachment to epithelial cells (Barenkamp and StGeme, 1996) and is considered to be major nonpilus adhesin (StGeme et al., 1996). A gene whose product has high homology to the H. influenzae Hsf protein was also found to be upregulated in A. pleuropneumoniae after contact with porcine lung epithelial cells (Auger et al., 2009). Hsf also confers serum-resistance on H. influenzae isolates by binding the extracellular matrix molecule vitronectin, a regulator of the terminal pathway of complement activation (Hallstrom et al., 2006). Vibronectin-binding proteins have also been identified in other Gram-negative bacteria including DsrA of Haemophilus ducreyi (Elkins et al., 2000, Leduc et al., 2009) and Usp of M. catarrhalis (Attia et al., 2006). Bacteria are shielded from complement attack when coated with vitronectin and, furthermore, can use the molecule as a bridge to cross-link other bacterial cells and to bind integrin receptors on host cells (Singh et al., 2010). M. haemolytica encounters host serum factors, including complement, as a result of lung tissue inflammation caused by the onset of disease (Ackermann and Brogden, 2000). Therefore, the Hsf-like protein identified in the present study under serum-supplemented and complete serum growth conditions may contribute to the protection of *M*. haemolytica in the presence of host serum.

PlpB is encoded in an operon containing the genes for two other similar lipoproteins, PlpA and PlpC (Cooney and Lo, 1993). Each of these proteins are immunogenic and recognised by serum from calves that have been naturally exposed or vaccinated with *M. haemolytica* cells (Dabo *et al.*, 1994). A *M. haemolytica* mutant lacking the *plpABC* operon was also more susceptible to bovine complement-mediated killing (Murphy *et al.*, 1998). Both PlpA and PlpC were identified in the previous chapter in the outer membranes of several *M*.

haemolytica isolates after growth in iron-replete BHIB. It is therefore surprising that PlpB has not identified alongside PlpA and PlpC given that the three proteins are expected to be expressed in equal quantities. The function of PlpB is currently unknown; however, PlpA has recently been demonstrated to be surface-exposed and capable of binding to bovine bronchial epithelial cells *in vitro* (Kisiela and Czuprynski, 2009).

The leukotoxin protein, LktA, was identified in outer membrane fractions of isolates PH2, PH8, PH202 and PH278 when grown in the presence of 10% SS, and in complete SS and NCS. LktA is a member of the repeats-in-toxin (RTX) exoprotein family produced by a variety of Gram-negative bacteria (Linhartova et al., 2010) and is a key virulence factor in the pathogenesis of pneumonic pasteurellosis (Chang et al., 1987, Maheswaran et al., 1993, Petras et al., 1995, Sutherland, 1985, Sutherland and Donachie, 1986). Surface-association of LktA has not previously been demonstrated in *M. haemolytica*, but has been shown in RTX proteins of other Gram-negative bacteria. The adenylate cyclase toxin of *B*. pertussis remains surface-associated following secretion, due to interaction with the filamentous haemagglutinin (Zaretzky et al., 2002). A putative filamentous haemagglutinin (FhaB\_1) was identified in the present study in the outer membrane fraction of one isolate (PH8) after growth on BHIA<sub>CR</sub>, but LktA was not concurrently identified. The leukotoxin of the closely-related organism Actinobacillus actinomycetemcomitans (LtxA) is both secreted as soluble protein (Kachlany et al., 2000, Kachlany et al., 2002) and retained at the bacteria cell surface within membranous vesicles and by electrostatic association with nucleic acids on the bacterial cell surface (Lally et al., 1991, Berthold et al., 1992, Ohta et al., 1991, Tsai et al., 1984, Kato et al., 2002). Paradoxically, in contrast to the finding in the present study of *M*. *haemolytica* LktA surface-association in the presence of serum, the LtxA protein of A. actinomycetemcomitans is released from the cell surface in the presence of serum (Johansson et al., 2003), although the mechanism of release has not been established. Several possible mechanisms might explain why M. haemolytica LktA is surface-associated in the presence of serum. Firstly, serum components which bind to the surface of M. haemolytica may also bind LktA and retain it on the surface. Secondly, the presence of serum may somehow disrupt the secretion of LktA into the extracellular medium leading to accumulation of LktA at the cell surface.

Thirdly, the presence of serum may stimulate outer membrane blebbing, whereby vesicles containing LktA are both released from the cell and retained at the cell surface. Furthermore, it is possible that LktA is normally associated with the outer membrane *in vivo* (or under conditions which *in vivo* conditions) but does not associate with the membrane when grown *in vitro* in complex growth media alone.

#### Growth on solid-surface agar

Surface-associated growth on BHIA resulted in mild expression of OMPs that were previously strongly upregulated under iron-restricted growth conditions (including FrpB, HmbR1, HxuB and HxuC) as has been observed for other Gramnegative bacteria grown on solid surfaces (Wang et al., 2004, Sampathkumar et al., 2006, Pysz et al., 2004). It has previously been suggested that immobilised growth, as opposed to growth in liquid culture, represents more physiologically appropriate baseline growth conditions and that iron-acquisition systems expressed during surface-associated growth may be more appropriately viewed as a repression of these systems during growth in liquid media (Sampathkumar et al., 2006). There were no new OMPs identified in any of the representative isolates after growth on BHIA that had not been identified in iron-replete or iron-restricted BHIB. Furthermore, no OMPs with roles in biofilm formation, such as those encoded in the Tad (tight adherence) locus of P. multocida (E-Komon et al., 2011a) and other organisms (Tomich et al., 2007) have been identified in the present study. Therefore, despite limited previous evidence of biofilm formation in *M. haemolytica* (Haig, 2011, Olson *et al.*, 2002), this study has not been able to provide evidence of biofilm-producing ability in the representative isolates examined.

Congo red dye is well known for its ability to bind highly aggregative and insoluble B-sheet-rich amyloid fibres found in several living organisms (Chapman *et al.*, 2002, Fowler *et al.*, 2007). It is also commonly used to differentiate between slime-producing and non-slime producing strains of Staphylococci, which result in black and pink colonies, respectively, when grown on agar that contains the dye (Freeman *et al.*, 1989, Jain and Agarwal, 2009, Arciola *et al.*, 2002, Arciola *et al.*, 2006). It can also be used to differentiate between virulent and avirulent strains of several Gram-negative bacteria (Deneer and Potter,

1989, Daskaleros and Payne, 1987, Stugard et al., 1989, Ishiguro et al., 1985, Prpic *et al.*, 1983). Notably, in *Shigella flexneri*, the presence of Congo red can stimulate the release of Ipa type III effector proteins (Parsot et al., 1995), regulate membrane protein expression (Sankaran et al., 1989) and is associated with increased infectivity in HeLa cells (Daskaleros and Payne, 1987). Despite these virulence-associated observations made across a broad range of organisms, the mechanism by which this dye achieves these effects is still unclear. A previously unknown effect of Congo red on the expression of high-molecular mass OMPs in *M. haemolytica* was demonstrated in the present study. Two high molecular mass OMPs, Iga1\_1 and Iga1\_2, were identified in all *M. haemolytica* isolates after growth in the presence of Congo red. Another high molecular mass protein, the filamentous haemagglutinin protein FhaB 1, was also identified in one isolate after growth in the presence of Congo red. These three proteins all contain domains which are expected to extend into the extracellular milieu and undergo subsequent proteolytic cleavage, yet each was identified at their intact molecular mass after growth in the presence of Congo red. Indeed, Iga1\_2 was identified in the previous chapter at 37 kDa after growth in iron-replete BHIB in the absence of Congo red, indicating that the extracellular domain of this protein is normally cleaved from the cell surface. This suggests that, rather than regulating the expression of these OMPs at the genetic level, Congo red might be interfering with their post-translational processing at the bacterial cell surface. Consistent with this is the suggestion that the enhanced secretion of S. *flexneri* effector proteins in the presence of Congo red is most likely due to the interference of the dye with the Type III secretion needle tip complex which controls effector protein release (Bahrani et al., 1997). At present, it can only be speculated as to how Congo red interferes with the processing of M. haemolytica OMPs. One explanation is that the dye is binding directly to these OMPs, preventing autoproteolysis and allowing them to remain intact at the cell surface. Alternatively, Congo red may bind to and inhibit the function of another as yet undefined surface-associated protein which is involved in the processing of these proteins. In neisserial species, Iga1 proteases are capable of autoproteolysis (Pohlner et al., 1987, Vitovski and Sayers, 2007) and can also be processed by the autotransporter NalP (van Ulsen et al., 2003). Similarly, B. pertussis expresses a filamentous haemagglutinin protein which is released from the cell surface by the autotransporter SphB1 (Coutte et al., 2001, Coutte et al.,

2003). Both NalP and SphB1 are members of the subtilisin-like protease family (Siezen and Leunissen, 1997) and share significant identity with serotype-specific antigen (Ssa), an autotransporter which has been identified in the outer membrane of all *M. haemolytica* and *M. glucosida* isolates examined to date. It is possible that Ssa could be responsible for releasing the surface-exposed domains of Iga1-like proteases and FhaB\_1 from the cell surface. Further experimentation will be required to determine the actual mechanism by which Congo red allows these OMPs to remain surface-associated.

#### Extracellular protein expression

To complement the information obtained about OMP expression, putative proteolytic cleavage of OMPs and putative secretion of HxuA, an examination of the extracellular subproteomes of the eight representative isolates was performed. Extracellular proteins were precipitated from cell-free culture supernatant after growth to stationary phase in iron-replete and iron-restricted BHIB. The extracellular protein profiles of the eight isolates appear to be as complex as their OMP profiles, and differed considerably after growth in ironreplete and iron-restricted medium. In E. coli, a proteomic analysis of the extracellular subproteomes of two isolates demonstrated that periplasmic and OMPs accounted for the majority of released proteins during stationary phase growth (Xia et al., 2008). Furthermore, the expression levels of porins OmpF and OmpC in the outer membrane did not change significantly between different cell growth densities, suggesting that these proteins are continuously secreted into the medium, possibly by OMV blebbing (Xia et al., 2008). Another possibility is that the extracellular proteins were the products of cell lysis, although this was proved not to be the case for E. coli (Xia et al., 2008). A proteomic analysis of the *M*. *haemolytica* extracellular subproteome is still to be completed.

# 5. FINAL DISCUSSION

The first objective of this study was to examine the surface-exposure of OmpA and to demonstrate whether the OmpA proteins from bovine (OmpA1) and ovine (OmpA2) isolates are antigenically distinct. This was achieved by examining whether antibodies that were raised against recombinant OmpA1 (rOmpA1) and OmpA2 (rOmpA2) proteins could interact with OmpA in a strain-specific manner. Recombinant OmpA1 and rOmpA2 were successfully expressed, purified and used generate anti-rOmpA1 and anti-rOmpA2 antibodies, respectively. to Immunogold-electron microscopy and immunofluorescence techniques clearly demonstrated that OmpA1 and OmpA2 are surface exposed, and are not masked by the polysaccharide capsule, in a selection of M. haemolytica isolates of various serotypes and grown under different growth conditions. An examination of the binding specificities of anti-rOmpA antibodies to *M. haemolytica* isolates representing different OmpA subclasses revealed that cross-absorbed antirOmpA1 antibodies recognised OmpA1-type proteins but not OmpA2-type proteins; conversely, cross-absorbed anti-rOmpA2 antibodies recognised OmpA2type proteins but not OmpA1-type proteins. The results of this study have therefore clearly demonstrated that OmpA1 and OmpA2 are surface-exposed and could potentially bind to different receptors in cattle and sheep. This work builds significantly upon what was previously known about *M. haemolytica* OmpA (Davies and Lee, 2004) but also raises some interesting questions to be addressed by future investigations. In particular, how are the loops of OmpA recognised by anti-rOmpA antibodies when the capsule is expected to mask them? This conundrum might be explored in future work by examining the possible roles of phase variable capsule expression and outer membrane vesicle blebbing on the exposure of OMPs to the host environment. Furthermore, the anti-rOmpA antibodies produced in this work could also be used in host epithelial cell binding assays to definitively demonstrate that *M. haemolytica* OmpA1 and OmpA2 are capable of selectively binding to different receptors within cattle and sheep, respectively. Preliminary crystallisation experiments determined a range of conditions under which protein crystals were produced; however, no Xray diffraction data could be obtained. Further optimisation of these conditions might yield higher quality crystals under which structural data can be obtained.

The second objective of this study was to provide a comparative analysis of the outer membrane subproteomes of several isolates of *M. haemolytica* and *M.* glucosida in order to identify those that are possibly involved in host-specific adaptation and virulence. This objective was achieved in two parts. First, the entire repertoire of OMPs encoded in three M. haemolytica genomes was predicted using a simple bioinformatic framework. This yielded a total of 93 confidently predicted OMPs which were assigned to six broad functional categories: outer membrane biogenesis and integrity, transport and receptor, adherence, enzymatic activity, other and unknown. The majority of these proteins (88) were present among all three genomes. There were no proteins present exclusively in the ovine genome, and only one protein (PulD) was exclusively present in a bovine genome (serotype A1). Furthermore, amino acid sequence comparisons were performed to identify OMPs present among bovine and ovine genomes that may be adapted to either cattle or sheep. Only three OMPs, OmpA, PlpE, and Ahs, had greater amino acid sequence identity between bovine genomes than between one of the bovine genomes and the ovine genome. A possible role in host-specific adaptation has already been suggested for OmpA (Davies and Lee, 2004), but has not yet been demonstrated for PlpE or Ahs. Several other OMPs (Table 3.4) also had divergent amino acid sequences among the genomes that were apparently unrelated to host-specificity. The bovine and ovine serotype A2 genomes were more similar both in the number of OMPs present in the two genomes and amino acid conservation of OMPs than between either of these two genomes and the bovine serotype A1 genome. This reflects the common ancestral origin of the bovine and ovine serotype A2 isolates and provides further evidence to support previous work which hypothesised the host-switching of this serotype from cattle to sheep (Davies et al., 1997, Davies et al., 2001, Davies and Lee, 2004, Davies et al., 2002).

Second, complementary proteomic approaches were used to identify and compare the OMPs present in the outer membrane fractions of seven *M*. *haemolytica* isolates and one *M*. *glucosida* isolate. Complementary proteomic approaches identified a total of 55 unique OMPs. Fifty of these proteins were confidently predicted by the bioinformatic approach, representing 54% of the confidently predicted outer membrane subproteome. Five identified OMPs (LemA, HbpA, OapA, RlpA and CsgG) were not predicted by the bioinformatic

approach but were considered likely to be OMPs after literature searches on these proteins were carried out. Eleven OMPs (MltC, FhaC, LppC, TonBdependent receptor MHA\_0860/COI\_1565/COK\_2304, OapA, TbpB, possible OMP MHA\_0964/COI\_1329/COK\_2563, Bor/Iss\_1, HxuC, TonB-dependent receptor MHA\_1346/COI\_1921 and OmpW) were identified among ovine M. haemolytica isolates that were not identified among bovine *M. haemolytica* isolates; however, the genes encoding these OMPs were identified in the genomes of bovine isolates, suggesting that they are possibly expressed under different growth conditions. There were no OMPs identified exclusively in bovine M. haemolytica isolates. The putative bovine-specific OMP, PulD, was not identified in any of the representative isolates. Despite the lack of evidence for roles in host-specific adaptation of identified OMPs, the results of this objective have produced a comprehensive overview of the outer membrane subproteomes of *M*. haemolytica and M. glucosida isolates that can be used to identify individual OMPs to be studied in further detail. Comparative nucleotide sequence analysis of genes encoding selected OMPs, such as PlpE and Ahs, should elucidate further evidence of host-specific adaptation, as has previously been determined for OmpA (Davies and Lee, 2004). Furthermore, the identified Ssa and Iga1\_2 autotransporter proteins showed evidence of proteolytic processing, a phenomenon that has not previously been described in M. haemolytica. A possible role in proteolytic processing of other OMPs at the bacterial cell surface was hypothesised for Ssa. This was based upon on its similarity to NalP of N. meningitidis (Turner et al., 2002, van Ulsen et al., 2003), AasP of A. pleuropneumoniae (Ali et al., 2008) and ShpB1 of B. pertussis (Coutte et al., 2001), which are involved in proteolytic processing of other OMPs in these species. Studies using ssa gene knockout and partial deletion mutants of M. haemolytica should further elucidate the exact function of Ssa.

The third and final objective of this study was to characterise the outer membrane subproteomes of the same representative isolates and identify differentially expressed OMPs after *in vitro* growth under conditions that were designed to mimic the *in vivo* host environment. A further 13 confidently predicted OMPs (Table 4.4) were identified under either iron-restricted, serum-supplemented or Congo red-supplemented growth conditions (or a combination of the three), that were not identified under iron-replete growth conditions.

Expression of several OMPs that were previously identified after growth in ironreplete media increased after growth in iron-restricted conditions. One of the most significant findings was that components of an HxuCBA haem-haemopexin acquisition system were upregulated in all representative M. haemolytica isolates, except for bovine serotype A1 isolate PH2, after growth under ironrestricted conditions. It is interesting that isolate PH2, a virulent disease isolate, should be lacking this system as it is a known virulence determinant in H. influenzae (Morton et al., 2007) and H. parasuis (Melnikow et al., 2005). There was also no expression of HxuCBA in the *M. glucosida* isolate after growth under iron-restricted conditions. This study is the first to describe the expression of this system in *M. haemolytica* outer membranes and demonstrates the great advantage of comparative analyses over that of individual isolates. With the exception of studies by this author's research group, the majority of previous M. haemolytica outer membrane studies have focused almost exclusively on bovine serotype A1 isolates. This is probably due to the fact that these isolates are responsible for most cases of bovine pneumonic pasteurellosis and are of greater interest to animal health practitioners and vaccine developers. The present study has demonstrated that comparative examination of several isolates, as opposed to individual isolates, provides a broader knowledge of the M. haemolytica species as a whole and is more conducive to identifying novel proteins. Further study is warranted for the HxuCBA system, and other putative virulence-associated OMPs which were upregulated after growth in ironrestricted medium including FrpB (a putative siderophore receptor), HmbR1 (a putative haemoglobin receptor) and FadL (a putative LCFA transporter). Biological uptake assays which examine the specificities of different siderophores, haemophores and transferrins might also further elucidate roles in host-specificity for these OMPs.

Association of the leukotoxin with the outer membrane was demonstrated in four *M. haemolytica* isolates (PH2, PH8, PH202 and PH278) grown in the presence of serum. This is a significant finding, as leukotoxin is considered to be the major virulence factor in *M. haemolytica* pathogenesis and has not previously been considered to associate with the outer membrane. The LtxA protein of *A. actinomycetemcomitans* can be retained at the surface of this organism in membrane vesicles and by electrostatic association with the

membrane (Lally *et al.*, 1991, Berthold *et al.*, 1992, Ohta *et al.*, 1991, Tsai *et al.*, 1984, Kato *et al.*, 2002). Interestingly though, in the presence of serum, LtxA is released from the bacterial surface via an unknown mechanism (Johansson *et al.*, 2003). It will be worthwhile to establish if *M. haemolytica* leukotoxin attaches to the outer membrane by a similar mechanism as *A. actinomycetemcomitans* and, alternatively, if normally present in the outer membrane *in vivo*, its mechanism of detachment from the outer membrane *in vivo*.

One of the more serendipitous discoveries of this study was that OMPs with putative cleavable passenger domains appear to be stabilised in the presence of Congo red dye. Two OMPs, Iga1\_1 and Fhab\_1 were identified on 1-D SDS-PAGE gels at their intact molecular mass after growth in the presence of Congo red. However, these proteins were not identified under identical growth conditions in the absence of the dye. Another protein, Iga1 2, was also identified at its expected intact molecular mass after growth in the presence of Congo red. This protein that had been identified at a much lower-than-expected molecular mass after growth under identical growth conditions in the absence of the dye. These findings suggest that Congo red somehow interrupts extracellular passenger domain processing, allowing the proteins to remain intact at the cell surface. This finding is interesting not only from the point of view of this project, but also from a general microbiological perspective. It is feasible that bacterial growth in the presence of Congo red could be used as a general method of preventing proteolytic changes to OMPs at the cell surface, allowing examination of the outer membrane subproteome prior to these changes occurring. It would be interesting in future investigations to determine the mechanism by which the dye achieves these effects.

An investigation of the extracellular subproteomes of the eight representative isolates under iron-replete and iron-restricted growth conditions was performed. This was prompted by findings that suggested some OMPs, including Iga1\_2 and Ssa, undergo proteolytic cleavage of their passenger domains which are released from the bacterial surface. Also, the putative haemophore HxuA was only identified in the outer membrane fraction of one isolate (PH8) after growth under iron-restricted conditions, suggesting that it is secreted. One-dimensional SDS-PAGE separation of extracellular protein fractions demonstrated that the

extracellular subproteome is as complex as the outer membrane subproteome. Due to limitations of resources no MS data were obtained to identify these proteins. Future investigations will use MS to identify these proteins and elucidate whether they are proteolytically-cleaved fragments, secreted proteins, or cell envelope proteins that have blebbed away from the bacterial surface, as has been demonstrated for *E. coli* (Xia *et al.*, 2008).

The work presented in this thesis represents the most comprehensive coverage of *M. haemolytica* and *M. glucosida* outer membrane subproteomes to date. The only other previous study of an *M. haemolytica* outer membrane subproteome identified 25 of the confidently predicted OMPs described in the present work in a single bovine serotype A1 isolate (Ayalew *et al.*, 2010). In this thesis, a total of 68 OMPs were identified among several representative *M. haemolytica* isolates and an *M. glucosida* isolate under a range of different growth conditions. Of these 68 OMPs, 63 were confidently predicted by the bioinformatic approach, representing 67.8% of the confidently outer membrane subproteome. Despite the lack of evidence for roles in host-specificity of the identified OMPs, the work presented in this thesis will serve as a primer for further research into the roles of OMPs in the pathobiology of *M. haemolytica*, and has wide implications for the design of vaccines to treat pneumonic pasteurellosis.

# 6. **REFERENCES**

- ABDULLAH, K. M., LO, R. Y. C. & MELLORS, A. 1990. Distribution of glycoprotease activity and the glycoprotease gene among serotypes of *Pasteurella* haemolytica. Biochem. Soc. Trans., 18, 901-902.
- ABDULLAH, K. M., UDOH, E. A., SHEWEN, P. E. & MELLORS, A. 1992. A neutral glycoprotease of *Pasteurella haemolytica* A1 specifically cleaves O-sialoglycoproteins. *Infect. Immun.*, 60, 56-62.
- ACKERMANN, M. R. & BROGDEN, K. A. 2000. Response of the ruminant respiratory tract to *Mannheimia* (*Pasteurella*) *haemolytica*. *Microbes Infect.*, 2, 1079-1088.
- ADESSI, C., MIEGE, C., ALBRIEUX, C. & RABILLOUD, T. 1997. Two-dimensional electrophoresis of membrane proteins: A current challenge for immobilized pH gradients. *Electrophoresis*, 18, 127-135.
- ADLAM, C. 1989. The structure, function and properties of cellular and extracellular components of *Pasteurella haemolytica*. *In*: ADLAM, C. & RUTTER, J. M. (eds.) *Pasteurella and Pasteurellosis*. Academic Press, New York, N. Y.
- ADLAM, C., KNIGHTS, J. M., MUGRIDGE, A., LINDON, J. C., BAKER, P. R. W., BEESLEY, J. E., SPACEY, B., CRAIG, G. R. & NAGY, L. K. 1984. Purification, characterization and immunological properties of the serotype-specific capsular polysaccharide of *Pasteurella haemolytica* (serotype A1) organisms. J. Gen. Microbiol., 130, 2415-2426.
- ADLAM, C., KNIGHTS, J. M., MUGRIDGE, A., LINDON, J. C., WILLIAMS, J. M. & BEESLEY, J. E. 1986. Purification, characterization and immunological properties of the serotype-specific capsular polysaccharide of *Pasteurella haemolytica* serotype A7 organisms. J. Gen. Microbiol., 132, 1079-1087.
- ADLAM, C., KNIGHTS, J. M., MUGRIDGE, A., WILLIAMS, J. M. & LINDON, J. C. 1987. Production of colominic acid by *Pasteurella haemolytica* serotype A2 organisms. *FEMS Microbiol. Lett.*, 42, 23-25.
- AEBERSOLD, R. & MANN, M. 2003. Mass spectrometry-based proteomics. *Nature*, 422, 198-207.
- ALI, Q., DAVIES, R. L., PARTON, R., COOTE, J. G. & GIBBS, H. A. 1992. Lipopolysaccharide heterogeneity in *Pasteurella haemolytica* isolates from cattle and sheep. J. Gen. Microbiol., 138, 2185-2195.
- ALI, T., OLDFIELD, N. J., WOOLDRIDGE, K. G., TURNER, D. P. & ALA'ALDEEN, D. A. A. 2008. Functional characterization of AasP, a maturation protease autotransporter protein of Actinobacillus pleuropneumoniae. Infect. Immun., 76, 5608-5614.
- AMITAI, G., BELENKIY, O., DASSA, B., SHAINSKAYA, A. & PIETROKOVSKI, S. 2003. Distribution and function of new bacterial intein-like protein domains. *Mol. Microbiol.*, 47, 61-73.
- ANDREWS, S. C., ROBINSON, A. K. & RODRIGUEZ-QUINONES, F. 2003. Bacterial iron homeostasis. *FEMS Microbiol. Rev.*, 27, 215-237.
- ANGEN, O., MUTTERS, R., CAUGANT, D. A., OLSEN, J. E. & BISGAARD, M. 1999a. Taxonomic relationships of the [*Pasteurella*] haemolytica complex as evaluated by DNA-DNA hybridizations and 16S rRNA sequencing with proposal of Mannheimia haemolytica gen. nov., comb. nov., Mannheimia granulomatis comb. nov., Mannheimia glucosida sp. nov., Mannheimia ruminalis sp. nov. and Mannheimia varigena sp. nov. Int. J. Syst. Bacteriol., 49, 67-86.

- ANGEN, O., QUIRIE, M., DONACHIE, W. & BISGAARD, M. 1999b. Investigations on the species specificity of *Mannheimia* (*Pasteurella*) haemolytica serotyping. *Vet. Microbiol.*, 65, 253-260.
- ARCIOLA, C. R., CAMPOCCIA, D., BALDASSARRI, L., DONATI, M. E., PIRINI, V., GAMBERINI, S. & MONTANARO, L. 2006. Detection of biofilm formation in *Staphylococcus epidermidis* from implant infections. Comparison of a PCRmethod that recognizes the presence of *ica* genes with two classic phenotypic methods. J. Biomed. Mater. Res. A, 76A, 425-430.
- ARCIOLA, C. R., CAMPOCCIA, D., GAMBERINI, S., CERVELLATI, M., DONATI, E. & MONTANARO, L. 2002. Detection of slime production by means of an optimised Congo red agar plate test based on a colourimetric scale in *Staphylococcus epidermidis* clinical isolates genotyped for *ica* locus. *Biomaterials*, 23, 4233-4239.
- ARENDS, S. J. R., WILLIAMS, K., SCOTT, R. J., ROLONG, S., POPHAM, D. L. & WEISS, D. S. 2010. Discovery and characterization of three new *Escherichia coli* septal ring proteins that contain a SPOR domain: DamX, DedD, and RlpA. J. Bacteriol., 192, 242-255.
- ATTIA, A. S., RAM, S., RICE, P. A. & HANSEN, E. J. 2006. Binding of vitronectin by the *Moraxella catarrhalis* UspA2 protein interferes with late stages of the complement cascade. *Infect. Immun.*, 74, 1597-1611.
- AUGER, E., DESLANDES, V., RAMJEET, M., CONTRERAS, I., NASH, J. H. E., HAREL, J., GOTTSCHALK, M., OLIVIER, M. & JACQUES, M. 2009. Host pathogen interactions of *Actinobacillus pleuropneumoniae* with porcine lung and tracheal epithelial cells. *Infect. Immun.*, 77, 1426-1441.
- AYALEW, S., CONFER, A. W. & BLACKWOOD, E. R. 2004. Characterization of immunodominant and potentially protective epitopes of *Mannheimia haemolytica* serotype 1 outer membrane lipoprotein PlpE. *Infect. Immun.*, 72, 7265-7274.
- AYALEW, S., CONFER, A. W., HARTSON, S. D. & SHRESTHA, B. 2010. Immunoproteomic analyses of outer membrane proteins of *Mannheimia haemolytica* and identification of potential vaccine candidates. *Proteomics*, 10, 2151-2164.
- BABU, M. M. & SANKARAN, K. 2002. DOLOP-database of bacterial lipoproteins. *Bioinformatics*, 18, 641-643.
- BACON, D. J., SZYMANSKI, C. M., BURR, D. H., SILVER, R. P., ALM, R. A. & GUERRY, P. 2001. A phase-variable capsule is involved in virulence of *Campylobacter jejuni* 81-176. *Mol. Microbiol.*, 40, 769-777.
- BAGOS, P. G., LIAKOPOULOS, T. D. & HAMODRAKAS, S. J. 2004. Finding betabarrel outer membrane proteins with a markov chain model. WSEAS Transac. Biol. Biomed., 2, 186-189.
- BAHRANI, F. K., SANSONETTI, P. J. & PARSOT, C. 1997. Secretion of Ipa proteins by *Shigella flexneri*: Inducer molecules and kinetics of activation. *Infect. Immun.*, 65, 4005-4010.
- BAIK, S. C., KIM, K. M., SONG, S. M., KIM, D. S., JUN, J. S., LEE, S. G., SONG, J. Y., PARK, J. U., KANG, H. L., LEE, W. K., CHO, M. J., YOUN, H. S., KO, G. H. & RHEE, K. H. 2004. Proteomic analysis of the sarcosine-insoluble outer membrane fraction of *Helicobacter pylori* strain 26695. J. Bacteriol., 186, 949-955.
- BALTES, N., TONPITAK, W., HENNIG-PAUKA, I., GRUBER, A. D. & GERLACH, G. F. 2003. *Actinobacillus pleuropneumoniae* serotype 7 siderophore receptor FhuA is not required for virulence. *FEMS Microbiol. Lett.*, 220, 41-48.

- BARENKAMP, S. J. & STGEME, J. W. 1996. Identification of a second family of high-molecular-weight adhesion proteins expressed by non-typable *Haemophilus influenzae*. *Mol. Microbiol.*, 19, 1215-1223.
- BARNARD, T. J., DAUTIN, N., LUKACIK, P., BERNSTEIN, H. D. & BUCHANAN, S. K. 2007. Autotransporter structure reveals intra-barrel cleavage followed by conformational changes. *Nat. Struct. Mol. Biol.*, 14, 1214-1220.
- BARNHART, M. M. & CHAPMAN, M. R. 2006. Curli biogenesis and function. Annu. Rev. Microbiol., 60, 131-147.
- BARONDESS, J. J. & BECKWITH, J. 1995. Bor gene of phage-lambda, involved in serum resistance, encodes a widely conserved outer membrane lipoprotein. J. Bacteriol., 177, 1247-1253.
- BAUMAN, S. J. & KUEHN, M. J. 2006. Purification of outer membrane vesicles from *Pseudomonas aeruginosa* and their activation of an IL-8 response. *Microbes Infect.*, 8, 2400-2408.
- BEHER, M. G., SCHNAITMAN, C. A. & PUGSLEY, A. P. 1980. Major heat-modifiable outer membrane protein in gram-negative bacteria: comparison with the OmpA protein of *Escherichia Coli*. J. Bacteriol., 143, 906-913.
- BERROW, N. S., ALDERTON, D., SAINSBURY, S., NETTLESHIP, J., ASSENBERG, R., RAHMAN, N., STUART, D. I. & OWENS, R. J. 2007. A versatile ligationindependent cloning method suitable for high-throughput expression screening applications. *Nucleic Acids Res.*, 35, e45.
- BERTHOLD, P., FORTI, D., KIEBA, I. R., ROSENBLOOM, J., TAICHMAN, N. S. & LALLY, E. T. 1992. Electron immunocytochemical localization of *Actinobacillus actinomycetemcomitans* leukotoxin. *Oral Microbiol. Immunol.*, 7, 24-27.
- BERVEN, F. D., KARLSEN, O. S., STRAUME, A. H., FLIKKA, K., MURRELL, J. C., FJELLBIRKELAND, A., LILLEHAUG, J. R., EIDHAMMER, I. & JENSEN, H. B. 2006. Analysing the outer membrane subproteome of *Methylococcus capsulatus* (Bath) using proteomics and novel biocomputing tools. *Arch. Microbiol.*, 184, 362-377.
- BERVEN, F. S., FLIKKA, K., JENSEN, H. B. & EIDHAMMER, I. 2004. BOMP: a program to predict integral beta-barrel outer membrane proteins encoded within genomes of Gram-negative bacteria. *Nucleic Acids Res.*, 32, W394-W399.
- BEUCHER, M. & SPARLING, P. F. 1995. Cloning, sequencing, and characterization of the gene encoding FrpB, a major iron-regulated, outer membrane protein of *Neisseria gonorrhoeae*. J. Bacteriol., 177, 2041-2049.
- BIBERSTEIN, E. L. & FRANCIS, C. K. 1968. Nucleic acid homologies between A and T types of *Pasteurella haemolytica*. J. Med. Microbiol., 1, 105-&.
- BIBERSTEIN, E. L., GILLS, M. & KNIGHT, H. 1960. Serological types of Pasteurella haemolytica. Cornell. Vet., 50, 283-300.
- BIBERSTEIN, E. L. & GILLS, M. G. 1962. The relationship of antigenic types of the A and T types of *Pasteurella haemolytica*. J. Comp. Pathol. Ther., 72, 316-320.
- BIRDSELL, D. C. & COTA-ROBLES, E. H. 1967. Production and ultrastructure of lysozyme and ethylenediaminetetraacetate-lysozyme spheroplasts of *Escherichia coli. J. Bacteriol.*, 93, 427-437.
- BISHOP, R. E., LESKIW, B. K., HODGES, R. S., KAY, C. M. & WEINER, J. H. 1998. The entericidin locus of *Escherichia coli* and its implications for programmed bacterial cell death. J. Mol. Biol., 280, 583-596.

- BLACK, P. N. & DIRUSSO, C. C. 2003. Transmembrane movement of exogenous long-chain fatty acids: Proteins, enzymes, and vectorial esterification. *Microbiol. Mol. Biol. Rev.*, 67, 454-+.
- BLACK, P. N., SAID, B., GHOSN, C. R., BEACH, J. V. & NUNN, W. D. 1987. Purification and characterization of an outer membrane-bound protein involved in long-chain fatty acid transport in *Escherichia coli*. J. Biol. Chem., 262, 1412-1419.
- BLOCKER, A., KOMORIYA, K. & AIZAWA, S. 2003. Type III secretion systems and bacterial flagella: insights into their function from structural similarities. *Proc. Natl. Acad. Sci. U.S.A.*, 100, 3027-3030.
- BLONDER, J., GOSHE, M. B., MOORE, R. J., PASA-TOLIC, L., MASSELON, C. D., LIPTON, M. S. & SMITH, R. D. 2002. Enrichment of integral membrane proteins for proteomic analysis using liquid chromatography-tandem mass spectrometry. J. Proteome Res., 1, 351-360.
- BOLDUC, G. R., BOUCHET, V., JIANG, R.-Z., GEISSELSODER, J., TRUONG-BOLDUC, Q. C., RICE, P. A., PELTON, S. I. & GOLDSTEIN, R. 2000. Variability of outer membrane protein P1 and its evaluation as a vaccine candidate against experimental otitis media due to nontypeable *Haemophilus influenzae*: an unambiguous, multifaceted approach. *Infect. Immun.*, 68, 4505-4517.
- BOOKWALTER, J. E., JURCISEK, J. A., GRAY-OWEN, S. D., FERNANDEZ, S., MCGILLIVARY, G. & BAKALETZ, L. O. 2008. A carcinoembryonic antigenrelated cell adhesion molecule 1 homologue plays a pivotal role in nontypeable *Haemophilus influenzae* colonization of the chinchilla nasopharynx via the outer membrane protein P5-homologous adhesin. *Infect. Immun.*, 76, 48-55.
- BOWLAND, S. L. & SHEWEN, P. E. 2000. Bovine respiratory disease: commercial vaccines currently available in Canada. *Can. Vet. J.*, 41, 33-48.
- BOYCE, J. D., CULLEN, P. A., NGUYEN, V., WILKIE, I. & ADLER, B. 2006. Analysis of the *Pasteurella multocida* outer membrane sub-proteome and its response to the *in vivo* environment of the natural host. *Proteomics*, 6, 870-880.
- BRIDGES, D. J., PITT, A. R., HANRAHAN, O., BRENNAN, K., VOORHEIS, H. P., HERZYK, P., DE KONING, H. P. & BURCHMORE, R. J. S. 2008. Characterisation of the plasma membrane subproteome of bloodstream form *Trypanosoma brucei*. *Proteomics*, 8, 83-99.
- BROGDEN, K. A., ADLAM, C., LEHMKUHL, H. D., CUTLIP, R. C., KNIGHTS, J. M. & ENGEN, R. L. 1989. Effect of *Pasteurella haemolytica* (A1) capsular polysaccharide on sheep lung *in vivo* and on pulmonary surfactant *in vitro*. Am. J. Vet. Res., 50, 555-559.
- BROK, R., VAN GELDER, P., WINTERHALTER, M., ZIESE, U., KOSTER, A. J., DE COCK, H., KOSTER, M., TOMMASSEN, J. & BITTER, W. 1999. The Cterminal domain of the *Pseudomonas* secretin XcpQ forms oligomeric rings with pore activity. J. Mol. Biol., 294, 1169-1179.
- BROWN, R. N., ROMINE, M. F., SCHEPMOES, A. A., SMITH, R. D. & LIPTON, M. S. 2010. Mapping the subcellular proteome of *Shewanella oneidensis* MR-1 using sarkosyl-based fractionation and LC-MS/MS protein identification. J. Proteome Res., 9, 4454-4463.
- BRUYNEEL, B., VANDEWOESTYNE, M. & VERSTRAETE, W. 1989. Lactic acid bacteria - microorganisms able to grow in the absence of available iron and copper. *Biotechnol. Lett.*, 11, 401-406.

- BUCHANAN, S. K., SMITH, B. S., VENKATRAMANI, L., XIA, D., ESSER, L., PALNITKAR, M., CHAKRABORTY, R., VAN DER HELM, D. & DEISENHOFER, J. 1999. Crystal structure of the outer membrane active transporter FepA from *Escherichia coli*. *Nat*. *Struct*. *Biol.*, 6, 56-63.
- BUETTNER, F. F. R., BENDALLA, I. M., BOSSE, J. T., MEENS, J., NASH, J. H. E., HARTIG, E., LANGFORD, P. R. & GERLACH, G. F. 2009. Analysis of the Actinobacillus pleuropneumoniae HlyX (FNR) regulon and identification of iron-regulated protein B as an essential virulence factor. Proteomics, 9, 2383-2398.
- BURGHOUT, P., VAN BOXTEL, R., VAN GELDER, P., RINGLER, P., MULLER, S. A., TOMMASSEN, J. & KOSTER, M. 2004. Structure and electrophysiological properties of the YscC secretin from the type III secretion system of Yersinia enterocolitica. J. Bacteriol., 186, 4645-4654.
- BURROWS, L. L., OLAH-WINFIELD, E. & LO, R. Y. C. 1993. Molecular analysis of the leukotoxin determinants from *Pasteurella haemolytica* serotypes 1 to 16. Infect. Immun., 61, 5001-5007.
- BUSCHER, A. Z., GRASS, S., HEUSER, J., ROTH, R. & ST GEME, J. W. 2006. Surface anchoring of a bacterial adhesin secreted by the two-partner secretion pathway. *Mol. Microbiol.*, 61, 470-483.
- CARSON, S. D. B., KLEBBA, P. E., NEWTON, S. M. C. & SPARLING, P. F. 1999. Ferric enterobactin binding and utilization by *Neisseria gonorrhoeae*. J. *Bacteriol.*, 181, 2895-2901.
- CASADIO, R., JACOBONI, I., MESSINA, A. & DE PINTO, V. 2002. A 3D model of the voltage-dependent anion channel (VDAQ). *FEBS Lett.*, 520, 1-7.
- CHAE, C. H., GENTRY, M. J., CONFER, A. W. & ANDERSON, G. A. 1990. Resistance to host immune defense mechanisms afforded by capsular material of *Pasteurella haemolytica*, serotype 1. *Vet. Microbiol.*, 25, 241-251.
- CHAMI, M., GUILVOUT, I., GREGORINI, M., REMIGY, H. W., MULLER, S. A., VALERIO, M., ENGEL, A., PUGSLEY, A. P. & BAYAN, N. 2005. Structural insights into the secretin PulD and its trypsin-resistant core. J. Biol. Chem., 280, 37732-37741.
- CHANDRAN, V., FRONZES, R., DUQUERROY, S., CRONIN, N., NAVAZA, J. & WAKSMAN, G. 2009. Structure of the outer membrane complex of a type IV secretion system. *Nature*, 462, 1011-U66.
- CHANG, Y. F., RY, Y., POST, D. & STRUCK, D. K. 1987. Identification and characterization of the *Pasteurella haemolytica* leukotoxin. *Infect. Immun.*, 55, 2348-2354.
- CHAPMAN, M. R., ROBINSON, L. S., PINKNER, J. S., ROTH, R., HEUSER, J., HAMMAR, M., NORMARK, S. & HULTGREN, S. J. 2002. Role of *Escherichia coli* curli operons in directing amyloid fiber formation. *Science*, 295, 851-855.
- CHIMALAKONDA, G., RUIZ, N., CHNG, S. S., GARNER, R. A., KAHNE, D. & SILHAVY, T. J. 2011. Lipoprotein LptE is required for the assembly of LptD by the beta-barrel assembly machine in the outer membrane of *Escherichia coli. Proc. Natl. Acad. Sci. U.S.A.*, 108, 2492-2497.
- CHRISTIE, P. J., ATMAKURI, K., KRISHNAMOORTHY, V., JAKUBOWSKI, S. & CASCALES, E. 2005. Biogenesis, architecture, and function of bacterial type IV secretion systems. *Annu. Rev. Microbiol.*, 59, 451-485.
- CHUNG, J. W., NG-THOW-HING, C., BUDMAN, L. I., GIBBS, B. F., NASH, J. H. E., JACQUES, M. & COULTON, J. W. 2007. Outer membrane proteome of

Actinobacillus pleuropneumoniae: LC-MS/MS analyses validate in silico predictions. Proteomics, 7, 1854-1865.

- CLANTIN, B., DELATTRE, A. S., RUCKTOOA, P., SAINT, N., MELI, A. C., LOCHT, C., JACOB-DUBUISSON, F. & VILLERET, V. 2007. Structure of the membrane protein FhaC: A member of the Omp85-TpsB transporter superfamily. Science, 317, 957-961.
- CLARKE, J. M. & MORTON, R. J. 2000. Development of an *in vitro* fluorometric assay to study adherence of *Pasteurella haemolytica* to bovine cells. *Am. J. Vet. Res.*, 61, 129-132.
- CLINKENBEARD, K. D., CLARKE, C. R., HAGUE, C. M., CLINKENBEARD, P., SRIKUMARAN, S. & MORTON, R. J. 1994. *Pasteurella haemolytica* leukotoxin-induced synthesis of eicosanoids by bovine neutrophils *in vitro*. *J. Leukoc. Biol.*, 56, 644-649.
- CLINKENBEARD, K. D., MOSIER, D. A. & CONFER, A. W. 1989. Transmembrane pore size and role of cell swelling in cytotoxicity caused by *Pasteurella haemolytica* leukotoxin. *Infect. Immun.*, 57, 420-425.
- CLINKENBEARD, K. D. & UPTON, M. L. 1991. Lysis of bovine platelets by Pasteurella haemolytica leukotoxin. Am. J. Vet. Res., 52, 453-457.
- COLLINS, R. F., DAVIDSEN, L., DERRICK, J. P., FORD, R. C. & TONJUM, T. 2001. Analysis of the PilQ secretin from *Neisseria meningitidis* by transmission electron microscopy reveals a dodecameric quaternary structure. *J. Bacteriol.*, 183, 3825-3832.
- COLLINS, R. F. & DERRICK, J. P. 2007. Wza: a new structural paradigm for outer membrane secretory proteins? *Trends Microbiol.*, 15, 96-100.
- CONFER, A. W., AYALEW, S., PANCIERA, R. J., MONTELONGO, M., WHITWORTH, L. C. & HAMMER, J. D. 2003. Immunogenicity of recombinant *Mannheimia haemolytica* serotype 1 outer membrane protein PlpE and augmentation of a commercial vaccine. *Vaccine*, 21, 2821-2829.
- CONFER, A. W., AYALEW, S., PANCIERA, R. J., MONTELONGO, M. & WRAY, J. H. 2006. Recombinant *Mannheimia haemolytica* serotype 1 outer membrane protein PlpE enhances commercial *M. haemolytica* vaccine-induced resistance against serotype 6 challenge. *Vaccine*, 24, 2248-2255.
- CONFER, A. W., MCCRAW, R. D., DURHAM, J. A., MORTON, R. J. & PANCIERA, R. J. 1995. Serum antibody responses of cattle to iron-regulated outer membrane proteins of *Pasteurella haemolytica* A1. Vet. Immunol. Immunopathol., 47, 101-110.
- CONRAD, D. R. 2007. Ferric and ferrous iron in cell culture. Sigma-Aldrich Co., St. Louis, MO. <u>http://www.sigmaaldrich.com/life-science/cell-</u> <u>culture/learning-center/media-expert/iron.html</u>.
- COONEY, B. J. & LO, R. Y. C. 1993. Three contiguous lipoprotein genes in *Pasteurella haemolytica* A1 which are homologous to a lipoprotein gene in *Haemophilus influenzae* type b. *Infect. Immun.*, 61, 4682-4688.
- COPE, L. D., LOVE, R. P., GUINN, S. E., GILEP, A., USANOV, S., ESTABROOK, R.
   W., HRKAL, Z. & HANSEN, E. J. 2001. Involvement of HxuC outer membrane protein in utilization of hemoglobin by *Haemophilus influenzae*. *Infect. Immun.*, 69, 2353-2363.
- COPE, L. D., THOMAS, S. E., HRKAL, Z. & HANSEN, E. J. 1998. Binding of hemehemopexin complexes by soluble HxuA protein allows utilization of this complexed heme by *Haemophilus influenzae*. *Infect. Immun.*, 66, 4511-4516.
- COPE, L. D., THOMAS, S. E., LATIMER, J. T., SLAUGHTER, C. A., MULLEREBERHARD, U. & HANSEN, E. J. 1994. The 100 Kda

haem:haemopexin binding protein of *Haemophilus influenzae*: structure and localization. *Mol. Microbiol.*, 13, 863-873.

- COPE, L. D., YOGEV, R., MULLEREBERHARD, U. & HANSEN, E. J. 1995. A gene cluster involved in the utilization of both free heme and heme:hemopexin by *Haemophilus influenzae* type B. J. Bacteriol., 177, 2644-2653.
- CORBEIL, L. B., WOODWARD, W., WARD, A. C. S., MICKELSEN, W. D. & PAISLEY, L. 1985. Bacterial interactions in bovine respiratory and reproductive infections. J. Clin. Microbiol., 21, 803-807.
- CORCIONIVOSCHI, N., CLYNE, M., LYONS, A., ELMI, A., GUNDOGDU, O., WREN, B.
   W., DORRELL, N., KARLYSHEV, A. V. & BOURKE, B. 2009. Campylobacter jejuni cocultured with epithelial cells reduces surface capsular polysaccharide expression. Infect. Immun., 77, 1959-1967.
- CORDWELL, S. J., ALICE, C. L. L., TOUMA, R. G., SCOTT, N. E., FALCONER, L., JONES, D., CONNOLLY, A., BEN, C. & DJORDJEVIC, S. P. 2008. Identification of membrane-associated proteins from *Campylobacter jejuni* strains using complementary proteomics technologies. *Proteomics*, 8, 122-139.
- CORSTVET, R. E., GENTRY, M. J., NEWMAN, P. R., RUMMAGE, J. A. & CONFER, A.
   W. 1982. Demonstration of age-dependent capsular material on Pasteurella haemolytica serotype 1. J. Clin. Microbiol., 16, 1123-1126.
- COSTERTO.JW, FORSBERG, C., MATULA, T. I., BUCKMIRE, F. L. & MACLEOD, R. A. 1967. Nutrition and Metabolism of Marine Bacteria .16. Formation of Protoplasts Spheroplasts and Related Forms from a Gram-Negative Marine Bacterium. Journal of Bacteriology, 94, 1764-&.
- COTTER, P. A., YUK, M. H., MATTOO, S., AKERLEY, B. J., BOSCHWITZ, J., RELMAN, D. A. & MILLER, J. F. 1998. Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization. Infect. Immun., 66, 5921-5929.
- COTTER, S. E., SURANA, N. K. & ST GEME, J. W. 2005. Trimeric autotransporters: a distinct subfamily of autotransporter proteins. *Trends Microbiol.*, 13, 199-205.
- COUTTE, L., ANTOINE, R., DROBECQ, H., LOCHT, C. & JACOB-DUBUISSON, F. 2001. Subtilisin-like autotransporter serves as maturation protease in a bacterial secretion pathway. *EMBO J.*, 20, 5040-5048.
- COUTTE, L., WILLERY, E., ANTOINE, R., DROBECQ, H., LOCHT, C. & JACOB-DUBUISSON, F. 2003. Surface anchoring of bacterial subtilisin important for maturation function. *Mol. Microbiol.*, 49, 529-539.
- COWAN, S. W., SCHIRMER, T., RUMMEL, G., STEIERT, M., GHOSH, R., PAUPTIT, R. A., JANSONIUS, J. N. & ROSENBUSCH, J. P. 1992. Crystal structures explain functional properties of two *E. coli* porins. *Nature*, 358, 727-733.
- CZUPRYNSKI, C. J., NOEL, E. J. & ADLAM, C. 1989. Modulation of bovine neutrophil antibacterial activities by *Pasteurella haemolytica* A1 purified capsular polysaccharide. *Microb. Pathog.*, 6, 133-141.
- CZUPRYNSKI, C. J., NOEL, E. J., ORTIZCARRANZA, O. & SRIKUMARAN, S. 1991. Activation of bovine neutrophils by partially purified *Pasteurella haemolytica* leukotoxin. *Infect. Immun.*, 59, 3126-3133.
- DABO, S. M., CONFER, A. W. & QUIJANO-BLAS, R. A. 2003. Molecular and immunological characterization of *Pasteurella multocida* serotype A:3 OmpA: evidence of its role in *P. multocida* interaction with extracellular matrix molecules. *Microb. Pathog.*, 35, 147-157.

- DABO, S. M., CONFER, A. W., STYRE, D. & MURPHY, G. L. 1994. Expression, purification and immunological analysis of three *Pasteurella haemolytica* A1 28-30 kDa lipoproteins. *Microb. Pathog.*, 17, 149-158.
- DAIGNEAULT, M. C. & LO, R. Y. C. 2009. Analysis of a collagen-binding trimeric autotransporter adhesin from *Mannheimia haemolytica* A1. *FEMS Microbiol. Lett.*, 300, 242-248.
- DASKALEROS, P. A. & PAYNE, S. M. 1987. Congo red binding phenotype is associated with hemin binding and increased infectivity of *Shigella flexneri* in the Hela cell model. *Infect. Immun.*, 55, 1393-1398.
- DAVIES, R. L., ALI, Q., PARTON, R., COOTE, J. G., GIBBS, A. & FREER, J. H. 1991. Optimal conditions for the analysis of *Pasteurella haemolytica* lipopolysaccharide by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. *FEMS Microbiol. Lett.*, 90, 23-28.
- DAVIES, R. L., ARKINSAW, S. & SELANDER, R. K. 1997. Evolutionary genetics of *Pasteurella haemolytica* isolates recovered from cattle and sheep. *Infect. Immun.*, 65, 3585-3593.
- DAVIES, R. L., CAMPBELL, S. & WHITTAM, T. S. 2002. Mosaic structure and molecular evolution of the leukotoxin operon (*lktCABD*) in *Mannheimia* (*Pasteurella*) haemolytica, *Mannheimia* glucosida, and *Pasteurella* trehalosi. J. Bacteriol., 184, 266-277.
- DAVIES, R. L. & DONACHIE, W. 1996. Intra-specific diversity and host specificity within *Pasteurella haemolytica* based on variation of capsular polysaccharide, lipopolysaccharide and outer-membrane proteins. *Microbiology*, 142, 1895-1907.
- DAVIES, R. L. & LEE, I. 2004. Sequence diversity and molecular evolution of the heat-modifiable outer membrane protein gene (*ompA*) of *Mannheimia* (*Pasteurella*) haemolytica, *Mannheimia* glucosida, and *Pasteurella* trehalosi. J. Bacteriol., 186, 5741-5752.
- DAVIES, R. L., MACCORQUODALE, R., BAILLIE, S. & CAFFREY, B. 2003a. Characterization and comparison of *Pasteurella multocida* strains associated with porcine pneumonia and atrophic rhinitis. *J. Med. Microbiol.*, 52, 59-67.
- DAVIES, R. L., MACCORQUODALE, R. & CAFFREY, B. 2003b. Diversity of avian *Pasteurella multocida* strains based on capsular PCR typing and variation of the OmpA and OmpH outer membrane proteins. *Vet. Microbiol.*, 91, 169-182.
- DAVIES, R. L., MACCORQUODALE, R. & REILLY, S. 2004. Characterisation of bovine strains of *Pasteurella multocida* and comparison with isolates of avian, ovine and porcine origin. *Vet. Microbiol.*, 99, 145-158.
- DAVIES, R. L., MCCLUSKEY, J., GIBBS, H. A., COOTE, J. G., FREER, J. H. & PARTON, R. 1994a. Comparison of outer-membrane proteins of Pasteurella haemolytica expressed in vitro and in vivo in cattle. Microbiology, 140, 3293-3300.
- DAVIES, R. L., PARTON, R., COOTE, J. G., GIBBS, H. A. & FREER, J. H. 1992. Outer membrane protein and lipopolysaccharide variation in *Pasteurella haemolytica* serotype A1 under different growth conditions. J. Gen. *Microbiol.*, 138, 909-922.
- DAVIES, R. L., PARTON, R., COOTE, J. G., GIBBS, H. A. & FREER, J. H. 1994b. Evaluation of different methods for the detection of outer membrane proteins and lipopolysaccharides of *Pasteurella haemolytica* by immunoblotting. J. Immunol. Methods, 167, 35-45.

- DAVIES, R. L., PASTER, B. J. & DEWHIRST, F. E. 1996. Phylogenetic relationships and diversity within the *Pasteurella haemolytica* complex based on 16S rRNA sequence comparison and outer membrane protein and lipopolysaccharide analysis. *Int. J. Syst. Bacteriol.*, 46, 736-744.
- DAVIES, R. L., WHITTAM, T. S. & SELANDER, R. K. 2001. Sequence diversity and molecular evolution of the leukotoxin (lktA) gene in bovine and ovine strains of *Mannheimia* (*Pasteurella*) *haemolytica*. J. Bacteriol., 183, 1394-1404.
- DE JONGE, M. I., HAMSTRA, H. J., VAN ALPHEN, L., DANKERT, J. & VAN DER LEY, P. 2003. Mapping the binding domains on meningococcal Opa proteins for CEACAM1 and CEA receptors. *Mol. Microbiol.*, 50, 1005-1015.
- DE LA MORA, A., TRIGO, F., JARAMILLO, L., GARFIAS, Y., SOLORZANO, C., AGUNDIS, C., PEREYRA, A., LASCURAIN, R., ZENTENO, E. & SUAREZ-GUEMES, F. 2006. The N-acetyl-D-glucosamine specific adhesin from Mannheimia haemolytica activates bovine neutrophils oxidative burst. Vet. Immunol. Immunopathol., 113, 148-156.
- DEGHMANE, A. E., GIORGINI, D., LARRIBE, M., ALONSO, J. M. & TAHA, M. K. 2002. Down-regulation of pili and capsule of *Neisseria meningitidis* upon contact with epithelial cells is mediated by CrgA regulatory protein. *Mol. Microbiol.*, 43, 1555-1564.
- DEMOT, R. & VANDERLEYDEN, J. 1994. The C-Terminal sequence conservation between OmpA-related outer membrane proteins and MotB suggests a common function in both Gram-positive and Gram-negative bacteria, possibly in the interaction of these domains with peptidoglycan. *Mol. Microbiol.*, 12, 333-334.
- DENEER, H. G. & POTTER, A. A. 1989. Effect of iron restriction on the outer membrane proteins of *Actinobacillus* (*Haemophilus*) pleuropneumoniae. Infect. Immun., 57, 798-804.
- DESLANDES, V., DENICOURT, M., GIRARD, C., HAREL, J., NASH, J. H. E. & JACQUES, M. 2010. Transcriptional profiling of *Actinobacillus pleuropneumoniae* during the acute phase of a natural infection in pigs. *BMC Genomics*, 11.
- DEVRIES, F. P., VANDERENDE, A., VANPUTTEN, J. P. M. & DANKERT, J. 1996. Invasion of primary nasopharyngeal epithelial cells by *Neisseria meningitidis* is controlled by phase variation of multiple surface antigens. *Infect. Immun.*, 64, 2998-3006.
- DIAZ-MEJIA, J. J., BABU, M. & EMILI, A. 2009. Computational and experimental approaches to chart the *Escherichia coli* cell-envelope-associated proteome and interactome. *FEMS Microbiol. Rev.*, 33, 66-97.
- DOERRLER, W. T. & RAETZ, C. R. H. 2002. ATPase activity of the MsbA lipid flippase of *Escherichia coli*. J. Biol. Chem., 277, 36697-36705.
- DOERRLER, W. T. & RAETZ, C. R. H. 2005. Loss of outer membrane proteins without inhibition of lipid export in an *Escherichia coli* YaeT mutant. J. *Biol. Chem.*, 280, 27679-27687.
- DOERRLER, W. T., REEDY, M. C. & RAETZ, C. R. H. 2001. An *Escherichia coli* mutant defective in lipid export. J. Biol. Chem., 276, 11461-11464.
- DONACHIE, W., FRASER, J., QUIRIE, M. & GILMOUR, N. J. L. 1984. Studies on strains of *Pasteurella haemolytica* not typable by the indirect hemagglutination test. *Res. Vet. Sci.*, 37, 188-193.
- DONG, C. J., BEIS, K., NESPER, J., BRUNKAN-LAMONTAGNE, A. L., CLARKE, B. R., WHITFIELD, C. & NAISMITH, J. H. 2006. Wza the translocon for *E. coli*

capsular polysaccharides defines a new class of membrane protein. *Nature*, 444, 226-229.

- DORNMAIR, K., KIEFER, H. & JAHNIG, F. 1990. Refolding of an integral membrane protein OmpA of *Escherichia coli*. J. Biol. Chem., 265, 18907-18911.
- DRIESSEN, A. J. M. & NOUWEN, N. 2008. Protein translocation across the bacterial cytoplasmic membrane. *Annu. Rev. Biochem.*, 77, 643-667.
- DRUMMELSMITH, J. & WHITFIELD, C. 2000. Translocation of group 1 capsular polysaccharide to the surface of *Escherichia coli* requires a multimeric complex in the outer membrane. *EMBO J.*, 19, 57-66.
- DUHUTREL, P., BORDAT, C., WU, T.-D., ZAGOREC, M., GUERQUIN-KERN, J.-L. & CHAMPOMIER-VERGES, M.-C. 2010. Iron sources used by the nonpathogenic lactic acid bacterium *Lactobacillus sakei* as revealed by electron energy loss spectroscopy and secondary-ion mass spectrometry. *Appl. Environ. Microbiol.*, 76, 560-565.
- DUIM, B., BOWLER, L. D., EIJK, P. P., JANSEN, H. M., DANKERT, J. & VANALPHEN, L. 1997. Molecular variation in the major outer membrane protein P5 gene of nonencapsulated *Haemophilus influenzae* during chronic infections. *Infect. Immun.*, 65, 1351-1356.
- DUNCAN, J. R., WILKIE, B. N., WINTER, A. J. & HIESTAND, F. 1972. Serum and secretory immunoglobulins of cattle: characterization and quantitation. *J. Immunol.*, 108, 965-976.
- DUTZLER, R., WANG, Y. F., RIZKALLAH, P. J., ROSENBUSCH, J. P. & SCHIRMER, T. 1996. Crystal structures of various maltooligosaccharides bound to maltoporin reveal a specific sugar translocation pathway. *Structure*, 4, 127-134.
- DYER, D. W., WEST, E. P., MCKENNA, W., THOMPSON, S. A. & SPARLING, P. F. 1988. A pleiotropic iron-uptake mutant of *Neisseria meningitidis* lacks a 70-kilodalton iron-regulated protein. *Infect. Immun.*, 56, 977-983.
- E-KOMON, T., BURCHMORE, R. & DAVIES, R. L. 2011a. Comparative outer membrane proteomic analyses of *Pasteurella multocida* isolates from different host species. *Proteomics*, In press.
- E-KOMON, T., BURCHMORE, R., HERZYK, P. & DAVIES, R. L. 2011b. Predicting the outer membrane proteome of *Pasteurella multocida* using a simple prediction framework. *BMC Genomics*, In press.
- ELKINS, C., MORROW, K. J. & OLSEN, B. 2000. Serum resistance in *Haemophilus ducreyi* requires outer membrane protein DsrA. *Infect. Immun.*, 68, 1608-1619.
- ENG, J. K., MCCORMACK, A. L. & YATES, J. R. 1994. An approach to correlate tandem mass-spectral data of peptides with amino-acid-sequences in a protein database. J. Am. Soc. Mass Spectrom., 5, 976-989.
- FAVRE-BONTE, S., JOLY, B. & FORESTIER, C. 1999. Consequences of reduction of *Klebsiella pneumoniae* capsule expression on interactions of this bacterium with epithelial cells. *Infect. Immun.*, 67, 554-561.
- FENN, J. B., MANN, M., MENG, C. K., WONG, S. F. & WHITEHOUSE, C. M. 1989. Electrospray ionization for mass spectrometry of large biomolecules. *Science*, 246, 64-71.
- FERGUSON, A. D., HOFMANN, E., COULTON, J. W., DIEDERICHS, K. & WELTE, W. 1998. Siderophore-mediated iron transport: crystal structure of FhuA with bound lipopolysaccharide. *Science*, 282, 2215-2220.
- FILIP, C., FLETCHER, G., WULFF, J. L. & EARHART, C. F. 1973. Solubilization of cytoplasmic membrane of *Escherichia coli* by ionic detergent sodium-lauryl sarcosinate. J. Bacteriol., 115, 717-722.

- FORST, D., WELTE, W., WACKER, T. & DIEDERICHS, K. 1998. Structure of the sucrose-specific porin ScrY from Salmonella typhimurium and its complex with sucrose. Nat. Struct. Biol., 5, 37-46.
- FOURNIER, C., SMITH, A. & DELEPELAIRE, P. 2011. Haem release from haemopexin by HxuA allows *Haemophilus influenzae* to escape host nutritional immunity. *Mol. Microbiol.*, 80, 133-148.
- FOWLER, D. M., KOULOV, A. V., BALCH, W. E. & KELLY, J. W. 2007. Functional amyloid from bacteria to humans. *Trends Biochem. Sci.*, 32, 217-224.
- FRANK, G. H. 1989. Pasteurellosis of cattle. In: ADLAM, C. & RUTTER, J. M. (eds.) Pasteurella and pasteurellosis. Academic Press, New York, N.Y.
- FRASER, J., DONACHIE, W., QUIRIE, M. & GILMOUR, N. J. L. 1983. Rapid indirect hemagglutination test for serotyping *Pasteurella haemolytica*. J. Clin. Microbiol., 18, 206-207.
- FREEMAN, D. J., FALKINER, F. R. & KEANE, C. T. 1989. New method for detecting slime production by coagulase negative Staphylococci. J. Clin. Pathol., 42, 872-874.
- FREY, J., BOSSE, J. T., CHANG, Y. F., CULLEN, J. M., FENWICK, B., GERLACH, G. F., GYGI, D., HAESEBROUCK, F., INZANA, T. J., JANSEN, R., KAMP, E. M., MACDONALD, J., MACINNES, J. I., MITTAL, K. R., NICOLET, J., RYCROFT, A. N., SEGERS, R., SMITS, M. A., STENBAEK, E., STRUCK, D. K., VANDENBOSCH, J. F., WILLSON, P. J. & YOUNG, R. 1993. Actinobacillus pleuropneumoniae RTX-toxins: uniform designation of haemolysins, cytolysins, pleurotoxin and their genes. J. Gen. Microbiol., 139, 1723-1728.
- FRONZES, R., SCHAFER, E., WANG, L., SAIBIL, H. R., ORLOVA, E. V. & WAKSMAN, G. 2009. Structure of a type IV secretion system core complex. *Science*, 323, 266-268.
- GALDIERO, M., PISCIOTTA, M. G., MARINELLI, A., PETRILLO, G. & GALDIERO, E. 2002. Coinfection with BHV-1 modulates cell adhesion and invasion by *P. multocida* and *Mannheimia* (*Pasteurella*) *haemolytica*. *Microbiologica*, 25, 427-436.
- GARDY, J. L., LAIRD, M. R., CHEN, F., REY, S., WALSH, C. J., ESTER, M. & BRINKMAN, F. S. L. 2005. PSORTb v.2.0: expanded prediction of bacterial protein subcellular localization and insights gained from comparative proteome analysis. *Bioinformatics*, 21, 617-623.
- GARDY, J. L., SPENCER, C., WANG, K., ESTER, M., TUSNADY, G. E., SIMON, I., HUA, S., DEFAYS, K., LAMBERT, C., NAKAI, K. & BRINKMAN, F. S. L. 2003.
   PSORT-B: improving protein subcellular localization prediction for Gramnegative bacteria. *Nucleic Acids Res.*, 31, 3613-3617.
- GARRIDO, M. E., BOSCH, M., MEDINA, R., BIGAS, A., LLAGOSTERA, M., DE ROZAS,
   A. M. P., BADIOLA, I. & BARBE, J. 2003. *fur*-independent regulation of the *Pasteurella multocida hbpA* gene encoding a haemin-binding protein. *Microbiology*, 149, 2273-2281.
- GARROW, A. G., AGNEW, A. & WESTHEAD, D. R. 2005. TMB-Hunt: an amino acid composition based method to screen proteomes for beta-barrel transmembrane proteins. *BMC Bioinformatics*, 6, 56.
- GASTEIGER, E., HOOGLAND, C., GATTIKER, A., DUVAUD, S., WILKINS, M. R., APPEL, R. D. & BAIROCH, A. 2005. Protein identification and analysis tools on the ExPASy server. *In:* WALKER, J. M. (ed.) *The Proteomics Protocols Handbook* Humana Press, New York, N. Y.
- GATEWOOD, D. M., FENWICK, B. W. & CHENGAPPA, M. M. 1994. Growthcondition dependent expression of *Pasteurella haemolytica* A1 outer

membrane proteins, capsule, and leukotoxin. *Vet. Microbiol.*, 41, 221-233.

- GENTSCHEV, I., DIETRICH, G. & GOEBEL, W. 2002. The *E. coli* alpha-hemolysin secretion system and its use in vaccine development. *Trends Microbiol.*, 10, 39-45.
- GILMOUR, N. J. L., DONACHIE, W., SUTHERLAND, A. D., GILMOUR, J. S., JONES, G. E. & QUIRIE, M. 1991. Vaccine containing iron-regulated proteins of *Pasteurella haemolytica* A2 enhances protection against experimental pasteurellosis in lambs. *Vaccine*, 9, 137-140.
- GILMOUR, N. J. L. & GILMOUR, J. S. 1989. Pasteurellosis of sheep. In: ADLAM, C. & RUTTER, J. M. (eds.) Pasteurella and pasteurellosis. Academic Press, New York, N.Y.
- GIOIA, J. & HIGHLANDER, S. K. 2007. Identification and characterization of transcriptional regulation of the *Mannheimia haemolytica* ferric uptake regulator. *Vet. Microbiol.*, 124, 298-309.
- GIOIA, J., QIN, X., JIANG, H. Y., CLINKENBEARD, K., LO, R., LIU, Y. M., FOX, G.
  E., YERRAPRAGADA, S., MCLEOD, M. P., MCNEILL, T. Z., HEMPHILL, L., SODERGREN, E., WANG, Q. Y., MUZNY, D. M., HOMSI, F. J., WEINSTOCK, G. A. & HIGHLANDER, S. K. 2006. The genome sequence of *Mannheimia haemolytica* A1: insights into virulence, natural competence, and Pasteurellaceae phylogeny. J. Bacteriol., 188, 7257-7266.
- GOHAR, M., OKSTAD, O. A., GILOIS, N., SANCHIS, V., KOLSTO, A. B. & LERECLUS,
   D. 2002. Two-dimensional electrophoresis analysis of the extracellular proteome of *Bacillus cereus* reveals the importance of the PlcR regulon. *Proteomics*, 2, 784-791.
- GONZALEZ, C., MURTAUGH, M. P. & MAHESWARAN, S. K. 1991. Genomic distribution of a serotype 1-specific antigen-coding DNA fragment of Pasteurella haemolytica. J. Vet. Med. B Infect. Dis. Vet. Public Health, 38, 599-609.
- GONZALEZ, C. T., MAHESWARAN, S. K. & MURTAUGH, M. P. 1995. Pasteurella haemolytica serotype 2 contains the gene for a noncapsular serotype 1-specific antigen. Infect. Immun., 63, 1340-1348.
- GONZALEZRAYOS, C., LO, R. Y. C., SHEWEN, P. E. & BEVERIDGE, T. J. 1986. Cloning of a Serotype-Specific Antigen from Pasteurella-Haemolytica-A1. Infection and Immunity, 53, 505-510.
- GORG, A., WEISS, W. & DUNN, M. J. 2004. Current two-dimensional electrophoresis technology for proteomics. *Proteomics*, 4, 3665-3685.
- GOSHE, M. B., BLONDER, J. & SMITH, R. D. 2003. Affinity labeling of highly hydrophobic integral membrane proteins for proteome-wide analysis. J. *Proteome Res.*, 2, 153-161.
- GRAHAM, M. R. & LO, R. Y. C. 2002. A putative iron-regulated TonB-dependent receptor of *Mannheimia* (*Pasteurella*) *haemolytica* A1: possible mechanism for phase variation. *Vet. Microbiol.*, 84, 53-67.
- GREINER, L. L., EDWARDS, J. L., SHAO, J., RABINAK, C., ENTZ, D. & APICELLA, A. A. 2005. Biofilm formation by *Neisseria gonorrhoeae*. *Infect. Immun.*, 73, 1964-1970.
- GROMIHA, M. M. 2005. Motifs in outer membrane protein sequences: applications for discrimination. *Biophys. Chem.*, 117, 65-71.
- GROMIHA, M. M. & SUWA, M. 2006. Influence of amino acid properties for discriminating outer membrane proteins at better accuracy. *Biochim. Biophys. Acta*, 1764, 1493-1497.
- HAIG, S. 2011. Adherence of *Mannheimia haemolytica* to ovine bronchial epithelial cells. *Bioscience Horizons*, 4, 50-60.
- HALL-STOODLEY, L., HU, F. Z., GIESEKE, A., NISTICO, L., NGUYEN, D., HAYES, J., FORBES, M., GREENBERG, D. P., DICE, B., BURROWS, A., WACKYM, P. A., STOODLEY, P., POST, J. C., EHRLICH, G. D. & KERSCHNER, J. E. 2006. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 296, 202-211.
- HALLSTROM, T., TRAJKOVSKA, E., FORSGREN, A. & RIESBECK, K. 2006. Haemophilus influenzae surface fibrils contribute to serum resistance by interacting with vitronectin. J. Immunol., 177, 430-436.
- HAN, D. K., ENG, J., ZHOU, H. L. & AEBERSOLD, R. 2001. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. *Nature Biotechnology*, 19, 946-951.
- HANSON, M. S. & HANSEN, E. J. 1991. Molecular cloning, partial purification, and characterization of a haemin-binding lipoprotein from *Haemophilus influenzae* type b. *Mol. Microbiol.*, 5, 267-278.
- HANSON, M. S., PELZEL, S. E., LATIMER, J., MULLEREBERHARD, U. & HANSEN, E. J. 1992. Identification of a genetic locus of *Haemophilus influenzae* type b necessary for the binding and utilization of heme bound to human hemopexin. *Proc. Natl. Acad. Sci. U. S. A.*, 89, 1973-1977.
- HANTKE, K. 1983. Identification of an iron uptake system specific for coprogen and rhodotorulic acid in *Escherichia coli* K12. *Mol. Gen. Genet.*, 191, 301-306.
- HAYASHI, S. & WU, H. C. 1990. Lipoproteins in bacteria. J. Bioenerg. Biomembr., 22, 451-471.
- HELLMAN, J., LOISELLE, P. M., TEHAN, M. M., ALLAIRE, J. E., BOYLE, L. A., KURNICK, J. T., ANDREWS, D. M., KIM, K. S. & WARREN, H. S. 2000. Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by *Escherichia coli* bacteria into serum. *Infect. Immun.*, 68, 2566-2572.
- HENDERSON, I. R., NAVARRO-GARCIA, F., DESVAUX, M., FERNANDEZ, R. C. & ALA'ALDEEN, D. 2004. Type V protein secretion pathway: the autotransporter story. *Microbiol. Mol. Biol. Rev.*, 68, 692-+.
- HIGHLANDER, S. K. 2001. Molecular genetic analysis of virulence in Mannheimia (Pasteurella) haemolytica. Front. Biosci., 6, D1128-D1151.
- HILL, D. J., TOLEMAN, M. A., EVANS, D. J., VILLULLAS, S., VAN ALPHEN, L. & VIRJI, M. 2001. The variable P5 proteins of typeable and non-typeable *Haemophilus influenzae* target human CEACAM1. *Mol. Microbiol.*, 39, 850-862.
- HILL, R. A. & SILLENCE, M. N. 1997. Improved membrane isolation in the purification of beta(2)-adrenoceptors from transgenic *Escherichia coli*. *Protein Expr. Purif.*, 10, 162-167.
- HITCHCOCK, P. J., LEIVE, L., MAKELA, P. H., RIETSCHEL, E. T., STRITTMATTER,
  W. & MORRISON, D. C. 1986. Lipopolysaccharide nomenclature past, present, and future. J. Bacteriol., 166, 699-705.
- HJERPE, C. A. 1990. Bovine vaccines and herd vaccination programs. Vet. Clin. North Am. Food Anim. Pract., 6, 167-260.
- HOBB, R. I., FIELDS, J. A., BURNS, C. M. & THOMPSON, S. A. 2009. Evaluation of procedures for outer membrane isolation from *Campylobacter jejuni*. *Microbiology*, 155, 979-988.
- HODGKINSON, J. L., HORSLEY, A., STABAT, D., SIMON, M., JOHNSON, S., DA FONSECA, P. C. A., MORRIS, E. P., WALL, J. S., LEA, S. M. & BLOCKER, A.

J. 2009. Three-dimensional reconstruction of the *Shigella* T3SS transmembrane regions reveals 12-fold symmetry and novel features throughout. *Nat. Struct. Mol. Biol.*, 16, 477-485.

- HOICZYK, E., ROGGENKAMP, A., REICHENBECHER, M., LUPAS, A. & HEESEMANN, J. 2000. Structure and sequence analysis of *Yersinia* YadA and *Moraxella* UspAs reveal a novel class of adhesins. *EMBO J.*, 19, 5989-5999.
- HUNT, D. F., HENDERSON, R. A., SHABANOWITZ, J., SAKAGUCHI, K., MICHEL, H., SEVILIR, N., COX, A. L., APPELLA, E. & ENGELHARD, V. H. 1992. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science, 255, 1261-1263.
- HUNTLEY, J. F., CONLEY, P. G., HAGMAN, K. E. & NORGARD, M. V. 2007. Characterization of *Francisella tularensis* outer membrane proteins. *J. Bacteriol.*, 189, 561-574.
- IMAI, K., ASAKAWA, N., TSUJI, T., AKAZAWA, F., INO, A., SONOYAMA, M. & MITAKU, S. 2008. SOSUI-GramN: high performance prediction for subcellular localization of proteins in Gram-negative bacteria. *Bioinformation*, 2, 417-21.
- INOUYE, S., WANG, S., SEKIZAWA, J., HALEGOUA, S. & INOUYE, M. 1977. Amino acid sequence for peptide extension on prolipoprotein of *Escherichia coli* outer membrane. *Proc. Natl. Acad. Sci. U.S.A.*, 74, 1004-1008.
- ISHIGURO, E. E., AINSWORTH, T., TRUST, T. J. & KAY, W. W. 1985. Congo red agar, a diferential medium for *Aeromonas salmonicida*, detects the presence of the cell-surface protein array involved in virulence. *J. Bacteriol.*, 164, 1233-1237.
- JACKUPS, R., CHENG, S. & LIANG, J. 2006. Sequence motifs and antimotifs in beta-barrel membrane proteins from a genome-wide analysis: the Ala-Tyr dichotomy and chaperone binding motifs. J. Mol. Biol., 363, 611-623.
- JACOB-DUBUISSON, F., FERNANDEZ, R. & COUTTE, L. 2004. Protein secretion through autotransporter and two-partner pathways. *Biochim. Biophys. Acta*, 1694, 235-257.
- JAIN, A. & AGARWAL, A. 2009. Biofilm production, a marker of pathogenic potential of colonizing and commensal staphylococci. J. Microbiol. Methods, 76, 88-92.
- JEYASEELAN, S., HSUAN, S. L., KANNAN, M. S., WALCHECK, B., WANG, J. F., KEHRLI, M. E., LALLY, E. T., SIECK, G. C. & MAHESWARAN, S. K. 2000. Lymphocyte function-associated antigen 1 is a receptor for *Pasteurella haemolytica* leukotoxin in bovine leukocytes. *Infect. Immun.*, 68, 72-79.
- JOHANSSON, A., CLAESSON, R., HANSTROM, L. & KALFAS, S. 2003. Serummediated release of leukotoxin from the cell surface of the periodontal pathogen Actinobacillus actinomycetemcomitans. Eur. J. Oral Sci., 111, 209-215.
- JONES, F. S. 1921. A study of Bacillus bovisepticus. J. Exp. Med., 34, 561-577.
- JUNCKER, A. S., WILLENBROCK, H., VON HEIJNE, G., BRUNAK, S., NIELSEN, H. & KROGH, A. 2003. Prediction of lipoprotein signal peptides in Gramnegative bacteria. *Protein Sci.*, 12, 1652-1662.
- KACHLANY, S. C., FINE, D. H. & FIGURSKI, D. H. 2000. Secretion of RTX leukotoxin by *Actinobacillus actinomycetemcomitans*. *Infect. Immun.*, 68, 6094-6100.
- KACHLANY, S. C., FINE, D. H. & FIGURSKI, D. H. 2002. Purification of secreted leukotoxin (LtxA) from Actinobacillus actinomycetemcomitans. Protein Expr. Purif., 25, 465-471.

- KAEHLER, K. L., MARKAM, R. J. F., MUSCOPLAT, C. C. & JOHNSON, D. W. 1980. Evidence of cytocidal effects of *Pasteurella haemolytica* on bovine peripheral-blood mononuclear leukocytes. *Am. J. Vet. Res.*, 41, 1690-1693.
- KANEMASA, Y., AKAMATSU, Y. & NOJIMA, S. 1967. Composition and turnover of phospholipids in *Escherichia coli*. *Biochim*. *Biophys*. *Acta*, 144, 382-390.
- KAPLAN, J. B., VELLIYAGOUNDER, K., RAGUNATH, C., ROHDE, H., MACK, D., KNOBLOCH, J. K. M. & RAMASUBBU, N. 2004. Genes involved in the synthesis and degradation of matrix polysaccharide in Actinobacillus actinomycetemcomitans and Actinobacillus pleuropneumoniae biofilms. J. Bacteriol., 186, 8213-8220.
- KARAS, M. & HILLENKAMP, F. 1988. Laser desorption ionization of proteins with molecular masses exceeding 10000 daltons. *Anal. Chem.*, 60, 2299-2301.
- KATO, S., KOWASHI, Y. & DEMUTH, D. R. 2002. Outer membrane-like vesicles secreted by *Actinobacillus actinomycetemcomitans* are enriched in leukotoxin. *Microb. Pathog.*, 32, 1-13.
- KAUR, R., SHARMA, A., MAJUMDAR, S., GANGULY, N. K. & CHAKRABORTI, A. 2003. Outer-membrane-protein subtypes of *Haemophilus influenzae* isolates from North India. J. Med. Microbiol., 52, 693-696.
- KEISS, R. E., WILL, D. H. & COLLIER, J. R. 1964. Skin toxicity and hemodynamic properties of endotoxin derived from *Pasteurella haemolytica*. *Am. J. Vet. Res.*, 25, 935-941.
- KELLY, S. M., JESS, T. J. & PRICE, N. C. 2005. How to study proteins by circular dichroism. *Biochim. Biophys. Acta*, 1751, 119-139.
- KIM, D. W., CHATER, K., LEE, K. J. & HESKETH, A. 2005. Changes in the extracellular proteome caused by the absence of the *bldA* gene product, a developmentally significant tRNA, reveal a new target for the pleiotropic regulator AdpA in *Streptomyces coelicolor*. J. Bacteriol., 187, 2957-2966.
- KISIELA, D. I., AULIK, N. A., ATAPATTU, D. N. & CZUPRYNSKI, C. J. 2010. Nterminal region of *Mannheimia haemolytica* leukotoxin serves as a mitochondrial targeting signal in mammalian cells. *Cell. Microbiol.*, 12, 976-987.
- KISIELA, D. I. & CZUPRYNSKI, C. J. 2009. Identification of *Mannheimia haemolytica* adhesins involved in binding to bovine bronchial epithelial cells. *Infect. Immun.*, 77, 446-455.
- KITT, T. 1885. Uber eine experimentelle, der Rinderseuche ahnliche Infektionskranheit. Sitzunbsber Ges Morphol Physiol Muenchen, 140-168.
- KLAUSER, T., KRAMER, J., OTZELBERGER, K., POHLNER, J. & MEYER, T. F. 1993. Characterization of the *Neisseria* Iga(beta)-core - the essential unit for outer membrane targeting and extracellular protein secretion. J. Mol. *Biol.*, 234, 579-593.
- KLEINSCHMIDT, J. H., WIENER, M. C. & TAMM, L. K. 1999. Outer membrane protein A of *E. coli* folds into detergent micelles, but not in the presence of monomeric detergent. *Protein Sci.*, 8, 2065-2071.
- KLITGAARD, K., FRIIS, C., ANGEN, O. & BOYE, M. 2010. Comparative profiling of the transcriptional response to iron restriction in six serotypes of *Actinobacillus pleuropneumoniae* with different virulence potential. *BMC Genomics*, 11.
- KNOWLES, T. J., SCOTT-TUCKER, A., OVERDUIN, M. & HENDERSON, I. R. 2009. Membrane protein architects: the role of the BAM complex in outer membrane protein assembly. *Nat. Rev. Microbiol.*, 7, 206-214.

- KOEBNIK, R., LOCHER, K. P. & VAN GELDER, P. 2000. Structure and function of bacterial outer membrane proteins: barrels in a nutshell. *Mol. Microbiol.*, 37, 239-253.
- KORONAKIS, V., ESWARAN, J. & HUGHES, C. 2004. Structure and function of TolC: the bacterial exit duct for proteins and drugs. *Annu. Rev. Biochem.*, 73, 467-489.
- KORONAKIS, V., SHARFF, A., KORONAKIS, E., LUISI, B. & HUGHES, C. 2000. Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. *Nature*, 405, 914-919.
- KOVACS-SIMON, A., TITBALL, R. W. & MICHELL, S. L. 2011. Lipoproteins of bacterial pathogens. *Infect. Immun.*, 79, 548-561.
- KRAIG, E., DAILEY, T. & KOLODRUBETZ, D. 1990. Nucleotide sequence of the leukotoxin gene from *Actinobacillus actinomycetemcomitans*: homology to the alpha-hemolysin leukotoxin gene family. *Infect. Immun.*, 58, 920-929.
- KRINOS, C. M., COYNE, M. J., WEINACHT, K. G., TZIANABOS, A. O., KASPER, D. L.
   & COMSTOCK, L. E. 2001. Extensive surface diversity of a commensal microorganism by multiple DNA inversions. *Nature*, 414, 555-558.
- KROGH, A., LARSSON, B., VON HEIJNE, G. & SONNHAMMER, E. L. 2001. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J. Mol. Biol., 305, 567-580.
- KULP, A. & KUEHN, M. J. 2010. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. *Annu. Rev. Microbiol.*, 64, 163-84.
- LACROIX, R. P., DUNCAN, J. R., JENKINS, R. P., LEITCH, R. A., PERRY, J. A. & RICHARDS, J. C. 1993. Structural and serological specificities of *Pasteurella haemolytica* lipopolysaccharides. *Infect. Immun.*, 61, 170-181.
- LAEMMLI, U. K. 1970. Cleavage of structural proteins during assembly of head of bacteriophage T4. *Nature*, 227, 680-&.
- LAFLEUR, R. L., ABRAHAMSEN, M. S. & MAHESWARAN, S. K. 1998. The biphasic mRNA expression pattern of bovine interleukin-8 in *Pasteurella haemolytica* lipopolysaccharide-stimulated alveolar macrophages is primarily due to tumor necrosis factor alpha. *Infect. Immun.*, 66, 4087-4092.
- LAFLEUR, R. L., MALAZDREWICH, C., JEYASEELAN, S., BLEIFIELD, E., ABRAHAMSEN, M. S. & MAHESWARAN, S. K. 2001. Lipopolysaccharide enhances cytolysis and inflammatory cytokine induction in bovine alveolar macrophages exposed to *Pasteurella* (*Mannheimia*) *haemolytica* leukotoxin. *Microb. Pathog.*, 30, 347-357.
- LALLY, E. T., GOLUB, E. E., KIEBA, I. R., TAICHMAN, N. S., DECKER, S., BERTHOLD, P., GIBSON, C. W., DEMUTH, D. R. & ROSENBLOOM, J. 1991. Structure and function of the B-gene and D-gene of the Actinobacillus actinomycetemcomitans leukotoxin complex. *Microb. Pathog.*, 11, 111-121.
- LAM, J., CHAN, R., LAM, K. & COSTERTON, J. W. 1980. Production of mucoid microcolonies by *Pseudomonas aeruginosa* within infected lungs in cystic fibrosis. *Infect. Immun.*, 28, 546-556.
- LANE, C. S. 2005. Mass spectrometry-based proteomics in the life sciences. *Cell. Mol. Life Sci.*, 62, 848-869.
- LAWRENCE, P. K., KITTICHOTIRAT, W., BUMGARNER, R. E., MCDERMOTT, J. E., HERNDON, D. R., KNOWLES, D. P. & SRIKUMARAN, S. 2010a. Genome sequences of *Mannheimia haemolytica* serotype A2: ovine and bovine isolates. J. Bacteriol., 192, 1167-1168.

- LAWRENCE, P. K., KITTICHOTIRAT, W., MCDERMOTT, J. E. & BUMGARNER, R. E. 2010b. A three-way comparative genomic analysis of *Mannheimia haemolytica* isolates. *BMC Genomics*, 11.
- LEDUC, I., OLSEN, B. & ELKINS, C. 2009. Localization of the domains of the *Haemophilus ducreyi* trimeric autotransporter DsrA involved in serum resistance and binding to the extracellular matrix proteins fibronectin and vitronectin. *Infect. Immun.*, 77, 657-666.
- LEE, C. W., LO, R. Y. C., SHEWEN, P. E. & MELLORS, A. 1994. The detection of the sialoglycoprotease gene and assay for sialoglycoprotease activity among isolates of *Pasteurella haemolytica* A1 strains, serotypes A13, A14, T15 and A16. FEMS Microbiol. Lett., 121, 199-205.
- LEE, C. W. & SHEWEN, P. E. 1996. Evidence of bovine immunoglobulin G<sub>1</sub> (IgG<sub>1</sub>) protease activity in partially purified culture supernate of *Pasteurella* haemolytica A1. Can. J. Vet. Res., 60, 127-132.
- LEE, I. & DAVIES, R. L. 2011. Evidence for a common gene pool and frequent recombinational exchange of the tbpBA operon in *Mannheimia haemolytica*, *Mannheimia* glucosida and Bibersteinia trehalosi. *Microbiology*, 157, 123-135.
- LEE, R. W. H., CORNELISSE, M., ZIAUDDIN, A., SLACK, P. J., HODGINS, D. C., STROMMER, J. N., SHEWEN, P. E. & LO, R. Y. C. 2008. Expression of a modified *Mannheimia haemolytica* GS60 outer membrane lipoprotein in transgenic alfalfa for the development of an edible vaccine against bovine pneumonic pasteurellosis. J.Biotechnol., 135, 224-231.
- LENZ, L. L., DERE, B. & BEVAN, M. J. 1996. Identification of an H2-M3-restricted Listeria epitope: implications for antigen presentation by M3. *Immunity*, 5, 63-72.
- LI, J. & CLINKENBEARD, K. D. 1999. Lipopolysaccharide complexes with *Pasteurella haemolytica* leukotoxin. *Infect. Immun.*, 67, 2920-2927.
- LI, J., CLINKENBEARD, K. D. & RITCHEY, J. W. 1999. Bovine CD18 identified as a species specific receptor for *Pasteurella haemolytica* leukotoxin. *Vet. Microbiol.*, 67, 91-97.
- LIAO, Y. H., DENG, J. H., ZHANG, A. D., ZHOU, M. G., HU, Y., CHEN, H. C. & JIN, M. L. 2009. Immunoproteomic analysis of outer membrane proteins and extracellular proteins of *Actinobacillus pleuropneumoniae* JL03 serotype 3. *BMC Microbiol.*, 9.
- LINHARTOVA, I., BUMBA, L., MASIN, J., BASLER, M., OSICKA, R., KAMANOVA, J., PROCHAZKOVA, K., ADKINS, I., HEJNOVA-HOLUBOVA, J., SADILKOVA, L., MOROVA, J. & SEBO, P. 2010. RTX proteins: a highly diverse family secreted by a common mechanism. *FEMS Microbiol. Rev.*, 34, 1076-1112.
- LIU, G. Y., NIE, P., ZHANG, J. & LI, N. 2008. Proteomic analysis of the sarcosineinsoluble outer membrane fraction of *Flavobacterium columnare*. J. Fish Dis., 31, 269-276.
- LO, R. Y. C., MCKERRAL, L. J., HILLS, T. L. & KOSTRZYNSKA, M. 2001. Analysis of the capsule biosynthetic locus of *Mannheimia* (*Pasteurella*) haemolytica A1 and proposal of a nomenclature system. *Infect. Immun.*, 69, 4458-4464.
- LO, R. Y. C., SATHIAMOORTHY, S. & SHEWEN, P. E. 2006. Analysis of *in vivo* expressed genes in *Mannheimia haemolytica* A1. *FEMS Microbiol. Lett.*, 265, 18-25.
- LO, R. Y. C. & SORENSEN, L. S. 2007. The outer membrane protein OmpA of Mannheimia haemolytica A1 is involved in the binding of fibronectin. *FEMS Microbiol. Lett.*, 274, 226-231.

- LO, R. Y. C., STRATHDEE, C. A., SHEWEN, P. E. & COONEY, B. J. 1991. Molecular studies of Ssa1, a serotype-specific antigen of *Pasteurella haemolytica* A1. Infect. Immun., 59, 3398-3406.
- LOBLEY, A., WHITMORE, L. & WALLACE, B. A. 2002. DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra. *Bioinformatics*, 18, 211-212.
- LOBODA, A. V., KRUTCHINSKY, A. N., BROMIRSKI, M., ENS, W. & STANDING, K. G. 2000. A tandem quadrupole/time-of-flight mass spectrometer with a matrix-assisted laser desorption/ionization source: design and performance. *Rapid Commun. Mass Spectrom.*, 14, 1047-1057.
- LOCHER, K. P., REES, B., KOEBNIK, R., MITSCHLER, A., MOULINIER, L., ROSENBUSCH, J. P. & MORAS, D. 1998. Transmembrane signaling across the ligand-gated FhuA receptor: crystal structures of free and ferrichrome-bound states reveal allosteric changes. *Cell*, 95, 771-778.
- LOCHT, C., GEOFFROY, M. C. & RENAULD, G. 1992. Common accessory genes for the *Bordetella pertussis* filamentous hemagglutinin and fimbriae share sequence similarities with the *papC* and *papD* gene families. *EMBO J.*, 11, 3175-3183.
- LOFERER, H., HAMMAR, M. & NORMARK, S. 1997. Availability of the fibre subunit CsgA and the nucleator protein CsgB during assembly of fibronectinbinding curli is limited by the intracellular concentration of the novel lipoprotein CsgG. *Mol. Microbiol.*, 26, 11-23.
- LUGTENBERG, E. J. J. & PETERS, R. 1976. Distribution of lipids in cytoplasmic and outer membranes of *Escherichia coli* K12. *Biochim. Biophys. Acta*, 441, 38-47.
- LUKE, N. R., JURCISEK, J. A., BAKALETZ, L. O. & CARNPAGNARI, A. A. 2007. Contribution of *Moraxella catarrhalis* type IV pili to nasopharyngeal colonization and biofilm formation. *Infect. Immun.*, 75, 5559-5564.
- MAHAN, M. J., TOBIAS, J. W., SLAUCH, J. M., HANNA, P. C., COLLIER, R. J. & MEKALANOS, J. J. 1995. Antibiotic-based selection for bacterial genes that are specifically induced during infection of a host. *Proc. Natl. Acad. Sci. U.S.A.*, 92, 669-673.
- MAHASRESHTI, P. J., MURPHY, G. L., WYCKOFF, J. H., FARMER, S., HANCOCK, R. E. W. & CONFER, A. W. 1997. Purification and partial characterization of the OmpA family of proteins of *Pasteurella haemolytica*. *Infect. and Immun.*, 65, 211-218.
- MAHESWARAN, S. K., KANNAN, M. S., WEISS, D. J., REDDY, K. R., TOWNSEND, E. L., YOO, H. S., LEE, B. W. & WHITELEY, L. O. 1993. Enhancement of neutrophil-mediated injury to bovine pulmonary endothelial cells by *Pasteurella haemolytica* leukotoxin. *Infect. Immun.*, 61, 2618-2625.
- MAHESWARAN, S. K., WEISS, D. J., KANNAN, M. S., TOWNSEND, E. L., REDDY, K. R., WHITELEY, L. O. & SRIKUMARAN, S. 1992. Effects of Pasteurella haemolytica A1 leukotoxin on bovine neutrophils: degranulation and generation of oxygen-derived free radicals. Vet. Immunol. Immunopathol., 33, 51-68.
- MALINVERNI, J. C., WERNER, J., KIM, S., SKLAR, J. G., KAHNE, D., MISRA, R. & SILHAVY, T. J. 2006. YfiO stabilizes the YaeT complex and is essential for outer membrane protein assembly in Escherichia coli. *Molecular Microbiology*, 61, 151-164.
- MALORNY, B., MORELLI, G., KUSECEK, B., KOLBERG, J. & ACHTMAN, M. 1998. Sequence diversity, predicted two-dimensional protein structure, and epitope mapping of neisserial Opa proteins. J. Bacteriol., 180, 1323-1330.

- MANN, M. & WILM, M. 1994. Error tolerant identification of peptides in sequence databases by peptide sequence tags. *Anal. Chem.*, 66, 4390-4399.
- MARKWELL, M. A. K., HAAS, S. M., BIEBER, L. L. & TOLBERT, N. E. 1978. Modification of Lowry procedure to simplify protein determination in membrane and lipoprotein samples. *Anal. Biochem.*, 87, 206-210.
- MARLOVITS, T. C., KUBORI, T., SUKHAN, A., THOMAS, D. R., GALAN, J. E. & UNGER, V. M. 2004. Structural insights into the assembly of the type III secretion needle complex. *Science*, 306, 1040-1042.
- MARTIN, P. R., HOBBS, M., FREE, P. D., JESKE, Y. & MATTICK, J. S. 1993. Characterization of *pilQ*, a new gene required for the biogenesis of type 4 fimbriae in *Pseudomonas aeruginosa*. *Mol. Microbiol.*, 9, 857-868.
- MARTIN, S. L., BORROW, R., VAN DER LEY, P., DAWSON, M., FOX, A. J. & CARTWRIGHT, K. A. V. 2000. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. *Vaccine*, 18, 2476-2481.
- MCCLUSKEY, J., GIBBS, H. A. & DAVIES, R. L. 1994. Variation in outer membrane protein and lipopolysaccharide profiles of *Pasteurella haemolytica* isolates of serotypes A1 and A2 obtained from pneumonic and healthy cattle. *Microbiology*, 140, 807-814.
- MCHUGH, J. P., RODRIGUEZ-QUINONES, F., ABDUL-TEHRANI, H., SVISTUNENKO, D. A., POOLE, R. K., COOPER, C. E. & ANDREWS, S. C. 2003. Global irondependent gene regulation in *Escherichia coli* - a new mechanism for iron homeostasis. J. Biol. Chem., 278, 29478-29486.
- MCKERRAL, L. J. & LO, R. Y. C. 2002. Construction and characterization of an acapsular mutant of *Mannheimia haemolytica* A1. *Infect. Immun.*, 70, 2622-2629.
- MCVICKER, J. K. & TABATABAI, L. B. 2002. Isolation of immunogenic outer membrane proteins from *Mannheimia haemolytica* serotype 1 by use of selective extraction and immunoaffinity chromatography. *Am. J. Vet. Res.*, 63, 1634-1640.
- MEDZIHRADSZKY, K. F., CAMPBELL, J. M., BALDWIN, M. A., FALICK, A. M., JUHASZ, P., VESTAL, M. L. & BURLINGAME, A. L. 2000. The characteristics of peptide collision-induced dissociation using a high-performance MALDI-TOF/TOF tandem mass spectrometer. *Anal. Chem.*, 72, 552-558.
- MEKALANOS, J. J. 1992. Environmental signals controlling expression of virulence determinants in bacteria. J. Bacteriol., 174, 1-7.
- MELNIKOW, E., DORNAN, S., SARGENT, C., DUSZENKO, M., EVANS, G., GUNKEL, N., SELZER, P. M. & ULLRICH, H. J. 2005. Microarray analysis of *Haemophilus parasuis* gene expression under *in vitro* growth conditions mimicking the *in vivo* environment. *Vet. Microbiol.*, 110, 255-263.
- MERRELL, D. S., THOMPSON, L. J., KIM, C. C., MITCHELL, H., TOMPKINS, L. S., LEE, A. & FALKOW, S. 2003. Growth phase-dependent response of *Helicobacter pylori* to iron starvation. *Infect. Immun.*, 71, 6510-6525.
- MIKAEL, L. G., PAWELEK, P. D., LABRIE, J., SIROIS, M., COULTON, J. W. & JACQUES, M. 2002. Molecular cloning and characterization of the ferric hydroxamate uptake (*fhu*) operon in *Actinobacillus pleuropneumoniae*. *Microbiology*, 148, 2869-2882.
- MILLMAN, K. L., TAVARE, S. & DEAN, D. 2001. Recombination in the ompA gene but not the omcB gene of Chlamydia contributes to serovar-specific differences in tissue tropism, immune surveillance, and persistence of the organism. J. Bacteriol., 183, 5997-6008.

- MOLLOY, M. P., HERBERT, B. R., SLADE, M. B., RABILLOUD, T., NOUWENS, A. S., WILLIAMS, K. L. & GOOLEY, A. A. 2000. Proteomic analysis of the *Escherichia coli* outer membrane. *Eur. J. Biochem.*, 267, 2871-2881.
- MORAES, T. F., YU, R. H., STRYNADKA, N. C. J. & SCHRYVERS, A. B. 2009. Insights into the bacterial transferrin receptor: the structure of transferrin-binding protein B from *Actinobacillus pleuropneumoniae*. *Mol. Cell*, 35, 523-533.
- MORCK, D. W., OLSON, M. E., ACRES, S. D., DAOUST, P. Y. & COSTERTON, J. W. 1989. Presence of bacterial glycocalyx and fimbriae on *Pasteurella haemolytica* in feedlot cattle with pneumonic pasteurellosis. *Can. J. Vet. Res.*, 53, 167-171.
- MORCK, D. W., RAYBOULD, T. J. G., ACRES, S. D., BABIUK, L. A., NELLIGAN, J. & COSTERTON, J. W. 1987. Electron microscopic description of glycocalyx and fimbriae on the surface of *Pasteurella haemolytica*-A1. *Can. J. Vet. Res.*, 51, 83-88.
- MORCK, D. W., WATTS, T. C., ACRES, S. D. & COSTERTON, J. W. 1988. Electron microscopic examination of cells of *Pasteurella haemolytica*-A1 in experimentally infected cattle. *Can. J. Vet. Res.*, 52, 343-348.
- MORIYON, I. & BERMAN, D. T. 1982. Effects of non-ionic, ionic, and dipolar ionic detergents and EDTA on the *Brucella* cell envelope. *J. Bacteriol.*, 152, 822-828.
- MORTON, D. J., SEALE, T. W., MADORE, L. L., VANWAGONER, T. M., WHITBY, P.
   W. & STULL, T. L. 2007. The haem-haemopexin utilization gene cluster (hxuCBA) as a virulence factor of Haemophilus influenzae. Microbiology, 153, 215-224.
- MORTON, R. J., PANCIERA, R. J., FULTON, R. W., FRANK, G. H., EWING, S. A., HOMER, J. T. & CONFER, A. W. 1995. Vaccination of cattle with outer membrane protein-enriched fractions of *Pasteurella haemolytica* and resistance against experimental challenge exposure. *Am. J. Vet. Res.*, 56, 875-879.
- MORTON, R. J., SIMONS, K. R. & CONFER, A. W. 1996. Major outer membrane proteins of *Pasteurella haemolytica* serovars 1-15: comparison of separation techniques and surface-exposed proteins on selected serovars. *Vet. Microbiol.*, 51, 319-330.
- MOSIER, D. A., SIMONS, K. R., CONFER, A. W., PANCIERA, R. J. & CLINKENBEARD, K. D. 1989. Pasteurella haemolytica antigens associated with resistance to pneumonic pasteurellosis. Infect. Immun., 57, 711-716.
- MURPHY, G. L. & WHITWORTH, L. C. 1993. Analysis of tandem, multiple genes encoding 30-kDa membrane proteins in *Pasteurella haemolytica* A1. *Gene*, 129, 107-111.
- MURPHY, G. L., WHITWORTH, L. C., CLINKENBEARD, K. D. & CLINKENBEARD, P. A. 1995. Hemolytic activity of the *Pasteurella haemolytica* leukotoxin. *Infect. Immun.*, 63, 3209-3212.
- MURPHY, G. L., WHITWORTH, L. C., CONFER, A. W., GASKINS, J. D., PANDHER, K. & DABO, S. M. 1998. Characterization of a *Pasteurella haemolytica* A1 mutant deficient in production of three membrane lipoproteins. *Am. J. Vet. Res.*, 59, 1275-1280.
- MUTTERS, R., IHM, P., POHL, S., FREDERIKSEN, W. & MANNHEIM, W. 1985. Reclassification of the genus *Pasteurella* Trevisan 1887 on the basis of deoxyribonucleic acid homology, with proposals for the new species *Pasteurella* dagmatis, *Pasteurella* canis, *Pasteurella* stomatis, *Pasteurella* anatis, and *Pasteurella* langaa. Int. J. Syst. Bacteriol., 35, 309-322.

- MUTTERS, R., MANNHEIM, W. & BISGAARD, M. 1989. Taxonomy of the group. In: ADLAM, C. & RUTTER, J. M. (eds.) Pasteurella and pasteurellosis. Academic Press, New York, N. Y.
- NAKAMOTO, H. & BARDWELL, J. C. A. 2004. Catalysis of disulfide bond formation and isomenization in the *Escherichia coli* peniplasm. *Biochim. Biophys. Acta*, 1694, 111-119.
- NAKAMURA, K. & MIZUSHIMA, S. 1976. Effects of heating in dodecyl-sulfate solution on conformation and electrophoretic mobility of isolated major outer membrane proteins from *Escherichia coli* K-12. J. Biochem., 80, 1411-1422.
- NANDAKUMAR, M. P., CHEUNG, A. & MARTEN, M. R. 2006. Proteomic analysis of extracellular proteins from *Escherichia coli* W3110. *J. Proteome Res.*, 5, 1155-1161.
- NARDINI, P. M., MELLORS, A. & LO, R. Y. C. 1998. Characterization of a fourth lipoprotein from *Pasteurella haemolytica* A1 and its homology to the OmpA family of outer membrane proteins. *FEMS Microbiol. Lett.*, 165, 71-77.
- NARITA, S. I. & TOKUDA, H. 2007. Amino acids at positions 3 and 4 determine the membrane specificity of *Pseudomonas aeruginosa* lipoproteins. *J. Biol. Chem.*, 282, 13372-13378.
- NEWSOME, I. E. & CROSS, F. 1932. Some bipolar organisms found in pneumonia in sheep. J. Am. Vet. Med. Assoc., 80, 711-719.
- NICHOLSON, T. L., BROCKMEIER, S. L. & LOVING, C. L. 2009. Contribution of *Bordetella bronchiseptica* filamentous hemagglutinin and pertactin to respiratory disease in swine. *Infect. Immun.*, 77, 2136-2146.
- NIKAIDO, H. 2003. Molecular basis of bacterial outer membrane permeability revisited. *Microbiol. Mol. Biol. Rev.*, 67, 593-+.
- NUMMELIN, H., MERCKEL, M. C., LEO, J. C., LANKINEN, H., SKURNIK, M. & GOLDMAN, A. 2004. The *Yersinia* adhesin YadA collagen-binding domain structure is a novel left-handed parallel beta-roll. *EMBO J.*, 23, 701-711.
- NYARKO, K. A., COOMBER, B. L., MELLORS, A. & GENTRY, P. A. 1998. Bovine platelet adhesion is enhanced by leukotoxin and sialoglycoprotease isolated from *Pasteurella haemolytica* A1 cultures. *Vet. Microbiol.*, 61, 81-91.
- OGUNNARIWO, J. A. & SCHRYVERS, A. B. 1990. Iron acquisition in *Pasteurella haemolytica*: expression and identification of a bovine-specific transferrin receptor. *Infect. Immun.*, 58, 2091-2097.
- OGUNNARIWO, J. A., WOO, T. K. W., LO, R. Y. C., GONZALEZ, G. C. & SCHRYVERS, A. B. 1997. Characterization of the *Pasteurella haemolytica* transferrin receptor genes and the recombinant receptor proteins. *Microb. Pathog.*, 23, 273-284.
- OHNISHI, S., KAMEYAMA, K. & TAKAGI, T. 1998. Characterization of a heat modifiable protein, *Escherichia coli* outer membrane protein OmpA in binary surfactant system of sodium dodecyl sulfate and octylglucoside. *Biochim. Biophys. Acta*, 1375, 101-109.
- OHTA, H., KATO, K., KOKEGUCHI, S., HARA, H., FUKUI, K. & MURAYAMA, Y. 1991. Nuclease-sensitive binding of an Actinobacillus actinomycetemcomitans leukotoxin to the bacterial cell surface. Infect. Immun., 59, 4599-4605.
- OKUDA, S. & TOKUDA, H. 2009. Model of mouth-to-mouth transfer of bacterial lipoproteins through inner membrane LolC, periplasmic LolA, and outer

membrane LolB. Proceedings of the National Academy of Sciences of the United States of America, 106, 5877-5882.

- OLSON, M. E., CERI, H., MORCK, D. W., BURET, A. G. & READ, R. R. 2002. Biofilm bacteria: formation and comparative susceptibility to antibiotics. *Can. J. Vet. Res.*, 66, 86-92.
- OOMEN, C. J., VAN ULSEN, P., VAN GELDER, P., FEIJEN, M., TOMMASSEN, J. & GROS, P. 2004. Structure of the translocator domain of a bacterial autotransporter. *EMBO J.*, 23, 1257-1266.
- OPALKA, N., BECKMANN, R., BOISSET, N., SIMON, M. N., RUSSEL, M. & DARST, S. A. 2003. Structure of the filamentous phage pIV multimer by cryo-electron microscopy. J. Mol. Biol., 325, 461-470.
- OSBORN, M. J. & MUNSON, R. 1974. Separation of the inner membrane (cytoplasmic) and outer membranes of Gram-negative bacteria. *Methods Enzymol.*, 31, 642-653.
- OSBORN, M. J., PARISI, E. & GANDER, J. E. 1972. Mechanism of assembly of outer membrane of Salmonella typhimurium. J. Biol. Chem., 247, 3973-&.
- OTULAKOWSKI, G. L., SHEWEN, P. E., UDOH, A. E., MELLORS, A. & WILKIE, B. N. 1983. Proteolysis of sialoglycoprotein by *Pasteurella haemolytica* cytotoxic culture supernatant. *Infect. Immun.*, 42, 64-70.
- OU, Y. Y., GROMIHA, M. M., CHEN, S. A. & SUWA, M. 2008. TMBETADISC-RBF: discrimination of beta-barrel membrane proteins using RBF networks and PSSM profiles. *Comput. Biol. Chem.*, 32, 227-231.
- PANDHER, K., CONFER, A. W. & MURPHY, G. L. 1998. Genetic and immunologic analyses of PlpE, a lipoprotein important in complement-mediated killing of *Pasteurella haemolytica* serotype 1. *Infect. Immun.*, 66, 5613-5619.
- PANDHER, K. & MURPHY, G. L. 1996. Genetic and immunological analyses of a 38 kDa surface-exposed lipoprotein of *Pasteurella haemolytica* A1. *Vet. Microbiol.*, 51, 331-341.
- PANDHER, K., MURPHY, G. L. & CONFER, A. W. 1999. Identification of immunogenic, surface-exposed outer membrane proteins of *Pasteurella haemolytica* serotype 1. *Vet. Microbiol.*, 65, 215-226.
- PAPADIOTI, A., MARKOUTSA, S., VRANAKIS, I., TSELENTIS, Y., KARAS, M., PSAROULAKI, A. & TSIOTIS, G. 2011. A proteomic approach to investigate the differential antigenic profile of two *Coxiella burnetii* strains. J *Proteomics*, 74, 1150-1159.
- PAPPIN, D. J. C., HOJRUP, P. & BLEASBY, A. J. 1993. Rapid identification of proteins by peptide-mass fingerprinting. *Curr. Biol.*, 3, 327-332.
- PARSOT, C., MENARD, R., GOUNON, P. & SANSONETTI, P. J. 1995. Enhanced secretion through the *Shigella flexneri* Mxi-Spa translocon leads to assembly of extracellular proteins into macromolecular structures. *Mol. Microbiol.*, 16, 291-300.
- PASQUALI, C., FIALKA, I. & HUBER, L. A. 1997. Preparative two-dimensional gel electrophoresis of membrane proteins. *Electrophoresis*, 18, 2573-2581.
- PAULSEN, D. B., MOSIER, D. A., CLINKENBEARD, K. D. & CONFER, A. W. 1989. Direct effects of *Pasteurella haemolytica* lipopolysaccharide on bovine pulmonary endothelial cells *in vitro*. Am. J. Vet. Res., 50, 1633-1637.
- PAUSTIAN, M. L., MAY, B. J. & KAPUR, V. 2001. *Pasteurella multocida* gene expression in response to iron limitation. *Infect. Immun.*, 69, 4109-4115.
- PAUTSCH, A. & SCHULZ, G. E. 1998. Structure of the outer membrane protein A transmembrane domain. *Nat. Struct. Biol.*, 5, 1013-1017.

- PERKINS, D. N., PAPPIN, D. J. C., CREASY, D. M. & COTTRELL, J. S. 1999. Probability-based protein identification by searching sequence databases using mass spectrometry data. *Electrophoresis*, 20, 3551-3567.
- PETRAS, S. F., CHIDAMBARAM, M., ILLYES, E. F., FROSHAUER, S., WEINSTOCK, G.
   M. & REESE, C. P. 1995. Antigenic and virulence properties of *Pasteurella* haemolytica leukotoxin mutants. *Infect. Immun.*, 63, 1033-1039.
- POHLNER, J., HALTER, R., BEYREUTHER, K. & MEYER, T. F. 1987. Gene structure and extracellular secretion of *Neisseria gonorrhoeae* Iga protease. *Nature*, 325, 458-462.
- POTTER, A. A., READY, K. & GILCHRIST, J. 1988. Purification of fimbriae from *Pasteurella haemolytica* A-1. *Microb. Pathog.*, 4, 311-316.
- POULSEN, K., REINHOLDT, J. & KILIAN, M. 1992. A comparative genetic study of serologically distinct *Haemophilus influenzae* type 1 immunoglobulin A1 proteases. J. Bacteriol., 174, 2913-2921.
- PRADO, M. E., DABO, S. M. & CONFER, A. W. 2005. Immunogenicity of ironregulated outer membrane proteins of *Pasteurella multocida* A : 3 in cattle: molecular characterization of the immunodominant heme acquisition system receptor (HasR) protein. *Vet. Microbiol.*, 105, 269-280.
- PRASADARAO, N. V. 2002. Identification of *Escherichia coli* outer membrane protein A receptor on human brain microvascular endothelial cells. *Infect. Immun.*, 70, 4556-4563.
- PRASADARAO, N. V., LYSENKO, E., WASS, C. A., KIM, K. S. & WEISER, J. N. 1999. Opacity-associated protein A contributes to the binding of *Haemophilus influenzae* to Chang epithelial cells. *Infect. and Immun.*, 67, 4153-4160.
- PRASADARAO, N. V., WASS, C. A., WEISER, J. N., STINS, M. F., HUANG, S. H. & KIM, K. S. 1996. Outer membrane protein A of *Escherichia coli* contributes to invasion of brain microvascular endothelial cells. *Infect. Immun.*, 64, 146-153.
- PRESTON, A., MANDRELL, R. E., GIBSON, B. W. & APICELLA, M. A. 1996. The lipooligosaccharides of pathogenic Gram-negative bacteria. *Crit. Rev. Microbiol.*, 22, 139-180.
- PROFT, T. & BAKER, E. N. 2009. Pili in Gram-negative and Gram-positive bacteria structure, assembly and their role in disease. *Cell. Mol. Life Sci.*, 66, 613-635.
- PROVENCHER, S. W. & GLOCKNER, J. 1981. Estimation of globular protein secondary structure from circular dichroism. *Biochemistry*, 20, 33-37.
- PRPIC, J. K., ROBINSBROWNE, R. M. & DAVEY, R. B. 1983. Differentiation between virulent and avirulent *Yersinia enterocolitica* isolates by using Congo red agar. J. Clin. Microbiol., 18, 486-490.
- PUGSLEY, A. P. 1993. The complete general secretory pathway in Gram-negative bacteria. *Microbiol. Rev.*, 57, 50-108.
- PUGSLEY, A. P., KORNACKER, M. G. & POQUET, I. 1991. The general protein export pathway is directly required for extracellular pullulanase secretion in *Escherichia coli* K12. *Mol. Microbiol.*, 5, 343-352.
- PYSZ, M. A., CONNERS, S. B., MONTERO, C. I., SHOCKLEY, K. R., JOHNSON, M. R., WARD, D. E. & KELLY, R. A. 2004. Transcriptional analysis of biofilm formation processes in the anaerobic, hyperthermophilic bacterium *Thermotoga maritima*. Appl. Environ. Microbiol., 70, 6098-6112.

RAPPUOLI, R. 2000. Reverse vaccinology. Curr. Opin. Microbiol., 3, 445-450.

REDDY, M. S., BERNSTEIN, J. M., MURPHY, T. F. & FADEN, H. S. 1996. Binding between outer membrane proteins of nontypeable *Haemophilus*  *influenzae* and human nasopharyngeal mucin. *Infect. Immun.*, 64, 1477-1479.

- REISSBRODT, R., ERLER, W. & WINKELMANN, G. 1994. Iron supply of *Pasteurella* multocida and *Pasteurella* haemolytica. J. Basic Microbiol., 34, 61-63.
- REITHMEIER, R. A. F. & BRAGG, P. D. 1974. Purification and characterization of a heat-modifiable protein from the outer membrane of *Escherichia coli*. *FEBS Lett.*, 41, 195-198.
- ROBERT, V., VOLOKHINA, E. B., SENF, F., BOS, M. P., VAN GELDER, P. & TOMMASSEN, J. 2006. Assembly factor Omp85 recognizes its outer membrane protein substrates by a species-specific C-terminal motif. *PLoS Biol.*, 4, 1984-1995.
- ROBINSON, L. S., ASHMAN, E. M., HULTGREN, S. J. & CHAPMAN, M. R. 2006. Secretion of curli fibre subunits is mediated by the outer membranelocalized CsgG protein. *Mol. Microbiol.*, 59, 870-881.
- ROEHRIG, S. C., TRAN, H. Q., SPEHR, V., GUNKEL, N., SELZER, P. M. & ULLRICH, H. J. 2007. The response of *Mannheimia haemolytica* to iron limitation: implications for the acquisition of iron in the bovine lung. *Vet. Microbiol.*, 121, 316-329.
- ROUSSEL-JAZEDE, V., JONGERIUS, I., BOS, M. P., TOMMASSEN, J. & VAN ULSEN, P. 2010. NalP-mediated proteolytic release of lactoferrin-binding protein B from the meningococcal cell surface. *Infect. Immun.*, 78, 3083-3089.
- RUDEL, T., SCHEUERPFLUG, I. & MEYER, T. F. 1995. Neisseria PilC protein identified as type-4 pilus tip-located adhesin. *Nature*, 373, 357-359.
- RUIZ, N., KAHNE, D. & SILHAVY, T. J. 2006. Advances in understanding bacterial outer-membrane biogenesis. *Nat. Rev. Microbiol.*, 4, 57-66.
- RUTZ, J. M., ABDULLAH, T., SINGH, S. P., KALVE, V. I. & KLEBBA, P. E. 1991. Evolution of the ferric enterobactin receptor in Gram-negative bacteria. *J. Bacteriol.*, 173, 5964-5974.
- SAADATI, M., GIBBS, H. A., PARTON, R. & COOTE, J. G. 1997. Characterisation of the leukotoxin produced by different strains of *Pasteurella haemolytica*. *J. Med. Microbiol.*, 46, 276-284.
- SAMPATHKUMAR, B., NAPPER, S., CARRILLO, C. D., WILLSON, P., TABOADA, E., NASH, J. H. E., POTTER, A. A., BABIUK, L. A. & ALLAN, B. J. 2006. Transcriptional and translational expression patterns associated with immobilized growth of *Campylobacter jejuni*. *Microbiology*, 152, 567-577.
- SANCHEZ-PULIDO, L., DEVOS, D., GENEVROIS, S., VICENTE, M. & VALENCIA, A. 2003. POTRA: a conserved domain in the FtsQ family and a class of betabarrel outer membrane proteins. *Trends Biochem. Sci.*, 28, 523-526.
- SANDAL, I., SHAO, J. Q., ANNADATA, S., APICELLA, M. A., BOYE, M., JENSEN, T. K., SAUNDERS, G. K. & INZANA, T. J. 2009. *Histophilus somni* biofilm formation in cardiopulmonary tissue of the bovine host following respiratory challenge. *Microbes Infect.*, 11, 254-263.

SANDKVIST, M. 2001. Biology of type II secretion. Mol. Microbiol., 40, 271-283.

SANKARAN, K., RAMACHANDRAN, V., SUBRAHMANYAM, Y., RAJARATHNAM, S., ELANGO, S. & ROY, R. K. 1989. Congo red-mediated regulation of levels of Shigella flexneri 2a membrane proteins. Infect. Immun., 57, 2364-2371.

- SANKARAN, K. & WU, H. C. 1994. Lipid modification of bacterial prolipoprotein transfer of diacylglyceryl moiety from phosphatidylglycerol. J. Biol. Chem., 269, 19701-19706.
- SANTONI, V., MOLLOY, M. & RABILLOUD, T. 2000. Membrane proteins and proteomics: Un amour impossible? *Electrophoresis*, 21, 1054-1070.

- SAUER, M., HANTKE, K. & BRAUN, V. 1990. Sequence of the *fhuE* outermembrane receptor gene of *Escherichia coli* K12 and properties of mutants. *Mol. Microbiol.*, 4, 427-437.
- SCHAAR, V., DE VRIES, S. P. W., VIDAKOVICS, M., BOOTSMA, H. J., LARSSON, L., HERMANS, P. W. M., BJARTELL, A., MORGELIN, M. & RIESBECK, K. 2011. Multicomponent *Moraxella catarrhalis* outer membrane vesicles induce an inflammatory response and are internalized by human epithelial cells. *Cell. Microbiol.*, 13, 432-449.
- SCHAUER, K., RODIONOV, D. A. & DE REUSE, H. 2008. New substrates for TonBdependent transport: do we only see the 'tip of the iceberg'? *Trends Biochem. Sci.*, 33, 330-338.
- SCHEMBRI, M. A., DALSGAARD, D. & KLEMM, P. 2004. Capsule shields the function of short bacterial adhesins. J. Bacteriol., 186, 1249-1257.
- SCHINDLER, M. & OSBORN, M. J. 1979. Interaction of divalent cations and polymyxin B with lipopolysaccharide. *Biochemistry*, 18, 4425-4430.
- SCHIRMER, T., KELLER, T. A., WANG, Y. F. & ROSENBUSCH, J. P. 1995. Structural basis for sugar translocation through maltoporin channels at 3.1 angstrom resolution. *Science*, 267, 512-514.
- SCHLEIFF, E., EICHACKER, L. A., ECKART, K., BECKER, T., MIRUS, O., STAHL, T. & SOLL, J. 2003. Prediction of the plant beta-barrel proteome: a case study of the chloroplast outer envelope. *Protein Sci.*, 12, 748-759.
- SCHLUESENER, D., FISCHER, F., KRUIP, J., ROGNER, M. & POETSCH, A. 2005. Mapping the membrane proteome of *Corynebacterium glutamicum*. *Proteomics*, 5, 1317-1330.
- SCHNAITMAN, C. A. 1971. Solubilization of cytoplasmic membrane of *Escherichia* coli by Triton X-100. J. Bacteriol., 108, 545-&.
- SCHULZ, G. E. 2000. Beta-barrel membrane proteins. *Curr. Opin. Struct. Biol.*, 10, 443-447.
- SCHULZ, G. E. 2002. The structure of bacterial outer membrane proteins. *Biochim. Biophys. Acta*, 1565, 308-317.
- SELANDER, R. K., CAUGANT, D. A., OCHMAN, H., MUSSER, J. M., GILMOUR, M. N. & WHITTAM, T. S. 1986. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. *Appl. Environ. Microbiol.*, 51, 873-884.
- SEYDEL, A., GOUNON, P. & PUGSLEY, A. P. 1999. Testing the '+2 rule' for lipoprotein sorting in the *Escherichia coli* cell envelope with a new genetic selection. *Mol. Microbiol.*, 34, 810-821.
- SHEETS, A. J., GRASS, S. A., MILLER, S. E. & ST GEME, J. W. 2008. Identification of a novel trimeric autotransporter adhesin in the cryptic genospecies of *Haemophilus*. J. Bacteriol., 190, 4313-4320.
- SHEWEN, P. E. & WILKIE, B. N. 1982. Cytotoxin of *Pasteurella haemolytica* acting on bovine leukocytes. *Infect. Immun.*, 35, 91-94.
- SHIFRIN, Y., PELEG, A., ILAN, O., NADLER, C., KOBI, S., BARUCH, K., YERUSHALMI, G., BERDICHEVSKY, T., ALTUVIA, S., ELGRABLY-WEISS, M., ABE, C., KNUTTON, S., SASAKAWA, C., RITCHIE, J. M., WALDOR, M. K. & ROSENSHINE, I. 2008. Transient shielding of intimin and the type III secretion system of enterohemorrhagic and enteropathogenic *Escherichia coli* by a group 4 capsule. *J. Bacteriol.*, 190, 5063-5074.
- SIEZEN, R. J. & LEUNISSEN, J. A. M. 1997. Subtilases: The superfamily of subtilisin-like serine proteases. *Protein Sci.*, 6, 501-523.

- SILVA-HERZOG, E., FERRACCI, F., JACKSON, M. W., JOSEPH, S. S. & PLANO, G. V. 2008. Membrane localization and topology of the Yersinia pestis YscJ lipoprotein. *Microbiology*, 154, 593-607.
- SINGH, B., SU, Y. C. & RIESBECK, K. 2010. Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. *Mol. Microbiol.*, 78, 545-560.
- SINGH, K., RITCHEY, J. W. & CONFER, A. W. 2011. Mannheimia haemolytica: Bacterial-host Interactions in bovine pneumonia. Vet. Pathol., 48, 338-348.
- SKLAR, J. G., WU, T., KAHNE, D. & SILHAVY, T. J. 2007. Defining the roles of the periplasmic chaperones SurA, Skp, and DegP in Escherichia coli. Genes & Development, 21, 2473-2484.
- SMITH, A. M., GUZMAN, C. A. & WALKER, M. J. 2001. The virulence factors of Bordetella pertussis: a matter of control. FEMS Microbiol. Rev., 25, 309-333.
- SMITH, G. R. 1959. Isolation of two types of *Pasteurella haemolytica* from sheep. *Nature*, 183, 1132-1133.
- SMITH, G. R. 1961. The characteristics of two types of *Pasteurella haemolytica* associated with different pathological conditions in sheep. *J. Pathol. Bacteriol.*, 81, 431-440.
- SMITH, S. G. J., MAHON, V., LAMBERT, M. A. & FAGAN, R. P. 2007. A molecular Swiss army knife: OmpA structure, function and expression. FEMS Microbiol. Lett., 273, 1-11.
- SNEATH, P. H. A. & STEVENS, M. 1990. Actinobacillus rossii sp. nov., Actinobacillus seminis sp. nov., nom. rev., Pasteurella bettii sp. nov., Pasteurella lymphangitidis sp. nov., Pasteurella mairi sp. nov., and Pasteurella trehalosi sp. nov. Int. J. Syst. Bacteriol., 40, 148-153.
- SPERANDEO, P., DEHO, G. & POLISSI, A. 2009. The lipopolysaccharide transport system of Gram-negative bacteria. *Biochim. Biophys. Acta*, 1791, 594-602.
- SQUIRE, P. G., SMILEY, D. W. & CROSKELL, R. B. 1984. Identification and extraction of *Pasteurella haemolytica* membrane proteins. *Infect. Immun.*, 45, 667-673.
- ST GEME, J. W. 2000. The pathogenesis of nontypable *Haemophilus influenzae* otitis media. *Vaccine*, 19, S41-S50.
- STEVENS, P. K. & CZUPRYNSKI, C. J. 1996. *Pasteurella haemolytica* leukotoxin induces bovine leukocytes to undergo morphologic changes consistent with apoptosis *in vitro*. *Infect*. *Immun.*, 64, 2687-2694.
- STGEME, J. W., CUTTER, D. & BARENKAMP, S. J. 1996. Characterization of the genetic locus encoding Haemophilus influenzae type b surface fibrils. *Journal of Bacteriology*, 178, 6281-6287.
- STRATHDEE, C. A. & LO, R. Y. C. 1987. Extensive homology between the leukotoxin of *Pasteurella haemolytica* A1 and the alpha-hemolysin of *Escherichia coli*. Infect. Immun., 55, 3233-3236.
- STRAUS, D. C., JOLLEY, W. L. & PURDY, C. W. 1993. Characterization of neuraminidases produced by various serotypes of *Pasteurella haemolytica*. *Infect*. *Immun.*, 61, 4669-4674.
- STRAUS, D. C., PURDY, C. W., LOAN, R. W., BRIGGS, R. E. & FRANK, G. H. 1998. *In vivo* production of neuraminidase by *Pasteurella haemolytica* in market stressed cattle after natural infection. *Curr. Microbiol.*, 37, 240-244.
- STRUYVE, M., MOONS, M. & TOMMASSEN, J. 1991. Carboxy-terminal phenylalanine is essential for the correct assembly of a bacterial outer membrane protein. J. Mol. Biol., 218, 141-148.

- STUGARD, C. E., DASKALEROS, P. A. & PAYNE, S. M. 1989. A 101-kilodalton heme-binding protein associated with Congo red binding and virulence of Shigella flexneri and enteroinvasive Escherichia coli strains. Infect. Immun., 57, 3534-3539.
- SUITS, M. D. L., SPERANDEO, P., DEHO, G., POLISSI, A. & JIA, Z. 2008. Novel structure of the conserved Gram-negative lipopolysaccharide transport protein A and mutagenesis analysis. J. Mol. Biol., 380, 476-488.
- SUN, Y. D., CLINKENBEARD, K. D., CLARKE, C., CUDD, L., HIGHLANDER, S. K. & DABO, S. M. 1999. Pasteurella haemolytica leukotoxin induced apoptosis of bovine lymphocytes involves DNA fragmentation. Vet. Microbiol., 65, 153-166.
- SUTHERLAND, A. D. 1985. Effects of *Pasteurella haemolytica* cytotoxin on ovine peripheral blood leukocytes and lymphocytes obtained from gastric lymph. *Vet. Microbiol.*, 10, 431-438.
- SUTHERLAND, A. D. & DONACHIE, W. 1986. Cytotoxic effect of serotypes of *Pasteurella haemolytica* on sheep bronchoalveolar macrophages. *Vet. Microbiol.*, 11, 331-336.
- SUTHERLAND, A. D., JONES, G. E. & POXTON, I. R. 1990. The susceptibility of in vivo-grown Pasteurella haemolytica to ovine defence mechanisms in vitro. FEMS Microbiol. Immunol., 2, 269-78.
- SUTHERLAND, D. R., ABDULLAH, K. M., CYOPICK, P. & MELLORS, A. 1992. Cleavage of the cell-surface O-sialoglycoproteins CD34, CD43, CD44, and CD45 by a novel glycoprotease from *Pasteurella haemolytica*. J. *Immunol.*, 148, 1458-1464.
- SZAFRON, D., LU, P., GREINER, R., WISHART, D. S., POULIN, B., EISNER, R., LU, Z., ANVIK, J., MACDONELL, C., FYSHE, A. & MEEUWIS, D. 2004. Proteome Analyst: custom predictions with explanations in a web-based tool for high-throughput proteome annotations. *Nucleic Acids Res.*, 32, W365-W371.
- THULASIRAMAN, P., NEWTON, S. M. C., XU, J. D., RAYMOND, K. N., MAI, C., HALL, A., MONTAGUE, M. A. & KLEBBA, P. E. 1998. Selectivity of ferric enterobactin binding and cooperativity of transport in Gram-negative bacteria. J. Bacteriol., 180, 6689-6696.
- TOKUDA, H. 2009. Biogenesis of outer membranes in Gram-negative bacteria. *Biosci. Biotechnol. Biochem.*, 73, 465-473.
- TOKUDA, H. & MATSUYAMA, S. 2004. Sorting of lipoproteins to the outer membrane in *E. coli. Biochim. Biophys. Acta*, 1693, 5-13.
- TOMICH, M., PLANET, P. J. & FIGURSKI, D. H. 2007. The tad locus: postcards from the widespread colonization island. *Nat. Rev. Microbiol.*, 5, 363-375.
- TORRES, A. G. & KAPER, J. B. 2003. Multiple elements controlling adherence of enterohemorrhagic *Escherichia coli* 0157 : H7 to HeLa cells. *Infect. Immun.*, 71, 4985-4995.
- TSAI, C. C., SHENKER, B. J., DIRIENZO, J. M., MALAMUD, D. & TAICHMAN, N. S. 1984. Extraction and isolation of a leukotoxin from Actinobacillus actinomycetemcomitans with polymyxin B. *Infect. Immun.*, 43, 700-705.
- TURNER, D. P. J., WOOLDRIDGE, K. G. & ALA'ALDEEN, D. A. A. 2002. Autotransported serine protease A of *Neisseria meningitidis*: an immunogenic, surface-exposed outer membrane, and secreted protein. *Infect. Immun.*, 70, 4447-4461.
- ULI, L., CASTELLANOS-SERRA, L., BETANCOURF, L., DOMINGUEZ, F., BARBERA, R., SOTOLONGO, F., GUILLEN, G. & PAJON, R. 2006. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of *Neisseria*

*meningitidis*: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. *Proteomics*, 6, 3389-3399.

- VAN DEN BERG, B. 2010. Crystal structure of a full-length autotransporter. J. Mol. Biol., 396, 627-633.
- VAN ULSEN, P., VAN ALPHEN, L., TEN HOVE, J., FRANSEN, F., VAN DER LEY, P. & TOMMASSEN, J. 2003. A Neisserial autotransporter NaIP modulating the processing of other autotransporters. *Mol. Microbiol.*, 50, 1017-1030.
- VANSTOKKUM, I. H. M., SPOELDER, H. J. W., BLOEMENDAL, M., VANGRONDELLE, R. & GROEN, F. C. A. 1990. Estimation of protein secondary structure and error analysis from circular dichroism spectra. *Anal. Biochem.*, 191, 110-118.
- VAUGHAN, T. E., SKIPP, P. J., O'CONNOR, C. D., HUDSON, M. J., VIPOND, R., ELMORE, M. J. & GORRINGE, A. R. 2006. Proteomic analysis of Neisseria lactamica and Neisseria meningitidis outer membrane vesicle vaccine antigens. Vaccine, 24, 5277-5293.
- VEITH, P. D., O'BRIEN-SIMPSON, N. M., TAN, Y., DJATMIKO, D. C., DASHPER, S. G.
   & REYNOLDS, E. C. 2009. Outer membrane proteome and antigens of Tannerella forsythia. J. Proteome Res., 8, 4279-4292.
- VERGAUWEN, B., ELEGHEERT, J., DANSERCOER, A., DEVREESE, B. & SAVVIDES, S. N. 2010. Glutathione import in *Haemophilus influenzae* Rd is primed by the periplasmic heme-binding protein HbpA. *Proc. Natl. Acad. Sci. U.S.A.*, 107, 13270-13275.
- VILELA, C. L., FITZPATRICK, J. & MORGAN, K. L. 2004. *In vitro* adherence and invasion of ovine mammary epithelium by *Mannheimia* (*Pasteurella*) *haemolytica*. *Vet. J.*, 167, 211-213.
- VIPOND, C., SUKER, J., JONES, C., TANG, C., FEAVERS, I. M. & WHEELER, J. X. 2006. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. *Proteomics*, 6, 3400-3413.
- VIRATYOSIN, W., INGSRISWANG, S., PACHARAWONGSAKDA, E. & PALITTAPONGARNPIM, P. 2008. Genome-wide subcellular localization of putative outer membrane and extracellular proteins in *Leptospira interrogans* serovar Lai genome using bioinformatics approaches. *BMC Genomics*, 9.
- VIRJI, M., MAKEPEACE, K., PEAK, I. R. A., FERGUSON, D. J. P., JENNINGS, M. P. & MOXON, E. R. 1995. Opc- and pilus-dependent interactions of meningococci with human endothelial cells: molecular mechanisms and modulation by surface polysaccharides. *Mol. Microbiol.*, 18, 741-754.
- VITOVSKI, S. & SAYERS, J. R. 2007. Relaxed cleavage specificity of an immunoglobulin A1 protease from *Neisseria meningitidis*. *Infect. Immun.*, 75, 2875-2885.
- VIVONA, S., GARDY, J. L., RAMACHANDRAN, S., BRINKMAN, F. S. L., RAGHAVA, G. P. S., FLOWER, D. R. & FILIPPINI, F. 2008. Computer-aided biotechnology: from immuno-informatics to reverse vaccinology. *Trends Biotechnol.*, 26, 190-200.
- VOIGT, B., SCHWEDER, T., SIBBALD, M., ALBRECHT, D., EHRENREICH, A., BERNHARDT, J., FEESCHE, J., MAURER, K. H., GOTTSCHALK, G., VAN DIJL, J. M. & HECKER, M. 2006. The extracellular proteome of *Bacillus licheniformis* grown in different media and under different nutrient starvation conditions. *Proteomics*, 6, 268-281.
- VONHEIJNE, G. 1989. The structure of signal peptides from bacterial lipoproteins. *Protein Eng.*, 2, 531-534.

- VOULHOUX, R., BALL, G., IZE, B., VASIL, M. L., LAZDUNSKI, A., WU, L. F. & FILLOUX, A. 2001. Involvement of the twin-arginine translocation system in protein secretion via the type II pathway. *EMBO J.*, 20, 6735-6741.
- WALKER, R. D., HOPKINS, F. M., SCHULTZ, T. W., MCCRACKEN, M. D. & MOORE, R. N. 1985. Changes in leukocyte populations in pulmonary lavage fluids of calves after inhalation of *Pasteurella haemolytica*. Am. J. Vet. Res., 46, 2429-2433.
- WANDERSMAN, C. & DELEPELAIRE, P. 2004. Bacterial iron sources: From siderophores to hemophores. *Annu. Rev. Microbiol.*, 58, 611-647.
- WANG, Q. F., FRYE, J. G., MCCLELLAND, M. & HARSHEY, R. M. 2004. Gene expression patterns during swarming in *Salmonella typhimurium*: genes specific to surface growth and putative new motility and pathogenicity genes. *Mol. Microbiol.*, 52, 169-187.
- WANG, Z. C., CLARKE, C. & CLINKENBEARD, K. 1998. Pasteurella haemolytica leukotoxin-induced increase in phospholipase A(2) activity in bovine neutrophils. Infect. Immun., 66, 1885-1890.
- WASHBURN, M. P., WOLTERS, D. & YATES, J. R. 2001. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. *Nat. Biotechnol.*, 19, 242-247.
- WEBB, D. C. & CRIPPS, A. W. 1998. Secondary structure and molecular analysis of interstrain variability in the P5 outer-membrane protein of non-typable *Haemophilus influenzae* isolated from diverse anatomical sites. J. Med. Microbiol., 47, 1059-1067.
- WEINBERG, E. D. 1997. The Lactobacillus anomaly; Total iron abstinence. Perspect. Biol. Med., 40, 578-583.
- WEISER, J. N., CHONG, S. T. H., GREENBERG, D. & FONG, W. 1995. Identification and characterization of a cell envelope protein of *Haemophilus influenzae* contributing to phase variation in colony opacity and nasopharyngeal colonization. *Mol. Microbiol.*, 17, 555-564.
- WEISS, M. S., ABELE, U., WECKESSER, J., WELTE, W., SCHILTZ, E. & SCHULZ, G. E. 1991. Molecular architecture and electrostatic properties of a bacterial porin. Science, 254, 1627-1630.
- WELSCH, J. A. & RAM, S. 2008. Factor H and Neisserial pathogenesis. *Vaccine*, 26, 140-145.
- WERNER, J. & MISRA, R. 2005. YaeT (Omp85) affects the assembly of lipiddependent and lipid-independent outer membrane proteins of *Escherichia coli*. *Mol. Microbiol.*, 57, 1450-1459.
- WEST, S. E. H. & SPARLING, P. F. 1987. Aerobactin utilization by *Neisseria* gonorrhoeae and cloning of a genomic DNA fragment that complements *Escherichia coli fhuB* mutations. J. Bacteriol., 169, 3414-3421.
- WHITE, D. A., SCHNAITM.CA & LENNARZ, W. J. 1972. Distribution of lipids in wall and cytoplasmic membrane subtractions of cell envelope of *Escherichia* coli. J. Bacteriol., 109, 686-&.
- WHITELEY, L. O., MAHESWARAN, S. K., WEISS, D. J. & AMES, T. R. 1990. Immunohistochemical localization of *Pasteurella haemolytica* A1-derived endotoxin, leukotoxin, and capsular polysaccharide in experimental bovine *Pasteurella* pneumonia. *Vet. Pathol.*, 27, 150-161.
- WHITMORE, L. & WALLACE, B. A. 2008. Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. *Biopolymers*, 89, 392-400.

- WILKIE, B. N. & MARKHAM, R. J. F. 1981. Bronchoalveolar washing cells and immunoglobulins of clinically normal calves. *Am. J. Vet. Res.*, 42, 241-243.
- WILLEMS, R. J. L., GEUIJEN, C., VANDERHEIDE, H. G. J., RENAULD, G., BERTIN, P., VANDENAKKER, W. M. R., LOCHT, C. & MOOI, F. R. 1994. Mutational analysis of the *Bordetella pertussis fim/fha* gene cluster - identification of a gene with sequence similarities to hemolysin accessory genes involved in export of FHA. *Mol. Microbiol.*, 11, 337-347.
- WILLIAMS, J. N., SKIPP, P. J., HUMPHRIES, H. E., CHRISTODOULIDES, M., O'CONNOR, C. D. & HECKELS, J. E. 2007. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect. Immun., 75, 1364-1372.
- WITHOLT, B., BOEKHOUT, M., BROCK, M., KINGMA, J., VANHEERIKHUIZEN, H. & LEIJ, L. D. 1976. Efficient and reproducible procedure for formation of spheroplasts from variously grown *Escherichia coli*. *Anal. Biochem.*, 74, 160-170.
- WONG, J. C. Y., PATEL, R., KENDALL, D., WHITBY, P. W., SMITH, A., HOLLAND, J. & WILLIAMS, P. 1995. Affinity, conservation, and surface exposure of hemopexin-binding proteins in *Haemophilus influenzae*. *Infect. Immun.*, 63, 2327-2333.
- WOOLDRIDGE, K. G. & WILLIAMS, P. H. 1993. Iron uptake mechanisms of pathogenic bacteria. FEMS Microbiol. Rev., 12, 325-348.
- WORRALL, L. J., LAMEIGNERE, E. & STRYNADKA, N. C. J. 2011. Structural overview of the bacterial injectisome. *Curr. Opin. Microbiol.*, 14, 3-8.
- WU, C. C. & YATES, J. R. 2003. The application of mass spectrometry to membrane proteomics. *Nat. Biotechnol.*, 21, 262-267.
- WU, T., MALINVERNI, J., RUIZ, N., KIM, S., SILHAVY, T. J. & KAHNE, D. 2005. Identification of a multicomponent complex required for outer membrane biogenesis in *Escherichia coli*. *Cell*, 121, 235-245.
- WU, T., MCCANDLISH, A. C., GRONENBERG, L. S., CHNG, S. S., SILHAVY, T. J. & KAHNE, D. 2006. Identification of a protein complex that assembles lipopolysaccharide in the outer membrane of *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A.*, 103, 11754-11759.
- XIA, X. X., HAN, M. J., LEE, S. Y. & YOO, J. S. 2008. Comparison of the extracellular proteomes of *Escherichia coli* B and K-12 strains during high cell density cultivation. *Proteomics*, 8, 2089-2103.
- YAMAGAMI, A., YOSHIOKA, T. & KANEMASA, Y. 1970. Differences in phospholipid composition between wild strains and streptomycin resistant mutants of certain enteric bacteria. Jpn. J. Microbiol., 14, 174-176.
- YAMAGUCHI, K., YU, F. & INOUYE, M. 1988. A single amino acid determinant of the membrane localization of lipoproteins in *E. coli. Cell*, 53, 423-432.
- YAMASHITA, M. & FENN, J. B. 1984a. Electrospray ion source another variation on the free-jet theme. J. Phys. Chem., 88, 4451-4459.
- YAMASHITA, M. & FENN, J. B. 1984b. Negative ion production with the electrospray ion source. J. Phys. Chem., 88, 4671-4675.
- YAU, W. M., WIMLEY, W. C., GAWRISCH, K. & WHITE, S. H. 1998. The preference of tryptophan for membrane interfaces. *Biochemistry*, 37, 14713-14718.
- YI, K., RASMUSSEN, A. W., GUDLAVALLETI, S. K., STEPHENS, D. S. & STOJILJKOVIC, I. 2004. Biofilm formation by Neisseria meningitidis. Infect. Immun., 72, 6132-6138.

- YOO, H. S., MAHESWARAN, S. K., LIN, G. F., TOWNSEND, E. L. & AMES, T. R. 1995a. Induction of inflammatory cytokines in bovine alveolar macrophages following stimulation with *Pasteurella haemolytica* lipopolysaccharide. *Infect. Immun.*, 63, 381-388.
- YOO, H. S., RAJAGOPAL, B. S., MAHESWARAN, S. K. & AMES, T. R. 1995b. Purified Pasteurella haemolytica leukotoxin induces expression of inflammatory cytokines from bovine alveolar macrophages. *Microb.* Pathog., 18, 237-252.
- YOO, H. S., RUTHERFORD, M. S., MAHESWARAN, S. K., SRINAND, S. & AMES, T. R. 1996. Induction of nitric oxide production by bovine alveolar macrophages in response to *Pasteurella haemolytica* A1. *Microb. Pathog.*, 20, 361-375.
- YU, C. S., CHEN, Y. C., LU, C. H. & HWANG, J. K. 2006. Prediction of protein subcellular localization. *Proteins*, 64, 643-651.
- YU, R. H., GRAYOWEN, S. D., OGUNNARIWO, J. & SCHRYVERS, A. B. 1992. Interaction of ruminant transferrins with transferrin receptors in bovine isolates of *Pasteurella haemolytica* and *Haemophilus somnus*. *Infect*. *Immun.*, 60, 2992-2994.
- ZARETZKY, F. R., GRAY, M. C. & HEWLETT, E. L. 2002. Mechanism of association of adenylate cyclase toxin with the surface of *Bordetella pertussis*: a role for toxin-filamentous haemagglutinin interaction. *Mol. Microbiol.*, 45, 1589-1598.
- ZENG, H., PANDHER, K. & MURPHY, G. L. 1999. Molecular cloning of the *Pasteurella haemolytica* pomA gene and identification of bovine antibodies against PomA surface domains. *Infect. Immun.*, 67, 4968-4973.
- ZHAI, Y., ZHANG, K., HUO, Y., ZHU, Y., ZHOU, Q., LU, J., BLACK, I., PANG, X., ROSZAK, A. W., ZHANG, X., ISAACS, N. W. & SUN, F. 2011. Autotransporter passenger domain secretion requires a hydrophobic cavity at the extracellular entrance of the beta-domain pore. *Biochemical Journal*, 435, 577-587.
- ZHU, Y. S., BLACK, I., ROSZAK, A. W. & ISAACS, N. W. 2007. Crystallization and preliminary X-ray diffraction analysis of P30, the transmembrane domain of pertactin, an autotransporter from *Bordetella pertussis*. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 63, 593-595.

# 7. APPENDICES

# 7.1 Growth media composition

### Brain Heart Infusion broth (BHIB)

| 1 litre                                       |            |
|---|------------|
| Brain Heart Infusion, dehydrated (Oxoid)      | 37.0 g     |
| Distilled water                               | to 1 litre |
| Autoclaved at 121°C for 15 min.               |            |
| Brain Heart Infusion agar (BHIA)              |            |
| 1 litre                                       |            |
| Brain Heart Infusion Agar, dehydrated (Oxoid) | 47.2 g     |
| Distilled water                               | to 1 litre |
| Autoclaved at 121°C for 15 min.               |            |
| Luria-Bertani (LB) broth                      |            |
| 1 litre                                       |            |
| LB broth powder (Sigma-Aldrich)               | 20.0 g     |
| Distilled water                               | to 1 litre |
| Autoclaved at 121°C for 15 min.               |            |
| Luria-Bertani (LB) agar                       |            |
| 1 litre                                       |            |
| LB agar powder (Sigma-Aldrich)                | 35.0 g     |
| Distilled water                               | to 1 litre |
| Autoclaved at 121°C for 15 min.               |            |

## 7.2 Plasmid DNA

pOPINF (Berrow et al., 2007)



| Tube # | Salt 1                | Salt 2                   | Buffer              | pН  | Precipitant               |
|--------|-----------------------|--------------------------|---------------------|-----|---------------------------|
| 1      | None                  | None                     | 0.1 M Na citrate    | 5.5 | 2.5 M ammonium sulphate   |
| 2      | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M Na citrate    | 3.5 | 30% v/v PEG 400           |
| 3      | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M Na<br>acetate | 4.5 | 30% v/v PEG 400           |
| 4      | 0.1 M sodium chloride | None                     | 0.1 M Na citrate    | 5.5 | 30% v/v PEG 400           |
| 5      | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M Na citrate    | 5.5 | 30% v/v PEG 400           |
| 6      | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M Na citrate    | 5.5 | 30% v/v PEG 400           |
| 7      | None                  | None                     | 0.1 M MES           | 6.5 | 2.5 M ammonium sulphate   |
| 8      | None                  | None                     | 0.1 M MES           | 6.5 | 30% v/v PEG 400           |
| 9      | 0.1 M sodium chloride | None                     | 0.1 M MES           | 6.5 | 30% v/v PEG 400           |
| 10     | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M MES           | 6.5 | 30% v/v PEG 400           |
| 11     | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M MES           | 6.5 | 30% v/v PEG 400           |
| 12     | None                  | None                     | 0.1 M MOPS          | 7.0 | 30% v/v PEG 400           |
| 13     | None                  | None                     | 0.1 M Na HEPES      | 7.5 | 2.5 M ammonium sulphate   |
| 14     | 0.1 M sodium chloride | None                     | 0.1 M MOPS          | 7.0 | 30% v/v PEG 400           |
| 15     | None                  | None                     | 0.1 M Na HEPES      | 7.5 | 30% v/v PEG 400           |
| 16     | 0.1 M sodium chloride | None                     | 0.1 M Na HEPES      | 7.5 | 30% v/v PEG 400           |
| 17     | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M Na HEPES      | 7.5 | 30% v/v PEG 400           |
| 18     | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M Na HEPES      | 7.5 | 30% v/v PEG 400           |
| 19     | None                  | None                     | 0.1 M Tris          | 8.5 | 1.5 M lithium sulphate    |
| 20     | 0.1 M sodium chloride | None                     | 0.1 M Tris          | 8.5 | 30% v/v PEG 400           |
| 21     | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M Tris          | 8.5 | 30% v/v PEG 400           |
| 22     | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M Tris          | 8.5 | 30% v/v PEG 400           |
| 23     | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M CAPSO         | 9.5 | 30% v/v PEG 400           |
| 24     | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M CAPSO         | 9.5 | 30% v/v PEG 400           |
| 25     | None                  | None                     | 0.1 M Na citrate    | 5.5 | 1.5 M sodium phosphate    |
| 26     | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M Na citrate    | 3.5 | 12% w/v PEG 4000          |
| 27     | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M Na<br>acetate | 4.5 | 12% w/v PEG 4000          |
| 28     | 0.1 M sodium chloride | None                     | 0.1 M Na citrate    | 5.5 | 12% w/v PEG 4000          |
| 29     | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M Na citrate    | 5.5 | 12% w/v PEG 4000          |
| 30     | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M Na citrate    | 5.5 | 12% w/v PEG 4000          |
| 31     | None                  | None                     | 0.1 M MES           | 6.5 | 1.5 M sodium phosphate    |
| 32     | None                  | None                     | 0.1 M MES           | 6.5 | 12% w/v PEG 4000          |
| 33     | 0.1 M sodium chloride | None                     | 0.1 M MES           | 6.5 | 12% w/v PEG 4000          |
| 34     | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M MES           | 6.5 | 12% w/v PEG 4000          |
| 35     | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M MES           | 6.5 | 12% w/v PEG 4000          |
| 36     | None                  | None                     | 0.1 M MOPS          | 7.0 | 12% w/v PEG 4000          |
| 37     | None                  | None                     | 0.1 M Na HEPES      | 7.5 | 1.5 M potassium phosphate |
| 38     | 0.1 M sodium chloride | None                     | 0.1 M MOPS          | 7.0 | 12% w/v PEG 4000          |
| 39     | None                  | None                     | 0.1 M Na HEPES      | 7.5 | 12% w/v PEG 4000          |
| 40     | 0.1 M sodium chloride | None                     | 0.1 M Na HEPES      | 7.5 | 12% w/v PEG 4000          |
| 41     | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M Na HEPES      | 7.5 | 12% w/v PEG 4000          |
| 42     | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M Na HEPES      | 7.5 | 12% w/v PEG 4000          |
| 43     | None                  | None                     | 0.1 M Tris          | 8.5 | 1.5 M potassium phosphate |
| 44     | 0.1 M sodium chloride | None                     | 0.1 M Tris          | 8.5 | 12% w/v PEG 4000          |
| 45     | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M Tris          | 8.5 | 12% w/v PEG 4000          |
| 46     | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M Tris          | 8.5 | 12% w/v PEG 4000          |
| 47     | 0.1 M sodium chloride | 0.1 M lithium sulfate    | 0.1 M CAPSO         | 9.5 | 12% w/v PEG 4000          |
| 48     | 0.1 M sodium chloride | 0.1 M magnesium chloride | 0.1 M CAPSO         | 9.5 | 12% w/v PEG 4000          |

## 7.3 MemSys screen (Molecular Dimensions, UK)

#### Abbreviations:

CAPSO; 3-(Cyclohexylamino)-2-hydroxyl-1-propanesulfonic Acid Sodium Salt, Na HEPES; N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid sodium salt, MES; 2-(N-morpholino)ethanesulfonic acid, MOPS; 3-(N-Morpholino)propanesulfonic acid, PEG; Polyethylene glycol, Tris; 2-Amino-2-(hydroxymethyl)propane-1,3-diol.

# 7.4 MemGold screen (Molecular Dimensions, UK)

| Tube<br># | Salt  | Buffer pH                  |     | Precipitant  |
|-----------|---|----------------------------|-----|--|
| 1         | None  | 0.08 M sodium citrate      | 5.2 | 2.2 M ammonium sulfate                             |
| 2         | None  | 0.01 M Tris                | 8.0 | 1.2 M tri-sodium citrate                           |
| 3         | None  | 0.015 M tricine            | 8.5 | 24% w/v PEG 4000                                   |
| 4         | 0.36 M sodium chloride/0.1% w/v sodium azide                                  | 0.015 M sodium phosphate   | 7.0 | 9.9% w/v PEG 4000                                  |
| 5         | 0.3 M sodium chloride   | 0.01 M Tris                | 8.0 | 27.5% w/v PEG 4000                                 |
| 6         | None  | 0.225 M MES/bis-tris       | 6.6 | 6.6% w/v PEG 6000                                  |
| 7         | 0.1 M ammonium sulfate  | 0.1 M HEPES                | 7.5 | 12.0% w/v PEG 4000/22%<br>v/v glycerol             |
| 8         | 0.02 M calcium chloride/0.01 M<br>magnesium sulfate/0.02 M<br>sodium chloride | 0.02 M MES                 | 6.5 | 7.7% w/v PEG 1500                                  |
| 9         | None  | 0.05 M HEPES               | 7.5 | 2.5 M ammonium sulfate                             |
| 10        | None  | 0.0665 M HEPES             | 7.5 | 1.1 M tri-sodium citrate                           |
| 11        | None  | 0.15 M potassium phosphate | 6.5 | 3.3 M ammonium sulfate                             |
| 12        | 0.1 M magnesium acetate   | 0.1 M sodium citrate       | 5.8 | 14% w/v PEG 5000 MME                               |
| 13        | 0.1 M sodium chloride   | 0.02 M sodium citrate      | 5.6 | 11% w/v PEG 3350                                   |
| 14        | 0.1 M sodium chloride   | 0.02 M sodium citrate      | 5.6 | 5.5% w/v PEG 3350                                  |
| 15        | 0.05 M calcium chloride/0.05 M<br>barium chloride                             | 0.1 M Tris                 | 8.2 | 32% v/v PEG 400                                    |
| 16        | 0.05 M sodium chloride  | 0.1 M sodium phosphate     | 6.2 | 16% w/v PEG 4000                                   |
| 17        | 0.1 M magnesium chloride  | 0.03 M Tris-hydrochloride  | 8.2 | 19% w/v PEG 4000                                   |
| 18        | 0.2 M sodium chloride   | 0.025 M HEPES              | 7.5 | 13% w/v PEG 4000                                   |
| 19        | None  | 0.1 M HEPES                | 7.5 | 11% w/v PEG 3350                                   |
| 20        | 0.1 M sodium chloride   | 0.02 M KMES                | 6.7 | 6.6% w/v PEG 4000                                  |
| 21        | 0.1 M potassium chloride  | 0.02 M Tris                | 7.0 | 20% w/v PEG 4000                                   |
| 22        | 0.05 M magnesium chloride/0.1%<br>w/v sodium azide                            | 0.1 M sodium cacodylate    | 6.7 | 6.6% w/v PEG 3350                                  |
| 23        | 0.2 M potassium chloride  | 0.1 M sodium citrate       | 5.5 | 37% v/v pentaerythritol<br>propoxylate (5/4 PO/OH) |
| 24        | None  | 0.1 M Tris                 | 8.0 | 5.5% w/v PEG 4000                                  |
| 25        | 0.1 M sodium chloride   | 0.02 M Tris                | 7.0 | 7.7% w/v PEG 4000                                  |
| 26        | 0.1 M magnesium chloride  | 0.1 M Tris                 | 7.5 | 22% v/v PEG 400                                    |
| 27        | 0.04 M sodium chloride  | 0.04 M Tris                | 8.0 | 27% v/v PEG 350 MME                                |
| 28        | 0.05 M sodium chloride/0.02 M magnesium chloride                              | 0.1 M sodium citrate       | 6.0 | 22% v/v PEG 400                                    |
| 29        | None  | 0.1 M sodium acetate       | 5.5 | 8.8% w/v PEG 2000 MME                              |
| 30        | None  | 0.4 M ammonium acetate     | 8.0 | 13% w/v PEG 2000 MME                               |
| 31        | None  | 0.02 M bis Tris            | 7.0 | 15% w/v PEG 2000                                   |
| 32        | 0.1 M sodium chloride/0.1 M<br>magnesium chloride                             | 0.02 M Tris                | 7.5 | 11% w/v PEG 1500                                   |
| 33        | 0.1 M sodium chloride/0.1 M<br>magnesium chloride                             | 0.1 M HEPES                | 8.0 | 11% w/v PEG 1500                                   |
| 34        | U.2 M sodium acetate/0.2 M potassium chloride                                 | 0.1 M HEPES                | 7.0 | 22% w/v PEG 3000                                   |
| 35        | 0.02 M nickel sulfate   | 0.01 M HEPES               | 7.0 | 33% v/v Jeffamine-M600                             |
| 36        | 0.15 M sodium chloride  | 0.1 M Tris                 | 8.0 | 13% w/v PEG 6000                                   |
| 37        | 0.2 M calcium chloride  | 0.1 M HEPES                | 7.5 | 53% v/v PEG 400                                    |
| 38        | 0.05 M magnesium acetate  | 0.05 M sodium acetate      | 5.0 | 28% v/v PEG 400                                    |
| 39        | None  | 0.05 M HEPES               | 7.5 | 22% v/v PEG 4000                                   |
| 40        | 0.2 M calcium chloride  | 0.1 M Tris hydrochloride   | 8.0 | 44% v/v PEG 400                                    |
| 41        | 0.05 M magnesium acetate  | 0.05 M sodium acetate      | 5.4 | 24% v/v PEG 400                                    |
| 42        | 0.2 M calcium chloride  | 0.1 M MES                  | 6.5 | 26% v/v PEG 350 MME                                |
| 43        | 0.1 M potassium chloride  | 0.1 M Tris                 | 8.5 | 39% v/v PEG 400                                    |
| 44        | 0.05 M magnesium chloride   | 0.1 M glycine              | 9.0 | 22% v/v PEG 400                                    |
| 45        | 0.1 M ammonium sulfate  | 0.1 M glycine              | 3.8 | 28% w/v tri-ethylene glycol                        |
| 46        | 0.15 M sodium formate   | 0.1 M HEPES                | 7.2 | 18% w/v PEG 3350                                   |
| 47        | None  | 0.2 M sodium acetate       | 6.8 | 8.8% w/v PEG 6000                                  |
| 48        | 0.2 M potassium chloride  | 0.1 M MES                  | 6.5 | 18% w/v PEG 6000                                   |
| 49        | 0.22 M sodium citrate   | 0.1 M Tris                 | 8.0 | 35% v/v PEG 400                                    |
| 50        | None  | 0.1 M sodium acetate       | 4.5 | 17% v/v PEG 400                                    |

| 51   | None  | 0.02 M Tris  | 8.5  | 1.0 M lithium sulfate/1.8%<br>w/v PEG 8000  |
|--|---|--|--|---|
| 52   | None  | 0.02 M Tris  | 7.5  | 22% v/v PEG 550 MME   |
| 53   | 0.05 M sodium chloride  | 0.02 M glycine   | 10.0   | 33% w/v PEG 1000  |
| 54   | 0.2 M magnesium chloride  | 0.1 M Tris   | 8.5  | 25% w/v PEG 4000  |
| 55   | 0.2 M magnesium chloride  | 0.1 M sodium cacodylate  | 6.5  | 31% w/v PEG 2000  |
| 56   | None  | 0.64 M sodium acetate  | 4.6  | 18% w/v PEG 3350  |
| 57   | 0.1 M sodium chloride/0.1 M<br>cadmium chloride   | 0.1 M Tris hydrochloride   | 8.0  | 33% v/v PEG 400   |
| 58   | None  | 0.1 M Bicine   | 8.9  | 31% w/v PEG 2000  |
| 59   | 0.05 M sodium sulfate/0.05 M<br>lithium sulfate   | 0.05 M Tris  | 8.5  | 35% v/v PEG 400   |
| 60   | 0.1 M sodium chloride   | 0.05 M glycine   | 9.5  | 33% v/v PEG 300   |
| 61   | 0.3 M magnesium nitrate   | 0.1 M Tris   | 8.0  | 23% w/v PEG 2000  |
| 62   | 0.12 M lithium sulfate  | 0.02 M Tris/0.1 M sodium citrate   | 7.5/5.0  | 20% v/v PEG 300   |
| 63   | 0.1 M sodium chloride   | 0.12 M Tris  | 9.4  | 20% v/v PEG 400   |
| 64   | 0.2 M sodium chloride   | 0.1 M HEPES  | 7.0  | 22% v/v PEG 550 MME   |
| 65   | 0.1 M sodium chloride/0.325 M<br>sodium acetate   | 0.1 M Tris   | 8.0  | 21% v/v PEG 400   |
| 66   | 0.02 M sodium citrate   | 0.08 M sodium phosphate  | 6.2  | 18% w/v PEG 2000  |
| 67   | 0.02 M potassium nitrate  | 0.03 M potassium citrate   | 6.5  | 7.7% w/v PEG 4000   |
| 68   | 0.1 M sodium chloride/0.005 M<br>magnesium chloride   | 0.1 M Tris   | 8.5  | 30% w/v PEG 2000 MME  |
| 69   | 0.2 M calcium chloride  | 0.1 M HEPES  | 7.0  | 33% v/v PEG 400   |
| 70   | 0.1 M calcium chloride  | 0.1 M Tris   | 6.5  | 13% w/v PEG 2000 MME  |
| 71   | 0.2 M ammonium sulfate/0.02 M sodium chloride   | 0.02 M sodium acetate  | 4.0  | 33% v/v PEG 200   |
| 72   | 0.07 M sodium chloride  | 0.05 M sodium citrate  | 4.5  | 22% v/v PEG 400   |
| 73   | 0.2 M ammonium sulfate  | 0.1 M sodium acetate   | 4.6  | 28% v/v PEG 550 MME   |
|  |   |  |  |   |
| 74   | None  | 0.05 M glycine   | 9.0  | 55% v/v PEG 400   |
| 74<br>75   | None<br>0.1 M magnesium chloride/0.1 M<br>sodium chloride   | 0.05 M glycine<br>0.1 M Tris   | 9.0<br>8.5   | 55% v/v PEG 400<br>33% v/v PEG 400  |
| 74<br>75<br>76   | None<br>0.1 M magnesium chloride/0.1 M<br>sodium chloride<br>0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate  | 0.05 M glycine<br>0.1 M Tris<br>0.05 M citric acid   | 9.0<br>8.5<br>None   | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000  |
| 74<br>75<br>76<br>77   | None<br>0.1 M magnesium chloride/0.1 M<br>sodium chloride<br>0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate<br>0.2 M magnesium chloride/0.1 M<br>potassium chloride  | 0.05 M glycine<br>0.1 M Tris<br>0.05 M citric acid<br>0.025 M sodium citrate   | 9.0<br>8.5<br>None<br>4.0  | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000<br>33% v/v PEG 400   |
| 74<br>75<br>76<br>77<br>78   | None<br>0.1 M magnesium chloride/0.1 M<br>sodium chloride<br>0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate<br>0.2 M magnesium chloride/0.1 M<br>potassium chloride<br>0.05 M zinc acetate   | 0.05 M glycine<br>0.1 M Tris<br>0.05 M citric acid<br>0.025 M sodium citrate<br>0.05 M MES   | 9.0<br>8.5<br>None<br>4.0<br>6.1   | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000<br>33% v/v PEG 400<br>11% w/v PEG 8000   |
| 74<br>75<br>76<br>77<br>78<br>79   | None<br>0.1 M magnesium chloride/0.1 M<br>sodium chloride<br>0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate<br>0.2 M magnesium chloride/0.1 M<br>potassium chloride<br>0.05 M zinc acetate<br>0.3 M magnesium nitrate  | 0.05 M glycine<br>0.1 M Tris<br>0.05 M citric acid<br>0.025 M sodium citrate<br>0.05 M MES<br>0.1 M Tris   | 9.0<br>8.5<br>None<br>4.0<br>6.1<br>8.0  | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000<br>33% v/v PEG 400<br>11% w/v PEG 8000<br>22% w/v PEG 8000   |
| 74<br>75<br>76<br>77<br>78<br>79<br>80   | None<br>0.1 M magnesium chloride/0.1 M<br>sodium chloride<br>0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate<br>0.2 M magnesium chloride/0.1 M<br>potassium chloride<br>0.05 M zinc acetate<br>0.3 M magnesium nitrate<br>0.1 M sodium chloride/4% v/v<br>ethylene glycol   | 0.05 M glycine<br>0.1 M Tris<br>0.05 M citric acid<br>0.025 M sodium citrate<br>0.05 M MES<br>0.1 M Tris<br>0.1 M MES  | 9.0<br>8.5<br>None<br>4.0<br>6.1<br>8.0<br>6.5   | 55% v/v PEG 400         33% v/v PEG 400         19% w/v PEG 1000         33% v/v PEG 400         11% w/v PEG 8000         22% w/v PEG 8000         33% v/v PEG 400  |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81   | None<br>0.1 M magnesium chloride/0.1 M<br>sodium chloride<br>0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate<br>0.2 M magnesium chloride/0.1 M<br>potassium chloride<br>0.05 M zinc acetate<br>0.3 M magnesium nitrate<br>0.1 M sodium chloride/4% v/v<br>ethylene glycol<br>0.05 M sodium chloride   | 0.05 M glycine<br>0.1 M Tris<br>0.05 M citric acid<br>0.025 M sodium citrate<br>0.05 M MES<br>0.1 M Tris<br>0.1 M MES<br>0.1 M sodium citrate  | 9.0<br>8.5<br>None<br>4.0<br>6.1<br>8.0<br>6.5<br>5.5  | 55% v/v PEG 400         33% v/v PEG 400         19% w/v PEG 1000         33% v/v PEG 400         11% w/v PEG 8000         22% w/v PEG 8000         33% v/v PEG 400         22% w/v PEG 400         26% v/v PEG 400  |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>81   | None<br>0.1 M magnesium chloride/0.1 M<br>sodium chloride<br>0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate<br>0.2 M magnesium chloride/0.1 M<br>potassium chloride<br>0.05 M zinc acetate<br>0.3 M magnesium nitrate<br>0.1 M sodium chloride/4% v/v<br>ethylene glycol<br>0.05 M sodium chloride<br>0.1 M lithium sulfate  | 0.05 M glycine<br>0.1 M Tris<br>0.05 M citric acid<br>0.025 M sodium citrate<br>0.05 M MES<br>0.1 M Tris<br>0.1 M MES<br>0.1 M sodium citrate<br>0.1 M glycine   | 9.0<br>8.5<br>None<br>4.0<br>6.1<br>8.0<br>6.5<br>5.5<br>9.3   | 55% v/v PEG 400         33% v/v PEG 400         19% w/v PEG 1000         33% v/v PEG 400         11% w/v PEG 8000         22% w/v PEG 8000         33% v/v PEG 400         26% v/v PEG 400         30% v/v PEG 400         30% v/v PEG 400  |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83   | None<br>0.1 M magnesium chloride/0.1 M<br>sodium chloride<br>0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate<br>0.2 M magnesium chloride/0.1 M<br>potassium chloride<br>0.05 M zinc acetate<br>0.3 M magnesium nitrate<br>0.1 M sodium chloride/4% v/v<br>ethylene glycol<br>0.05 M sodium chloride<br>0.1 M lithium sulfate<br>0.15 M potassium citrate/0.05 M<br>lithium citrate  | 0.05 M glycine0.1 M Tris0.05 M citric acid0.05 M sodium citrate0.05 M MES0.1 M Tris0.1 M Sodium citrate0.1 M sodium citrate0.1 M sodium citrate0.1 M sodium citrate0.1 M sodium citrate  | 9.0<br>8.5<br>None<br>4.0<br>6.1<br>8.0<br>6.5<br>5.5<br>9.3<br>-  | 55% v/v PEG 400         33% v/v PEG 400         19% w/v PEG 1000         33% v/v PEG 400         11% w/v PEG 8000         22% w/v PEG 400         33% v/v PEG 400         26% v/v PEG 400         30% v/v PEG 400         22% w/v PEG 400         22% w/v PEG 400         22% w/v PEG 400         22% w/v PEG 400   |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>83<br>84   | None<br>0.1 M magnesium chloride/0.1 M<br>sodium chloride<br>0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate<br>0.2 M magnesium chloride/0.1 M<br>potassium chloride<br>0.05 M zinc acetate<br>0.3 M magnesium nitrate<br>0.1 M sodium chloride/4% v/v<br>ethylene glycol<br>0.05 M sodium chloride<br>0.1 M lithium sulfate<br>0.15 M potassium citrate/0.05 M<br>lithium citrate<br>0.001 M zinc sulfate  | 0.05 M glycine0.1 M Tris0.05 M citric acid0.05 M sodium citrate0.05 M MES0.1 M Tris0.1 M Sodium citrate0.1 M sodium citrate0.1 M glycine0.1 M sodium phosphate0.05 HEPES   | 9.0           8.5           None           4.0           6.1           8.0           6.5           9.3           -           7.8   | 55% v/v PEG 400         33% v/v PEG 400         19% w/v PEG 1000         33% v/v PEG 400         11% w/v PEG 8000         22% w/v PEG 400         33% v/v PEG 400         26% v/v PEG 400         30% v/v PEG 400         22% w/v PEG 400         26% v/v PEG 400         22% w/v PEG 400         22% w/v PEG 400         22% w/v PEG 6000  |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>83<br>84<br>85   | None0.1 M magnesium chloride/0.1 M<br>sodium chloride0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate0.2 M magnesium chloride/0.1 M<br>potassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/v<br>ethylene glycol0.05 M sodium chloride0.1 M lithium sulfate0.1 M lithium sulfate0.15 M potassium citrate/0.05 M<br>lithium citrate0.001 M zinc sulfate0.1 M sodium chloride  | 0.05 M glycine0.1 M Tris0.05 M citric acid0.025 M sodium citrate0.05 M MES0.1 M Tris0.1 M Sodium citrate0.1 M sodium citrate0.1 M glycine0.1 M sodium phosphate0.05 HEPES0.1 M sodium phosphate  | 9.0<br>8.5<br>None<br>4.0<br>6.1<br>8.0<br>6.5<br>5.5<br>9.3<br>-<br>7.8<br>7.0  | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000<br>33% v/v PEG 400<br>11% w/v PEG 8000<br>22% w/v PEG 8000<br>33% v/v PEG 400<br>26% v/v PEG 400<br>30% v/v PEG 400<br>22% w/v PEG 6000<br>28% v/v PEG 600<br>33% v/v PEG 300  |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>83<br>84<br>85<br>86   | None0.1 M magnesium chloride/0.1 M<br>sodium chloride0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate0.2 M magnesium chloride/0.1 M<br>potassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/v<br>ethylene glycol0.05 M sodium chloride0.1 M lithium sulfate0.1 M lithium sulfate0.15 M potassium citrate/0.05 M<br>lithium citrate0.001 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride   | 0.05 M glycine0.1 M Tris0.05 M citric acid0.025 M sodium citrate0.05 M MES0.1 M Tris0.1 M MES0.1 M sodium citrate0.1 M glycine0.1 M sodium phosphate0.05 HEPES0.1 M sodium phosphate0.05 M Bicine  | 9.0<br>8.5<br>None<br>4.0<br>6.1<br>8.0<br>6.5<br>5.5<br>9.3<br>-<br>7.8<br>7.0<br>9.0   | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000<br>33% v/v PEG 400<br>11% w/v PEG 8000<br>22% w/v PEG 8000<br>33% v/v PEG 400<br>26% v/v PEG 400<br>22% w/v PEG 400<br>22% w/v PEG 600<br>28% v/v PEG 600<br>33% v/v PEG 300<br>33% v/v PEG 300  |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>83<br>84<br>83<br>83<br>84<br>85<br>86<br>87   | None0.1 M magnesium chloride/0.1 M<br>sodium chloride0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate0.2 M magnesium chloride/0.1 M<br>potassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/v<br>ethylene glycol0.05 M sodium chloride0.1 M lithium sulfate0.1 M lithium sulfate0.15 M potassium citrate/0.05 M<br>lithium citrate0.001 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.05 M sodium chloride0.05 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.1 M sodium chloride0.5 M zinc acetate/6% v/v<br>ethylene glycol   | 0.05 M glycine0.1 M Tris0.05 M citric acid0.025 M sodium citrate0.05 M MES0.1 M Tris0.1 M Sodium citrate0.1 M sodium citrate0.1 M sodium phosphate0.05 HEPES0.1 M sodium phosphate0.05 M Bicine0.1 M sodium cacodylate   | 9.0           8.5           None           4.0           6.1           8.0           6.5           9.3           -           7.8           7.0           9.0           6.0   | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000<br>33% v/v PEG 400<br>11% w/v PEG 8000<br>22% w/v PEG 8000<br>33% v/v PEG 400<br>26% v/v PEG 400<br>22% w/v PEG 400<br>22% w/v PEG 600<br>33% v/v PEG 600<br>33% v/v PEG 300<br>33% v/v PEG 300<br>6.6% w/v PEG 8000   |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>84<br>83<br>84<br>85<br>86<br>87<br>88   | None0.1 M magnesium chloride/0.1 M<br>sodium chloride0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate0.2 M magnesium chloride/0.1 M<br>potassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/v<br>ethylene glycol0.05 M sodium chloride0.1 M lithium sulfate0.1 M lithium sulfate0.15 M potassium citrate/0.05 M<br>lithium citrate0.001 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.05 M zinc sulfate0.05 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.1 M sodium chloride0.2 M zinc acetate/6% v/v<br>ethylene glycol0.2 M lithium sulfate   | 0.05 M glycine0.1 M Tris0.05 M citric acid0.05 M sodium citrate0.05 M MES0.1 M Tris0.1 M MES0.1 M sodium citrate0.1 M glycine0.1 M sodium phosphate0.05 HEPES0.1 M sodium phosphate0.05 M Bicine0.1 M sodium cacodylate0.1 M sodium citrate  | 9.0           8.5           None           4.0           6.1           8.0           6.5           9.3           -           7.8           7.0           9.0           6.0           3.5   | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000<br>33% v/v PEG 400<br>11% w/v PEG 8000<br>22% w/v PEG 8000<br>33% v/v PEG 400<br>26% v/v PEG 400<br>22% w/v PEG 400<br>22% w/v PEG 600<br>33% v/v PEG 600<br>33% v/v PEG 300<br>6.6% w/v PEG 8000<br>28% v/v PEG 400   |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>83<br>84<br>85<br>86<br>86<br>87<br>88<br>88<br>89   | None0.1 M magnesium chloride/0.1 M<br>sodium chloride0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate0.2 M magnesium chloride/0.1 M<br>potassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/v<br>ethylene glycol0.05 M sodium chloride0.1 M lithium sulfate0.1 M lithium sulfate0.15 M potassium citrate/0.05 M<br>lithium citrate0.001 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.2 M zinc sulfate0.1 M sodium chloride0.2 M zinc acetate/6% v/v<br>ethylene glycol0.2 M lithium sulfate0.1 M sodium chloride  | 0.05 M glycine0.1 M Tris0.05 M citric acid0.025 M sodium citrate0.05 M MES0.1 M Tris0.1 M MES0.1 M sodium citrate0.1 M glycine0.1 M sodium phosphate0.05 HEPES0.1 M sodium phosphate0.05 M Bicine0.1 M sodium citrate0.1 M Tris  | 9.0           8.5           None           4.0           6.1           8.0           6.5           9.3           -           7.8           7.0           9.0           6.0           3.5           7.5   | 55% v/v PEG 400         33% v/v PEG 400         19% w/v PEG 1000         33% v/v PEG 400         11% w/v PEG 8000         22% w/v PEG 8000         33% v/v PEG 400         26% v/v PEG 400         26% v/v PEG 400         22% w/v PEG 600         33% v/v PEG 600         28% v/v PEG 300         33% v/v PEG 400         28% v/v PEG 300         6.6% w/v PEG 400         11% w/v PEG 400         11% w/v PEG 400   |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>80<br>81<br>82<br>83<br>83<br>84<br>85<br>86<br>87<br>88<br>88<br>89<br>90                               | None0.1 M magnesium chloride/0.1 Msodium chloride0.1 M lithium sulfate/0.05 Mdisodium hydrogen phosphate0.2 M magnesium chloride/0.1 Mpotassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/vethylene glycol0.05 M sodium chloride0.1 M lithium sulfate0.15 M potassium citrate/0.05 Mlithium citrate0.001 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.2 M lithium sulfate0.1 M sodium chloride0.2 M lithium sulfate0.1 M sodium chloride0.1 M sodium chloride0.2 M lithium sulfate0.1 M sodium chloride0.1 M sodium chloride  | 0.05 M glycine0.1 M Tris0.05 M citric acid0.025 M sodium citrate0.025 M MES0.1 M Tris0.1 M Tris0.1 M sodium citrate0.1 M sodium citrate0.1 M sodium phosphate0.05 HEPES0.1 M sodium phosphate0.05 M Bicine0.1 M sodium citrate0.1 M tris0.1 M tricine                    | 9.0           8.5           None           4.0           6.1           8.0           6.5           9.3           -           7.8           7.0           9.0           6.0           3.5           7.5           7.4   | 55% v/v PEG 400         33% v/v PEG 400         19% w/v PEG 1000         33% v/v PEG 400         11% w/v PEG 8000         22% w/v PEG 400         33% v/v PEG 400         26% v/v PEG 400         30% v/v PEG 400         22% w/v PEG 600         33% v/v PEG 600         33% v/v PEG 300         6.6% w/v PEG 8000         28% v/v PEG 400         11% w/v PEG 400         7% w/v PEG 3000   |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>84<br>85<br>86<br>87<br>88<br>88<br>89<br>90<br>91   | None0.1 M magnesium chloride/0.1 M<br>sodium chloride0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate0.2 M magnesium chloride/0.1 M<br>potassium chloride0.2 M magnesium chloride/0.1 M<br>potassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/v<br>ethylene glycol0.05 M sodium chloride0.1 M lithium sulfate0.15 M potassium citrate/0.05 M<br>lithium citrate0.001 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.1 M sodium chloride0.1 M sodium chloride0.05 M zinc acetate/6% v/v<br>ethylene glycol0.2 M lithium sulfate0.1 M sodium chloride0.2 M lithium sulfate0.2 M lithium sulfate0.2 M lithium sulfate0.2 M calcium chloride  | 0.05 M glycine0.1 M Tris0.05 M citric acid0.05 M sodium citrate0.025 M sodium citrate0.05 M MES0.1 M Tris0.1 M Sodium citrate0.1 M sodium citrate0.1 M sodium phosphate0.05 HEPES0.1 M sodium phosphate0.05 M Bicine0.1 M sodium citrate0.1 M tricine0.1 M MES   | 9.0           8.5           None           4.0           6.1           8.0           6.5           9.3           -           7.8           7.0           9.0           6.0           3.5           7.4   | 55% v/v PEG 400         33% v/v PEG 400         19% w/v PEG 1000         33% v/v PEG 400         11% w/v PEG 8000         22% w/v PEG 400         33% v/v PEG 400         26% v/v PEG 400         20% v/v PEG 400         28% v/v PEG 6000         28% v/v PEG 300         33% v/v PEG 400         28% v/v PEG 8000         28% v/v PEG 300         33% v/v PEG 400         11% w/v PEG 400         28% v/v PEG 400         28% v/v PEG 400         28% v/v PEG 400         33% v/v PEG 400         28% v/v PEG 400         33% v/v PEG 400         33% v/v PEG 400         33% v/v PEG 4000  |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>83<br>84<br>83<br>84<br>85<br>86<br>87<br>88<br>89<br>90<br>91<br>92                         | None0.1 M magnesium chloride/0.1 M<br>sodium chloride0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate0.2 M magnesium chloride/0.1 M<br>potassium chloride0.2 M magnesium chloride/0.1 M<br>potassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/v<br>ethylene glycol0.05 M sodium chloride0.1 M sodium chloride0.1 M lithium sulfate0.15 M potassium citrate/0.05 M<br>lithium citrate0.001 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.1 M sodium chloride0.2 M lithium sulfate0.1 M sodium chloride0.2 M lithium sulfate0.2 M calcium chloride0.2 M calcium chloride1 M sodium chloride1 M sodium chloride0.2 M calcium chloride1 M sodium chloride1 M sodium chloride   | 0.05 M glycine0.1 M Tris0.05 M citric acid0.025 M sodium citrate0.05 M MES0.1 M Tris0.1 M Tris0.1 M Sodium citrate0.1 M sodium citrate0.1 M sodium phosphate0.05 HEPES0.1 M sodium phosphate0.05 M Bicine0.1 M sodium citrate0.1 M Tris0.1 M MES0.1 M sodium citrate                         | 9.0<br>8.5<br>None<br>4.0<br>6.1<br>8.0<br>6.5<br>5.5<br>9.3<br>-<br>7.8<br>7.0<br>9.0<br>6.0<br>3.5<br>7.5<br>7.4<br>6.5<br>6.0   | 55% v/v PEG 400         33% v/v PEG 400         19% w/v PEG 1000         33% v/v PEG 400         11% w/v PEG 8000         22% w/v PEG 400         33% v/v PEG 400         26% v/v PEG 400         20% v/v PEG 400         22% w/v PEG 400         33% v/v PEG 400         28% v/v PEG 6000         28% v/v PEG 300         33% v/v PEG 300         28% v/v PEG 400         11% w/v PEG 400         11% w/v PEG 400         28% v/v PEG 400         11% w/v PEG 400         28% v/v PEG 400  |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>83<br>84<br>83<br>84<br>85<br>86<br>87<br>88<br>88<br>89<br>90<br>91<br>92<br>93             | None0.1 M magnesium chloride/0.1 Msodium chloride0.1 M lithium sulfate/0.05 Mdisodium hydrogen phosphate0.2 M magnesium chloride/0.1 Mpotassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/vethylene glycol0.05 M sodium chloride0.1 M lithium sulfate0.15 M potassium citrate/0.05 Mlithium citrate0.001 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.2 M lithium sulfate0.3 M sodium chloride0.4 M sodium chloride0.5 M zinc acetate/6% v/vethylene glycol0.2 M lithium sulfate0.1 M sodium chloride0.2 M lithium sulfate0.2 M lithium sulfate0.2 M calcium chloride1 M sodium chloride1 M sodium chloride0.2 M calcium chloride1 M sodium chloride | 0.05 M glycine0.1 M Tris0.05 M citric acid0.05 M sodium citrate0.05 M MES0.1 M Tris0.1 M Tris0.1 M Sodium citrate0.1 M Sodium citrate0.1 M sodium phosphate0.1 M sodium phosphate0.05 HEPES0.1 M sodium citrate0.1 M tricine0.1 M tricine0.1 M sodium citrate0.1 M sodium citrate0.1 M HEPES | 9.0<br>8.5<br>None<br>4.0<br>6.1<br>8.0<br>6.5<br>5.5<br>9.3<br>-<br>7.8<br>7.0<br>9.0<br>6.0<br>3.5<br>7.5<br>7.4<br>6.5<br>6.0<br>7.5  | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000<br>33% v/v PEG 400<br>11% w/v PEG 8000<br>22% w/v PEG 8000<br>23% v/v PEG 400<br>26% v/v PEG 400<br>26% v/v PEG 400<br>22% w/v PEG 6000<br>28% v/v PEG 600<br>33% v/v PEG 300<br>6.6% w/v PEG 300<br>28% v/v PEG 300<br>28% v/v PEG 400<br>11% w/v PEG 400<br>28% w/v PEG 400<br>11% w/v PEG 400<br>28% w/v PEG 400<br>11% w/v PEG 4000<br>11% w/v PEG 4000<br>11% w/v PEG 4000  |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>84<br>83<br>84<br>85<br>86<br>87<br>88<br>88<br>89<br>90<br>91<br>92<br>93<br>94             | None0.1 M magnesium chloride/0.1 M<br>sodium chloride0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate0.2 M magnesium chloride/0.1 M<br>potassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/v<br>ethylene glycol0.05 M sodium chloride0.1 M lithium sulfate0.1 M lithium sulfate0.15 M potassium citrate/0.05 M<br>lithium citrate0.001 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.01 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.1 M sodium chloride0.1 M sodium chloride0.2 M lithium sulfate0.1 M sodium chloride0.2 M lithium sulfate0.2 M lithium sulfate0.2 M calcium chloride1 M sodium chloride0.2 M calcium chloride0.2 M zinc sulfate0.2 M zinc sulfate0.002 M zinc sulfate   | 0.05 M glycine0.1 M Tris0.05 M citric acid0.025 M sodium citrate0.05 M MES0.1 M Tris0.1 M Tris0.1 M Sodium citrate0.1 M Sodium citrate0.1 M sodium citrate0.1 M sodium phosphate0.05 HEPES0.1 M sodium phosphate0.05 M Bicine0.1 M sodium citrate0.1 M Tris0.1 M tricine0.1 M Sodium citrate0.1 M HEPES0.08 M HEPES                  | 9.0<br>8.5<br>None<br>4.0<br>6.1<br>8.0<br>6.5<br>5.5<br>9.3<br>-<br>7.8<br>7.0<br>9.0<br>6.0<br>3.5<br>7.5<br>7.4<br>6.5<br>6.0<br>7.5<br>7.0   | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000<br>33% v/v PEG 400<br>11% w/v PEG 8000<br>22% w/v PEG 8000<br>23% v/v PEG 400<br>26% v/v PEG 400<br>26% v/v PEG 400<br>22% w/v PEG 6000<br>28% v/v PEG 600<br>33% v/v PEG 300<br>6.6% w/v PEG 300<br>6.6% w/v PEG 8000<br>28% v/v PEG 400<br>11% w/v PEG 400<br>11% w/v PEG 4000<br>28% w/v PEG 4000<br>11% w/v PEG 4000<br>11% w/v PEG 4000<br>28% v/v PEG 4000<br>28% w/v PEG 4000<br>28% w/v PEG 4000<br>28% w/v PEG 4000<br>28% w/v PEG 4000<br>25% v/v Jeffamine ED2001 |
| 74<br>75<br>76<br>77<br>78<br>79<br>80<br>81<br>82<br>83<br>84<br>83<br>84<br>85<br>86<br>87<br>88<br>87<br>88<br>89<br>90<br>91<br>92<br>93<br>94<br>95 | None0.1 M magnesium chloride/0.1 M<br>sodium chloride0.1 M lithium sulfate/0.05 M<br>disodium hydrogen phosphate0.2 M magnesium chloride/0.1 M<br>potassium chloride0.05 M zinc acetate0.3 M magnesium nitrate0.1 M sodium chloride/4% v/v<br>ethylene glycol0.05 M sodium chloride0.1 M sodium chloride0.1 M sodium chloride0.1 M lithium sulfate0.15 M potassium citrate/0.05 M<br>lithium citrate0.001 M zinc sulfate0.1 M sodium chloride0.1 M sodium chloride0.1 M sodium chloride0.2 M lithium sulfate0.3 M ithium sulfate0.4 M sodium chloride0.5 M zinc acetate/6% v/v<br>ethylene glycol0.2 M lithium sulfate0.1 M sodium chloride0.2 M lithium sulfate0.2 M calcium chloride1 M sodium chloride0.002 M zinc sulfate0.001 M cadmium chloride/0.03<br>M magnesium chloride  | 0.05 M glycine0.1 M Tris0.05 M citric acid0.05 M sodium citrate0.05 M MES0.1 M Tris0.1 M Tris0.1 M Sodium citrate0.1 M sodium citrate0.1 M sodium citrate0.1 M sodium phosphate0.05 HEPES0.1 M sodium phosphate0.05 M Bicine0.1 M sodium citrate0.1 M tricine0.1 M tricine0.1 M HEPES0.08 M HEPES0.1 M MES0.1 M MES0.1 M MES         | 9.0           8.5           None           4.0           6.1           8.0           6.5           9.3           -           7.8           7.0           9.0           6.0           3.5           7.5           7.4           6.5           7.0           6.5 | 55% v/v PEG 400<br>33% v/v PEG 400<br>19% w/v PEG 1000<br>33% v/v PEG 400<br>11% w/v PEG 8000<br>22% w/v PEG 8000<br>23% v/v PEG 400<br>26% v/v PEG 400<br>26% v/v PEG 400<br>22% w/v PEG 6000<br>28% v/v PEG 600<br>33% v/v PEG 300<br>33% v/v PEG 300<br>6.6% w/v PEG 300<br>28% v/v PEG 400<br>11% w/v PEG 400<br>11% w/v PEG 400<br>28% w/v PEG 400<br>11% w/v PEG 400<br>28% v/v PEG 400<br>25% v/v PEG 400   |

### Abbreviations:

ADA; N-(2-Acetamido)iminodiacetic Acid, **Bicine**; N,N-Bis(2-hydroxyethyl)glycine, **CHES**; 2-(N-Cyclohexylamino)ethane sulfonic Acid, **HEPES**; N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid, **KMES**; 2-(N-morpholino)ethanesulfonic acid potassium salt, **MES**; 2-(N-morpholino)ethanesulfonic acid, **MME**; Monomethylether, **PEG**; Polyethylene glycol, **Tricine**; N-[Tris(hydroxymethyl)methyl]glycine, **Tris**; 2-Amino-2-(hydroxymethyl)propane-1,3-diol,**Tris HCI**; 2-Amino-2-(hydroxymethyl)propane-1,3-diol, hydrochloride]

INFECTION AND IMMUNITY, Nov. 2011, p. 000 0019-9567/11/\$12.00 doi:10.1128/IAI.05469-11 Copyright © 2011, American Society for Microbiology. All Rights Reserved.

### Outer Membrane Protein A of Bovine and Ovine Isolates of Mannheimia haemolytica Is Surface Exposed and Contains Host Species-Specific Epitopes<sup>∇</sup>

Jonathan D. A. Hounsome,<sup>1</sup> Susan Baillie,<sup>1</sup> Mojtaba Noofeli,<sup>1</sup> Alan Riboldi-Tunnicliffe,<sup>2</sup> Richard J. S. Burchmore,<sup>1</sup> Neil W. Isaacs,<sup>2</sup> and Robert L. Davies<sup>1</sup>\*

Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom,<sup>1</sup> and School of Chemistry, College of Science and Engineering, University of Glasgow, Glasgow, United Kingdom<sup>2</sup>

Received 25 May 2011/Returned for modification 23 June 2011/Accepted 8 August 2011

Mannheimia haemolytica is the etiological agent of pneumonic pasteurellosis of cattle and sheep; two different OmpA subclasses, OmpA1 and OmpA2, are associated with bovine and ovine isolates, respectively. These proteins differ at the distal ends of four external loops, are involved in adherence, and are likely to play important roles in host adaptation. M. haemolytica is surrounded by a polysaccharide capsule, and the degree of OmpA surface exposure is unknown. To investigate surface exposure and immune specificity of OmpA among bovine and ovine *M. haemolytica* isolates, recombinant proteins representing the transmembrane domain of OmpA from a bovine serotype A1 isolate (rOmpA1) and an ovine serotype A2 isolate (rOmpA2) were overexpressed, purified, and used to generate anti-rOmpA1 and anti-rOmpA2 antibodies, respectively. Immunogold electron microscopy and immunofluorescence techniques demonstrated that OmpA1 and OmpA2 are surface exposed, and are not masked by the polysaccharide capsule, in a selection of M. haemolytica isolates of various serotypes and grown under different growth conditions. To explore epitope specificity, anti-rOmpA1 and anti-rOmpA2 antibodies were cross-absorbed with the heterologous isolate to remove cross-reacting antibodies. These cross-absorbed antibodies were highly specific and recognized only the OmpA protein of the homologous isolate in Western blot assays. A wider examination of the binding specificities of these antibodies for M. haemolytica isolates representing different OmpA subclasses revealed that cross-absorbed anti-rOmpA1 antibodies recognized OmpA1-type proteins but not OmpA2-type proteins; conversely, cross-absorbed antirOmpA2 antibodies recognized OmpA2-type proteins but not OmpA1-type proteins. Our results demonstrate that OmpA1 and OmpA2 are surface exposed and could potentially bind to different receptors in cattle and sheep.

The Gram-negative bacterium Mannheimia haemolytica is a commensal of cattle, sheep, and other ruminants but also causes bovine and ovine pneumonic pasteurellosis; these infections are responsible for considerable economic losses to the livestock industries (33, 35). Twelve different capsular serotypes of M. haemolytica have been identified to date, but A1 and A2 are the most prevalent (37), and strains of these serotypes are responsible for the majority of pneumonia cases worldwide in cattle and sheep, respectively. M. haemolytica consists of genetically distinct subpopulations that are differentially adapted to, and elicit disease in, either cattle or sheep (20, 21). The molecular basis of host adaptation and host specificity in M. haemolytica is not understood, but it is likely that outer membrane proteins (OMPs) play important roles in these processes. The publication of the genome sequence of a bovine serotype A1 M. haemolytica isolate (36) and, more recently, of the genome sequences of bovine and ovine serotype A2 isolates (45) have revealed the presence of genes that

encode various OMPs. Many of these proteins serve as adhesins that are involved in host receptor-specific binding (19) or as iron transport proteins (69).

There is growing evidence to suggest that the OmpA protein of M. haemolytica functions as an adhesin (41, 48). OmpA is a highly conserved, integral, outer membrane protein of Gramnegative bacteria that has been implicated in a diverse range of functions in different species (reviewed in reference 72). It comprises an N-terminal transmembrane B-barrel domain embedded in the outer membrane and a C-terminal globular domain which extends into the periplasm to interact with the underlying peptidoglycan (28). The N-terminal domain consists of eight membrane-traversing antiparallel B-sheets and four relatively long, mobile, hydrophilic external loops (62). In previous studies, molecular mass heterogeneity of OmpA was observed among bovine and ovine M. haemolytica isolates that correlated with the host of origin (21). Subsequently, comparative nucleotide sequence analysis of the ompA gene from 31 *M. haemolytica* isolates revealed the presence of hypervariable domains within the four surface-exposed loops (22). The amino acid sequences of these domains are very different in bovine and ovine isolates but are highly conserved among isolates recovered from the same host species (22). The ompA gene can be categorized into four distinct allelic classes, I to IV. The class I (ompA1) alleles are associated almost exclu-

<sup>\*</sup> Corresponding author. Mailing address: Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Sir Graeme Davies Building, 120 University Place, Glasgow G12 8TA, United Kingdom. Phone: 44 141 330 6685. Fax: ••••.

<sup>&</sup>lt;sup>v</sup> Published ahead of print on 6 September 2011.

#### 2 HOUNSOME ET AL.

INFECT. IMMUN.

| Inglato | L'TW | 0        | Host    | Clinical  |                | ompA    | Immunogold labeling |             | Immunofluorescence |             |
|---------|------|----------|---------|-----------|----------------|---------|---------------------|-------------|--------------------|-------------|
| Isolate | E1"  | Serotype | species | status    | Site of origin | allele  | Anti-rOmpA1         | Anti-rOmpA2 | Anti-rOmpA1 Anti   | Anti-rOmpA2 |
| PH2     | 1    | A1       | Bovine  | Pneumonia | Lung           | ompA1.1 | +                   | -           | +                  | -           |
| PH30    | 1    | A1       | Bovine  | Healthy   | Nasopharynx    | ompA1.1 | +                   | -           | +                  | +/-         |
| PH376   | 1    | A6       | Bovine  | Pneumonia | Lung           | ompA1.1 | +                   |             | +                  | —           |
| PH540   | 2    | A1       | Bovine  |           | Nasopharynx    | ompA1.2 | +                   |             | +                  | -           |
| PH202   | 21   | A2       | Bovine  | Healthy   | Nasopharynx    | ompA1.3 | +                   | -           | +                  | +/-         |
| PH470   | 21   | A2       | Bovine  | Pneumonia | Lung           | ompA1.3 | +                   | -           | +                  | -           |
| PH494   | 16   | A2       | Ovine   | Pneumonia | Lung           | ompA1.4 | +                   | -           | +                  | —           |
| PH550   | 17   | A2       | Bovine  | Healthy   | Nasopharynx    | ompA1.5 | +                   | <u> </u>    | +                  | +/-         |
| PH8     | 6    | A1       | Ovine   | Pneumonia | Lung           | ompA2.1 | -                   | +           | +/-                | +           |
| PH284   | 8    | A6       | Ovine   | Pneumonia | Lung           | ompA2.1 | -                   | +           | +/-                | +           |
| PH66    | 10   | A14      | Ovine   |           | Lung           | ompA2.1 | -                   | +           | +/-                | +           |
| PH56    | 5    | A8       | Ovine   | Pneumonia | Lung           | ompA2.2 | -                   | +           | +/-                | +           |
| PH278   | 21   | A2       | Ovine   | Pneumonia | Lung           | ompA2.3 | 1                   | +           |                    | +           |
| PH292   | 22   | A2       | Ovine   | Pneumonia | Lung           | ompA2.3 |                     | +           | -                  | +           |
| PH196   | 18   | A2       | Bovine  | Healthy   | Nasopharynx    | ompA3.1 | 1 1 -               | +/-         | -                  | +/-         |
| PH296   | 12   | A7       | Ovine   | Pneumonia | Lung           | ompA4.1 | - 1                 | +/-         | -                  | +/-         |
| PH484   | 14   | A7       | Ovine   | Pneumonia | Lung           | ompA4.1 | - 1                 | +/-         | -                  | +/-         |
| PH588   | 15   | A13      | Ovine   | Pneumonia | Lung           | ompA4.2 | - (                 | +/-         | 1-                 | +/-         |

TABLE 1. Properties of bovine and ovine M. haemolytica isolates

<sup>a</sup> ET, electrophoretic type (16).

sively with bovine *M. haemolytica* isolates, whereas the class II to IV (*ompA2* to *ompA4*) alleles occur only in ovine *M. haemolytica* isolates (22). Significantly, the *ompA1*- and *ompA2*-type alleles are associated with the major pathogenic lineages of bovine (electrophoretic type [ET] 1) and ovine (ETs 21 and 22) isolates, respectively (16). Based on the distribution of the OmpA1 and OmpA2 proteins among bovine and ovine isolates, respectively, and the localization of the amino acid variation to the tips of the four loops, it was hypothesized that OmpA acts as a ligand, plays an important role in adherence, and is involved in host specificity (22). Subsequently, it was demonstrated that OmpA is involved in the binding of serotype A1 *M. haemolytica* to bovine bronchial epithelial cells (41) and that fibronectin is a potential host receptor molecule in cattle (48).

The cell envelope of *M. haemolytica* is surrounded by a layer of capsular polysaccharide (CPS) (1, 47) which has been implicated in a number of functions, including the adherence of the bacterium to alveolar surfaces (10, 79), inhibition of complement-mediated serum killing (11), and inhibition of the phagocytic and bactericidal activities of neutrophils (17, 77). Visibly thicker capsules have been observed in M. haemolytica during in vitro early-log-phase growth than during stationaryphase growth in both capsular serotype A1 (16) and A2 (73) isolates. Crucially, polysaccharide capsules have been shown to inhibit outer membrane adhesin function in a range of capsular types in different bacterial species (32, 70, 71, 76). Indeed, an acapsular serotype A1 M. haemolytica mutant was shown to have greater fibronectin-binding activity than that of the capsular parental strain, suggesting a shielding role of the capsule. In other species, CPS may be downregulated upon contact with host cells (2, 15, 26) or as a consequence of phase-variable expression (4, 29, 43), thus allowing transient exposure of outer membrane adhesins. The shielding of OMPs, including OmpA, by CPS is likely to have important implications for the function of surface proteins but has yet to be investigated in M. haemohtica.

The objectives of this study were 2-fold. First, we wished to determine if the *M. haemolytcia* OmpA protein is surface exposed or whether it is masked by the polysaccharide capsule under various growth conditions. Second, we wanted to demonstrate whether the bovine OmpA1 and ovine OmpA2 proteins are antigenically distinct, i.e., whether antibodies raised against each of these proteins interact in a strain-specific manner. This would provide clues as to whether these proteins are likely to interact with host cell receptors in a host-specific manner. To achieve these aims, recombinant OmpA1 (rOmpA1) and OmpA2 (rOmpA2) proteins were overexpressed, purified, and used to generate anti-OmpA1 and anti-OmpA2 antibodies, respectively. These antibodies were used to explore OmpA surface exposure and epitope specificity using electron microscopy and immunofluorescence techniques.

#### MATERIALS AND METHODS

Bacterial strains and growth conditions. The *M. haemolytica* isolates used in this study are shown in Table 1. *Escherichia coli* strains DH5 $\alpha$  and Rosetta 2(DE3)pLysS were obtained from Invitrogen and Novagen, respectively. The *M. haemolytica* isolates were stored at  $-80^{\circ}$ C in 50% (vol/vol) glycerol in brain heart infusion (BHI) broth and were subcultured on BHI agar containing 5% (vol/vol) defibrinated sheep's blood (blood agar) overnight at 37°C. Liquid starter cultures were prepared by inoculating a few colonies into 10-ml volumes of BHI broth and incubating them overnight at 37°C with shaking at 120 rpm. *E. coli* strain DH5 $\alpha$  was grown in Luria-Bertani (LB) broth containing 54 µg/ml carbenicillin. and 34 µg/ml chloramphenicol. Both *E. coli* strains were grown at 37°C with shaking at 120 rpm.

Capsule staining. The polysaccharide capsule of *M. haemolytica* was demonstrated using the Maneval method (16).

Preparation of chromosomal DNAs. Bacterial cells from 1 ml of overnight culture were harvested by centrifugation for 1 min at  $13,000 \times g$  and washed once with 1 ml of sterile distilled H<sub>2</sub>O (dH<sub>2</sub>O). DNAs were prepared using an InstaGene Matrix kit (Bio-Rad) according to the manufacturer's instructions and were stored at  $-20^{\circ}$ C.

PCR amplification and plasmid construction. The *M. haemolytica ompA* gene fragments corresponding to the transmembrane domain of OmpA1 (amino acid positions 19 to 217) and OmpA2 (amino acid positions 19 to 211) were amplified by PCR from total genomic DNA from *M. haemolytica* isolates PH2 and PH278, respectively, using the following forward and reverse primers: 5'-AAGTICITG

#### Vol. 79, 2011

TITCAGGGCCCGCAAGCTAACACTTTCTACGCAGG-3' and 5'-ATGGT CTAGAAAGCTTTAACCTTGACCGAAACGGTATG-3', PCR products containing the ompA1 or ompA2 gene fragments were amplified from chromosomal DNA in 50-µl reaction mixtures using Platinum Pfx DNA polymerase (Invitrogen) with 2 mM MgSO4 and 50 pmol of each forward and reverse primer. PCRs were carried out in a GeneAmp PCR System 9700 (Applied Biosystems) thermal cycler using the following amplification parameters: initial denaturation at 94°C for 2 min, followed by 30 cycles of denaturation at 94°C for 15 s, annealing at 65°C for 30 s, and extension at 68°C for 1 min 30 s. The production of PCR amplicons of the expected size was confirmed by electrophoresis in a 1% (wt/vol) agarose gel and visualization with SybrSafe (Invitrogen). The PCR amplicons were purified with a QIAquick PCR purification kit (Qiagen) and eluted in 30 µl of sterile distilled H2O. Yields were assessed by agarose gel electrophoresis, and the DNA was stored at -20°C. The PCR products were cloned into separate pOPINF vectors (Oxford Protein Production Facility) (6) according to the manufacturer's instructions. The resulting plasmids, designated ompA1/His-pOPINF and ompA2/His-pOPINF, were verified by DNA sequencing. Five microliters of ompA1/His-pOPINF or ompA2/His-pOPINF was added to a tube containing 50  $\mu$ L E. coli DH5 $\alpha$  cells (as supplied by the manufacturer) and incubated on ice for 30 min. The mixtures were heated in a water bath at 42°C for 30 s and returned to ice for 2 min. Four hundred fifty microliters of GS96 broth (QbioGene) was added to each tube, and the contents were mixed thoroughly and incubated at  $37^{\circ}$ C for 1 h. Transformant colonies were selected after plating onto LB agar containing 54 µg/ml carbenicillin and incubation overnight at  $37^{\circ}$ C. An individual colony was used to inoculate 50 ml of LB containing 54 µg/ml carbenicillin and grown overnight at 37°C with shaking at 170 rpm. Five milliliters of the overnight culture was centrifuged at 5,000  $\times$  g for 15 min at 4°C to pellet the cells. Plasmids were recovered using a QIAprep Spin Miniprep kit (Qiagen) according to the manufacturer's instructions and eluted in 50 µl of sterile distilled H2O. Plasmid size was confirmed by electrophoresis on a 1% (wt/vol) agarose gel and visualization with SybrSafe (Invitrogen). The DNA was stored at -20°C

Expression of rOmpA. Two microliters of ompA1/His-pOPINF or ompA2/His pOPINF plasmids recovered from E, coli DH5a transformant cultures was added to a tube containing 100 µl E. coli Rosetta 2(DE3)pLysS cells (Novagen) as supplied by the manufacturer and incubated on ice for 30 min. The bacterial cells were heated in a water bath at 42°C for 30 s and returned to ice for 2 min. Four hundred fifty microliters of GS96 broth was added to each tube, and the contents were mixed thoroughly and incubated at 37°C for 1 h. Transformant colonies were selected after plating onto LB agar containing 54 µg/ml carbenicillin and 34 µg/ml chloramphenicol and incubation overnight at 37°C. An individual colony was used to inoculate 15 ml LB and grown overnight at 37°C with shaking at 120 rpm. One hundred fifty microliters of overnight culture was inoculated into 30 ml LB broth containing 54 µg/ml carbenicillin and 34 µg/ml chloramphenicol and incubated at 37°C with shaking at 170 rpm until an optical density at 600 nm (OD<sub>600</sub>) of 0.7 to 1.0 was achieved. Thirty microliters of 1 M isopropyl-β-Dthiogalactopyranoside (IPTG) was added, and the culture was incubated at 25°C with shaking at 170 rpm for a further 18 h. One and one-half milliliters of overnight culture was centrifuged for 1 min at 13,000 imes g, and the pellet was resuspended in 100 µl of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. The sample was heated at 100°C for 5 min and analyzed by SDS-PAGE to check for the presence of recombinant protein. A second colony from the E. coli Rosetta 2(DE3)pLysS transformant plate was used to inoculate 15 ml LB broth and grown overnight at 37°C with shaking at 120 rpm. Two milliliters of overnight culture was used to inoculate each of eight 2-liter Erlenmeyer flasks containing 1 liter of LB broth supplemented with 54 µg/ml carbenicillin and 34 µg/ml chloramphenicol and incubated at 37°C with shaking at 170 rpm until an  $OD_{600}$  of 0.7 to 1.0 was achieved. One milliliter of 1 M IPTG was added, and the culture was incubated at 25°C with shaking at 170 rpm for a further 18 h.

Purification of recombinant OmpA proteins (rOmpA1 and rOmpA2). The protein purification protocol of Zhu et al. (82) was followed, with modifications. Bacterial cells from each 1 liter of culture were harvested by centrifugation at 10,000 × g for 20 min at 4°C, resuspended in 25 ml of buffer A (25 mM Tris, 200 mM NaCl [pH 8.0]), and stored at  $-20^{\circ}$ C. The cells from 2 liters of culture medium were disrupted by sonication (six cycles of 30 s on and 30 s off), and the lysates were centrifuged at 4,700 × g for 30 min at 4°C to pellet the inclusion bodies. These were resuspended in 1% Triton X-100 in buffer A and centrifuged at 4,700 × g for 30 min at 4°C to pellet the inclusion bodies. These were resuspended in 1% Triton X-100 in buffer A and centrifuged at 4,700 × g for 30 min at 4°C to pellet the inclusion bodies. These were resuspended in 1% Triton X-100 in buffer A and centrifuged at 4,700 × g for 30 mM at 4°C. The inclusion bodies were solubilized overnight at 4°C in 50 ml of 6 M urea. The solubilized protein was added dropwise to 500 ml of 50 mM HEPES, 300 mM NaCl, 3% *N*,*N*-dimethyldodecylamine-*N*-oxide (LDAO), 5 mM dithiothreitol (DTT) (pH 8.0) at 4°C; stirred slowly at 4°C for 72 h; and dialyzed against buffer B (50 mM Tris, 300 mM NaCl, 0.1% LDAO [pH 7.6]). The protein solution was loaded onto a 5-ml HiTrap (GE Healthcare)

#### M. HAEMOLYTICA OmpA SURFACE EXPOSURE AND SPECIFICITY 3

column equilibrated with buffer B. Bound recombinant protein was eluted from the column using an imidazole gradient (0 to 300 mM imidazole in buffer B) and collected in 5-ml fractions. Protein concentrations were quantified using a Perkin-Elmer Lambda 40 UV/VIS spectrophotometer. Ten miligrams of eluted protein was loaded onto a Superdex G-200 gel filtration column (Pharmacia Biotech) equilibrated with buffer B and collected in 5-ml fractions after running at 0.25 ml/min overnight. Concentrations of rOmpA in the collected fractions were determined by the modified Lowry procedure (52).

Circular dichroism spectroscopy. Circular dichroism spectroscopy (40) was performed to examine the secondary structure of refolded PH2 rOmpA1 and PH278 rOmpA2. Mean residue ellipticity was measured between 190 and 240 nm on a Jasco J-810 spectropolarimeter (Jasco, United Kingdom). Percentage estimates of secondary structure content ( $\alpha$ -helix,  $\beta$ -strands, turn, unordered) were calculated using the modified CONTINLL algorithm (66, 75) provided by the online server DICHROWEB (49, 80).

Anti-OmpA antibody preparation. Purified rOmpA1 and rOmpA2 were sent to Eurogentec (Belgium) and used to raise antibodies in rabbits using their 87-day classic polyclonal antibody protocol. This protocol involves the injection of 0.2 mg of protein into each of two rabbits at days 0, 14, 28, and 56. Serum bleeds were obtained before the first injection (preimmune) and 38, 66, and 87 (final bleed) days after the initial injection.

Serum cross-absorption. Two hundred fifty milliliters of overnight cultures of PH2 and PH278 was centrifuged at  $10,000 \times g$  for 20 min at 4°C, and the cells were washed three times in 50 ml phosphate-buffered saline (PBS). The bacterial cells were resuspended in 5 ml PBS, and 1 ml was aliquoted into each of five microcentrifuge tubes. Each microcentrifuge tube was centrifuged ( $13,000 \times g$ , 3 min) to pellet the cells, and the supernatants were removed. Cells from one tube were resuspended in 1 ml of heterologous final bleed serum and incubated at 37°C for 30 min on an orbital shaker. The cells were pelleted by centrifuge tube. These were incubated at 37°C for 30 min on an orbital shaker. This process was repeated for the remaining three tubes. The cross-absorbed sera were diluted 1:5 with distilled water (dH<sub>2</sub>O), filter sterilized, and stored at = 80°C. Isolation of OMPs. The OMPs of *M. haemolytica* isolates PH2 and PH278

where prepared as previously described (24). SDS-PAGE. OMPS were separated by SDS-PAGE in a 12% polyacrylamide

gel as previously described (24).

Western blotting. Briefly, Western blotting was performed essentially as described by Davies et al. (23). SDS-PAGE gels were equilibrated in transfer buffer (25 mM Tris, 192 mM glycine [pH 8.3]) for 30 min, and the proteins were transferred to nitrocellulose membranes overnight at 30 V. The nitrocellulose membranes were washed twice in TBS (20 mM Tris, 50 mM NaCl [pH 7.5]) for 5 min, blocked with 3% gelatin in TBS for 1 h, and washed twice in TTBS (0.05% Tween 20 in TBS) for 5 min each. The membranes were incubated with final bleed anti-rOmpA antibody diluted 1:100 in antibody buffer (1% gelatin in TTBS) for 1 h at room temperature and washed twice in TTBS for 5 min each. This was followed by incubation with secondary horseradish peroxidase-conjugated anti-rabbit antibody diluted 1:1,000 in antibody buffer for 1 h at room temperature, two 5-min washes in TTBS, and one 5-min wash in TBS. The membranes were developed in a substrate solution containing 0.05% (wt/vol) 4-chloro-naphthol (dissolved in 20 ml of ice-cold methanol) and 0.05% (vol/vol) hydrogen peroxide in 100 ml of TBS. Development was stopped by washing the membranes in distilled  $H_2O$ .

Immunogold electron microscopy. Bacterial cells from 25-ml volumes of 6- or 8-h BHI broth cultures, or 6-h BHI broth cultures containing 100 µM 2,2dipyridyl, were harvested by centrifugation at  $3,500 \times g$  for 5 min and washed once with PBS. Alternatively, overnight cultures of bacteria were scraped off blood agar plates and washed once in PBS. The washed cells were resuspended in PBS to an  $\rm OD_{600}$  of 0.4 equivalent to  $1.0\times 10^8$  CFU/ml. One milliliter of this suspension was centrifuged at  $13,000 \times g$  for 1 min, and the pellet was resuspended in 1 ml 4% paraformaldehyde in PBS (pH 7.2) for 30 min at room temperature. The cells were washed twice in 50 mM glycine in PBS and resuspended in 0.5 ml of 0.2% bovine serum albumin (BSA) in PBS for 30 min. The cells were centrifuged and resuspended in 100 µl primary anti-rOmpA antibody (1:10 dilution) in 0.2% BSA in PBS, incubated for 1 h, washed three times in 0.2% BSA in PBS, and finally resuspended in 200 µl of 0.2% BSA in PBS. Twenty microliters of this suspension was dropped onto a freshly prepared poly-L-lysine-coated Formvar carbon-coated nickel grid and allowed to stand for 15 min, and the excess fluid was removed. The grids were floated facedown on 50 ul of secondary goat anti-rabbit IgG antibody conjugated to 10-nm gold particles (1:20 dilution) in 0.2% BSA in PBS and incubated for 1 h at room temperature. The grids were washed once in 0.2% BSA in PBS, three times in PBS (1 min each), and once in 1% glutaraldehyde in PBS (pH 7.4) for 5 min. The grids were

4 HOUNSOME ET AL.

B А PH<sub>2</sub> PH2 PH278 PH278 50 60 70 80 90 100 50 60 70 80 90 100 kDa 60 70 80 90 100 50 60 70 80 90 100 kDa 50 ----== 97 66 45 45 14.4 14.4



finally washed three times with filtered deionized water (1 min each) and allowed to air dry, and the bacteria were visualized using a Zeiss 912 AB energy-filtering transmission electron microscope operating under standard conditions at 80 kV.

Immunofluorescence staining. Bacteria were grown overnight on blood agar, resuspended in 5 ml PBS, and adjusted to an  $OD_{600}$  of 0.5. The bacterial cells were mixed 1:1 with 8% paraformaldehyde in PBS (2×) for 10 min. Five micro-liters of bacterial suspension was added to each well of a multiwell microscope slide (Hendley-Essex, United Kingdom), allowed to air dry, and incubated with 20 µl of primary anti-rOmpA antibody (1:100 dilution) in 0.1% BSA in PBS for 60 min at room temperature. The slides were washed three times in 0.1% BSA in PBS and incubated with 20 µl of Alexa Fluor 488 (Invitrogen) goat anti-rabbit IgG antibody (15 µg/ml in 0.1% BSA in PBS) for 30 min. The slides were washed three times in 0.1% BSA in PBS and allowed to air dry. One or two drops of fluorescence mounting medium (Dako, Sweden) were added to each slide, covered with a coverslip, and sealed with clear nail varnish. Bacteria were visualized with 21 a slides with a 26 size Axioskop fluorescence microscope.

#### RESULTS

Recombinant OmpA proteins are comprised predominantly of B-sheets and exhibit heat modifiability after heat treatment in the presence of SDS. Heat modifiability is a characteristic property of the OmpA family of proteins (5, 58, 68). The native form of the complete OmpA protein unfolds in the presence of SDS only after heat treatment at 100°C, which exposes additional SDS-binding sites (30, 59). When analyzed by SDS-PAGE, OmpA migrates through the gel according to its structural compactness, with the native protein migrating faster than the fully denatured polypeptide (30, 42). Recombinant OmpA proteins from the M. haemolytica bovine isolate PH2 (rOmpA1) and ovine isolate PH278 (rOmpA2) were successfully expressed, purified, and refolded after cloning the ompA gene fragments encoding the OmpA transmembrane domains into an E. coli protein expression strain. Mass spectrometric analysis of gel-extracted protein bands confirmed that native and heat-modified proteins (described below) represented M. haemolytica OmpA (results not shown). The rOmpA1 and rOmpA2 proteins were heated at a range of temperatures between 50 and 100°C for 5 min prior to SDS-PAGE, and both proteins exhibited heat modifiability when analyzed by SDS-PAGE, although this occurred at different temperatures (Fig. 1A). The native and heat-modified proteins migrated at approximately 24 and 22.5 kDa, respectively; however, PH2 rOmpA1 unfolded at 70°C whereas PH278 rOmpA2 unfolded at 100°C (Fig. 1A, arrows). In contrast, the native and heatmodified forms of the complete OmpA protein recovered from the outer membrane of M. haemolytica isolates PH2 and PH278 migrated at approximately 32 and 38 kDa, respectively, on SDS-polyacrylamide gels (Fig. 1B). In this case, the fulllength OmpA protein of both isolates underwent heat modification at 100°C (Fig. 1B, arrows). The finding that rOmpA1 unfolds more readily at a lower temperature than does rOmpA2 indicates a less stable structure for rOmpA1. Circular dichroism spectroscopy analysis predicted that the secondary structures of both recombinant proteins comprised predominantly B-sheets and turns, indicating that they have folded into a β-barrel conformation similar to that of native M. haemolytica OmpA (Fig. 2). However, PH2 rOmpA1 has a lower β-sheet composition than does PH278 rOmpA2 (33.6% and 40.6%, respectively), which is consistent with the heat modifiability results indicating a less stable structure for PH2 rOmpA1.

Anti-rOmpA1 and anti-rOmpA2 antibodies exhibit immune specificity for the homologous proteins. The binding specificities of the anti-rOmpA1 and anti-rOmpA2 antibodies to Sarkosyl-extracted OMPs and rOmpA from the bovine isolate PH2 and the ovine isolate PH278 were assessed by Western blotting (Fig. 3). Unabsorbed anti-rOmpA1 antibodies bound to the full-length OmpA and rOmpA proteins of both PH2 (Fig. 3A, panel ii) and PH278 (Fig. 3B, panel ii). Similarly, unabsorbed anti-rOmpA2 antibodies bound to the full-length

INFECT. IMMUN.



FIG. 2. Circular dichroism spectroscopy analysis of purified rOmpA proteins. Mean residue ellipticity was measured between 190 and 240 nm for PH2 rOmpA1 ( $\blacktriangle$ ) and PH278 rOmpA2 ( $\blacksquare$ ). Percentage estimates of secondary structure content ( $\alpha$ -helix,  $\beta$ -strands, turn, unordered) for each recombinant protein were calculated using the modified CONTINLL algorithm (66, 75) provided by the online server DICHROWEB (49, 80).

OmpA and rOmpA proteins of both PH2 (Fig. 3A, panel iii) and PH278 (Fig. 3B, panel iii). Significantly, no other M. haemolytica proteins were recognized by either antibody in the complete Sarkosyl-extracted outer membrane protein samples. After cross-absorption with the heterologous isolate PH278, anti-rOmpA1 antibodies bound to PH2 OmpA and rOmpA1 (Fig. 3A, panel iv) but not PH278 OmpA and rOmpA2 (Fig. 3B, panel iv). Similarly, anti-rOmpA2 antibodies cross-absorbed with the heterologous isolate PH2 bound to PH278 OmpA and rOmpA2 (Fig. 3B, panel v) but not PH2 OmpA and rOmpA1 (Fig. 3A, panel v). However, the intensity of staining with the cross-absorbed antisera was noticeably weaker than that for the unabsorbed antisera. These results indicate that the cross-absorbed anti-rOmpA1 and -rOmpA2 antibodies bind specifically to OmpA1 and OmpA2, respectively

M. haemolytica OmpA is surface exposed and recognized by anti-rOmpA antibodies in vitro in a strain-specific manner. The ability of anti-rOmpA antibodies to recognize OmpA on the surface of M. haemolytica was assessed by immunogold labeling (Fig. 4) and immunofluorescent staining (Fig. 5). Immunogold labeling demonstrated that the OmpA proteins of M. haemolytica isolates PH2 and PH278 are both recognized by unabsorbed anti-rOmpA1 (Fig. 4A and B, panel i) and antirOmpA2 (Fig. 4A and B, panel ii) antibodies. However, crossabsorbed anti-rOmpA1 antibodies recognized OmpA of isolate PH2 (Fig. 4A, panel iii) but not of isolate PH278 (Fig. 4B, panel iii); conversely, cross-absorbed anti-rOmpA2 antibodies recognized OmpA of isolate PH278 (Fig. 4B, panel iv) but not of isolate PH2 (Fig. 4A, panel iv). Antibody binding was evenly distributed over the surface of the bacterial cells and was not concentrated in any particular area. In addition, the density of labeling of isolate PH278 by the cross-absorbed anti-rOmpA2 antibody (Fig. 4B, panel iv) was greater than that of PH2 by the cross-absorbed anti-rOmpA1 antibody (Fig. 4A, panel iii), suggesting greater exposure of the OmpA2 protein in isolate PH278. Immunofluorescent staining confirmed that cross-absorbed anti-rOmpA1 antibodies recognized OmpA in isolate PH2 (Fig. 5A, panel i) but not in isolate PH278 (Fig. 5B, panel i) and that cross-absorbed anti-rOmpA2 antibodies recognized OmpA in isolate PH278 (Fig. 5A, panel i) but not in isolate PH278 (Fig. 5B, panel i) but not in isolate PH278 (Fig. 5A, panel i) but not in isolate PH278 (Fig. 5A, panel i) but not in isolate PH278 (Fig. 5A, panel ii) but not in

OmpA is surface exposed at different stages of the growth cycle and after growth in different media. Isolates PH2 and PH278 were grown for 6 h (logarithmic phase) and 18 h (stationary phase) in BHI broth, and cells were incubated with cross-absorbed anti-rOmpA1 or anti-rOmpA2 antibodies. No differences were observed in the degree of antibody binding between bacteria grown for 6 h and those grown for 18 h (results not shown). These results demonstrated that there was no appreciable difference in OmpA surface exposure between logarithmic- and stationary-phase cells. Isolates PH2 and PH278 were also grown for 18 h on blood agar or in ironrestricted (100 µM dipyridyl) BHI broth, and cells were incubated with cross-absorbed anti-rOmpA1 or anti-rOmpA2 antibodies. Again, no differences were observed in antibody binding between bacteria grown in iron-restricted BHI broth or on blood agar plates and bacteria grown in BHI broth (results not shown). We also examined the capsulation of bacteria grown under these various conditions by Maneval staining (results not shown); there were no major differences between isolates grown under different conditions with the exception that 18-h stationary-phase cultures contained cells that were less consistent in overall size and shape. Taken together, our results demonstrated that OmpA is not masked by the polysaccharide capsule and that the degree of surface exposure

#### 6 HOUNSOME ET AL.



FIG. 3. Western blot analysis of anti-rOmpA antibody binding to full-length OmpA and rOmpA of *M. haemolytica* isolates PH2 and PH278. Panels A and B represent protein samples from bovine isolate PH2 and ovine isolate PH278, respectively. Lanes 1 and 2 represent Sarkosyl-extracted OMPs and purified rOmpA, respectively. The protein samples were separated by SDS-PAGE and either stained with Coomassie blue (i) or transferred to nitrocellulose (ii to v). The blotted proteins were probed with anti-rOmpA1 antibodies (ii), anti-rOmpA2 antibodies (iii), anti-rOmpA1 antibodies after cross-absorption with isolate PH278 (iv), and anti-rOmpA2 antibodies after cross-absorption with isolate PH278 (iv). This was followed by incubation with secondary goat horseradish peroxidase-conjugated anti-rabbit antibody. Molecular mass markers (in kDa) are shown on the right.

remains relatively unchanged when bacteria are grown under different growth conditions. For subsequent experiments, bacterial cells were grown in BHI broth for 6 h.

Binding specificities of cross-absorbed anti-rOmpA1 and anti-rOmpA2 antibodies to *M. haemolytica* isolates representing different OmpA subclasses. Eleven distinct *ompA* alleles have previously been identified among 31 *M. haemolytica* isolates; these alleles were assigned to four subclasses, *ompA1* to *ompA4* (22). Individual alleles within each subclass were designated *ompA1.1*, *ompA1.2*, etc. The binding specificities of cross-absorbed anti-rOmpA1 and anti-rOmpA2 antibodies to 18 *M. haemolytica* isolates representing all 11 *ompA* alleles were determined by immunogold labeling and immunofluorescent staining (Table 1). Five *ompA1*-type alleles, representing the class I lineage, have been identified in *M. haemolytica*, and INFECT. IMMUN.



FIG. 4. Immunogold labeling of the OmpA protein of *M. haemohytica* isolates PH2 and PH278 using anti-rOmpA antibodies. Panels A and B represent bovine isolate PH2 and ovine isolate PH278, respectively. Isolates were incubated with anti-rOmpA1 antibodies (i), anti-rOmpA2 antibodies (ii), anti-rOmpA1 antibodies after crossabsorption with isolate PH278 (iii), and anti-rOmpA2 antibodies after cross-absorption with isolate PH278 (iii), This was followed by incubation with secondary goat anti-rabbit IgG antibody conjugated with 10-nm gold particles. Isolates were visualized by electron microscopy. Magnification, ×10,000.

these are associated almost exclusively with bovine isolates (22). The single exception, ovine isolate PH494, possesses a bovine-like LktA2-type leukotoxin (25) in addition to a bovinelike OmpA1-type protein and most likely represents a strain of bovine origin that has recently transferred to sheep. AntirOmpA1 antibodies were raised against bovine isolate PH2 OmpA, which possesses the ompA1.1 allele. At the amino acid level, OmpA1.1 is identical to OmpA1.2 and OmpA1.3; OmpA1.4 differs from OmpA1.1 at two amino acid positions in hypervariable region 1 (HV1) and OmpA1.5 differs from OmpA1.1 in having four amino acid deletions in HV1. Crossabsorbed anti-rOmpA1 antibodies bound to all eight OmpA1type M. haemolytica isolates when examined by both immunogold labeling and immunofluorescent staining (Table 1). Cross-absorbed anti-rOmpA2 antibodies showed a negative binding response to all OmpA1-type isolates when examined by immunogold labeling, although weak fluorescence was de-



FIG. 5. Immunofluorescent staining of *M. haemolytica* isolates PH2 and PH278 using cross-absorbed anti-rOmpA1 and anti-rOmpA2 antibodies. Panels A and B represent bovine isolate PH2 and ovine isolate PH278, respectively. Isolates were incubated with anti-rOmpA1 antibodies after cross-absorption with isolate PH278 (i) or anti-rOmpA2 antibodies after cross-absorption with isolate PH278 (ii). These were then incubated with Alexa Fluor 488 (Invitrogen) goat anti-rabbit IgG antibody. Bound antibodies were visualized by immunofluorescence microscopy.

tected in three isolates when examined by immunofluorescent staining (Table 1).

Three *ompA2*-type alleles, representing the class II lineage, have been identified in *M. haemolytica* and these are associated exclusively with ovine isolates (22). Anti-rOmpA2 antibodies were raised against ovine isolate PH278 OmpA, which possesses the *ompA2.3* allele. OmpA2.1 and OmpA2.2 are identical and differ from OmpA2.3 at one amino acid position in HV1 and one in HV3. Cross-absorbed anti-rOmpA2 antibodies showed positive binding to all six OmpA2-type *M. haemolytica* isolates when examined by both immunogold labeling and immunofluorescent staining (Table 1). There was a negative binding response to all OmpA2-type isolates with cross-absorbed anti-rOmpA1 antibodies when examined by immunogold labeling, although weak fluorescence was detected in four isolates by immunofluorescent staining (Table 1).

The *ompA3.1* allele, also belonging to the class II lineage, is associated with the bovine isolate PH196. The OmpA3.1 protein was recognized by cross-absorbed anti-rOmpA2 (weakly) but not by anti-rOmpA1 antibodies when examined by immunogold labeling and immunofluorescent staining. Two *ompA4*-type alleles, representing the class III lineage, have been identified in *M. haemolytica*, and these are associated with ovine serotype A7 and A13 isolates. The OmpA4-type proteins (OmpA4.1 and OmpA4.2) were recognized by cross-absorbed anti-rOmpA2 (weakly) but not by anti-rOmpA1 antibodies

when examined by immunogold labeling and immunofluorescent staining.

#### DISCUSSION

In the present study, we have clearly demonstrated that the OmpA protein of M. haemolytica is surface exposed and able to bind anti-rOmpA antibodies in vitro. This was initially demonstrated in the bovine and ovine isolates PH2 and PH278 (Fig. 4 and 5) but was subsequently confirmed in a wide range of M. haemolytica isolates (Table 1). The degree of surface exposure of OmpA in PH2 and PH278 was not affected by the stage of growth (i.e., logarithmic versus stationary phase) or the growth medium (i.e., blood agar and iron-replete or iron-restricted broth). Since a well-developed capsule was observed by Maneval staining in these isolates under different growth conditions, our findings strongly suggest that the capsule does not mask the OmpA protein since antibody binding seemed unaffected. However, in a previous study the OmpA protein of an acapsular mutant was shown to have higher fibronectin-binding activity than that of the capsular parental strain (48), suggesting that the capsule may partially mask the protein.

The loops of the *M. haemolytica* OmpA protein range from 25 to 31 amino acids in length (22) and are estimated to extend less than 10 nm from the bacterial surface (unpublished data). However, the capsule of the parental strain of the acapsular

#### 8 HOUNSOME ET AL.

mutant described above has been observed by electron microscopy to extend almost 200 nm from the bacterial surface (54). It is therefore puzzling as to how the loops of OmpA are recognized by antibodies and, presumably, by host cell molecules through a capsule of this thickness. The M. haemolytica capsule is structurally fragile, and it is possible that in vitro manipulation of bacterial cells causes sloughing of the capsule in some areas which exposes the tips of the loops and allows antibody binding. However, uniform immunogold labeling clearly demonstrated that OmpA is evenly distributed over the bacterial cell surface. The loops of the OmpA protein of M. haemolytica are longer than those of the OmpA protein of E. coli (62) but not as long as the loops of other OMPs such as neisserial opacity (Opa) proteins, which can extend to over 50 amino acids in length (27). There are a number of reasons why OMPs might evolve loops of different lengths. The neisserial Opa proteins are involved in binding to host receptors, and longer loops could be seen as advantageous for increasing the distance range to which they can bind host molecules. It is also reasonable to hypothesize that OMPs involved in host molecule binding might evolve loops which are long enough to traverse the capsule. However, this is contradicted by findings that long loops are still present in unencapsulated species such as Neisseria gonorrhoeae and Haemophilus influenzae. Longer loops have also been correlated with virulence in neisserial species, where commensal organisms have shorter hypervariable domains (and thus shorter loops) than pathogenic species (51). There is evidence to suggest that in a number of bacterial species the capsule can be downregulated upon contact with host cells (2, 15, 26) and as a consequence of phase-variable expression (4, 29, 43), thus allowing transient exposure of OMP adhesins. Also, blebbing of outer membrane vesicles has been observed in several Gram-negative bacteria (reviewed in reference 44), allowing OMPs to traverse the capsule and reach the extracellular environment. These phenomena have not been demonstrated in M. haemolytica, although they would provide appropriate mechanisms for the transient exposure of OmpA and other adhesin molecules for host molecule binding.

A wider examination of the binding specificities of the crossabsorbed antibodies to M. haemolytica isolates representing different ompA subclasses demonstrated that anti-rOmpA1 antibodies recognize OmpA1-type (class I) proteins present in bovine isolates but not OmpA2-type (class II) proteins that occur in ovine isolates. Conversely, cross-absorbed antirOmpA2 antibodies recognize OmpA2- but not OmpA1-type proteins. The ability of cross-absorbed anti-rOmpA antibodies to discriminate between OmpA proteins of the OmpA1 and OmpA2 subclasses is due to the greater degree of amino acid sequence variation (within the hypervariable domains) between each of the two subclasses than of the variation within each subclass (22). There are only two variable amino acid sites within the OmpA1-type proteins; similarly, there are only two variable amino acid sites within the OmpA2-type proteins. However, there are 18 variable amino acid sites within the transmembrane domains of OmpA1 and OmpA2, all of which occur within the hypervariable regions (i.e., HV1 to HV4) located at the distal ends of the four external loops. The greater degree of variation between the two OmpA subclasses, compared to that within each subclass, is sufficient to allow the cross-absorbed antibodies to discriminate between the bovine

OmpA1- and ovine OmpA2-type subclasses. Overall, these results clearly demonstrate that the OmpA1 and OmpA2 proteins are sufficiently different in structure and epitope specificity that they are potentially capable of recognizing host receptor molecules of differing specificities in cattle and sheep.

Previous studies have demonstrated that OmpA functions as a ligand, is involved in binding to specific host cell receptor molecules, and plays an important role in adherence and colonization in a number of Gram-negative bacteria (8, 18, 38, 55, 64, 65, 67, 74). In particular, it has been shown that the OmpA protein of bovine serotype A1 isolates of M. haemolytica binds to fibronectin (48) and to bovine bronchial epithelial cells (41). However, a potential role of OmpA as an adhesin has yet to be investigated in ovine isolates of M. haemolytica. We have previously shown that the OmpA1 and OmpA2 proteins are associated exclusively with bovine and ovine isolates, respectively, which led to the hypothesis that they are involved in binding to host-specific receptors in the upper respiratory tracts of these animals (22). This, in turn, might partially account for the different host specificities of strains carrying the OmpA1 and OmpA2 protein types. Importantly, we have now extended the previous study (22) by demonstrating that the binding specificities of the OmpA1 and OmpA2 proteins are very different from each other but are conserved within bovine and ovine M. haemolytica isolates representing different capsular serotypes and evolutionary lineages; there is no association between allele/protein type and clinical status (Table 1). From our findings, it is reasonable to conclude that OmpA1 and OmpA2 are capable of binding to different receptors within cattle and sheep, respectively. Although bovine fibronectin has been demonstrated to be a potential receptor for the OmpA protein of a bovine serotype A1 strain (48), it is interesting that the OmpA (P5) protein of the related species H. influenzae targets a different molecule, namely, the carcinoembryonic antigen (CEA) family of cell adhesion molecules. Thus, it is reasonable to speculate that different molecular variants or regions of fibronectin, or even different molecules, are targeted in cattle and sheep. The production of antibodies against OmpA1 and OmpA2, and the demonstration that they are highly strain and protein specific, will allow further studies to be performed designed to investigate the role of OmpA in the adherence and colonization of M. haemolytica in cattle and sheep.

Commercial vaccines have been produced and are important for the prevention of respiratory disease in both cattle and sheep (9, 39). Several studies have demonstrated the importance of M. haemolytica OMPs as surface antigens and their potential as vaccine components (3, 14, 56, 57, 61). Antibodies against the immunogenic and surface-exposed lipoprotein PlpE contribute toward host defense (60), and the addition of recombinant PlpE to commercial vaccines significantly enhances protection against experimental challenge (12, 13). The incorporation of iron-regulated proteins into a vaccine was shown to enhance protection against experimental pasteurellosis in lambs (34). An edible vaccine that expresses a fragment of the outer membrane antigen GS60 has also been developed (46). Immune sera from cattle vaccinated with live or killed M. haemolytica cells (50), and immune sera from naturally infected cattle (81), contain antibodies that recognize OmpA. In addition, in the closely related species Pasteurella multocida, VOL. 79, 2011

OmpA is the major protein that cattle produce antibodies to after experimental challenge (63). Clearly, OmpA is an important immunogen that should be considered for inclusion in M. haemolytica subunit vaccines. However, a critical property of any vaccine candidate is a high degree of amino acid conservation throughout bacterial populations. Hypervariability of surface-exposed loop regions is a common occurrence within OMPs of many bacterial species and poses a serious problem for vaccine design (7, 31, 53, 78). We previously demonstrated that four distinct OmpA classes occur within bovine and ovine M. haemolytica strains; OmpA1 and OmpA2 are associated with those strains that are responsible for the majority of disease in cattle and sheep, respectively, and have very different hypervariable domains within their surface-exposed loops (22). In the present study, we have now shown that antibodies specific for the surface-exposed loops of OmpA1 will not recognize the same regions of OmpA2 and vice versa. Therefore, an animal exposed to OmpA1 will generate anti-OmpA antibodies that are unlikely to confer protection against M. haemolytica isolates possessing OmpA2 and vice versa (although some cross-reacting antibodies may be present). These findings clearly have important implications with regard to vaccine development and, in particular, to the inclusion of OmpA in subunit vaccines that are designed to provide universal protection against heterologous M. haemolytica isolates. Essentially, an OmpA-based M. haemolytica subunit vaccine would need to include OmpA from more than one class to provide universal protection against heterologous strains.

#### ACKNOWLEDGMENTS

This research was funded by the Biotechnology and Biological Sciences Research Council (grant no. BB/D018137/1). J.D.A.H. was supported by a BBSRC Industrial CASE studentship with Pfizer.

We thank Sharon Kelly for her assistance with the circular dichroism analyses. Proteomic analyses were performed in the Sir Henry Wellcome Functional Genomics Facility.

#### REFERENCES

- 1. Adlam, C., et al. 1984. Purification, characterization and immunological properties of the serotype-specific capsular polysaccharide of *Pasteurella* haemolytica (serotype A1) organisms. J. Gen. Microbiol. 130:2415–2426.
  Auger, E., et al. 2009. Host pathogen interactions of *Actinobacillus pleuro*-
- with porcine lung and tracheal epithelial cells. Infect. Immun. 77:1426-1441
- 3. Ayalew, S., A. W. Confer, S. D. Hartson, and B. Shrestha. 2010. Immunoproteomic analyses of outer membrane proteins of Mannheimia haemolytica and identification of potential vaccine candidates. Proteomics 10:2151–2164.
- Bacon, D. J., et al. 2001. A phase-variable capsule is involved in virulence of *Campylobacter jejuni* 81-176. Mol. Microbiol. 40:769–777.
   Beher, M. G., C. A. Schnaitman, and A. P. Pugsley. 1980. Major heatmodifiable outer membrane protein in gram-negative bacteria: comparison with the OmpA protein of *Escherichia coli*. J. Bacteriol. 143:906–913.
- Berrow, N. S., et al. 2007. A versatile ligation-independent cloning method suitable for high-throughput expression screening applications. Nucleic Acids Res. 35:e45
- 7. Bolduc, G. R., et al. 2000. Variability of outer membrane protein P1 and its Pointer of R, et al. 2005 minibility of ouer memorate protein 11 and its evaluation as a vaccine candidate against experimental otitis media due to nontypeable *Haemophilus influenzae*: an unambiguous, multifaceted ap-proach. Infect. Immun. 68:4505–4517.
- 8. Bookwalter, J. E., et al. 2008. A carcinoembryonic antigen-related cell adhesion molecule 1 homologue plays a pivotal role in nontypeable Haemo-philus influenzae colonization of the chinchilla nasopharynx via the outer membrane protein P5-homologous adhesin. Infect. Immun. 76:48-55. 9. Bowland, S. L., and P. E. Shewen. 2000. Bovine respiratory disease: com-
- mercial vaccines currently available in Canada. Can. Vet. J. 41:33-48. 10. Brogden, K. A., et al. 1989. Effect of *Pasteurella haemolytica* (A1) capsular
- polysaccharide on sheep lung in vivo and on pulmonary surfactant in vitro. Am. J. Vet. Res. 50:555-559.
- 11. Chae, C. H., M. J. Gentry, A. W. Confer, and G. A. Anderson. 1990. Resis-

tance to host immune defense mechanisms afforded by capsular material of Pasteurella haemolytica, serotype 1. Vet. Microbiol. 25:241-251.

- 12. Confer, A. W., et al. 2003. Immunogenicity of recombinant Mannheimia haemolytica serotype 1 outer membrane protein PIpE and augmentation of a commercial vaccine. Vaccine 21:2821–2829.
- 13. Confer, A. W., S. Ayalew, R. J. Panciera, M. Montelongo, and J. H. Wray. 2006. Recombinant Mannheimia haemolytica serotype 1 outer membrane protein PIpE enhances commercial M. haemolytica vaccine-induced resis-
- Forther Fipe emances commercial in memorylical vacchie-induced resis-tance against serotype 6 challenge. Vaccine 24:2248–2255. Confer, A. W., R. D. McCraw, J. A. Durham, R. J. Morton, and R. J. Panciera. 1995. Serum antibody responses of cattle to iron-regulated outer membrane proteins of *Pasteurella haemolytica* A1. Vet. Immunol. Immuno-resched 47:101–110. pathol. 47:101-110.
- Corcionivoschi, N., et al. 2009. Campylobacter jejuni cocultured with epithelial cells reduces surface capsular polysaccharide expression. Infect, Immun. 77:1959-1967
- Corstvet, R. E., M. J. Gentry, P. R. Newman, J. A. Rummage, and A. W. Confer. 1982. Demonstration of age-dependent capsular material on *Pasteu-*rella haemolytica serotype 1, J. Clin. Microbiol. 16:1123–1126.
- 17. Czuprynski, C. J., E. J. Noel, and C. Adlam. 1989. Modulation of bovine neutrophil antibacterial activities by *Pasteurella haemolytica* A1 purified cap-sular polysaccharide. Microb. Pathog. 6:133–141.
- Dabo, S. M., A. W. Confer, and R. A. Quijano-Blas. 2003. Molecular and immunological characterization of *Pasteurella multocida* serotype A:3 OmpA: evidence of its role in *P. multocida* interaction with extracellular 18. matrix molecules of its for in 17 million and interaction and extractional matrix molecules. Microb. Pathog. 35:147–157.
  19. Daigneault, M. C., and R. Y. C. Lo. 2009. Analysis of a collagen-binding
- trimeric autotransporter adhesin from Mannheimia haemolytica A1. FEMS Microbiol. Lett. 300:242-248.
- 20. Davies, R. L., S. Arkinsaw, and R. K. Selander. 1997. Evolutionary genetics of Pasteurella haemolytica isolates recovered from cattle and sheep. Infect. mmun. 65:3585-3593
- Davies, R. L., and W. Donachie. 1996. Intra-specific diversity and host spec-ificity within *Pasteurella haemolytica* based on variation of capsular polysaccharide, lipopolysaccharide and outer-membrane proteins. Microbiology 142:1895-1907
- 22. Davies, R. L., and I. Lee. 2004. Sequence diversity and molecular evolution of the heat-modifiable outer membrane protein gene (ompA) of Mannheim (Pasteurella) haemolytica, Mannheimia glucosida, and Pasteurella trehalosi. J. Bacteriol. 186:5741-5752
- 23. Davies, R. L., R. Parton, J. G. Coote, H. A. Gibbs, and J. H. Freer. 1994. Evaluation of different methods for the detection of outer membrane pro-teins and lipopolysaccharides of *Pasteurella haemolytica* by immunoblotting. I Immunol Methods 167:35-45
- 24. Davies, R. L., R. Parton, J. G. Coote, H. A. Gibbs, and J. H. Freer. 1992. Outer membrane protein and lipopolysaccharide variation in Pasteurella haemolytica serotype A1 under different growth conditions. J. Gen. Microbiol. 138:909-922
- 25. Davies, R. L., T. S. Whittam, and R. K. Selander. 2001. Sequence diversity and molecular evolution of the leukotoxin (*lktA*) gene in bovine and ovine strains of *Mannheimia* (*Pasteurella*) haemolytica. J. Bacteriol. 183:1394–1404.
- Strains of indimitantial (Lastratical Indimoval) and a participation of the participation of the participation of pills and capsule of *Neisseria meningitidis* upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol. Microbiol. 43:1555–1564.
- de Jonge, M. I., H. J. Hamstra, L. van Alphen, J. Dankert, and P. van der Ley. 2003. Mapping the binding domains on meningococcal Opa proteins for
- CEACAM1 and CEA receptors. Mol. Microbiol. 50:1005-1015. 28. De Mot, R., and J. Vanderleyden. 1994. The C-terminal sequence conservation between OmpA-related outer membrane proteins and MotB suggests a common function in both gram-positive and gram-negative bacteria, possibly in the interaction of these domains with peptidoglycan. Mol. Microbiol. 12:333–334.
- 29. de Vries, F. P., A. van Der Ende, J. P. M. van Putten, and J. Dankert. 1996. Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens. Infect. Immun. 64:2998-3006.
- 30. Dornmair, K., H. Kiefer, and F. Jahnig. 1990. Refolding of an integral membrane protein-OmpA of Escherichia coli. J. Biol. Chem. 265:18907-18911
- 31. Duim, B., et al. 1997. Molecular variation in the major outer membrane protein P5 gene of nonencapsulated Haemophilus influenzae during chronic infections. Infect. Immun. 65:1351–1356.
- Favre-Bonte, S., B. Joly, and C. Forestier. 1999. Consequences of reduction of *Klebsiella pneumoniae* capsule expression on interactions of this bacterium with epithelial cells. Infect. Immun. 67:554-561.
- 33. Frank, G. H. 1989. Pasteurellosis of cattle, p. 197-222. In C. Adlam and J. M. Rutter (ed.), Pasteurella and pasteurellosis. Academic Press, New York, NY. Gilmour, N. J. L., et al. 1991. Vaccine containing iron-regulated proteins of
- Pasteurella haemolytica A2 enhances protection against experimental pas-teurellosis in lambs. Vaccine 9:137-140.
- 35. Gilmour, N. J. L., and J. S. Gilmour. 1989. Pasteurellosis of sheep, p.

#### 10 HOUNSOME ET AL

223-262. In C. Adlam and J. M. Rutter (ed.), Pasteurella and pasteurellosis. Academic Press, New York, NY.

- 36. Gioia, J., et al. 2006. The genome sequence of Mannheimia haemolytica A1: insights into virulence, natural competence, and Pasteurellaceae phylogeny. J. Bacteriol 188:7257-7266
- 37. Highlander, S. K. 2001. Molecular genetic analysis of virulence in Mannheimia (Pasteurella) haemolytica. Front. Biosci. 6:D1128–D1151.
   Hill, D. J., et al. 2001. The variable P5 proteins of typeable and non-typeable Haemophilus influenzae target human CEACAM1. Mol. Microbiol. 39:850–
- Hjerpe, C. A. 1990. Bovine vaccines and herd vaccination programs. Vet. Clin. North Am. Food Anim. Pract. 6:167–260.
- Kelly, S. M., T. J. Jess, and N. C. Price. 2005. How to study proteins by circular dichroism. Biochim. Biophys. Acta 1751:119–139.
   Kisiela, D. I., and C. J. Czuprynski. 2009. Identification of *Mannheimia* haemolytica adhesins involved in binding to bovine bronchial epithelial cells. Infect J. Comp. 72146 455. Infect, Immun, 77:446-455,
- 42. Kleinschmidt, J. H., M. C. Wiener, and L. K. Tamm. 1999. Outer membrane protein A of *E. coli* folds into detergent micelles, but not in the presence of monomeric detergent. Protein Sci. 8:2065–2071.
- Krinos, C. M., et al. 2001. Extensive surface diversity of a commensal mi-croorganism by multiple DNA inversions. Nature 414:555–558.
   Kulp, A., and M. J. Kuehn. 2010. Biological functions and biogenesis of
- secreted bacterial outer membrane vesicles. Annu. Rev. Microbiol. 64:163-184
- 45. Lawrence, P. K., et al. 2010. Genome sequences of Mannheimia haemolytical serotype A2: ovine and bovine isolates. J. Bacteriol. 192:1167-1168.
- 46. Lee, R. W. H., et al. 2008. Expression of a modified Mannheimia haemolytica GS60 outer membrane lipoprotein in transgenic alfalfa for the development of an edible vaccine against bovine pneumonic pasteurellosis. J. Biotechnol. 135:224-231.
- 47. Lo, R. Y. C., L. J. McKerral, T. L. Hills, and M. Kostrzynska. 2001. Analysis
- Lo, R. T. C., E. J. MCREIALT L. Z. MINS, and M. ROMZHARAZZON ANALYSIS of the capsule biosynthetic locus of Mannheimia (Pasteurella) haemolytica A1 and proposal of a nomenclature system. Infect. Immun. 69:4458–4464.
   Lo, R. Y. C., and L. S. Sorensen. 2007. The outer membrane protein OmpA of Mannheimia haemolytica A1 is involved in the binding of fibronectin. FEMS Microbiol. Lett. 274:226–231.
- FEMS Microbiol. Lett. 274:226–231.
   Lobley, A., L. Whitmore, and B. A. Wallace. 2002. DICHROWEB: an inter-active website for the analysis of protein secondary structure from circular dichroism spectra. Bioinformatics 18:211–212.
   Mahasreshti, P. J., et al. 1997. Purification and partial characterization of
- the OmpA family of proteins of Pasteurella haemolytica. Infect. Immun. 65:211-218
- 51. Malorny, B., G. Morelli, B. Kusecek, J. Kolberg, and M. Achtman. 1998. Sequence diversity, predicted two-dimensional protein structure, and epitope mapping of neisserial Opa proteins. J. Bacteriol. 180:1323–1330.
  52. Markwell, M. A. K., S. M. Haas, L. L. Bieber, and N. E. Tolbert. 1978.
- Modification of Lowy procedure to simplify protein determination in mem-brane and lipoprotein samples. Anal. Biochem. 87:206–210.
- Martin, S. L., et al. 2000. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA
- outer membrane vesicle vaccine. Vaccine 18:2476–2481. 54. McKerral, L. J., and R. Y. C. Lo. 2002. Construction and characterization of an acapsular mutant of Mannheimia haemolytica A1. Infect. Immun. 70: 2622-2629.
- 55. Millman, K. L., S. Tavare, and D. Dean. 2001. Recombination in the ompA gene but not the omcB gene of Chlamydia contributes to serovar-specific differences in tissue tropism, immune surveillance, and persistence of the organism. J. Bacteriol. 183:5997-6008.
- 56. Morton, R. J., et al. 1995. Vaccination of cattle with outer membrane protein-enriched fractions of *Pasteurella haemolytica* and resistance against ex-
- perimental challenge exposure. Am. J. Vet. Res. 56:875-879. Mosier, D. A., K. R. Simons, A. W. Confer, R. J. Panciera, and K. D. 57. Clinkenbeard. 1989. Pasteurella haemolytica antigens associated with resis-tance to pneumonic pasteurellosis. Infect. Immun. 57:711–716.
- 58. Nakamura, K., and S. Mizushima. 1976. Effects of heating in dodecyl-sulfate solution on conformation and electrophoretic mobility of isolated major outer membrane proteins from Escherichia coli K-12, J. Biochem. 80:1411-
- 59. Ohnishi, S., K. Kameyama, and T. Takagi. 1998. Characterization of a heat modifiable protein, Escherichia coli outer membrane protein OmA indi-nary surfactant system of sodium dodecyl sulfate and octylglucoside. Biochim. Biophys. Acta 1375:101–109.

Editor: R. P. Morrison

- 60. Pandher, K., A. W. Confer, and G. L. Murphy. 1998. Genetic and immunologic analyses of PlpE, a lipoprotein important in complement-mediated
- killing of Pasteurella haemolytica serotype 1. Infect. Immun. 66:5613-5619. Pandher, K., G. L. Murphy, and A. W. Confer. 1999. Identification of im-61. hunogenic, surface-exposed outer membrane proteins of Pasteurella haemo-lytica serotype 1. Vet. Microbiol. 65:215–226.
- 62. Pautsch, A., and G. E. Schulz. 1998. Structure of the outer membrane protein A transmembrane domain. Nat. Struct. Biol. 5:1013-1017. 63. Prado, M. E., S. M. Dabo, and A. W. Confer. 2005. Immunogenicity of
- iron-regulated outer membrane proteins of Pasteurella multocida A:3 in cattle: molecular characterization of the immunodominant heme acquisition Prasadarao, N. V. 2002. Identification of Escherichia coli outer membrane
- protein A receptor on human brain microvascular endothelial cells. Infect. Immun. 70:4556-4563.
- 65. Prasadarao, N. V., et al. 1996. Outer membrane protein A of Escherichia coli contributes to invasion of brain microvascular endothelial cells. Infect. Immun. 64:146-153.
- Provencher, S. W., and J. Glockner, 1981. Estimation of globular protein secondary structure from circular dichroism. Biochemistry 20:33-37
- Reddy, M. S., J. M. Bernstein, T. F. Murphy, and H. S. Faden. 1996. Binding 67. between outer membrane proteins of nontypeable Haemophilus influenzae and human nasopharyngeal mucin. Infect. Immun. 64:1477-1479.
- 68. Reithmeier, R. A. F., and P. D. Bragg. 1974. Purification and characterization of a heat-modifiable protein from the outer membrane of *Escherichia coli*, FEBS Lett, **41**:195–198.
- Robertig, S. C., et al. 2007. The response of *Mannheimia haemolytica* to iron limitation: implications for the acquisition of iron in the bovine lung. Vet. 69. Microbiol. 121:316-329
- Schembri, M. A., D. Dalsgaard, and P. Klemm. 2004. Capsule shields the 70.
- function of short bacterial adhesins. J. Bacteriol. 186:1249–1257.
  71. Shifrin, Y., et al. 2008. Transient shielding of intimin and the type III secretion system of enterohemorrhagic and enteropathogenic *Escherichia*
- coli by a group 4 capsule. J. Bacteriol. 190:5063-5074.
   Smith, S. G. J., V. Mahon, M. A. Lambert, and R. P. Fagan. 2007. A molecular Swiss army knife: OmpA structure, function and expression. FEMS Microbiol. Lett. 273:1–11. 72
- 73 Sutherland, A. D., G. E. Jones, and I. R. Poxton. 1990. The susceptibility of in vivo-grown Pasteurella haemolytica to ovine defence mechanisms in vitro. FEMS Microbiol. Immunol. 2:269-278.
- 74. Torres, A. G., and J. B. Kaper. 2003. Multiple elements controlling adherence of enterohemorrhagic Escherichia coli O157:H7 to HeLa cells. Infect. Immun. 71:4985-4995
- van Stokkum, I. H. M., H. J. W. Spoelder, M. Bloemendal, R. van Grondelle, 75. and F. C. A. Groen. 1990. Estimation of protein secondary structure and error analysis from circular dichroism spectra. Anal. Biochem. 191:110–118.
- Virji, M., et al. 1995. Opc- and pilus-dependent interactions of meningococci with human endothelial cells: molecular mechanisms and modulation by urface polysaccharides. Mol. Microbiol. 18:741-754.
- Walker, R. D., F. M. Hopkins, T. W. Schultz, M. D. McCracken, and R. N. Moore. 1985. Changes in leukocyte populations in pulmonary lavage fluids of calves after inhalation of *Pasteurella haemolytica*. Am. J. Vet. Res. 46:2429– 1999. 2433
- 78. Webb, D. C., and A. W. Cripps. 1998. Secondary structure and molecular analysis of interstrain variability in the P5 outer-membrane protein of nontypable Haemophilus influenzae isolated from diverse anatomical sites. J. Med. Microbiol. 47:1059–1067.
- Whiteley, L. O., S. K. Maheswaran, D. J. Weiss, and T. R. Ames. 1990. Immunohistochemical localization of Pasteurella haemolytica A1-derived endotoxin, leukotoxin, and capsular polysaccharide in experimental bovine Pasteurella pneumonia. Vet. Pathol. 27:150-161.
- 80. Whitmore, L., and B. A. Wallace. 2008. Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databa Biopolymers 89:392-400.
- 81. Zeng, H., K. Pandher, and G. L. Murphy. 1999. Molecular cloning of the Pasteurella haemolytica ponA gene and identification of bovine antibodies against PomA surface domains. Infect. Immun. 67:4968–4973.
- 82. Zhu, Y. S., I. Black, A. W. Roszak, and N. W. Isaacs. 2007. Crystallization and preliminary X-ray diffraction analysis of P30, the transmembrane domain of pertactin, an autotransporter from Bordetella pertussis. Acta Crys-tallogr. Sect. F Struct. Biol. Cryst. Commun. 63:593–595.